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CHAPTER  1  
 
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS 
 
 
Taken in part from: 
 
Viral infections and mechanisms of thrombosis and bleeding 
M. Goeijenbier1 & M. van Wissen2,  C. van de Weg1, E. Jong2, V.E.A. Gerdes2, J.C.M. Meijers3, 
D.P.M. Brandjes2, E.C.M. van Gorp1 
J. Med. Vir. 2012, 84(10):1680-96 
 
Ebola Virus Disease; a review on epidemiology, symptoms, treatment and pathogenesis 
M. Goeijenbier1, J.J.A. van Kampen1, C.B.E.M. Reusken 1 , M.P.G.  Koopmans1, E.C.M van Gorp1 
 
1. Erasmus MC, Rotterdam, the Netherlands, Department of Virology 
2. Slotervaart Hospital, Amsterdam, the Netherlands, Department of Internal medicine 
3. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, the 
Netherlands 
Neth. J. Med. 2014, 72(9):442-8 
  
Virus infections and mechanisms of thrombosis and bleeding 
 
Viral infections of any kind can influence the haemostatic balance.  This means that during, or 
shortly after infection with certain viruses the ability of blood to clot in humans can be 
drastically changed which can lead to both thrombotic as well as haemorrhagic complications. 
Direct or indirect activation of the endothelium by viruses (or other pathogens) may result in 
alterations in the coagulation- and the fibrinolytic systems (1). Normally, coagulation is a 
balance between procoagulant and (natural) anticoagulant mechanisms and actually it seems 
that a well regulated activation of coagulation is part of the host’s defence against infectious 
agents (2). However, the inflammation caused by certain viral infections may lead to such 
alterations in coagulation resulting in an imbalance between the pro- and anticoagulant state. 
The clinical picture of altered coagulation in several viral infections manifests itself in mild or 
even severe bleeding (haemorrhage), thrombosis, or both. In severe cases this may even lead to 
disseminated intravascular coagulation with the formation of micro vascular thrombi in various 
organs (3). Disseminated intravascular coagulation contributes to multiple organ failure and is 
associated with high mortality in both bacterial and nonbacterial diseases (3;4). It is not yet 
clear why some viruses cause haemorrhage (e.g. the viral haemorrhagic fevers like hantavirus 
and Ebola), others are associated with thrombosis (e.g. cytomegalovirus and influenza) and 
others show both (e.g. varicella zoster virus) (5-8). In addition, the bleeding complications 
caused by viral haemorrhagic fever pathogens vary in severity, such as more minor bleeding 
complications in dengue and more severe bleeding seen in patients infected with Crimeon 
Congo Haemorrhagic fever virus or one of the Old-World hantaviruses. Both bleeding and 
thrombotic complications during or shortly after viral infection are associated with a worse 
outcome of disease, while for most of the viral infections no targeted therapy is available and 
only supportive care can be provided. Therefore, a better understanding is needed of the 
pathogenesis of bleeding and thrombotic complications due to viral infections.  
 
Principles of haemostasis, coagulation, and fibrinolysis: general aspects 
One of the most important functions of the endothelial cell layer is the maintenance of 
haemostasis, a physiologic mechanism that maintains blood in a fluid state within the 
vasculature and responds with coagulation at time of injury to prevent exsanguination (9). For 
this to work properly, a perfect balance between pro- and anti-coagulant factors is necessary. 
The formation of a blood clot is a well-regulated process comprising three elements: 1) primary 
haemostasis, 2) secondary haemostasis/coagulation, and 3) fibrinolysis (Figure 1) (10). The 
onset of clotting arises when the vasculature is damaged and blood is exposed to platelet 
activating- and pro-coagulant factors. The first response, primary haemostasis, is the adherence 
and aggregation of activated platelets to the side of injury, due to Von Willebrand factor (VWF). 
Von Willebrand factor is a very sensitive marker of endothelial cell activation and is a large 
glycoprotein synthesized in the vascular endothelium. Endothelial cells store VWF in the 
Weibel-Palade bodies in the form of unusually large vWF multimers. The function of vWF 
comprises adhesion of platelets to exposed subendothelium, forming the basis for the 
haemostatic plug. At the side of injury activated platelets provide cell-surface phospholipids to 
further facilitate secondary haemostasis, the formation of fibrin strands, which stabilise the 
platelet plug. Coagulation results from a series of linked coagulation protease-zymogen 
reactions, ultimately resulting in the formation of fibrin. Tissue factor is the main initiator of the 
coagulation cascade, which is localised in the subendothelium, but also on non-circulating 
leukocytes and possibly on platelets. Thrombin generation is induced by the assembly of the 
tissue factor-factor VIIa complex. Thrombin is able to convert fibrinogen into (insoluble) fibrin. 
Coagulation is regulated by different inhibitory mechanisms. A first mechanism is made up of 
the circulating inhibitors of blood coagulation: antithrombin and heparin cofactor II (both 
inhibitors of thrombin), and tissue factor pathway inhibitor. Two other circulating inhibitors of 
blood coagulation are protein C and protein S (the latter of which is a cofactor for the proper 
functioning of activated protein C). A second inhibitory mechanism consists of the endothelium-
bound modulators heparin sulphate and thrombomodulin, which facilitate the inhibitory 
activity of antithrombin and the activation of protein C, respectively. The third element, the 
fibrinolytic system, is necessary to degrade the formed fibrin strands. This system is initiated by 
tissue plasminogen activators and urokinase after their synthesis by, and release from, 
endothelial cells. These activators initiate the conversion of plasminogen to plasmin, which 
hydrolyses polymerised fibrin strands into soluble fibrin degradation products, thus degrading 
the fibrin clot. The activity of the fibrinolytic system is, among other things, regulated by 
plasminogen activator inhibitor type I, which may greatly increase during acute phase reactions. 
Thrombin-activatable fibrinolysis inhibitor is also an inhibitor of fibrinolysis and is activated, as 
suggested by the name, by thrombin. Fibrinolysis may be activated primarily – and thus 
independently of the activation of the coagulation cascade – or secondarily, in response to 
fibrin formation. 
 
Procoagulant/prothrombotic changes 
Procoagulant and prothrombotic are two terms used in literature to indicate the same 
mechanism; a tendency to develop thrombosis. In this thesis the term procoagulant is used to 
refer to a change in coagulation markers determined in the laboratory, while a prothrombotic 
state indicates a clinical risk situation. In other words the risk for the development of 
thrombosis is increased in a patient due to any factor (immobility, malignancy). Generally 
speaking, in viral infections several procoagulant markers are elevated, indicating that the 
coagulation system is activated. 
 
Figure 1. Simplified model of the coagulation cascade. Coagulation proteins are given in roman 
numerals. TF = tissue factor, PAI-1 = plasminogen activator inhibitor type 1, u-PA = urokinase-
type plasminogen activator, t-PA = tissue-type plasminogen activator, TAFI = thrombin 
activatable fibrinolysis inhibitor 
 
A clear procoagulant state can be defined by a number of alterations in the blood. Firstly,  
increased levels of clotting factors (e.g. factor VIII, factor XI), soluble tissue factor and von 
Willebrand factor. Secondly, deficiency of the regulatory [anti-coagulant] proteins , e.g.  protein 
C, protein S, antithrombin, and tissue factor pathway inhibitor. Furthermore, markers of 
thrombin generation (prothrombin fragment 1+2 and thrombin-antithrombin complexes), 
platelet activation, fibrin degradation and fibrinolysis (e.g. D-dimer and plasmin-2-antiplasmin 
complexes) can also be increased.  
 
The effect of inflammation on coagulation 
An increasing amount of evidence suggests the existence of an extensive correlation between 
inflammation and coagulation, whereby inflammation not only leads to coagulation, but 
coagulation also affects inflammatory activity (2;11-13). Inflammation impacts the initiation, 
propagation and inhibitory phases of blood coagulation (2). Many studies have been carried out 
on the influence of inflammation, in particular the (pro)inflammatory cytokines on the 
coagulation system. The activation of the coagulation cascade during inflammation is the result 
of the stimulation of coagulant synthesis, the decreased synthesis of anti-coagulants and the 
suppression of fibrinolysis (14). This is the net result of an increased expression of tissue factor 
leading to the activation of the extrinsic coagulation pathway, together with the down 
regulation of activated protein C and the inhibition of fibrinolysis (15). Pro-inflammatory 
cytokines like IL-6, IL-1, IL-12 and TNF-α are known to increase the production and subsequent 
expression on the endothelial cell surface of VWF, which may result in platelet activation. They 
upregulate tissue factor expression via the activation of protease-activated receptors, on 
monocytes, and endothelial cells (2;11;16). Furthermore, the generation of activated protein C 
is also impaired, due to a lowered expression of thrombomodulin on the surface of endothelial 
cells, which acts as a cofactor in the thrombin-mediated activation of protein C. While on the 
one hand anticoagulants are decreased, on the other hand there is an upregulation of 
plasminogen activator inhibitor-1, which is able to block the activation of plasminogen, thus 
creating a downregulation of  the breakdown of fibrin clots (2;16). The generation of thrombin, 
as a net result,  is generally increased due to inflammation, all of which results in a 
procoagulant state of the clotting cascade (17).  
 
Viral infection and haemorrhage  
Viruses that most severely affect coagulation are collectively categorized as the viral 
haemorrhagic fever pathogens. Viral haemorrhagic fever (VHF) is a syndrome characterized by 
the hallmark symptoms of (high) fever, bleeding in various organs and complicated by multi-
organ failure (MOF) and eventually shock. The pathogens associated with this severe clinical 
condition in humans originate from different families like the Filoviridae (Ebola virus and 
Marburg virus), Bunyaviridae (hantavirus, Crimeon-Congo haemorrhagic fever (CCHF) and Rift 
Valley fever), Flaviviridae (dengue, yellow fever) and the family of the Arenaviridae (Lassa and 
South American haemorrhagic fever). Infection with one specific VHF pathogen may result in a 
different clinical course compared to another, but all seem to have in common that the 
endothelium is activated and dysfunctional. Endothelial stress in patients who develop VHF are 
at first characterized by (mild) hypotension, conjunctival vasodilation and flushing of the skin in 
the early phase of the disease (18). As the disease progresses endothelial dysfunction becomes 
more prominent and may result in capillary leakage, fluid effusion in body cavities, 
haemorrhage and eventually shock. The number of patients that develop haemorrhage and/or 
shock differs greatly within the VHF pathogens. For instance in Lassa fever, shock is relatively 
common, while bleeding complications are quite rare. On the other hand in patients with CCHF 
bleeding is quite prominent (19). In VHF bleeding often occurs from various mucous 
membranes together with easy bruising and persistent bleeding after venapuncture. Massive 
bleeding may occur in the gastro-intestinal tract and/or intra-cerebrally (Kortepeter et al, 
2011). These bleeding complications are often observed in severe forms of infection and they 
correlate with the case fatality rate. Bleeding is thought to be the consequence of a 
multifactorial process of which an imbalanced coagulation cascade sometimes results in 
disseminated intravascular coagulation, as seen in hantavirus-, Ebola-, Marburg-, Crimean-
Congo haemorrhagic fever- and dengue virus infections (5). Multiple mechanisms have been 
suggested in literature to explain haemorrhage and plasma leakage in VHF. Of these most 
generally accepted are those suggesting direct endothelial injury, platelet aggregation and 
consumption, liver damage, cytokine storm and (over)activation of the coagulation system (20). 
However, in many other viral infections that do not cause haemorrhage the coagulation system 
is also activated, thrombocytopenia occurs and cytokines are produced up to comparable high 
levels. Thus far the pathophysiologic basis for the occurrence of haemorrhage and shock in this 
distinct group of VHF pathogens is poorly understood.  
 
Viral infection and thrombosis 
Where VHF pathogens, and in severe cases some herpes and influenza viruses (varicella zoster 
virus, pandemic H1N1), are able to cause bleeding during the course of infection, many other 
viruses are associated with the occlusion of a vessel; thrombosis. For instance, many respiratory 
tract infections increase the risk of deep venous thrombosis and possibly pulmonary embolism 
too (21).  Also multiple herpes viruses have been associated with thrombosis of any kind both in 
human and animal models (22). In humans, most reports describe thrombosis during CMV 
infection in immunocompromised patients (23-26), but also immune competent individuals 
may develop (most often deep vein) thrombosis during CMV infection (6;27-29). However, 
many of the reported cases had known additional procoagulant risk factors, such as a protein C 
deficiency, factor V Leiden mutation or a heterozygous prothrombin G20210A mutation (30-
32). Chronic infections like hepatitis B, C and HIV are also notorious risk factors for the 
development of thrombosis. Both venous- and arterial thrombosis occur far more often in 
patients with these chronic infections compared to healthy controls. For instance the overall 
risk of venous thrombotic disease in HIV-infected patients is estimated to be between two and 
ten times as high as it is in healthy individuals (33;34). Furthermore, the treatment with first 
and second generation protease inhibitors is linked to venous as well as arterial thrombotic 
events (34;35). The mechanisms behind these procoagulant changes have been studied for 
some of the viruses mentioned. In general there seems to be a central role for the vascular 
endothelium, which under the pressure of viral infection, shifts to a more procoagulant state.  
This procoagulant state is characterized by:  “the inhibition of anticoagulant/antithrombotic 
properties, the induction of procoagulant properties of the endothelium by changing the 
phospholipid exposure resulting in enhanced thrombin generation and secretion of VWF and an 
increase in binding sites for inflammatory cells, which leads to a further procoagulant shift of 
the endothelial cell surface (36-39). The exact mechanism by which these viruses activate or 
inhibit the production of these pro- and anti-coagulant proteins is not clear yet.  
 
Ebola virus disease 
Ebola virus and the closely related Marburg virus are often typed as textbook examples of viral 
haemorrhagic fever pathogens. Ebolaviruses enter the human body via mucosal surfaces, 
abrasions and injuries in the skin or by direct parental transmission. Infection through intact 
skin is considered unlikely, although not excluded. The virus has been successfully isolated from 
skin (biopsy) and body fluids (40). Several laboratory associated infections have been reported 
the past decades, often after needle accidents or direct contact with infectious materials (41).  
The route of transmission seems to affect the disease outcome; in the early EBOV outbreak in 
1976, case fatality rate (CFR) after transmission by injection was 100% versus 80% in contact 
exposure cases (42). This has been confirmed in a non-human primate model, showing faster 
disease progression in animals infected via injection versus those who received an aerosol 
challenge (43). Due to the high CFR in Ebola virus disease (EVD) and the potential threat for use 
of EBOV as a biodefense weapon, the pathogenesis of EVD has been relatively well studied 
during the past 15 years (44). Most studies have been performed in rodent-, guinea pig-, 
primate- and in vitro models. Upon entry, EBOV has proven to be able to infect numerous cell 
types. Post mortem studies  of patients and experimentally infected animals showed infection 
of immune cells (macrophages, monocytes and dendritic cells), epithelial- and endothelial cells, 
fibroblasts, hepatocytes and adrenal gland tissue (45). Replication in infected cells is very 
efficient resulting in a rapid and high peak viremia (45). Furthermore, death of infected cells has 
been hypothesized to play an important role in the signs and symptoms seen in EVD patients, 
for instance the decreased ability of the immune system to respond to the infection due to 
apoptosis of infected lymphocytes or a decreased production of clotting factor due to the loss 
of hepatocytes (42).  Studies addressing the mechanism behind coagulation abnormalities first 
showed that haemorrhage was most likely  not the direct effect of endothelial cell infection, 
followed by cytolysis (46). A more likely explanation seems to be an overexpression of tissue 
factor in monocytes/macrophages resulting in (over)activation of the extrinsic pathway of 
coagulation followed by a consumptive coagulopathy and eventually a disseminated 
intravascular coagulation (47). Furthermore antibody enhancement has been hypothesized to 
play a role in the later phase of the EVD course (48). Although data on this theory is still limited, 
antibody depended enhancement seems to enhance infectivity of the virus in vitro not only for 
EBOV but also the closely related Marburg virus (48;49). However, due to the high CFR seen in 
EVD and the fact that in many patients antibody response is lowered or even absent, the 
mechanism of antibody enhancement does not seem clinically relevant.  However, antibody 
enhancement has been hypothesized to play an important role in the development of dengue 
haemorrhagic fever (50;51) and therefore might be of interest.  Interesting data about EVD 
pathogenesis comes from asymptomatic cases and EVD patients that survived infection. A 
cluster of asymptomatic infections has been described after EBOV infection. Of these 24 
contacts, 11 were asymptomatically infected and developed an IgM and IgG response plus a 
mild viremia between day 7 (first day of sampling) and day 16 (52). Although further research in 
mechanisms behind the haemorrhage and endothelial dysfunction seen in Ebola virus disease is 
of great interest bio-safety issues complicate widespread in vitro and in vivo studies.  
 
Hantavirus infection  
In regards of endothelial cell dysfunction and coagulation disturbances pathogenic hantaviruses 
are most interesting to study.  First of all because these negative stranded RNA viruses seem to 
directly infect endothelial cells at an early stage of disease, in contrast to Ebola viruses 
discussed in the paragraph above. Furthermore, viral effects on endothelial cell function most 
likely contribute to the characteristic clinical features seen in hantavirus associated disease 
(53). Hantaviruses circulating in Europe and Asia are associated with haemorrhagic fever and 
renal syndrome (HFRS) (54;55). Hallmark symptoms of HFRS are fever, acute renal failure and 
alterations in haemostasis, ranging from mild thrombocytopenia to disseminated intravascular 
coagulation (56). At first, less severe bleeding complications like epistaxis, conjunctival 
bleeding, haematuria, petechiae and mucosal bleeding occur, while in a later phase 
gastrointestinal, intra-cerebral and pleural bleedings are reported in severe HFRS. Less common 
haemorrhagic events are right atrial haemorrhage (57), spleen haemorrhage (58) and pituitary 
gland haemorrhage resulting in endocrinal disturbance or even panhypopituitarism (59;60). 
Hantaviruses circulating in North and South America can cause Hantavirus Cardio-Pulmonary 
Syndrome (HCPS), resulting in acute respiratory distress and cardiac failure. However, bleeding 
disorders play a less significant role in the pathology of this disease. Clinical studies focusing on 
alterations in primary and secondary haemostasis during hantavirus disease showed 
thrombocytopenia in both HFRS and HCPS, a decreased plasma activity of coagulation factors II, 
V, VIII, IX and X in acute HFRS patients, prolongation of the prothrombin and activated partial 
thromboplastin time, increased thrombin generation and D-dimer levels and a decrease in 
ADAMTS13 activity in acute Puumala hantavirus infected patients (61-64).  Furthermore, 
multiple in vitro studies investigated the role of endothelial cells in hantavirus infection and 
most important findings from these experiments are summarized in Figure 2.  Two very 
different processes seem to contribute to the activation of endothelial cells and subsequent 
activation of coagulation in hantavirus disease. At first, macrophages (MO) and dendritic cells 
(DC) induce pro-inflammatory cytokines, which evoke a changing phenotype of the 
endothelium towards a pro-adhesive (for immune cells) and pro-coagulant response during 
inflammation as discussed above. Activation of macrophages and platelets further promote the 
procoagulant shift. The infection of endothelial cells by hantaviruses leads to presentation of 
the virus glycoproteins on the surface of the infected endothelial cell. Subsequently platelets 
bind to the virus glycoproteins present on the cell surface via ανβ3 integrins. This integrin is 
proven to be the hantavirus receptor and loss of function seems to contribute to increased 
permeability of the endothelium in a mechanism by which vitronectin is removed from its 
physiological binding place on the integrin receptor. Recent work from Raftery et al. showed 
the release of neutrophil extracellular traps (NETs) from neutrophils upon binding of 
hantaviruses to integrin receptors present on neutrophils. These NETs are known to have pro 
coagulant effects on both primary and secondary haemostasis (65).  The mechanism by which 
hantaviruses cause these changes in coagulation remains unknown.  
 
Figure 2. Summary of the current knowledge on the interaction between haemostasis, 
endothelial cells and hantavirus infection 
The changes in haemostasis seen during hantavirus infection are the result of two different 
pathways. At first, dendritic cells (DC) and macrophages (MO) produce pro-inflammatory 
cytokines during hantavirus infection promoting the procoagulant shift. Platelets bind to 
hantavirus infected cells via virus glycoproteins present on the infected cells. Furthermore, 
polymorphonucleur neutrophils (PMN) release neutrophil extracellular traps (NETs) upon 
binding of hantaviruses, which on their turn continue to stimulate platelet aggregation and 
secondary coagulation.  
Influenza virus infection 
Like many respiratory infections influenza virus infections tend to cause a procoagluant shift in 
the haemostatic balance. Due to the magnitude of the population at risk for influenza virus 
infection and the solid evidence of the association between influenza virus infection and 
vascular thrombosis, influenza can be seen as an important representative of virus associated 
thrombosis.  There are three manifestations of influenza in humans: seasonal, avian and 
pandemic influenza. Seasonal influenza is caused by influenza A or B viruses, which infect 5-15% 
of the human population every year (66). Symptoms vary from mild respiratory complaints 
up to fatal respiratory distress. Symptoms depend largely, however, on the health and immune 
status of the infected individual and the pathogenicity of the specific virus involved. 
Coagulation wise patients infected with an influenza A virus have been reported to suffer from 
disseminated intravascular coagulation and pulmonary micro-embolism in rare cases (67;68). In 
the latest outbreak of pandemic H1N1 influenza, multiple thrombotic complications were 
reported, such as deep venous thrombosis and pulmonary embolism. In several cases the 
thrombotic events resulted in bleeding complication such as pulmonary haemorrhage with 
haemoptysis, haematemesis, petechial rash and one case of disseminated petechial brain 
haemorrhage (69-78).  There is a strong increased risk for the development of cardiovascular 
disease during or shortly after influenza virus infection, an observation that has been confirmed 
in large epidemiological studies and vaccination intervention trials using of seasonal influenza 
vaccines (79). It seems the driver behind the increased risk of thrombosis is an imbalance in 
haemostasis manifested by a procoagulant state (80-82). Indications for the increased clotting 
come from clinical, experimental mouse and in vitro data. Clinical reports range from mild 
increased coagulation and fibrinolysis markers such as VWF and D-dimer levels, to disseminated 
intravascular coagulation observed in severe avian influenza (83-85). Experimental mouse data 
indicate a procoagulant state characterized by increased thrombin generation, fibrin 
deposition, and an impaired fibrinolysis (86;87). How frequently influenza infection leads to 
clinically relevant thrombotic disease and in what magnitude and how the coagulation cascade 
is activated have yet to be investigated. 
 
 
Aim and outline of this thesis 
 
In this thesis the relation between viral infections and mechanisms of thrombosis and bleeding 
were investigated, focussing on viral haemorrhagic fever and infections known to cause 
thrombosis. More specifically, this thesis focussed on three essential areas of research in this 
field, namely: “Epidemiology, pathogenesis and prevention”.  Hantaviruses were chosen as a 
useful model for viral haemorrhagic fever pathogens while influenza was chosen as a 
representative virus for viral infections associated with thrombosis. The thesis starts with the 
epidemiological studies related to hantavirus infection. The direct cause for us to start studying 
hantavirus infections was a clinical case discussed in the introduction of Chapter 2.1. Unique 
features in this case report, from presenting symptoms to diagnosis and course of disease, 
triggered us to further look into the epidemiology, diagnosis and treatment of these neglected 
rodent-borne haemorrhagic fever pathogens. This resulted to the design of the Hanta-Hunting 
study to test the possibility of hantavirus unawareness in the Netherlands, discussed in Chapter 
2.2.  Eventually the results from this study made us expand the study design to a cohort study 
in the Republic of Suriname of which the results are presented in Chapter 2.3.  
After the section on epidemiology of this thesis we discuss pathogenesis studies pathogenesis 
in Chapter 3:  “clotting and haemorrhage in infectious diseases”. We start with the in vitro 
analysis of direct effects of hantavirus infection on the haemostatic function of endothelial cells 
in Chapter 3.1 followed by a helicopter view approach of the proteome of these hantavirus 
infected endothelial cells in Chapter 3.2. For this proteomics study we used the rodent-borne 
haemorrhagic fever pathogen Leptospira interrogans as a control,  since it is a bacteria that 
causes a comparable disease while this pathogen has a very different infection and replication 
cyclus in humans compared to hantaviruses. Results from this non-virus control infection 
suggested both common and different endothelial cell effects, which we further discuss in 
Chapter 3.3 by using an in vivo – in vitro – in vivo study design. The chapter on pathogenesis is 
concluded with Chapter 3.4 where an in depth study on coagulation activation during a virus 
associated with thrombosis is described. For this purpose we analysed infection with different 
influenza viruses in the ferret model, while focussing on both circulatory and tissue 
haemostasis. This thesis ends with a section on how to prevent these emerging pathogens 
responsible for haemorrhage and/or thrombosis. In Chapter 4.1 a large collaborative 
international study on the association between selenium concentration and hantavirus 
infections in mainland China, a country severely affected by hantavirus infections, is discussed. 
In Chapter 4.2 we discussed the results of a phase 1/2a clinical trial on one of the most 
effective ways of prevention:  vaccination making use of a modified vaccinia Ankara (MVA) 
platform suitable for many of the emerging and dangerous viruses studied in this thesis. Finally, 
Chapter 5 is a summarizing discussion of the findings described in this thesis. 
 
 
  
  
CHAPTER 2   
 
EPIDEMIOLOGY: 
“Viral Haemorrhagic Fever in the Netherlands and republic of Suriname” 
 
Consists of: 
 
2.1  A viral haemorrhagic fever case in the Netherlands and review of the literature 
2.2  The hanta hunting study: underdiagnosis of Puumala hantavirus infections in 
 symptomatic non-travelling leptospirosis-suspected patients in the Netherlands 
2.3  Hantavirus and chikungunya as newly identified causes of haemorrhagic fever in the 
 republic of Surinam.  
  
CHAPTER 2.1 
 
A viral haemorrhagic fever case in the Netherlands and review of the 
literature 
 
Taken in part from: 
 ‘An unusual cause of an usual presentation’     
M. Goeijenbier1, E. Nur2 , M. Goris 3, J.F.P. Wagenaar 2, K. Grünberg4, S.A. Nurmohamed 2,5, B.E. 
Martina 1 A.D. Osterhaus 1, E.C.M. van Gorp1 
1. Department of Virology, Erasmus MC, Rotterdam, the Netherlands  
2. Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands  
3. Royal Tropical Institute (KIT), KIT Biomedical Research, Amsterdam, the Netherlands 
4. Department of Pathology, VU Medical Center, Amsterdam, the Netherlands 
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CASE REPORT  
Case A is a 61 year old HIV positive male who presented with fever and extreme tiredness since 
one week. Additional complaints were myalgia, headache and macroscopic haematuria. On 
physical examination the patient was ill with a temperature of 40 oC, blood pressure 135/84 
mmHg, pulse rate of 82/min and had bilateral flank tenderness. The patient’s medical history 
shows a well regulated HIV status with an undetectable viral load and a repeated deep venous 
thrombosis for which he used acenocoumarol. The patient had not been abroad but recently 
visited his vacation home in the eastern part of The Netherlands. Laboratory values are listed in 
Table 1. Urinalysis showed proteinuria and haematuria. On suspicion of a possible auto-immune 
acute renal failure, antineutrophil cytoplasmic antibodies, antinucleair-antibody and anti-
glomerular basal membrane were determined acutely, which were negative. Empirical 
treatment with antibiotics was started after obtaining blood cultures. While fever and other 
physical complaints resolved after a few days, renal function did not improve initially. Therefore 
a kidney biopsy was performed (Figure 1) which showed a nonspecific acute inflammation with 
lymphocyte invasion and tubular necrosis. However renal function improved soon and the 
patient was discharged. Several days later he visited the outpatient clinic with high fever and 
malaise again. A swollen right leg was present due to a recurrent deep vein thrombosis, after 
anticoagulant therapy was temporarily interrupted for the kidney biopsy procedure. Based on 
the history with high fever and acute renal failure, leptospirosis and hantavirus infections were 
considered. Serology for leptospirosis was negative, but the patient tested positive for the 
presence of IgM antibodies against Puumala hantavirus. In conclusion the diagnosis of 
nephropathia epidemica was confirmed. After a total period of 6 weeks with periods of 
relapsing fever the patient renal function recovered completely. A second serum sample, taken 
six weeks later, showed a seroconversion confirmed by the presence of IgG antibodies against 
Puumala hantavirus.  
 
  
   
 
 
Figure 1. Renal biopsy taken at acute phase of the disease. The biopsy shows a patchy tubulo-
interstitial lymphocytic infiltrate, but no tubulitis A pleomorphic tubular epithelial celles with 
enlarged nuclei (black arrow). Sludging of necrotic epithelial cells in the tubular lumen (open 
arrow) B Cristallyne matter in tubular lumen. C Mitotis of tubular epithelial cells, indicative of 
epithelial repair in acute tubular necrosis. Detail of glomerulus (400x, PAS-methenamine stain). 
Glomeruli were normal, showing well-expanded glomerular capillaries and normal glomerular 
basement membranes, without spikes or irregularities indicative of immune-complex 
depositions. Immune fluorescence was negative for complement (C3, C1q), light chains (kappa, 
lambda), and heavy chains (IgG, IgM, IgA). 
  
Review of the literature on rodent-borne haemorrhagic fever 
Due to increased international travelling and adventurous tourism to regions with conditions 
that are conducive for transmitting diseases, imported infectious haemorrhagic fever has 
become a  serious challenge for clinicians and laboratory research (88;89). Viral and bacterial 
pathogens that cause haemorrhagic fever have the potency to result in fulminant disease, 
accompanied by high mortality. A significant part of these haemorrhagic fevers originate from 
rodents as their reservoir host. For this reason the routes of disease transmission, 
epidemiological patterns and preventative measures overlap significantly. Although outbreaks 
of rodent-borne haemorrhagic fever and imported cases have been increasingly reported 
during the past decade, epidemiological and clinical studies are still scarce for several diseases 
(90;91). The clinical picture of the rodent-borne haemorrhagic fevers, particularly in the early 
phase, is rather non-specific, leading to misdiagnosis and under recognition. The efficacy of 
treatment strategies is mainly based on small groups of patients or case reports, rather than 
randomised control trails. This means that making treatment protocols is more anecdotal than 
evidence based. Vaccines are often unavailable or will not have been approved by the 
authorities. This review summarises the epidemiology, diagnosis and treatment of hantaviruses, 
Leptospira, Lassa virus and New World arenaviruses as the most significant rodent-borne 
haemorrhagic fevers. Knowledge of (local) epidemiology, clinical symptoms and adequate 
diagnostics will aid the clinician in correctly recognising and diagnosing rodent-borne 
haemorrhagic fever in patients. Furthermore, adequate treatment and supportive care, 
preventative measures and new developments are discussed. 
 
Methods 
Citations were retrieved from PubMed and MEDLINE databases and from locally accessible files 
of the KIT Royal Tropical Institute Library Amsterdam, the Netherlands. After thorough 
evaluation we chose the pathogens proven to cause haemorrhagic fever and being directly 
transmitted from rodents to humans (not needing a vector). Databases were searched using the 
search terms “hantavirus”, “Leptospirosis”, “Lassa Fever”, “South-American Haemorrhagic 
Fever”, in combination with “clinical symptoms”, “treatment” and “epidemiology”. Titles, 
abstracts and references were scanned for relevance and implication for clinical settings using 
the following criteria: “epidemiology, clinical symptoms, diagnosis and/or treatment of rodent-
borne haemorrhagic fever pathogens”.  
 
  
Hantaviruses 
Hantaviruses are distributed worldwide. The disease was first reported in Asia and later 
recognised in Europe, and the Americas, and seems to be under-recognised in Africa (54). Two 
known syndromes are caused by hantaviruses: haemorrhagic fever with renal syndrome (HFRS), 
with the milder subtype nephropathia epidemica (NE) and the hantavirus cardiopulmonary 
syndrome (HCPS). HFRS is endemic in large parts of Eastern and Northern Europe and Asia, 
while small clustered outbreaks of HCPS have been reported in North and South America 
(92;93). NE is prevalent in Europe and transcontinental countries like Russia (54). While we 
describe the generally accepted separated hantavirus syndromes recent publications give rise to 
the thought that typical symptoms defining HFRS and HPS can actually be caused by both Old 
and New-World hantaviruses (94). 
 
Transmission and host 
Hantaviruses are spread from infected rodents to humans (95). Transmission occurs through 
the inhalation of aerosols of virus-contaminated faeces or urine. Infection through rodent bites 
via infectious saliva or tissue handling in laboratory settings has also been reported, but is rare 
(95-97). There are at least 54 hantaviruses of which no less than 22 are known to cause disease 
in humans (98). While for some serotypes there is an ongoing debate about their pathogenicity 
in humans like the Tula virus. Each hantavirus seems to be strictly related to one host species, 
or to closely related host species, like the striped field mouse (Apodemus agrarius) for 
Hantaanvirus that causes HFRS in Asia, the bank vole (Myodes glareolus) for the Puumala virus 
(PUUV) that causes mild HFRS/NE in Europe and the deer mouse (Peromyscus maniculatus) for 
the New-World Sin Nombre virus, which is one of the causative agents of HCPS (99-101). With 
the exception of spill-over infection between the reservoirs of Dobrava-Aa and Dobrava-Af 
(102) and in addition to rodents, insectivores; mainly shrews and moles, are a large group of 
natural reservoir hosts for often non-pathogenic hantaviruses (103). Also two different 
hantaviruses have been isolated in Africa from bats. However transmission to humans has not 
yet been proven (104). Humans are a dead-end host and do not seem to shed the virus. 
However, human-to-human transmission has been reported in some hantavirus cases of Andes 
infection and Andes virus antigen has been detected in both the secretory cells of the salivary 
glands as in urine from patients with HCPS (105;106). While PUUV RNA has also been isolated 
from the saliva of HFRS patients raising the question inter-human transmission may occur (107). 
Andes virus seems to have a lower sensitivity to the antiviral effect of human saliva compared 
to other hantaviruses (108). Case reports of hantavirus infections during pregnancy did not 
include vertical transmission (109). The distribution and incidence of hantavirus infections in 
humans depends on the availability and the density of the rodent host. Incidence of PUUV 
caused NE is highest in Fennoscandia but in recent years outbreaks have occurred in Western 
and Central-Europe, in addition to the Balkan area. While in Russia, certain regions close to the 
Volga River PUUV infections are highly endemic. Next to PUUV three other pathogenic 
hantaviruses circulate in Europe being: “Dobrava-Belgrade (with the subtypes Dobrava-Ap, 
Dobrava Af and the milder variant Dobrava-Aa) and Seoul”. Dobrava-Belgrade transmitted by 
the yellow-necked mouse (Apodemus flavicollis), infections are reported from South-East 
Europe with incidence being highest in “Croatia, Slovenia, European Russia, Bosnia-Herzegovina 
and Hungary” while Dobrava-Aa is more restricted to the North-Eastern parts of Europe like the 
Baltic States and Russia (103). Seoul virus infections in humans appear very rare in Europe apart 
from laboratory acquired infections. However there are reports describing detection of Seoul 
virus antibodies in Rattus rattus and Rattus norvegius Belgium, Portugal and France (110;111). 
Hantavirus studies from Africa are limited, however there is evidence for hantavirus circulation 
in West-Africa (Guinea, Cote D’Ivoire). Hantaviruses detected in Africa seem to be closely 
related to other Murinae, Old-world mice and rats, associated hantaviruses (112). Risk factors 
for hantavirus infection are related to the exposure to rodents and the size of the rodent 
population (109;113-116). Presence of rodents or their droppings in and around a home 
significantly increases this risk (117). In addition using rodent traps, visiting forestry areas and 
participating in rural/recreational activities increase the risk of infection (118-122). Other risk 
factors include the handling of firewood, living close to a forest (<50 metres), staying in a house 
which is easy accessible for rodents or re-entering and cleaning a holiday house/cottage after 
the winter (119;122). For both the New and Old-world hantaviruses environmental and 
occupational factors play a role (119;120;122-124). Besides the risk associated with 
occupational exposure, particularly in the military, farming industry, and for forest workers and 
mammalogists/veterinarians, occasional specific outbreaks have been reported in people 
working with rodents in a laboratory setting (125-127). Studies in Europe have shown a 
correlation between smoking and hantavirus infection, possibly due to impaired ciliary activity 
in the respiratory tract facilitating hantavirus infection (120;122;128). The prevention of rodent 
infestation and rodent control seem to be the best way to reduce infection risk (125;129).  
 
Clinical picture and diagnosis 
 
Haemorrhagic fever with renal syndrome (HFRS):  
HFRS is recognisable by the triad of fever, renal failure and haemorrhage. The disease can be 
divided into five phases:  febrile, hypotensive, oliguric, diuretic, and convalescent. HFRS 
patients first develop a flu-like syndrome accompanied with atypical complaints like fever, 
myalgia, headache and flank pain. The hypotensive phase is thought to be the result of 
haemodynamic alterations, due to an impaired vascular tone and increased vascular 
permeability associated with pathological findings of pulmonary oedema and retroperitoneal 
edema (130). Renal failure in HFRS often develops in a late acute stage (131;132). Kidney 
biopsies show a damaged medulla, interstitial oedema and haemorrhage, together with 
cytotoxic T-cell infiltrates and the extravasation of erythrocytes (133). An elevated, left-shifted, 
serum leukocyte count and elevated C-reactive protein (CRP) up to a high level such as in 
bacterial infection, are present. Patients with HFRS may develop serious haemorrhagic 
complications, starting with petechiae, epistaxis and mucosal bleedings and in a later phase 
gastrointestinal bleedings, haematuria and pleural bleedings. More rare haemorrhagic events 
are right atrial haemorrhage (57), spleen haemorrhage (58) or pituitary haemorrhage with 
endocrinal disturbance or even panhypopituitarism (59;60). Coagulation disorders range from 
mild thrombocytopenia to diffuse intravascular coagulation (DIC) (134). An in-depth Korean 
study among HFRS patients showed the prolongation of bleeding time, prothrombin time and 
partial thromboplastin time, together with decreased plasma activity of factor II, V, VIII, IX, X 
(61). 
Depending on the hantavirus species case fatality rates in HFRS vary from 0.1 to 15% in 
hospitalised cases, where patients die due to circulatory and/or renal failure (101). 
Asymptomatic cases occur around five to ten times more frequently than symptomatic cases in 
HFRS (98).  However, this depends on the type of hantavirus and on human factors. Dobrava-
Belgrade is known to be the most pathogenic of the Old-World hantaviruses, whereas Puumala 
causes NE, a milder form of HFRS with CFR of 0.1%. Due to a long incubation time, typically 2-6 
weeks, infections contracted in areas endemic for a particular hantavirus may obscure 
differential diagnosis elsewhere. 
 
Nephropathia epidemica (NE):  
Nephropathia epidemica is considered to be a mild form of HFRS caused by PUUV with a CFR 
below 1% and haemorrhagic manifestations in only about 10% of the symptomatic patients. Up 
to 80% of the infections with PUUV remain asymptomatic. Patients who do develop the disease 
usually present with fever and acute renal failure. Accompanying symptoms are abdominal 
pain, nausea, blurred vision, flank pain and headache. Most patients with NE recover from the 
acute renal failure within 6 months. Follow-up studies have proven an increased hypertension 
risk >10 years post infection (135-139). Respiratory complaints can also arise during NE (140). A 
lung biopsy will show a local immune response with elevated expression of VCAM-1 (141). 
Clinical chemistry may show high serum creatinine and urea, haematuria and proteinuria in the 
acute phase. More than half of the patients presenting with NE show cardiac involvement. This 
varies from abnormalities on the electrocardiogram (t-top inversion) to, in rare cases, 
pericardial effusion (142;143). In severe cases NE patients may develop encephalitis (144) or 
more haemorrhages like petechiae, haematuria or epistaxis (145). Patients infected with PUUV 
showed coagulation activation, marked by an almost 24-fold D-dimer increase (134). Disease 
severity was reported to correlate with plasma IL-6 levels instead of CRP (146). Procalcitonin is 
also elevated in PUUV infections. The broad range in serum procalcitonin in PUUV makes it 
unsuitable to distinguish from bacterial infection. However, there is a correlation between 
procalcitonin and the severity NE (147). The symptoms in children do not differ greatly from 
adults with HFRS/NE (148). However, NE does seem to take a less severe course in children 
(149). 
 
Hanta cardiopulmonary syndrome (HCPS): 
HCPS-causing hantaviruses mainly target the lungs (150;151). HCPS begins with signs of fever, 
myalgia and respiratory symptoms, followed by the acute onset of severe respiratory distress 
(152;153). Clinical characteristics are not specific and are therefore not useful when 
differentiating between HCPS and other diseases. However, the combination of dizziness, 
nausea and the absence of a cough with a low platelet count, low serum bicarbonate and 
elevated haematocrit can be typical of a HCPS case (154). Besides respiratory distress, patients 
with HCPS show a decreased cardiac output and dysrhythmias (151). HCPS is characterised by 
oedema due to endothelial dysfunction instead of severe haemorrhage. Patients could develop 
thrombocytopenia and bleeding complications, but respiratory distress due to oedema is the 
main cause of death. CT images may show thickening of interlobular septa, ground-glass 
opacities, and occasionally small ill-defined nodular opacities (152;153). The acute onset of the 
respiratory distress leads to hypoxia, cardiac insufficiency, high intubation rates and a need for 
inotropics (117;155). Case-fatality rates vary from 30-60% in hospitalised cases (117;155;156). 
However, recent studies have shown that extracorporeal membrane oxygenation (ECMO) 
seems to drastically decrease mortality rates in HCPS (157). Histopathological examination of 
the lungs shows interstitial and alveolar oedema, sporadic alveolar haemorrhage, and mild 
interstitial pneumonia (158). The clinical picture in children does not seem to differ from that in 
adults with hantavirus cardiopulmonary syndrome (159). 
 
Hantavirus disease 
Recent papers debate the absolute difference between HFRS and HCPS hantavirus syndromes. 
It seemed in many cases that symptoms overlap and HFRS cases presented with acute 
respiratory failure without signs of kidney involvement while  HCPS patients may show renal 
complications (160). Therefore it is suggested to use the term “”hantavirus disease” for all 
hantavirus related described syndromes.  
    
Diagnostics 
Since almost all acute cases have IgM and IgG antibodies against the nucleocapsid protein of 
hantaviruses, serological diagnostics are most commonly used for verifying hantavirus infection 
using indirect IgG and IgM enzyme-linked immunosorbent assays (ELISA), IgM capture ELISAs or 
immunofluorescence assays (IFA) (54;151;161). A high level of cross reactivity exists in 
hantavirus serology. Cross reactivity occurs within the group of Serotype 1 “Dobrava-Belgrade 
virus, Saaremaa virus, Seoul virus and Hantaan virus” and within the Serotype 2 group 
“Puumala virus, Tula virus, Topografov virus and Sin-Nombre-like viruses” (162). Because of this 
high level of cross reactivity, a focus reduction neutralisation test (FRNT) remains the gold 
standard in hantavirus serology. However, neutralising antibodies are not yet produced in the 
acute phase of infection. More recently, a replication reduction neutralisation test (RRNT), 
which is based on a quantitative RT-PCR technique, showed promising results in efficiently and 
rapidly detecting hantavirus-neutralising antibodies (163). PCR can be performed on blood and 
serum samples during the first days after the onset of the symptoms. One-step RT-PCR assays 
for hantavirus detection showed high sensitivity and specificity (98;164). However, the 
molecular diagnosis of acute infections can be difficult, since the viraemic stage is often limited 
to the incubation period prior to the onset of the symptoms and shortly afterwards (165). Rapid 
immunochromatographic IgM-antibody diagnostic tests have been evaluated in different 
studies. Hujakka et al. found a 96-100% sensitivity and specificity for the specific immunoassays 
developed for Dobrava, Puumala and Hantaan hantaviruses. Combined rapid tests are less 
sensitive (166).   
 
Treatment 
In HFRS the initiation of prompt and proper supportive treatment is crucial. This support 
comprises measures such as monitoring fluid balance, diuresis, kidney function and the use of 
FFP/transfusions in the treatment of haemorrhagic complications (167;168). Ribavirin 
treatment can be useful in the very early phase of HFRS by reducing the risk of haemorrhagic 
events and the severity of renal insufficiency (169-171). Treatment with interferon only inhibits 
the virus in-vitro, while adjunctive prednisolone treatment showed no beneficial outcome 
(172;173). An open-label trial and a double-blind clinical trial only showed the adverse effects 
of the ribavirin treatment in HCPS, but no beneficial effects (174);(175). For the time being, the 
treatment of HCPS will mainly depend on critical care management which includes the 
avoidance of fluid overload, vasopressors to maintain cardiac output, and the use of 
extracorporeal membrane oxygenation in severe cases (98;175;176). Trials in Asia have shown a 
promising reduction of HFRS, with conventional and molecular vaccines, but these have not 
been approved by the responsible authorities (177;178). Problems for developing a European 
vaccine arise from the different circulating serovars (177;178). No vaccine for HCPS has been 
tested in humans so far, but it is believed that individuals surviving a hantavirus infection 
develop lifelong immunity (177;178).   
 
 
Figure 3. Global distribution of the rodent-borne haemorrhagic fever pathogens. Knowledge 
of the global distribution is important for clinicians. For instance travelers returning from South 
America may be infected with the SAHF viruses, HCPS viruses and Leptospira, whereas Lassa 
fever or NE would be considered highly unlikely. Leptospirosis, not added in this figure, occurs on 
every continent, with higherincidence in (sub)tropical areas. 
 
Leptospirosis 
Leptospirosis has been recognised as an emerging infectious disease with severe repercussions 
all over the world. Large outbreaks are closely related to heavy rainfall and flooding. The global 
incidence of endemic leptospirosis has been estimated at 5 per 100,000 head of population and 
that of epidemic leptospirosis at 14 per 100,000 (Report of the Second Meeting of the 
Leptospirosis Burden Epidemiology Reference Group, World Health organization, 2011, Geneva). 
Incidence rates are the highest in tropical areas such as southern Asia and South America 
(179;180). The disease has also emerged as an illness that impacts adventure tourists, especially 
those who participate in water sports. Incidence rates may vary due to the difficult diagnosis of 
leptospirosis and unfamiliarity, and the fact that incidence rates can vary significantly per year 
(88;179).    
 
 
 
Transmission and host 
Pathogenic Leptospira enter the environment through the shedding of bacteria via the urine of 
chronically infected hosts (181;182). Two different transmission routes are described: a) 
indirectly, through contact with infected water or soil, which is probably the main route for 
most serovars, and b) directly, through contact with infected animal urine or tissues (183;184). 
Different hosts can carry Leptospira serovars (185;186). Rodents and insectivores, particularly 
rats, are thought to be the major carrier-animals , but dogs, pigs, cattle and horses are also 
considered to be reservoirs. Infected rodents stay asymptomatic and are thought to chronically 
shed Leptospira (182). Infection through abraded skin in humans seems to be the most 
common portal of entry (187-189). However, infection can also occur after contact with 
exposed mucous membranes of the nose, mouth and eyes (189;190). The presence of 
Leptospira in mesenteric lymph nodes in autopsy studies is suggestive for an oral transmission 
route for leptospirosis (188). Infections with Leptospira are reported from all over the world. 
The infection risk most frequently correlates with rainfall, flooding, soil saturation and stagnant 
water pools on walking paths (182;191-193). Walking barefoot or living close to a sewer or 
trash belt also increases the risk of infection. Moreover, the incidence in many regions is at its 
highest during the rainy season. Outbreaks are seen after natural disasters like flooding and 
hurricanes (194). Rural and jungle areas in particular seem to provide the environmental 
conditions that are the most conducive for the survival and transmission of leptospires. 
However, urban leptospirosis occurs in areas with high rodent densities like city slums 
(195;196). The incidence is the highest in resource limited settings in Asia, South-America and 
probably Africa however data is limited. In Europe the highest incidence rates are reported 
from European part of Russia, Croatia and Ukraine (Pappas et al. 2008). Studies show a higher 
infection incidence in men, and this is the highest in men of working age (20-60 years old). This 
observation is probably due to occupational risk factors (197;198). During the past decades, 
recreational exposure is a factor of growing importance (199). Recreational activities related to 
leptospirosis infection include water-related activities such as canoeing, rafting and swimming 
(200-203). Indeed, outbreaks after sports events, mainly sports which includes water contact 
like triathlon or rafting, have been reported (188;200;204). There are reports of adventure 
tourists who were infected after jungle tracking or cave exploring, or a specific occurrence of 
wading through small streams in a mangrove forest in Malaysia(205;206). 
 
Clinical picture and diagnosis 
The presentation of patients with acute leptospirosis can vary greatly (182;207). Infections 
often remain asymptomatic or patients will develop a mild disease. Acute leptospirosis usually 
presents with one or more of the following symptoms: a fever of sudden onset, chills, 
headache, severe myalgia, conjunctival suffusion, anorexia, nausea, vomiting, and prostration 
(179). Severe disease is rapidly progressive with a high case-fatality rate. The classic triad of 
icterus, kidney failure and haemorrhagic diathesis is often recognised as Weil’s disease (208). 
However, atypical presentation of severe disease constitutes an important pitfall. The icterus 
seen in leptospirosis seems to be the result of a septic cholestasis instead of acute hepatitis. 
Indeed, liver function tests are only mildly impaired during acute disease. Severe leptospirosis 
can cause life threatening bleeding complications. There is evidence that both an impaired 
primary- and secondary haemostasis play roles. Primary haemostasis is impaired, due to 
thrombocytopenia, which frequently occurs during leptospirosis infection (209). Furthermore, 
patients with severe leptospirosis often have a prolonged activated partial thromboplastin time 
(APTT) and raised thrombotic markers like D-Dimer and Prothrombin up to DIC, according to 
the International Society on Thrombosis & Haemostasis criteria (207). Despite these 
disturbances in primary and secondary haemostasis there seems to be a role for endothelial cell 
dysfunction in leptospirosis. In vitro pathogenic Leptospira interfere with the endothelial cell 
barrier function (210).  A severe form of bleeding disorders in leptospirosis is the Leptospirosis 
Associated Pulmonary Haemorrhage Syndrome (LPHS). This syndrome is a major cause of 
haemorrhagic fever in developing countries, causing a fulminant presentation with heavy 
pulmonary bleeding and mortality ranging up to 75 or 80% (211;212). Symptoms are coughing, 
haemoptysis, often recognised at a late stage after intubation, and in around 50% of the cases 
there is a patchy infiltration seen on X-thorax. Based on clinical symptoms, leptospirosis is hard 
to distinguish from other endemic pathogens. During several outbreaks leptospirosis has often 
been under-recognised and misdiagnosed with, for example, dengue fever. CRP is elevated in 
acute phase of severe leptospirosis. Furthermore, there are some promising studies about 
experimental markers (soluble ST-2, long pentraxin-3 (PTX3) and procalcitonin) (213-215).  
 
Diagnostics 
The gold-standard test is the Microscopic Agglutination Test (MAT). This test requires a dark-
field microscope to determine agglutination titres (216-218). Because leptospirosis antibodies 
are formed 5 to 7 days after the onset of the disease, MAT is particularly accurate in its later 
phases (216;217).  Paired serum testing is necessary to determine seroconversion or a 
significant rise in titre. MAT titres can be indicative for infecting serogroups. However, the MAT 
is laborious, expensive and needs highly trained personal, so it can only be performed in 
specialised laboratories. The results of an MAT may be compromised by background titres in 
patients from endemic regions and cross-agglutinating antibodies (212;217;219). A combination 
of MAT with Enzyme-linked immunosorbent assay (ELISA) for the detection of IgM antibodies 
against Leptospira increases sensitivity (218;220). PCR is useful in the first 5 days of the disease 
and a validated RT-PCR is available (216). Cultures are usually not used for clinical practice but 
they do have relevance for the identification of reservoir hosts and epidemiological studies and 
they can be retrieved from blood and CSF fluids before the tenth day of the illness. Usually 
urine cultures can be positive after the seventh day of the disease (218;221). There are multiple 
rapid tests for leptospirosis diagnostics. For example, antibody-coated gold nanoparticles for 
the early detection of Leptospira in urine has proven highly sensitive and relatively cheap way 
of early diagnosis compared to PCR (217). Latex-based agglutination rapid tests show a 
sensitivity of around 70% in the early phase of the disease, becoming even more sensitive later 
(222). Immunochromotography-based rapid tests based on crude antigen, if properly used, can 
show good sensitivity (223). However, in endemic regions, due to high seroprevalence, such a 
format can have a limited value (224).  
 
Treatment 
Treatment with penicillin G results in lower morbidity and causes no harmful side effects in 
acute leptospirosis. The treatment is most effective during the first five days after symptom 
development (225). However, most cases still develop severe disease either due to late start of 
treatment or treatment failure. Doxycycline has been proven to be an alternative to penicillin, 
although it is prescribed for mild cases (226). Prophylactic doxycycline reduces severe 
complications of leptospirosis and symptomatic disease. However, there is a debate as to 
whether it prevents infection or only affects the severity of the disease (88;227). The side 
effects of a weekly 200mg oral dosage of doxycycline should be taken into account (227;228). 
The treatment of icteric leptospirosis and LPHS is more complicated and should be restricted to 
tertiary centres, if available (229). In these severe forms of leptospirosis supportive care is often 
necessary (229;230). Besides mechanical ventilation, inotropic therapy and renal dialysis, 
treatment of the bleeding disorders can be considered with fresh frozen plasma (FFP) and 
thrombocyte transfusions. 
 
  
Lassa Fever 
Lassa fever affects two to three million people in West Africa annually, with an estimated CFR of 
15-20% in hospitalised cases. It was first described in 1969 in Lassa, a town in northeast Nigeria, 
as causative agent of a haemorrhagic fever causing fulminant disease. Although only 20-30 
imported cases to Europe are described, most of them were fatal, mainly due to lack of 
awareness of the risk, delay in diagnosis and delay in initiation of therapy (231). While 
nosocomial transmission often occurs in West Africa, imported cases of Lassa  in-to Europe have 
never shown human-to-human transmission in hospital settings, with the exception of 
seroconversion in a healthcare worker in 2003 (232). Lassa fever is endemic in Guinea, Sierra 
Leone, Nigeria, Liberia and Ivory Coast. The disease also occurs in Ghana, Senegal, Togo, Benin, 
Mali and Burkina Faso.(233-236) The disease is caused by the Old-World arenavirus Lassa; an 
enveloped, single-stranded, bi-segmented RNA virus (237). The virus has a small and a large 
genome segment. Four lineages are identified: Josiah (Sierra Leone), GA391 (Nigeria), LP 
(Nigeria) and strain AV, which was isolated when imported into Germany and is closely related 
to Josiah (231;238). 
 
Transmission and host 
Lassa virus is restricted to one host, the African multimammate rat (Mastomys natalensis), 
other Mastomys species do not seem to shed the virus (239). This rodent breeds frequently, 
produces large numbers of offspring and is distributed widely throughout west, central, and the 
eastern parts of the African continent (240). Mastomys natalensis is a commensal rodent, 
readily colonising human settlements, thereby increasing the risk of rodent-human contact. 
When infected, these rodents carry and excrete the virus lifelong. Human infection occurs after 
inhalation of aerosolised excreta (often urine), consuming contaminated foods or by direct 
contact with abraded skin (237;241). Human-to-human transmission occurs through direct 
contact with blood or bodily secretions from infected persons. Living close to someone who had 
signs of infection in the past 12 months, was associated with almost a twofold infection risk in 
Guinea (242). Working in a hospital or laboratory without proper hygiene precautions also 
increases the risk of infection (243;244). These findings confirm the need for barrier nursing 
techniques and strict hygiene measures (245). Other risk factors include activities that increase 
rodent contact, such as poor housing conditions and rodent infestation (246). An exacerbating 
factor is that the multimammate rat is a known delicacy and food source in West Africa. 
Hunting them and consuming their meat is therefore a considerable risk factor (247). 
 
Clinical picture and diagnosis 
About 80% of patients infected with the Lassa fever virus will develop subclinical or mild 
disease. After the incubation period of 1 to 3 weeks patients first develop a high fever, general 
weakness and malaise. These symptoms occur typically 4-7 days upon the onset of disease 
followed by a typical pharyngitis (with yellow-white patches) and more non-specific symptoms 
such as headache, back-, chest- or abdominal pain, nausea and vomiting, diarrhoea, 
conjunctivitis, coughing and proteinuria (248-250). In endemic areas, the best discriminating 
symptoms in this early phase seem to be the combination of proteinuria and pharyngitis 
(160;161). When progressing into the next stage (after 7 days), clinical hallmarks typically 
include a facial oedema, neurological disorders, such as convulsions and encephalopathy and 
bleeding. Haemorrhagic manifestations vary from mucosal bleedings (gums, nose eyes) to 
severe internal bleeding from the stomach, bowel, kidney, brain and heart. These conditions 
only occur in one third of the patients and are associated with death (244;251). There are no 
data supporting evidence for a DIC in severe Lassa, since coagulation markers are almost always 
within normal range. Haemorrhage seems to be the result of endothelial cell dysfunction 
induced by a direct or indirect toxic effect on the endothelial cell by the virus and by 
inflammatory proteins (cytokines). Indeed, post-mortem findings show a generally damaged 
vascular endothelium, characterised by oedema in the submucosa, subcapsular haemorrhages 
in the liver, haemorrhage and oedema in the myocardium, gross oedema in the intestine and a 
focal pneumonitis (248);(252). There is some evidence that a diminished primary haemostasis 
may add to the haemorrhagic diathesis since acute-phase plasma from Lassa fever patients 
show the inhibition of APD, collagen and sodium-arachidonate-induced platelet aggregation 
(241). Moreover, plasma derived from patients with Lassa fever inhibits aggregation and 
thromboxane generation in normal platelets (253). In this stage with severe haemorrhages, 
shock and sometimes encephalitis, CFR increases to 38-52% (254;255). Patients may die in the 
late stage (>14 days) from shock and respiratory distress due to pleural effusion, possibly 
complicated with haemoptysis. When patients recover, deafness, hair loss and long-term 
psychiatric complications are reported (251;254). 
 
Diagnostics 
The first choice of diagnostics is an ELISA detecting anti-Lassa IgM and/or IgG antibodies (256). 
ELISA has shown sensitivity up to a 100% in experimental settings (256;257). Due to a persistent 
high viraemia for at least 10-15 days, PCR techniques are useful during a prolonged time in 
Lassa infection. Viral RNA has been isolated from patients’ semen up to three months post 
infection (258).  However, due to a high sequence diversity (up to 30%) between Lassa virus 
strains false negative results cannot be excluded (257).  
 
Treatment 
Ribavirin is considered effective in Lassa fever (251;259).  The treatment is effective in any stage 
of the disease (259;260). A ten-day dosage of 15 mg per kg bodyweight in acute disease was 
shown to effectively decrease mortality, CFR and morbidity (261). The treatment should start as 
soon as possible, preferably in the first six days of the disease. Intravenous therapy has a better 
clinical outcome than oral ribavirin (251;261). Ribavirin was also proven useful as a high-risk 
post-exposure prophylaxis (PEP). A dose of 800 mg, once a day, proved to be as effective as PEP 
in a small cohort (n=23) from Liberia (262).  
Despite the availability of antiviral treatment additional supportive care is often needed. Fluid 
replacement and blood transfusions, in particular, may be necessary (263;264). No vaccination 
is available yet but there are promising results with a replication-competent vaccine expressing 
the Lassa virus glycoproteins (265).  
 
South-American haemorrhagic fevers (SAHF) 
Isolated in 1958, the Junin virus (JUNV) was held responsible for a severe haemorrhagic 
syndrome that caused dengue-like symptoms in a clustered outbreak in Argentina. Argentinean 
haemorrhagic fever (AHF) is endemic in a limited area in the Pampas in Argentina. Outbreaks 
occur from March to June. Its incidence sharply decreased after the availability of an effective 
vaccine and neutralising antibody treatment (266;267). JUNV was the first of the New World 
arenavirus to be discovered. Other SAHF viruses include: Machupo, the causative agent of 
Bolivian haemorrhagic fever (BHF), Guanarito, the causative agent of Venezuelan haemorrhagic 
fever (VHF), and Sabia virus, the causative agent of a haemorrhagic fever case in Brazil. These 
New World arenaviruses are, in general, confined to certain areas and rodent-host species. VHF, 
whose causative agent Guanarito virus was  isolated in 1989, occurs in a rather well defined 
area in central Venezuela and peaks every year during harvest season (from November to 
January) (268). The causative agent of BHF, the Machupo virus, was isolated in 1964 after an 
outbreak with severe haemorrhagic disease with a CFR around 20%. This disease can also have 
outbreaks in rural areas, often related to agricultural work taking place during the dry season 
(from May to October). 
  
Transmission and host 
Transmission is thought to occur in a similar way to hantavirus and Lassa disease, i.e. through 
infective aerosols (266;267). Person-to-person transmission and nosocomial infections have 
been described for BHF (91;267). The main natural reservoirs of Junin virus (AHF) in Argentina 
are the dry land vesper mouse (Calomys musculinus) and the small vesper mouse (Calomys 
laucha). For the Machupo virus this is the large vesper mouse (Calomys callosus) and for 
Guanarito virus the short tailed zygodont (Zygodontomys brevicauda). The Sabia virus has only 
been related to one human case of the disease and the natural reservoir is, as yet, unknown 
(267;269). Risk factors are mainly linked to agricultural work and rodent-infested villages. Adult 
male agricultural workers are mostly at risk, but children and other adults of both sexes can 
also contract the disease. Despite several laboratory infections there are no reports of SAHF 
cases outside of the SAHF endemic areas. As the incubation periods for SAHF vary from 7-14 
days, travel-related import to non-endemic countries might occur (90). 
 Clinical picture and diagnosis 
After an incubation period of 7-14 days patients with AHF, BHF and/or VHF first develop a non-
specific flu-like syndrome. Other symptoms include coughing, prostration, abdominal pain, 
lumbar and muscle pain, severe headache, conjunctival injection, facial flushing, and 
generalised lymphadenopathy (268;270;271). Compared to Lassa, patients with SAHF have a 
higher tendency to develop serious neurological signs, such as encephalitis and cranial 
haemorrhages. Haemorrhagic complications consist mainly of petechiae, conjunctival 
haemorrhages, mucosal bleeding and gastrointestinal bleeding with melena. Bleeding normally 
starts after five days of illness. Laboratory results show thrombocytopenia, leukocytopenia and 
alterations in coagulation markers (e.g. prolonged partial thromboplastin time) (272). The 
increased bleeding tendency is thought to be related to both impaired primary haemostasis 
(thrombocytopenia and impaired platelet function) and secondary haemostasis (267;273). In 
AHF a prothrombotic phenotype is seen with elevated procoagulant markers (D-dimer), 
thrombin-antithrombin complexes (TAT) and thrombin fragment 1 and 2 (F1+F2). A raise in 
serum PAI-1 indicates inhibition of fibrinolysis in severe cases (274). The role of vascular 
endothelium dysfunction in SAHF has been studied in vitro. The up-regulation of ICAM-1 and 
VCAM-1 expression on Junin-virus-infected endothelial cells, the increased production of nitric 
oxide and prostaglandin PGI2 and the reduced production of coagulation factors (e.g. von 
Willebrand factor) are shown in vitro (273).  
Early diagnosis in SAHF is possible by RT-PCR as patients show viraemia for 5-10 days after the 
first symptoms. Molecular detection has proven to be sensitive in the early phase of AHF (a 
sensitivity of 98% and a specificity of 76%) (275). The gold-standard test is a proven 
seroconversion by ELISA or IFA using paired sera. Antibodies against the highly conserved 
nucleocapsid proteins (NP) of New World arenaviruses are commonly used for virus detection 
because the SAHF viruses occur very locally. However, this cross reactivity could be a limitation 
in diagnosing a returning traveller who visited multiple SAHF endemic areas.   
 
Treatment 
During the first eight days of the disease AHF can be treated with immune plasma containing 
high titres of neutralising antibodies (276). Also, Ribavirin can be effective in AHF as in the other 
SAHF (277-279). Further treatment should consist of supportive care regarding blood loss in 
haemorrhagic events and adequate handling of neurological complications such as seizures. An 
effective live-attenuated vaccine is available for AHF (280). 
 
 
 
 
Co-Infections 
The rodent-borne haemorrhagic fevers share several characteristics including areas of 
endemicity, transmission pathways and the majority of their clinical symptoms. Therefore, the 
possibility of co-infection with multiple rodent-borne pathogens can’t be excluded in 
differential diagnostics. However, reports on such co-infections are very rare. Two Reports from 
Croatia describe double infections with both Leptospira and a hantavirus in humans 
(281;282).  Interestingly both pathogens have been isolated from the same reservoir rodent, 
namely Apodemus flavicollis (Dobrava-Belgrade and Leptospira) and from a Myodes glareolus in 
Croatia (Puumala and Leptospira) (283;284). Co-infecitons between other rodent-borne 
haemorrhagic fever pathogens have not been reported. There are also reports describing co- 
and multi-infections with Leptospira and other pathogens such as dengue virus, malaria 
parasites, hepatitis A and E virus, Orientia tsutsugamushi, Toxoplasma gondii, Babesia and 
Francisella tularensis in humans and/or non-human reservoir species (284-291).The possibility 
of multiple pathogens in one patient can be both of clinical and diagnostic importance. Case 
reports showed more severe disease in co-infected patients and sometimes the occurrence of a 
co-infection warrants changes in treatment (290;292). Co-infections between Hanta and Lassa 
fevers have not been reported. However outbreaks of these viral diseases have poorly been 
investigated for the occurrence of co-infections. While in the Guinean Forests of West-Africa, 
an ecological very diverse region reaching from Guinea and Sierra Leone eastward to 
Cameroon, serological evidence is present both the Lassa virus infections as infections with the 
Sangassou hantavirus (SANV) (293).  
Figure 4. Routes of transmission in rodent-
borne haemorrhagic fever. Transmission of 
Rodent Borne haemorrhagic fever causing 
pathogens can occur directly via aerosol 
inhalation (hanta, Lassa, SAHF) or contact 
with skin and mucosa (leptospirosis). 
Furthermore indirect transmission is possible 
by non-rodent animals (often in 
leptospirosis). Birds do not seem to play a 
role in transmission routes of leptospirosis. 
Hantaviruses and the newand old-world 
arenaviruses were thought to be restricted to 
rodent reservoir hosts. However, 
hantaviruses have also recently been isolated 
from insectivores and African bats, although 
transmission to human has not been proven 
yet.  
Concluding remarks 
The rodent-borne haemorrhagic-fever pathogens belong to an important group of zoonotic 
diseases causing severe disease all over the world. Since the diseases described in this review 
share many common clinical symptoms and laboratory markers, and to some extent show an 
overlap in their geographic distribution, accurate diagnosis depends on the availability of 
sensitive and specific testing and high-level clinical practice. Rodent control, proper education 
aimed at avoiding contact with rodents or rodent excreta and the development of vaccines can 
decrease infection rates, such as in AHF. However, for these preventive measures to be 
effective, thorough knowledge of the pathogens, and particularly their specific rodent hosts, is 
necessary. Changes in climate and human behaviour (particularly land use) are predictors for 
the distribution of cases or outbreaks of rodent-borne pathogens outside their current areas of 
endemicity (294). The challenge lies in the timely recognition of the disease, followed by 
adequate risk management.  Knowledge of the clinical picture, epidemiology (including rodent 
ecology) and pathogenesis of these diseases are vital if we are to decrease morbidity and 
mortality (295). Proper knowledge of their epidemiology facilitates the choice of adequate 
diagnostics for the right pathogen.  
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Abstract 
 
“Leptospirosis and haemorrhagic fever with renal syndrome (HFRS) are hard to distinguish 
clinically since these two important rodent-borne zoonoses share hallmark symptoms such as 
renal failure and haemorrhage. Leptospirosis is caused by infection with a spirochete while HFRS 
is the result of an infection with certain hantaviruses. Both diseases are relatively rare in the 
Netherlands. Increased incidence of HFRS has been observed since 2007 in countries that border 
the Netherlands. Since a similar rise in incidence has not been registered in the Netherlands, we 
hypothesise that due to overlapping clinical manifestations, hantavirus infections may be 
confused with leptospirosis, leading to underdiagnosis. Therefore, we tested a cohort of non-
travelling Dutch patients with symptoms compatible with leptospirosis, but with a negative 
diagnosis, during 2010 and from April to November 2011. Sera were screened with pan-
hantavirus IgG and IgM enzyme-linked immunosorbent assays (ELISAs). Sera with IgM reactivity 
were tested by immunofluorescence assay (IFA). ELISA (IgM positive) and IFA results were 
confirmed using focus reduction neutralisation tests (FRNTs). We found hantavirus-specific IgG 
and/or IgM antibodies in 4.3% (11/255) of samples taken in 2010 and in 4.1% (6/146) of the 
samples during the 2011 period. After FRNT confirmation, seven patients were classed as having 
acute Puumala virus infections. A review of hantavirus diagnostic requests revealed that at least 
three of the seven confirmed acute cases as well as seven probable acute cases of hantavirus 
infection were missed in the Netherlands during the study period”. 
 
Introduction 
 
Hantaviruses, negative-stranded RNA viruses belonging to the Bunyaviridae family, can cause 
severe disease in humans. Depending on the type of hantavirus, either haemorrhagic fever with 
renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome may occur after inhalation of 
virus-containing aerosols (296). HFRS is characterised by acute renal failure, fever (above 38.5 
°C) and potentially accompanied by severe bleeding complications (98); it is a notifiable disease 
in the Netherlands. HFRS cases are found in large parts of Europe and Asia (297). Pathogenic 
hantaviruses are rodent-borne and each of these viruses are spread by a specific rodent 
species. For the HFRS-causing hantaviruses, these include Apodemus, Myodes, Rattus and 
possibly Microtus species (298). The causative agent of HFRS known to be endemic in the 
Netherlands is Puumala virus (PUUV), which is spread by its chronically infected reservoir, the 
bank vole (Myodes glareolus) (299). Symptomatic cases of PUUV infection may develop mild 
HFRS, often referred to as nephropathia epidemica. Recent reports describe PUUV infections 
with a broader clinical spectrum, ranging from mild febrile cases, without renal impairment or 
haemorrhage, to severe respiratory manifestations without any signs of renal involvement 
(300;301). Historically, the occurrence of PUUV infection in the Netherlands has been restricted 
to the eastern and southern parts of the country, with an incidence of 6–30 cases reported per 
year (approximately 0.04–0.18 cases per 100,000 population) (302). Since 2007, several studies 
have described an increase in the number of human PUUV infections in neighbouring countries 
at the eastern (Germany) and southern borders (Belgium) (303;304). To date, a similar increase 
in the number of human PUUV infections has not been observed in the Netherlands.  
In the early 1990s, Groen et al. tested 8,892 sera obtained in the Netherlands from different 
risk groups, such as renal disease patients, and subjects from suspected occupational risk 
groups, such as forestry workers and military personnel, for the presence of hantavirus 
antibodies (305). The highest prevalence (up to 6%) was seen in participants with known 
occupational risk factors associated with increased rodent exposure (299;305). Data (which are 
as yet unpublished but a summary of the main results is available) from a large serum bank 
study in the Netherlands that started in 2006 showed a hantavirus seroprevalence, in a cross-
sectional population based study, of 1.7% (306). Given that 70–80% of PUUV infections are 
asymptomatic and that only 5–10% of symptomatic patients will probably seek medical 
attention , the 25–30 cases reported every year in the Netherlands (with a population of 16.8 
million) are indicative of potential underdiagnosis of hantavirus infections (299;307). In 2011, 
we described a case report of a patient with nephropathia epidemica diagnosed outside the 
area known to be endemic for hantavirus circulation in the Netherlands, Overijssel  (308). 
Although the patient had visited a known PUUV-endemic area, this information in the patient 
history did not result in rapid diagnosis of the cause of the disease, illustrating unawareness of 
hantavirus infections. 
 Leptospira, a genus of helical-shaped bacteria, forms another important group of causative 
agents of rodent-borne haemorrhagic fever in the Netherlands (309). Pathogenic Leptospira 
cause leptospirosis, which shares many clinical manifestations with HFRS, such as renal failure, 
thrombocytopenia and potential bleeding complications (297). Interestingly, two studies, from 
Italy and Sri Lanka, showed an increased hantavirus seroprevalence in patients suspected of 
having leptospirosis. Compared with control groups consisting of office personnel or healthy 
blood donors, the number of confirmed cases of hantavirus infection was significantly higher 
among those who were clinically suspected, by a clinician, of having leptospirosis (310;311). 
Groen et al. reported a hantavirus seroprevalence of about 1% in patients suspected of having 
acute leptospirosis in the Netherlands in samples collected between 1972 and 1994. The actual 
prevalence of confirmed acute leptospirosis was slightly higher (3%) (305).  
In the Netherlands, a relatively low number of leptospirosis cases are registered annually, as are 
HFRS cases, with a reported incidence of 0.25 leptospirosis cases/100,000 population (309). To 
investigate the putative underdiagnosis of hantavirus infection in symptomatic patients, we 
tested a cohort of leptospirosis-suspected, but confirmed-negative, patients with no travel 
history for the previous three months, for the presence of hantavirus-specific antibodies, using 
a two-step strategy: pan-hantavirus enzyme-linked immunosorbent assays (ELISAs) followed by 
two separate immunofluorescence assays (IFA): one to detect PUUV serogroup antibodies and 
one to detect  Hantaan virus (HNTV) serogroup antibodies (HNTV was used as it belongs to the 
same serogroup as Seoul hantavirus (SEOV). Recent evidence indicates the circulation of SEOV 
in Europe (312-314), spread by Rattus norvegicus, which is also a well-known carrier of 
Leptospira (297).  To confirm the ELISA and IFA results, focus reduction neutralisation tests 
(FRNTs) were used, the gold standard technique in hantavirus serology. All IFA IgM-positive sera 
were tested in the FRNT with PUUV virus. In addition, because recent evidence indicates the 
circulation of SEOV in Europe, we included SEOV, as well as Dobrava virus (DOBV), in the FRNT, 
although not the main aim of this study, to gain insight into the potential introduction of these 
viruses in the Netherlands.  
 
  
Methods 
 
Serum bank 
Sera from non-travelling Dutch patients with a 
negative leptospirosis diagnosis – based on a 
microscopic agglutination test (MAT), ELISA and 
culture performed at the National Leptospirosis 
Reference laboratory (NRL) at the Royal Tropical 
Institute (KIT) in Amsterdam – were included in our 
study. A sample was deemed to be negative for 
leptospirosis if the patient did not meet the case 
definition for leptospirosis – i.e. the in-house ELISA 
for leptospirosis was below the cut-off titre of 1:80 
and the MAT showed no relevant titre of Leptospira-
specfic antibodies (<1:160) (315). The study cohort 
was taken from submissions of sera to the NRL in 
2010, as a large increase in the number of PUUV 
infections in Germany and Belgium were observed 
that year (298). In addition, we also included sera 
from patients meeting the above inclusion criteria 
that were received by the NRL during April to 
November 2011, the season for PUUV activity in 
northern and western Europe (316) (Figure 1).  
 
Figure 1. Design, inclusion criteria and confirmatory 
steps of the hanta hunting study, the Netherlands, 
2010 and April–November 2011 
 
 
As we were interested in patients who had pan-
hantavirus IgM antibodies, we selected patients 
whose samples had been collected at least two days after symptom onset, up to four weeks (28 
days) after symptom onset. All samples were heat inactivated (30 minutes at 56 °C) and stored 
at −20 °C until testing. Requests for leptospirosis testing were accompanied by a standardised 
form with information about place of residence, travel history, presenting symptoms and 
occupation: these data were reviewed.  
 
Hantavirus underdiagnosis was assessed by checking if testing for hantavirus was requested at 
either of the hantavirus diagnostic laboratories in the Netherlands (Erasmus MC in Rotterdam 
and RIVM in Bilthoven) for any of the pan-hantavirus ELISA-responsive sera (equivocal or 
positive result in an IgG or IgM ELISA).  
 
Patients whose sera were responsive in any of the diagnostic tests were ranked by likelihood of 
hantavirus infection. Patients whose sera were positive in the IgM ELISA, IFA and FRNT were 
considered a confirmed case of acute hantavirus infection. If only the IgM ELISA was positive (or 
equivocal) and IFA was positive, the patient was considered a probable acute case.  If only the 
IgG ELISA was positive and therefore IFA was not performed, but the FRNT was positive for 
PUUV, the patient was also considered a probable acute case. If only the IgM ELISA was positive 
or equivocal, the patient was considered not a case of hantavirus infection. 
 
Enzyme-linked immunosorbent assay 
Sera were screened using pan-hantavirus IgG and IgM DxSelect ELISAs (Focus Diagnostics). 
These ELISAs are used for testing a broad range of hantaviruses, although there are variations in 
sensitivity and specificity per specific hantavirus. According to the material supplied by the 
manufacturer, the IgM test has an overall sensitivity of 95.1% (83.5–99.4%) and a specificity of 
94.1% (83.8–98.8%). The IgG test has comparable performance characteristics, with an overall 
specificity of 95% (91.4–100%) and a sensitivity of 95% (75–98%); both tests are compared with 
a reference ELISA by external investigators. For the Netherlands, the performance of these 
ELISAs in detecting antibodies to PUUV and, potentially, SEOV, is of importance. Data supplied 
by the manufacturer showed a sensitivity of 70% (45.7–88.1%) in the IgM ELISA and 95% (83.2–
100%) in the IgG ELISA for PUUV-specific antibodies, as tested by FRNT. For SEOV FRNT-positive 
samples, the sensitivity was 50% (11.8–88.2%) in the IgM ELISA and 95% (54.1–100%) in the IgG 
ELISA.  An optical density (OD) of > 1.10 was regarded as positive, between ≥0.90 and ≤1.10 as 
equivocal and <0.90 as negative.  
 
Immunofluorescence assay 
ELISA IgM-positive or equivocal sera were tested in IFA by using commercial slides with PUUV- 
and HNTV-infected cells (PROGEN Biotechnik). Only IgM-reactive samples were chosen as these 
are indicative of a recent infection, possibly related to the clinical symptoms that were the basis 
of the initial request for leptospirosis testing. IFA was used because of its higher reported 
specificity and the possibility of being able to distinguish between PUUV- or HTNV-like serotype 
infections (manufacturer’s insert, PROGEN Biotechnik). Before testing, the sera were incubated 
with liver acetone powder from calves (Sigma-Aldrich, Germany) to reduce background 
fluorescence. For the IgM test, the sera were pretreated with GullSORB (Meridian Bioscience 
Inc., United States) to reduce isotype competition. Sera were serially diluted twofold starting at 
1:32 and incubated on the slides for 1 hour at 37 °C. After this step, the wells were incubated 
with either a fluorescein isothiocyanate (FITC)-labelled goat anti-human IgG or IgM conjugate. 
Fluorescence was scored under an immunofluorescence microscope. The cut-off titre for a 
positive result was defined as the sample dilution for which specific fluorescence was greater 
than the sample dilution for which specific fluorescence was just identifiable: in this study, it 
was >1:64.  
 
Focus reduction neutralisation test 
All samples positive in the pan-hantavirus IgM ELISA and PUUV IgM IFA were selected for FRNT 
confirmation (samples 4, 7, 10, 11, 12, 14, 19, 21 and 22).  We also selected two samples 
positive or equivocal in the pan-hantavirus IgM ELISA and positive in the IgM HNTV IFA for FRNT 
(samples 5 and 6). In addition, eight samples that were positive in the IgM ELISA but negative in 
the IFAs were also selected for FRNT (samples 2, 3, 9, 13, 15, 17, 18 and 20). As a fourth 
category, three samples that had not been included in the IFA analysis (as they were ELISA IgM 
negative), but that tested positive in the IgG ELISA (samples 1,8 and 16), were selected for FRNT 
confirmation. FRNTs for DOBV strain Slovenia, SEOV strain 80-39 and PUUV strain Kazaan were 
carried out as described elsewhere (317). Diluted sera were mixed with an equal volume of 
diluted virus containing 30–70 focus-forming units/100 µl. The serum end-concentration was 
1:40. The mixture was incubated at 37 °C for 1 hour and subsequently inoculated into wells of 
six-well tissue culture plates containing confluent Vero E6 cell monolayers. The wells were 
overlaid with a mixture of agarose and tissue culture medium and incubated for 7–13 days. The 
agarose was removed from the wells and the cells were fixed. For PUUV-infected cells, 
polyclonal macaque serum (318) was used as the primary antibody and the monoclonal 
antibody 1C12 for DOBV- and SEOV-infected cells as described elsewhere (319). This step was 
followed by adding peroxidase-labelled goat-anti-human IgG for the macaque serum and goat-
anti-mouse IgG for the 1C12 monoclonal antibody to the cells, to indicate virus-infected cells. 
Tetramethylbenzidine was used as substrate and foci were counted. An 80% reduction in the 
number of foci, compared with the virus control, was used as the criterion for virus 
neutralisation titres. 
 
Review of hantavirus diagnostic requests carried out during suspicion of leptospirosis at the 
time of sampling 
All samples responsive in the IgM and/or IgG pan-hantavirus ELISA were checked for patient-
specific characteristics (sex and date of birth). The combination of sex and date of birth was 
checked in the databases of the hantavirus diagnostic laboratories in the Netherlands. If the 
sample combination matched the information from the database and the diagnostic request 
was made in 2010 or 2011, the patient was scored as having been adequately diagnosed for 
hantavirus disease during the onset of their symptoms. If the sex and date of birth combination 
could not be found in the databases, but the patient’s sample was reactive in any of our tests, 
the case was scored as a missed probable or confirmed hantavirus case, as described in the 
serum bank section above.    
 
Ethical issues 
This study was exempted from ethical review of human subject research by the Medical Ethical 
Review Committee of the Erasmus MC Medical Centre, University of Rotterdam. All data have 
been anonymised and are not attributable to individual patients. 
 
Results 
 
Enzyme-linked immunosorbent assay and immunofluorescence assay serology 
Of the 1,262 samples received for leptospirosis diagnostic testing during January– December 
2010 and April–November 2011, 861 were excluded, as the patients did not meet the inclusion 
criteria of our study. 
All selected and available sera (n=401) were tested by pan-hantavirus ELISAs. Overall, the IgG 
ELISA resulted in 18 positive and 13 equivocal samples. The IgM testing resulted in 17 positive 
and 10 equivocal samples. A total of 11 samples reacted in both the IgG and IgM ELISAs, 
bringing the total number of samples that responded in both ELISAs to 47, i.e. 11.7% of the 401 
samples (4.3% (11/255) of samples taken in 2010 and 4.1% (6/146) of the samples taken in 
2011). 
Subsequently, the 27 samples with a positive or equivocal response in the IgM ELISA were 
tested using both PUUV and HTNV IFAs. In total, nine of the 27 IgM ELISA-responsive samples 
tested positive for both PUUV IgM and IgG by IFA.  
Interestingly, two serum samples were positive in the HTNV IFA, but negative in the PUUV IFA, 
despite repeated PUUV testing. One of the HTNV-positive samples tested positive for both 
HNTV IgG and IgM with titres of 1:512; the other sample was positive only for HNTV IgM, with a 
titre of 1:128.  
 
  
Confirmation by focus reduction neutralisation test 
FRNT was performed on eight of the nine sera with a positive IgM response in the PUUV IFA 
(there was an insufficient amount of serum in the ninth sample). It confirmed that seven of the 
eight samples tested were from patients with recent PUUV infections (samples 4, 7, 10, 11, 12, 
19 and 22) (Table 1). 
 
 
Table 1. Serological test results from samples selected for focus reduction neutralisation test 
confirmation of hantavirus infection, the Netherlands, 2010 and April–November 2011 (n=22) 
Sample  
number 
Date of 
sampling 
ELISAa IFAb FRNTc  Acute 
hantavirus 
infection 
case 
status IgM IgG 
PUUV 
IgM 
PUUV 
IgG 
HNTV 
IgM 
HNTV 
IgG PUUV SEOV DOBV 
PUUV IFA IgM positive 
4 May 2010 POS POS 1:128 1:128 NEG 1:128 POS NEG NEG Confirmed 
7 Jul 2010 POS POS 1:128 1:128 1:128 NEG POS NEG NEG Confirmed 
10 Aug 2010 POS POS 1:128 1:128 NEG 1:128 POS NEG NEG Confirmed 
11 Aug 2010 POS POS 1:128 1:128 NEG NEG POS NEG NEG Confirmed. 
12 Aug 2010 POS Equi 1:128 1:128 NEG NEG POS NEG NEG Confirmed. 
14 Aug 2010 POS NEG 1:128 1:128 NEG NEG NEG NEG NEG Probable 
19 Jul 2011 POS POS 1:128 1:128 1:128 1:128 POS NEG NEG Confirmed 
21 Sep 2011 POS NEG 1:128 1:128 NEG NEG NS NS NS Probable 
22 Sep 2011 POS Equi 1:128 1:128 1:128 1:128 POS NEG NEG Confirmed 
HNTV IFA IgM positive and ELISA IgM reactive 
6 Jun 2010 POS POS NEG NEG 1:512 1:512 NEG NEG NEG Probable 
5 Jun 2010 Equi NEG NEG NEG 1:128 NEG NEG NEG NEG Probable 
ELISA IgM reactive and PUUV or HNTV IFA negative 
2 Feb 2010 POS NEG NEG NEG NEG NEG NEG NEG NEG Not a case 
3 Feb 2010 POS NEG NEG NEG NEG NEG NEG NEG NEG Not a case 
13 Aug 2010 POS NEG NEG NEG NEG NEG NEG NEG NEG Not a case 
15 Oct 2010 POS NEG NEG NEG NEG NEG NEG NEG NEG Not a case 
17 May 2011 POS NEG NEG NEG NEG NEG NEG NEG NEG Not a case 
18 Jul 2011 POS POS NEG NEG NEG NEG NEG NEG NEG Not a case 
20 Aug 2011 POS NEG NEG NEG NEG NEG NEG NEG NEG Not a case 
9 Jul 2010 Equi POS NEG NEG NEG NEG NS NS NS Not a case 
Not tested by IFA (as ELISA IgM negative), but ELISA IgG positive 
1 Feb 2010 NEG POS NT NT NT NT POS NEG NEG Probabled 
8 Jul 2010 NEG POS NT NT NT NT POS NEG NEG Probabled 
16 Apr 2011 NEG POS NT NT NT NT POS NEG NEG Probabled 
We also tested the two sera with an HNTV IgM-positive IFA and a positive or equivocal ELISA 
IgM response (samples 5 and 6): both sera were negative by FRNT.  
To test if cases had been missed due to lack of sensitivity of the IFAs, we selected eight 
samples, of which seven samples had enough serum left for FRNT, with only IgM reactivity in 
the ELISAs and a negative PUUV or HNTV IFA (samples 2, 3, 13, 15, 17, 18 and 20): all seven 
samples were negative by FRNT.  
We also selected three samples that had not been included in the IFA analysis (as they were 
ELISA IgM negative), but that tested positive in the IgG ELISA (Cases 1,8 and 16). These samples 
were tested by FRNT because there was a high degree of suspicion of PUUV infection based on 
the application form for leptospirosis diagnostic request sent by the clinician (e.g. recorded 
renal failure and possible rodent exposure). All three patients had a long duration of their 
complaints (more than three weeks since symptom onset, making it possible that hantavirus 
disease, without the detection of IgM antibodies, was the cause of their symptoms. All three 
were positive in the PUUV FRNT.  
Thus in total, FRNT for PUUV, SEOV and DOBV was performed on 20 of the 22 selected samples, 
due to an insufficient amount of serum in two samples. Of the 20 serum samples tested, 10 
were confirmed as PUUV positive, seven of which were considered due to a recent infection, 
based on the presence of IgM antibodies.  
 
Patient characteristics and registered clinical signs and symptoms in confirmed cases 
Because of the retrospective nature of our study, we could confirm if patients had been 
adequately tested for hantavirus infection during their disease course or if the patient was a 
missed case of PUUV infection. Of the 27 samples with at least an equivocal response in the 
IgM ELISA in our study, which would necessitate further testing of a follow-up serum sample, 
four were adequately tested by routine serology for hantavirus infection at diagnostic centres 
at the time of sampling during suspicion of leptospirosis (samples 4, 10, 11 and 12).  
The two samples that were responsive in the ELISAs and HNTV IFA, but not in FRNT (samples 5 
and 6), were not tested for hantavirus antibodies by ELISA or IFA at the time the patients were 
sampled.  
All available information from retroactively determined probable or confirmed cases of 
hantavirus infection that were not tested for hantavirus infection during suspicion of 
leptospirosis at the time of sampling is shown in Table 2. In general, most of the cases were in 
the eastern parts of the Netherlands. Newly recognised areas with confirmed cases were in the 
northern province of Groningen and the western province of Zuid-Holland. The missed 
confirmed and probable cases of hantavirus infection are shown in Figure 2 according to the 
location of sampling, ranked by likelihood of hantavirus infection, with the highest level of 
evidence being that of a sample with a positive response in the IgM ELISA confirmed by IFA 
(IgM and IgG) tests and a positive FRNT result.  
Table 2. Information on cases of hantavirus infection undiagnosed at time of sampling during suspicion of leptospirosis, the 
Netherlands, 2010 and April–November 2011 
 
Sample 
number 
Date of 
request for 
leptospirosis 
testing 
Sex Age 
group  
in years 
State Information at time  
of request for  
leptospirosis testing  
Retroactive hantavirus diagnostic  
test results 
Acute 
hantaviru
s infection 
case 
status ELISA
a IFAb FRNTc 
16 Apr 2011 M 20–24 Overijssel Acute kidney failure and 
hepatitis 
IgG + 
 
NT PUUV + Probable 
1 Feb 2010 
 
M 20–24 Overijssel Prolonged severe disease IgG + NT PUUV + Probable 
8 Jul 2010 M 10–14 Groningen Contact with soil water and 
potential rodent exposure 
IgM Equi  
IgG +  
PUUV − 
HNTV − 
PUUV + Probable 
21 Sep 2011 F 25–30 Overijssel Icteric; non-responsive  
to antibiotics 
IgM + PUUV IgM + NS Probable 
14 Aug 2010 F 20–24 Zuid-Holland No additional information 
 
IgM + PUUV IgM + All − Probable 
5 Jun 2010 M 20–24 Limburg No additional information IgM + 
 
HNTV IgM + All − Probable 
6 Jun 2010 M 25–30 Gelderland Emergency hospital 
admission, to an  intensive-
care unit 
 
IgM +  
IgG + 
HNTV IgM + 
HNTV IgG + 
All − Probable 
22 Sep 2011 M 45–49 Gelderland Clinical picture not 
understood 
IgM +  
IgG + 
PUUV IgM + 
PUUV IgG + 
PUUV + Confirmed 
19 Jul 2011 M 50–54 Groningen Extreme tiredness, fever  
and diarrhoea 
IgM +  
IgG + 
PUUV IgM + 
PUUV IgG + 
PUUV + Confirmed 
7 Jul 2010 M 35–39 Noord-
Brabant 
Severe disease with high fever 
and emergency hospital 
admission  
 
IgM +  
IgG + 
PUUV IgM + 
PUUV IgG + 
PUUV + Confirmed 
  
 
 
Figure 2. Distribution of probable and confirmed cases of hantavirus infection in the 
Netherlands, 2010 and April–November 2011 (n=14) 
This figure shows the probable and confirmed cases of acute hantavirus infection in the 
Netherlands and if they were adequately diagnosed during their illness or if these were ‘missed’ 
cases. The cases are ranked by likelihood of hantavirus infection. A confirmed case of acute 
hantavirus infection being that of a positive IgG and IgM response in both pan-hantavirus 
enzyme-linked immunosorbent assay (ELISA) and immunofluoresence assay (IFA) and a positive 
result in the focus reduction neutralisation test (FRNT). A probable case is strongly suggestive of 
an acute case of hantavirus based on ELISA, IFA or FRNT results, but either the FRNT was 
negative or we were unable to show the presence of IgM antibodies.  
 
  
Discussion 
 
In the samples tested, a positive response of hantavirus IgM antibodies in the ELISA was 
observed in 4.3% (11/255) of samples taken in 2010 and 4.1% (6/146) of the samples taken in 
2011. When including samples with an equivocal ELISA result, the overall percentage with an 
IgM response was 6.7% (27/401). Confirmation with IFA IgM resulted in a 2.7% (11/401) 
seropositivity in the cohort. Of these 11 samples, seven were confirmed by FRNT, 
corresponding to an overall seropositivity in the cohort of almost 2%. However, this percentage 
could very well be an underestimation. For instance, one sample could not be confirmed by 
FRNT due to a lack of available serum after ELISA and IFA screening. It is conceivable that in our 
cohort of symptomatic patients, of the seven confirmed hantavirus diagnoses, at least three 
cases were not adequately diagnosed at the time of disease (Cases 7, 19 and 22). The other four 
confirmed cases were found in the databases of the hantavirus diagnostic centres in the 
Netherlands, and thus were adequately diagnosed at the time of disease.  We also identified 
seven probable cases of acute hantavirus infection: we consider that hantavirus infection was a 
highly plausible explanation for their symptoms, but either FRNT confirmation was not 
performed due to the lack of serum or the presence of IgM antibodies (confirming acute 
infection) could not be proved by ELISA and IFA.  
All samples confirmed by FRNT (n=10) only showed PUUV-neutralising activity. The vector of 
this hantavirus is Myodes glareoulus (bank vole), a small, reddish rodent that inhabits large 
parts of the Netherlands, solely in grasslands and forests. Case 6, with high OD values in IgM 
and IgG ELISA screening and a positive HNTV IFA, did not neutralise PUUV, DOBV or SEOV.  
This study revealed a high seroprevalence of about 2% of hantavirus antibodies in a cohort of 
leptospirosis-suspected patients who tested negative for leptospirosis. Leptospirosis in the 
Netherlands may be either endemic or imported (309). In our cohort, travel history was well 
documented and hence we consider it quite certain that the patients we studied contracted 
hantaviruses in the Netherlands.  
This cohort also gave us the opportunity to study the circulation of hantaviruses other than 
PUUV in The Netherlands. It is important to monitor this, since evidence is mounting of an 
increase in the number of SEOV infections in Europe and worldwide, with a recent case 
reported in the United Kingdom (320). However, in the samples tested from the Netherlands, 
the SEOV FRNT was negative. Results were also not indicative for infections with DOBV, which is 
vectored by the yellow-necked mouse (Apodemus flavicollis). It is possible that the ELISA and 
IFA results in samples 5 and 6 were false positives. The specificity of the ELISA and IFA is below 
100%, resulting in a (small) chance of cross-reactivity. Test specifications of the ELISA test 
showed no known cross-reactive pathogens, but this presumption is based on results from very 
small serum cohorts (manufacturer’s insert). Although SEOV and DOBV have been excluded as 
the causative agents in our study, the remaining hantaviruses in the HNTV serogroup are 
vectored by reservoir species not known to be present in the Netherlands.  Thus, while we 
cannot rule out the possibility that other hantaviruses from the HNTV serogroup caused the 
disease in patients from whom samples 5 and 6 were obtained, with no travel history, this 
remains highly unlikely. 
Our results show quite a large discrepancy between the initial ELISA screening, followed by IFA 
analysis and eventual gold standard FRNT confirmation. Samples that tested positive only in the 
IgM ELISA (n=7) were not confirmed positive by FRNT.  In most cases (7/9), a positive response 
in the IgM pan-hantavirus ELISA in combination with a positive result in the PUUV IgM IFA was 
later confirmed by FRNT (sample 14 tested negative in the FRNT and sample 21 could not be 
tested). Therefore, we underline the importance of FRNT validation in epidemiological studies 
before drawing any major conclusions, particularly since hantavirus serology is highly prone to 
giving false-positive results (321).  
Acute leptospirosis and HFRS share many clinical manifestations and certain epidemiological 
features. Exposure to rodents is a known risk factor for both diseases. Hallmark symptoms in 
both HFRS and leptospirosis include kidney failure. Two of the four cases who were diagnosed 
at the time of their disease course had documented kidney disorders (data not shown). 
However, of the 10 cases who were not diagnosed, only one (sample 16) had documented 
kidney failure. Of the other nine undiagnosed cases, one was described as having ‘high fever’ 
(sample 7), two as having ‘severe disease’ (samples 1 and 7) and one as ‘clinical picture not 
understood’ (sample 22): the fact that these cases were undiagnosed in the Netherlands during 
their disease course could be due to a potential lack of typical presenting symptoms for 
hantavirus disease in the Netherlands, meaning the absence of kidney failure.  Hepatic 
involvement, often present in leptospirosis – one of the classic triads in Weil’s disease (297) – 
could lead a clinician to think of leptospirosis, while not considering PUUV infection: this would 
have applied to the patient with hepatitis (sample 16), a probable case of acute hantavirus 
infection in our study. Atypical presentation of HFRS, as seen in some of the cases listed in 
Table 2 (samples 21 and 19), has been the subject of several recent case reports (322;323). 
However, unawareness and/or lack of clinicians’ knowledge of how to recognise hantavirus 
disease could also be a reason for underdiagnosis.  
Cases may also be underdiagnosed if the patients are outside the hantavirus-endemic area in 
the Netherlands. Such cases might not be identified due to the low, but clinically important 
number of infections, resulting in lack of awareness of the clinicians in these areas. If we 
compare the distribution of the previously undiagnosed cases in our cohort with the earlier 
serological data, for instance, data published by Groen et al. (305), 7 of 10 cases of hantavirus 
infection not tested at the time of sampling for hantavirus disease (listed in Table 2) were from 
outside the known endemic area. Our conclusions regarding underdiagnosis are supported by a 
recent study showing 1.7% hantavirus seroprevalence in the Dutch population, which should 
lead to more symptomatic cases than the 25–30 cases reported annually (306).  
In this relatively small cohort with specific clinical indications for leptospirosis diagnostics, we 
have shown the presence of undiagnosed hantavirus cases. Leptospirosis itself is potentially an 
often-missed diagnosis in the Netherlands, due to unawareness (309). It is conceivable that 
physicians, who do not include leptospirosis in their differential diagnosis, are even less aware 
of the possibility of hantavirus infections. Vice versa, it cannot be excluded that clinicians who 
are aware of hantavirus infections might miss potential leptospirosis. This hypothesis could be 
validated by performing larger-scale serological studies with broader cohorts, comprising 
patients who are suspected of having leptospirosis or hantavirus infection.  
On the basis of the results in this paper, we feel it is important to increase awareness of 
hantavirus infection in the Netherlands. The increased incidence of hantavirus infections in 
Europe in recent years makes this even more important. This increase is affected by a multitude 
of factors. Some, such as changes in landscape architecture (e.g. (de)forestation, fragmentation 
of land by motorways, railways and agriculture and available burrow space) and increased food 
availability for the rodent reservoirs, are beneficial for the spread of hantaviruses (324). The 
introduction or discovery of new hantavirus strains in Europe has been documented (320) and 
presents another major concern, necessitating epidemiological monitoring of vectors and 
patients. We advise that hantavirus and leptospirosis diagnostics should be considered for 
every patient with an undifferentiated fever in any area with potential rodent-borne infections, 
including typing of the causative agents if the results are positive. 
By decreasing the unnecessary use of antibiotics (325) and providing clinicians with an accurate 
prediction of the disease course and a choice of adequate biomarkers of disease severity (324), 
the identification of hantavirus infections might have a limited, but important, clinical 
importance. Furthermore, adequately diagnosing and typing hantavirus infections is of major 
public health importance in order to correctly identify and educate risk groups and to design 
tailor-made prevention programmes, such as rodent-control programmes and changes to 
landscape architecture. 
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Abstract 
Introduction: Suriname is a country on the north-eastern Atlantic coast of South America. It is 
unique in the sense that different ethnic cultures live together within the country, resulting in 
high levels of transport of both humans and products between the Asian, African and the 
European continent as well as the Caribbean. Travel is only one of the many factors present in 
Suriname contributing to the risk for the emergence or introduction of any infectious disease. 
Recently circulation of both chikungunya (CHIKV) and hantavirus was reported in areas 
neighbouring Suriname. Here we report a retrospective and prospective study into chikungunya 
and hantavirus circulation. Methods: A chikungunya and hantavirus retrospective serological 
study was conducted on samples submitted for dengue, leptospirosis and/or influenza virus 
diagnostics between 2008 and 2012 to the Bureau of Public Health in Suriname. This was 
followed by a prospective CHIKV serological and molecular surveillance study until the detection 
of the first autochthonous CHIKV cases in Suriname in May and June 2014. Results: None of the 
tested samples showed the presence of CHIKV antibodies in the retrospective serological study. 
Prospective testing of CHIKV suspected patients resulted in the detection of the first 
autochthonous CHIKV cases in Suriname in May 2015. In one sample we were able to isolate 
and sequence the virus. Retrospective testing for the presence of hantavirus antibodies showed 
a relative high response in both pan-hantavirus ELISA and IFA. However, neutralization tests did 
not yield any evidence for infection with either Seoul- or Andes hantavirus. Conclusion: Here we 
report the presence of CHIKV in the republic of Suriname and the first serological indication of 
hantavirus infections in symptomatic patients.  
Introduction 
The republic of Suriname is the smallest sovereign state in South America with a population of 
approximately 570.000. A large variety of ethnicities are present in Suriname mainly due to its 
colonial history (326). Currently, the five major ethnic groups are descendants of African 
migration due to the slave trade (Creole and Maroon 17.7% and 14.7%, respectively), 
Hindustani and Javanese (27.4% and 14.6%, respectively; both descendants of labour 
immigrants from India (former British Indies) and Indonesia (former Dutch Indies), and mixed 
ethnicity (12.5%). Other nationalities present in Suriname are Chinese, indigenous Amerindians 
and Caucasians (326). There is a high volume of travel between Suriname and Europe 
(especially the Netherlands) and between Suriname and the Caribbean, which potentially 
contributes to the importation of any infectious disease agent. Furthermore, the relative high 
level of biodiversity in general in South-America and the presence of many vectors for 
transmission of pathogens (Aedes mosquitos, rodents and sandflies) make Suriname prone to 
vector-borne and zoonotic diseases (327;328). The Bureau of Public Health in Suriname (B.O.G.) 
has put much effort in the control of two endemic mosquito-borne diseases ,yellow fever and 
malaria, resulting in a strong reduction and almost no reported cases of these diseases in the 
domestic areas in the past decennium (annual report B.O.G.). Despite sporadic cases of malaria 
in the amazons (tropical rainforest in the inlands of Suriname) both diseases are now 
successfully controlled, resulting in hardly any human cases reported the past ten years. 
However, sporadic cases of Mayaro virus have been reported in literature. In addition, dengue 
is endemic in Suriname, while currently an epidemic of chikungunya virus (CHIKV) is ongoing in 
the Caribbean and America’s. The first local transmission of CHIKV in the New World, in this 
case the Caribbean, was reported from the Saint Martin Island in December 2013 (329). As of 
January 30, 2015 a total of 1,135,892 cases have been reported in the America’s of which 
24,320 have been confirmed by RT-PCR, IgM IFA or a four-fold increase in CHIKV specific IgG 
antibodies (330). Next to fever, patients with CHIKV often show (poly)arthralgia, usually 
symmetric and bilateral. Arthralgia can be very severe and patients could have a long recovery 
resulting in a serious burden of disease.  
Besides mosquito-borne diseases Suriname knows rodent-borne diseases like leptospirosis. 
Furthermore, the circulation of hantaviruses in adjoining countries might be indicative for 
circulation of hantaviruses in Surinam as well (331). Hantaviruses are often neglected, emerging 
viruses.  Both unawareness and difficulties in both the clinical and laboratory diagnosis 
contribute to misdiagnosis of hantavirus cases (338). Pathogenic hantaviruses are able to cause 
two types of disease in humans, haemorrhagic fever with renal syndrome (HFRS) in Europe and 
Asia and hantavirus cardiopulmonary syndrome (HCPS) in North and South America (297). In 
South America many New World hantaviruses are able to cause, often clustered and small, 
outbreaks of HCPS of which Andes (ANDV) seems the most widespread (332;333). Furthermore, 
the world wide migration of rats resulted in the introduction of the Old World hantavirus Seoul 
(SEOV) in South America which is able to cause HFRS in human (334;335). 
  
 Currently, most of the diagnostics for (viral) infections are performed at the central 
laboratory of the Bureau of Public Health in Suriname. Starting from 2008, samples and clinical 
data have been stored from patients for which dengue, leptospirosis or influenza tests were 
negative, with the aim to use in future retrospective studies into the presence of (newly) 
emerging infectious diseases. Here we aimed to gain insight in the emergence of CHIKV in 
Suriname through retrospective analysis of samples collected in the period 2008-2012 and 
prospective analysis of samples collected in 2014. In addition we investigated the possibility of 
hantavirus infection in patients with no adequate diagnosis at the time of disease in Suriname. 
 
Materials and methods  
Study design and study site 
This study was executed in Paramaribo, at the central laboratory, department of virology, from 
the Bureau of Public Health. Paramaribo is the capital and largest city of Suriname, located in 
the Northern part of the country at the banks of the Suriname river close to the North Atlantic 
coast. The laboratory is the major diagnostic centre in Suriname. A CHIKV and hantavirus 
retrospective serological study was conducted, followed by a prospective CHIKV serological and 
molecular surveillance study until we detected the first autochthonous CHIKV cases in Suriname 
in May and June 2014.  
 
CHIKV serology 
CHIKV IgM and IgG serology was tested by use of an in-house immune fluorescence assays (IFA) 
and commercial available IFA (Euroimmun, Germany). Serum samples were diluted 1:10 and 
1:100. CHIKV diagnosis was confirmed in the laboratory of Erasmus MC, Rotterdam, the 
Netherlands which is a World Health Organization reference laboratory for arbovirus 
diagnostics.   
 
CHIKV  detection by real-time PCR 
The presence of CHIKV in patient serum samples was determined by qRT-PCR, in the secondary 
laboratory in Rotterdam, the Netherlands, by detection of the E1 gene (336). Briefly, CHIKV RNA 
was extracted from 100 µl serum using the MagNAPure LC robot system and MagNA Pure LC 
Total Nucleic Acid Isolation kit (Roche, Germany). The presence of viral RNA was measured with 
a real-time qRT-PCR assay (TaqMan®Fast Virus 1-Step Master Mix, Invitrogen, Life Sciences) 
using Applied Biosystems® 7500 Real-Time PCR system. 
 
 
CHIKV isolation and detection by electron microscopy 
Patient sera, with a positive result in the CHIKV real-time PCR, were diluted 1:100 in medium  
and added onto a 70-80% monolayer of C6/36 insect cells and incubated for 60 minutes at 30 
oC. The supernatant was discarded and cells were washed once and incubated with fresh 
Leibovitz-15 medium supplemented with 5% heat inactivated fetal bovine serum (HI-FBS), 10% 
tryptose phosphate broth, 0.75% sodium bicarbonate, 10 mM hepes buffer, 100 U penicillin, 
100 µg/ml streptomycin and 2mM L-glutamine for an additional five days. All culture reagents 
were obtained from Lonza, Breda, The Netherlands. Cultures were incubated for five days. 
Supernatant from passage two was used for electron microscopy. To this end, 2 µl of cell free 
supernatant was pipetted on the Formvar carbon grids (SPI Supplies, USA) and air-dried at room 
temperature. Subsequently, dried grids were incubated for five seconds on parafilm containing 
one droplet of 2% phosphotungstic acid solution (pH 6.5). Grids were stored in ampules and 
examined with a Morgagni electron microscope at 80 kV. 
 
Sequence and phylogenetic analysis of CHIKV E1 gene 
A PCR targeting a portion of the envelope protein 1 (E1) gene was performed  for one virus 
isolate. PCR products were separated on 1% agarose gel and bands of correct size were 
collected for DNA gel extraction using MinElute Gel Extraction Kit Protocol (Qiagen, U.S.A.). 
Amplicons were purified and sequenced using the Sanger method and the BigDye Terminator 
v3.1 Cycle Sequencing Kit on an ABI Prism 3130XL Genetic Analyser sequencer (both from Life 
Technologies). The phylogenetic tree was constructed using 800 nucleotides of the CHIKV E1 
gene. Sequences were aligned using MUSCLE (v3.7) and the phylogenetic tree was 
reconstructed using the maximum likelihood method implemented in the PhyML program 
(v3.0). Reliability for internal branch was assessed using the bootstrapping method (100 
bootstrap replicates). All software was used via http://phylogeny.lirmm.fr/ as described in 
(337). 
 
Hantavirus serology 
Sera were screened using pan-hantavirus IgG and IgM DxSelect ELISAs (Focus Diagnostics, USA). 
These ELISAs are used for testing a broad range of hantaviruses, although there are variations in 
sensitivity and specificity for each specific hantavirus (338). According to the manufacturer’s 
data both tests were compared with a reference in-house ELISA by external investigators. For 
Suriname the performance of these ELISA’s in detecting New World hantaviruses and, 
potentially, Seoul hantavirus, is of importance. For New World hantavirus infections the IgM 
ELISA sensitivity is reported to be 100% in a small cohort (11/11 samples from Andes virus 
patients tested positive) and for the IgG ELISA this was 60% (3/5 samples from Andes virus 
patients tested positive). Based on SEOV FRNT-positive samples, the sensitivity was 50% (11.8–
88.2%) in the IgM ELISA and 95% (54.1–100%) in the IgG ELISA (339). 
ELISA IgM-positive or equivocal sera were tested in IFA by using commercial slides, Euroimmun 
hantavirus Mosaic – 1 (Euroimmun, Germany). This test is based on biochip slides coated with 
Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Hantaan (HNVT), Saaremaa (SAAV) and Sin 
Nombre (SNV) antigen. Samples were pre-treated with Eurosorb IgG absorbent (Euroimmun) 
and subsequently tested in dilutions 1:10 and 1:100 according to the manufacturer’s protocol.      
 
Hantavirus focus reduction neutralization test (FRNT) 
All samples positive in the pan-hantavirus IgM ELISA and Euroimmun MOSAIC IgM IFA were 
selected for FRNT confirmation. FRNTs for Seoul (SEOV) strain 80-39 and Andes (ANDV) strain 
Chile-9717869 were carried out as described elsewhere (317;338). Diluted sera were mixed 
with an equal volume of diluted virus containing 30–70 focus-forming units/100 µl. The serum 
end-dilution was 1:40. The mixture was incubated at 37 °C for 1 hour and subsequently 
inoculated into wells of six-well tissue culture plates containing confluent Vero E6 cell 
monolayers. The wells were overlaid with a mixture of agarose and tissue culture medium and 
incubated for 7–13 days. The agarose was removed from the wells and the cells were fixed. 
Antibody detection of SEOV and ANDV infected cells was done as described elsewhere (319). 
This step was followed by adding peroxidase-labelled conjugate followed by substrate reaction 
(tetramethylbenzidine) and foci were counted. An 80% reduction in the number of foci, 
compared with the virus control, was used as the criterion for virus neutralisation titres. 
 
Results 
Retrospective analysis of the presence of CHIKV antibodies 
To test if CHIKV was already present in Suriname all samples sent to BOG in the period 2008-
2012 of patients with symptoms of fever and arthralgia or fever and rash were retrospectively 
tested for the presence of CHIKV IgM or IgG by in-house and commercial IFA. In total 194 
samples matched these criteria. Serum was available for 68 of these samples. All samples were 
non-reactive in the assays except one that showed low reactivity in the in-house developed 
CHIKV IgG IFA (positive in 1:10 dilution) drawn from a patient with a three day history of fever 
and rash, but no reactivity was seen in the in-house developed CHIKV IgM IFA or the 
commercially available IgM & IgG IFAs. 
 
Prospective surveillance for the introduction of CHIKV in to Suriname 
Starting from March 2014 CHIKV serological and molecular diagnosis was implemented in the 
diagnostic laboratory at BOG. Physicians in Suriname were informed about the possibility of 
CHIKV circulation and the availability of diagnostics. On average 8-10 samples were tested per 
week. The first cases testing positive by the IgM in-house developed IFA were observed in late 
spring (May 2014). All positive IFA results, and a random selection of the negatives, were sent 
for confirmation to a second laboratory. Serological results and clinical data for the first two 
months of prospective CHIKV screening are listed in Table 1,. In total, 23 samples tested 
positive in Suriname of which the secondary laboratory confirmed ten samples. All negative test 
results were confirmed in the second laboratory.   One sample (nr. 19) also tested positive by 
the RT-PCR for CHIKV. This sample was drawn from a patient presenting with arthralgia, 
haemorrhage (skin bleeding) and a macopapular rash over the whole body (Table 1). 
Table 1: Results from prospective analysis of chikungunya cases in Suriname in May and June 
2013. IFA = immunofluorescence assay, F = female, M = Male, Neg = Negative 1 =  travelled <15 
to the Caribbean, 2= Sample is drawn >4 weeks since onset of the symptoms, 3= originate from 
one family, IgM1 & IgG1= the results from the in-house developed CHIKV IFA, IgM2 & IgG2 = the 
results from commercially available CHIKV IFA.  
Case Date Ethnicity Age Sex IgM
1
 IgG
1 
IgM
2 
IgG
2
 PCR Clinical information 
1 May -14 Creole 25-29 M neg neg neg neg neg Fever, arthralgia, headache, myalgia, nausea 
2
1
 May-14 mixed 44-49 M neg neg neg neg neg Fever, Arthralgia, Weakness of limbs, Neck stiffness 
4
 
May-14 mixed 30-34 M ≥100 neg ≥64 neg neg Fever, generalized pain, headache, dizziness, nausea, vomiting 
5 June 14 Creole 55-59 F neg neg neg neg neg Fever, chills, conjunctivitis, diarrhea, dizziness, headache, malaise, 
myalgia, sore throat 
6 June 14 Hindi 25-29 F 10 neg 16 neg neg Fever, generalized pain, rash (whole body) 
7 June 14 unknown 25-29 F neg neg neg neg neg No additional information 
8
1,2 
June 14 mixed 60-64 F neg ≥100 neg ≥64 neg Fever, arthralgia, cough, dizziness, headache, malaise, neck stiffness, 
sore throat, vomiting, 4 weeks ago rash (whole body) 
3 June 14 Asian 25-29 F neg neg neg neg neg Fever, persistent arthralgia, rash 4 weeks ago, dizziness, headache, 
malaise, nausea, vomiting 
9
3 
June 14 Hindi 45-49 F neg neg neg neg neg Fever, arthralgia 
10
3 
June 14 Hindi 45-49 M neg neg neg neg neg Fever, arthralgia, conjunctivitis, headache, rash (whole body) 
11
3 
June 14 Hindi 10-14 F neg neg neg neg neg Fever, arthralgia, headache, rash (whole body) 
12 June 14 mixed 15-19 M ≥100 neg ≥64 neg neg Fever, back pain, conjunctivitis, cough, diarrhea 
13 June 14 Javanese 30-34 M neg neg neg neg neg Chills, rash (face), lower resp. complaints 
14 June 14 Creole 30-34 M ≥100 neg ≥64 neg neg Fever, pain (generalized), rash (whole body), headache 
15 June 14 Chinese 50-54 M ≥100 neg ≥64 neg neg Fever, pain (generalized), haemorrhage, malaise, myalgia, diarrhea 
16 June 14 Javanese 40-44 M ≥100 neg ≥64 neg neg Fever, arthralgia, rash (whole body) 
17 June 14 Hindi 20-24 F ≥100 neg ≥64 neg neg Fever, pain (generalized), rash (whole body) 
18 June 14 Creole 15-19 F 10 neg 16 neg neg Fever, pain (generalized), cough, nausea, vomiting 
19 June 14 mixed 30-34 F 10 neg 16 neg CT 
22.8 
Fever, rash (whole body), arthralgia, haemorrhage, headache, 
malaise, myalgia, vomiting 
20 June 14 mixed 65-69 F neg neg neg neg neg Fever, arthralgia, headache, neck stiffness, hemorrhage 
21 June 14 Javanese 55-59 F neg neg neg neg neg Fever, arthralgia, haemorrhage, myalgia, retro-orbital pain, sore 
throat 
22 June 14 Javanese 30-34 F neg 10 neg 16 neg Fever, haemorrhage, nausea, vomiting, myalgia, neck stiffness, rash 
23 June 14 mixed 25-29 M neg neg neg neg neg Fever,  pain (generalized)  
CHIKV virus isolation, sequence and phylogenetic analyses of the E1 gene and electron 
microscopy imaging 
To confirm the molecular detection of CHIKV RNA in the serum of case number 19, this sample 
was cultured. Figure 1A shows the CT values of the inoculum, supernatant after passage 
number one and of the supernatant after passage number two. The rapid increase in viral RNA 
suggested replicating CHIKV. This was confirmed by use of electron microscopy. Microscopy of 
multiple samples drawn from the culture supernatant revealed particles of typical size and 
shape of that reported from CHIKV particles (Figure 1C&D). Phylogenetic analyses of the 800 
nucleotides PCR product showed clustering of the Suriname isolate with isolates of the CHIKV 
Asian genotype. Closest relation was seen with the British Virgin Island isolate from 2014 (340). 
 
Figure 1. Panel A 
shows the decrease in 
CT value when 
sample from case 
number 19 was 
passaged over insect 
cells. Cultured virus 
was detected with 
electron microscopy, 
in panel B a cluster of 
virus particles is seen 
and in Panel C a 
single chikungunya 
virus particle in higher 
magnification. Panel 
D shows the result 
from phylogenetic 
analysis. The 
chikungunya isolate 
from Suriname is 
closely related to the 
strain isolated in the 
British Virgin Islands 
and seems to be of 
the Asian genotype. 
 
Serological indication of human hantavirus infections in Suriname based on enzyme-linked 
immunosorbent assay and immunofluorescence assay results 
In total 532 samples were submitted to BOG coming from patients suspected for leptospirosis 
or presenting with the combination of symptoms of fever and respiratory complaint or fever 
and signs of haemorrhage. All selected and available sera (n = 264) were screened by pan-
hantavirus ELISA. Results are listed in Table 2. IgM testing resulted in 45 samples with an 
Optical Density (OD) of >1.1 times the cut-off calibrator, which, according to the manufacturer 
can be regarded as a positive result. Furthermore, five samples gave an equivocal result in the 
IgM ELISA (OD 0.9-1.1 times the cut-off calibrator). In total 18 samples tested positive for the 
presence of hantavirus IgG antibodies and two samples had an equivocal test result. Samples 
with a positive result in IgM or IgG ELISA were tested with IFA slides reactive with six different 
hantaviruses (PUUV, SEOV, HNTV, SNV, DOBV, & SAAV). Results from individual samples are 
listed in Table 2 together with specific clinical data and additional information. In total 21 of the 
45 samples positive in IgM ELISA were also found positive by IFA testing. Reactivity against both 
Old and New World hantaviruses in IFA were found in multiple samples. Since recent published 
work has revealed numerous false positive samples in a comparable cohort study (338), we 
decided to repeat the initial ELISA screening by hands of a second investigator unaware of the 
first results. Twenty-five of the forty-five samples (56%) tested positive (OD of >1.1 times the 
cut off calibrator) in the second IgM ELISA. Second IgG ELISA analysis confirmed the presence of 
IgG hantavirus antibodies in 9 of these 18 samples (50%), while one equivocal sample tested 
negative and one positive (Table 2).       
 
 
Confirmation by focus reduction neutralisation test (FRNT)  
FRNT was performed on 21 sera with a positive IgM response in the hanta mosaic IFA. No 
samples showed significant neutralizing activity against SEOV or ANDV. Therefore, FRNT did not 
yield any evidence for infection with either SEOV or ANDV.  
Sample Number Date ELISA IFA MOSAIC Sex Race Age  
Group in 
years 
Information 
IgM1 IgM2 IgG1 IgG2 IgM M/F 
47 Jan-08 2.4 1.2 NEG NEG SEOV F Creole 40-44 Fever 
73 Feb-08 2.0 2.5 EQUI EQUI SEOV, SNV,DOBV,SAAV F Creole 25-29 Fever, Respiratory complaints, Chills, Sore throat, 
Abdominal pain, Headache  
90 Feb-08 1.5 0.9 NEG NEG SEOV,DOBV,SAAV F Chinese 45-49 Fever, Chills, Cough, Headache, Myalgia, Haemorrhage 
106 Feb-08 5.2 EQUI 1.5 1.1 ALL POS F Creole >60 Fever, Chills, Headache, Myalgia, Sore throat, Vomiting 
202 May-08 3 NEG 1.5 1.1 SEOV M Hindi >60 Fever, Diarrhea, Haemorrhage, vomiting, 
thrombocytopenia 
205 Jun-08 2.2 1.6 1.1 NEG HNTV, SNV F Creole 5-9 Fever, Respiratory complaints, Abdominal pain, Cough, 
Chills, Vomiting 
312 Aug-08 1.8 EQUI NEG NEG SAAV M Creole 55-59 Fever, Back and abdominal pain, Headache 
386 Oct-08 2.1 1.6 NEG NEG HNTV, SAAV F Dutch tourist 20-24 Fever (>40
o
C)  
418 Nov-08 1.5 1.2 NEG NEG HNTV M Caucasian >60 Fever, Haemorrhage 
311 Mar-09 3.2 2.1 NEG NEG ALL POS F Hindi 0-4 Fever, Respiratory complaints 
375 Mar-09 1.3 EQUI EQUI 1.1 ALL POS M Creole 30-34 Fever, Respiratory complaints, Oedema, Severe dyspnea 
403 Apr-09 EQUI EQUI 2.4 2.2 ALL POS F Creole >60 Fever, Respiratory complaints, Cough, Vomiting, Cardiac 
arrhythmia, Oedema 
404 Apr-09 2.5 2.8 NEG 1.1 SNV, SEOV, SAAV F Creole 20-24 Fever, Respiratory complaints, Abdominal pain 
 Table 2. Hantavirus screening results.  ELISA results are given in optical density (OD) ratio compared to the cut off calibrator. A 
result of >1.1 is considered positive while a result between 0.9 and 1.1 is considered as equivocal (EQUI). NEG = negative, M = Male, 
F = Female. IFA = Immune fluorescence assay for which an IFA test was used which is able to distinct between six hantaviruses being: 
SEOV = Seoul virus, SNV = Sin Nombre virus, SAAV = Saaremaa virus, HNTV = Hantaan virus, PUUV = Puumala virus. Only results 
positive in 1:100 dilution are given. 
 
 
 
426 Apr-09 2.2 NEG NEG NEG SNV F Hindi 45-49 Fever, Respiratory complaints, Vomiting 
749 Jun-090 1.4 EQUI NEG NEG SAAV M Hindi 20-24 Fever, Vomiting, Lepto Rapid positive 
1146 Aug-09 1.2 NEG NEG NEG SNV M Creole 20-24 Fever, Sore throat, Nausea, Retro-orbitale pain, Rash, 
Haemorrhage 
1449 Dec-09 1.9 1.2 NEG NEG PUUV, SAAV M Mixed 1-4 Fever, Respiratory complaints, Tachypneu, Rash 
559 Jul-10 1.8 EQUI NEG NEG SNV F Unknown 20-24 Fever, Respiratory complaints, Nausea, Vomiting 
084 Jan-11 2.3 1.1 NEG NEG SEOV F Unknown 20-24 Fever, Respiratory complaints, Dizzyness, Headache, 
Retro-orbital pain 
223 Apr-11 NEG NEG 2.8 1.7 DOBV, SEOV M Unknown 50-54 Fever, Cough 
269 May-11 2.4 2.3 NEG NEG SEOV F Unknown 10-14 Fever, Jaundice, Necrotic wounds 
374 Aug-11 3.8 3.0 NEG NEG SEOV, SAAV F Unknown 1-4 Fever, lymphadenopathy  
Discussion 
This study reports the methods and data on the first detection of CHIKV in the republic of 
Suriname. Furthermore, our results indicated the occurrence of human hantavirus infections in 
Suriname. The introduction of CHIKV in Suriname follows the large outbreak in the Caribbean, 
following the first reports of introduction of CHIKV to the New World in December 2013 (342). 
With the magnitude of trade and travel between the Caribbean (the CHIKV outbreak areas) and 
Suriname, the risk of introduction of CHKV into Suriname was relatively high at forehand. Latest 
numbers from the national centre for statistics (Algemeen Bureau voor Statistiek Suriname; 
ABS) show that up to 8% of all people who enter Suriname originate from the Caribbean (343). 
Therefore, local authorities have put much effort in raising CHIKV awareness in (returning) 
travellers and health care workers in all areas of the country, putting special emphasis on the 
border areas with neighbouring countries.  The fact that this eventually failed clearly shows the 
difficulties in preventing the spread of this emerging arthropod-borne virus. Analysis of the first 
cases in Suriname shows several interesting observations. First of all, the clinical signs and 
symptoms, as summarized in Table 1, include the classical symptoms of rash and arthralgia in 
almost all confirmed patients. Other symptoms include headache, myalgia, arthritis, 
conjunctivitis, vomiting, and maculopapular rash. Furthermore, in three out of the 11 confirmed 
CHIKV patients haemorrhage occurred, most often described as skin bleeding, conjunctival 
bleeding or nose bleedings. Although in our cohort this observation is based on a small number 
of patients, it does show the potency of haemorrhage in the course of infection of CHIKV. 
Something that could be validated by combining the clinical data from the Caribbean outbreak. 
Bleeding complications in CHIKV have been reported previously which raises the question if 
CHIKV should be categorized as a (mild) viral haemorrhagic fever pathogen (344-346).  
Currently, the Pan American Health organisation (PAHO) puts much effort in controlling and 
monitoring the CHIKV outbreak in the Caribbean and subsequently South America. The case 
definition used for CHIKV surveillance is formulated by PAHO and the WHO as follows: a 
suspected case is a person with fever >38.50C and severe arthralgia/arthritis not explained by 
other medical conditions who is residing or has visited epidemic areas within 15 days prior to 
onset of symptoms. A confirmed CHIKV case is a suspected patient meeting laboratory 
confirmation criteria, which are either virus culture, RT-PCR, IgM antibody assay in single 
sample or fourfold increase in CHIKV specific antibody titres IgG  (330). Potential problems in 
estimating the magnitude of the CHIKV outbreak in the Caribbean could be specificity and 
sensitivity of newly introduced diagnostics in centres not familiar with these procedures. In our 
small cohort, a large number of positive IgM IFA tests could not be confirmed in a secondary 
laboratory by gold standard serology testing. This illustrates the need for assay validation in 
epidemiological research, in order to get solid and trustworthy data. Reports depending on only 
IgM assays in one single sample should be interpreted with caution. Phylogenetic analysis of 
the E1 protein gene was in line with other reports coming from the Caribbean, indicating that 
CHIKV circulating in Suriname is of Asian genotype, same as the virus detected on St. Martin 
island. The Asian genotype introduced in the Caribbean is closely related to strains recently 
isolated in China and the Philippines, suggesting that CHIKV strains circulating currently in the 
Western hemisphere originated from strains recently circulating between China, the Philippines 
and Yap in Southeast Asia (340). CHIKV disease is highly debilitating and can have severe 
economic consequences (347). Therefore, there is an urgent need for studies focusing on 
prevention, intervention (antiviral and vaccine developments), pathogenesis and treatment of 
CHIKV infection. Screening for hantavirus antibodies in undiagnosed patients in samples 
submitted to the B.O.G. diagnostic laboratory indicated the possibility of human hantavirus 
infections in Suriname. Based on the results and case definition from the Dutch Hanta-Hunting 
study, confirmation of a routine serological test by FRNT is needed to define a ‘definite’ 
hantavirus case. Since FRNT did not confirm the presence of (neutralizing) hantavirus antibodies 
in any of our samples we cannot draw a firm conclusion about the presence and magnitude of 
hantavirus infections in Suriname. The lack of confirmation of the serological screening is the 
major limitation of our study. However, the high number of ‘probable’ hantavirus cases as 
presented in Table 2, do stress the need for prospective studies addressing the presence and 
burden of hantavirus disease in Suriname. For confirmation by neutralization tests we relied on 
the hanta virus species for which stocks are  available. For us this meant that FRNT could be 
performed with one New World hantavirus: ANDV and one Old-World hantavirus SEOV with a 
large global spread due to the global distribution of its vector the black and brown rats. New 
World ANDV is known to circulate in the Southern parts of South America and with the long 
tailed pygmy rice rat (Oligoryzomys longicaudatus) as its reservoir (98). Currently, no data are 
available of exact rodent species present in Suriname. Data from French Guiana, located on the 
eastern border of Suriname, showed the circulation and human cases of Maripa hantavirus 
infection, closely related to Rio Mamore hantavirus which circulates in Brazil (332). 
Furthermore, a recent publication described the circulation of both Araraquara and Juquitiba 
virus in a region in Brazil closely to the southern border of Suriname (331). Since pathogenic 
hantaviruses are (almost) always associated with one specific rodent species, different or even 
undiscovered hantaviruses might circulate in Suriname. This could explain positive results in 
routine serology due to cross-reactivity with hantavirus species in the panel, but lack of FRNT 
confirmation. Another option can be that both ELISA and IFA test generated false positive 
results. Potential limitation of routine diagnostic tests performed could have great implications 
for interpretation of epidemiological reports based on ELISA and IFA results only. Furthermore, 
the usability of these commercially available assays in areas where hantavirus epidemiology is 
not clearly studied could be debatable, with absence of FRNT confirmation. Especially the value 
of one positive result either in ELISA or IFA warrants further evaluation. Molecular detection of 
pathogenic hantaviruses either in rodents or symptomatic patients is needed to confirm the 
presence and circulation of hantaviruses in Suriname.  
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Abstract 
 
“Puumala virus (PUUV) infection causes over 5000 cases of haemorrhagic fever in Europe 
annually and can influence the hemostatic balance extensively. Infection might lead to 
haemorrhage, while a recent study showed an increased risk of myocardial infarction during or 
shortly after PUUV infection. The mechanism by which this hantavirus influences the 
coagulation system remains unknown. Therefore we aimed to elucidate mechanisms explaining 
alterations seen in primary and secondary haemostasis during  PUUV infection. By using low 
passage PUUV isolates to infect primary human umbilical vein endothelial cells (HUVEC) we 
were able to show alterations in the regulation of primary- and secondary haemostasis and in 
the release of fibrinolysis regulators. Our main finding was an activation of secondary 
haemostasis due to increased tissue factor expression leading to increased thrombin generation 
in a functional assay. Furthermore, we showed that during infection platelets adhered to HUVEC 
and subsequently specifically to PUUV virus particles. Infection of HUVEC with PUUV did not 
result in increased von Willebrand factor while they produced more plasminogen activator 
inhibitor type-1 (PAI-1) compared to controls. The PAI-1 produced in this model formed 
complexes with vitronectin.  This is the first report that reveals a potential mechanism behind 
the pro-coagulant changes in PUUV patients, which could be the result of increased thrombin 
generation due to an increased tissue factor expression on endothelial cells during infection. 
Furthermore, we provide insight into the contribution of endothelial cell responses regarding 
haemostasis in PUUV pathogenesis.”    
Introduction 
Puumala virus (PUUV), a hantavirus carried by chronically infected bank voles, is the 
causative agent of an estimated 5000 cases yearly of viral haemorrhagic fever in Europe (307). 
Hantaviruses are rodent-borne, negative stranded, RNA viruses belonging to the Bunyaviridae 
family, which may cause two types of disease in humans (297). In Europe and Asia, hantavirus 
infection causes Haemorrhagic Fever with Renal Syndrome (HFRS), characterized by renal 
failure and bleeding complications. In North and South America, hantavirus infection causes the 
Hantavirus Cardiopulmonary Syndrome (HCPS) where patients present with severe acute 
respiratory distress (348). Changing ecological factors determine fluctuations 
in hantavirus epidemiology resulting in sudden increases in incidence, for instance through 
increased food availability, prolonged virus survival and decreased biodiversity (324). Recent 
epidemiological studies reported an overall incidence increase of PUUV infections in Europe 
(349).  
 Although PUUV infections have a low case fatality rate (<1%) and in literature the virus is 
often described as the least virulent of the pathogenic viruses within the hantavirus genus, 
PUUV infections can cause severe disease in healthy adults, which may require a long recovery 
period lasting up to one year (350). Furthermore, several reports described cases with severe 
(haemorrhagic) complications like pituitary gland haemorrhage, hematemesis and gastro-
intestinal bleedings (322;351). In contrast to these bleeding complications, a recent study from 
Sweden reported increased risk for acute myocardial infarction shortly after PUUV infection 
(352). Given the high incidence in Northern Europe, acute myocardial infarction as a 
complication of PUUV infection could have a major impact in endemic areas. In light of both 
bleeding and thrombotic events that might complicate PUUV infections, we hypothesized that 
endothelial cells, also the target cells for hantaviruses and the major regulators of coagulation 
and inflammation, play a central role in the pathogenesis of the disease (353).  
During hantavirus infection drastic alterations in the coagulation system have been 
observed (354). Clinical studies focusing on primary and secondary haemostasis during 
hantavirus disease showed thrombocytopenia in both HFRS and HCPS, a decreased plasma 
activity of coagulation factors II, V, VIII, IX and X in acute HFRS patients, prolongation of the 
prothrombin and activated partial thromboplastin time, increased thrombin generation and D-
dimer levels and a decrease in ADAMTS13 activity in acute PUUV patients (61-64). The ability to 
infect endothelial cells by hantaviruses has been demonstrated both in vitro and in vivo (355-
357). Although infection does not lead to cytopathic changes, several studies observed 
endothelial cell dysfunction during hantavirus infection (356;357), ranging from increased 
clinical markers of a stressed endothelium in vivo (sICAM-1, VWF and circulating endothelial 
cells) (358;359), to increased permeability and decreased HUVEC integrin ligand migration in 
vitro (360;361).   
Integrin ανβ3, experimentally proven to be the receptor for hantavirus infection, is 
abundantly present on the surface of endothelial cells (362;363). Infection with pathogenic 
hantaviruses is suggested to result in the loss of function of the ανβ3 integrin (364), but also an 
increased ανβ3 expression on cultured endothelial cells and platelets has been observed (365). 
Furthermore Gavrilovskaya et al. studied  the adherence of quiescent platelets to Sin Nombre 
and Hantaan virus infected endothelial cells seems to be the result of virus binding to the ανβ3 
integrin present on platelets (366). 
How the abnormalities in the primary (thrombocytopenia) and secondary haemostasis 
(increase in thrombin generation and raised D-Dimer levels) are induced in PUUV infected 
patients and the mechanism by which Old-World hantaviruses cause haemorrhage and/or renal 
failure remain largely elusive (307). Lack of specific treatment and an effective vaccine makes 
understanding of the pathophysiology of hantavirus infection an important medical need, 
especially with the recently discovered association of PUUV with cardiovascular disease (352). 
Therefore, we have used an integrated approach to study changes in primary and secondary 
haemostasis using an in vitro endothelial cell model. 
Methods 
 
Cells 
VeroE6 cells (American Type Culture Collection, USA) were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% fetal bovine serum (FBS, Lonza the Netherlands), 100 U/ml 
penicillin-streptomycin solution, 1% Hepes buffer and 1% sodium bicarbonate (all from Gibco, 
Life Sciences, USA). Human umbilical vein endothelial cells (HUVEC) were harvested from 
umbilical veins, which were kindly provided by Erasmus MC birth center. Briefly, umbilical cords 
were stored in sterile 500 ml PBS supplemented with gentamycin (50 µg/ml) (Leo 
Pharmaceutical, Denmark). Veins were rinsed with PBS containing 50 U/ml heparin (Leo 
Pharmaceutical). Subsequently, cells were detached with 0.1% collagenase solution (C6885, 
Sigma Aldrich, USA). Cell suspension was collected in a sterile 50 ml tube followed by two times 
centrifugation (5 minutes 300 g). The cell pellet was re-suspended in HUVEC medium (human 
endothelial-SFM medium) (Invitrogen, Life Sciences, United States) containing 10% human 
serum (Lonza), 20% filtrated FBS (Lonza); penicilin/streptomycin 100 U/ml, 20 ng/ml fibroblast 
growth factor (Peprotech, United States) and 10 ng/ml of endothelial cell growth factor 
(Peprotech). HUVEC cell suspensions were cultured in flasks pre-coated with 20 μg/ml of 
fibronectin (Roche, the Netherlands). Only cells up to passage four, from one specific donor, 
were used for this study. Identity of the endothelial cells was confirmed by flow cytometry 
using Ulex europeus lectin, anti-CD31 and Von Willebrand Factor (VWF) staining and 
immunoblot.  
 
Anti-sera 
We made use of the following antibodies and conjugates: polyclonal rabbit anti- VWF, HRP 
labelled polyclonal goat anti-rabbit IgG and polyclonal rabbit anti-mouse (All from Dako, the 
Netherlands).  FITC labelled monoclonal anti-CD31 (Sigma Aldrich, USA), polyclonal rabbit anti-
CD41 (Perbio Science, the Netherlands), polyclonal rabbit anti-CD3 (Dako), polyclonal rabbit 
anti-PUUV nucleoprotein (BEI Resources, USA), monoclonal anti-PUUV glycoprotein (HY Test, 
Finland), monoclonal anti-ανβ3 integrin (Abcam, UK), monoclonal anti-vitronectin (Novus Bio, 
USA), polyclonal rabbit-anti PAI-1 (Bio Connect, the Netherlands), polyclonal rabbit anti-tissue 
factor (Bio Connect) human serum from a recovered PUUV case described in (308). Antibodies 
and conjugate were diluted in dilution buffer, which consisted of PBS with 0.5% bovine serum 
albumin, 2% NaCl and 1% normal goat serum. 
 
Virus isolation 
 Lungs of Myodes glareolus from Konnevesi, Finland,  infected with PUUV were homogenized in 
DMEM (10% w/v) and 100 µl was added onto a 70-80% monolayer of VeroE6 cells and 
incubated for 60 minutes at 37 oC in 5% CO2. The supernatant was discarded and cells were 
washed three times and incubated with fresh veroE6 medium for an additional five days. Virus 
stocks up to passage four were created by centrifugation (10 min. 400 g) of the supernatant to 
create a cell free virus stock. Virus titre was determined using immune peroxidase reaction 
(IPOX) and TCID50 was calculated using the Karber formula (367). Infectious virus was 
inactivated using beta-propiolactone (BPL) (Sigma Aldrich, USA; 1:4000 v/v) at 4 oC for 24 hours. 
Subsequently, BPL was inactivated for one hour at 37 oC. All virus stocks were stored at -80 
degrees until use. Vesicular stomatitis virus (VSV) strain Indiana, propagated also on VeroE6 
cells, was kindly provided by Dr. Bart Haagmans (Erasmus MC).  
 
Infection kinetics and dynamics 
HUVEC were seeded into 24-well- (2.4 x 105 cells) or 96-well plates (4 x 104 cells) (Corning, USA) 
depending on the experiment. Confluent monolayers were infected with a multiplicity of 
infection (MOI) of 0.5 or 3, with infectious and inactivated (BPL-inactivated) virus or a normal 
medium control for 60 minutes at 37 oC in 5% CO2. After incubation, the supernatant was 
discarded and cells were washed three times with RPMI 1640 (Gibco, Life Sciences). Fresh 
medium was added as described earlier. For VWF and plasminogen activator inhibitor type-1 
(PAI-1) quantification, medium did not contain FCS but was supplemented with 4% sterile 
filtered bovine serum albumin (BSA, Sigma Aldrich, USA) to avoid addition of fetal calf VWF and 
PAI-1 (368). To quantify the percentage of infected cells we used an in house developed IPOX 
procedure. HUVEC were washed three times with PBS. Cells were fixed with absolute -20oC 
methanol and incubated at -20oC for 30 minutes. After fixation, methanol was discarded and 
cells were incubated for 30 minutes at 37 oC with 100 μl of 0.05% H2O2 in PBS, to block 
endogenous peroxidases. Subsequently, cells were washed three times with PBS and incubated 
for 60 minutes with polyclonal rabbit anti-PUUV nucleoprotein antibody (1:500). Cells were 
washed with PBS 0.05% tween followed by incubation with HRP-labelled goat anti-rabbit IgG 
conjugate (1:500). Colour development was achieved by addition of 3-amino-9-ethylcarbazole 
(AEC) substrate (AEC dissolved in dimethylformamide buffered with acetate buffer of pH 5). 
Percentage of infected cells was determined by manual counting.  
For the quantification of viral replication we used a standard line of in house generated 
PUUV RNA run-off transcripts, as described for West-Nile virus (369). Briefly, RNA run-off 
transcripts were generated using a segment amplified with pan-hantavirus degenerative PCR 
primers from (370). PCR products were separated on 1% agarose gel and bands of correct size 
were collected for DNA gel extraction using the MinElute Gel Extraction Kit Protocol (Qiagen, 
United States). DNA fragments were cloned into the pCR4 vector using the TOPO® TA Cloning 
KIT (Life Technologies) and One Shot® TOP10 chemically competent E.coli were transformed 
with the recombinant vector (QIAGEN) according to manufacturer’s protocol. At least five 
colonies were collected for further analyses. Plasmid DNA was purified using MinElute DNA 
purification kit (QIAGEN). Plasmid DNA was linearized by restriction digestion (NotI for the 
negative strand RNA and PstI for the positive strand RNA). Run-off transcripts (in vitro 
transcripts) were synthesized using T3 RNA polymerase for negative strand and T7 RNA 
polymerase for positive strand (MEGAscript® T3 and T7 transcription kits, Life technologies), 
followed by DNase treatment (Ambion® TURBO DNA-free™ Life Technologies), according to 
manufacturer’s manual. The amount of RNA in the stock was determined using NanoDrop® and 
serially diluted. Copy numbers in the standards were calculated using RNA concentration and 
sequence length with help of an online calculator(http://endmemo.com/bio/dnacopynum.php). 
 
Platelet collection 
To study interaction between PUUV and platelets, platelets were collected according to the 
protocol described in (366) with minor modifications. Briefly, blood was collected in 0.105 M 
(end concentration) sodium citrate tubes (BD-plymouth, UK) supplemented with 1 µM 
prostaglandin E1 (Cayman Chemical, USA) to block platelet activation. Platelet-rich plasma 
(PRP) was prepared by centrifugation for 15 min at 700 × g at 25°C. Subsequently, platelets 
were pelleted for 15 min at 1300 x g at 25°C. Platelets were washed twice and resuspended 
with modified hepes buffer (25 mM Hepes, 137 mM NaCl, 0.1% Albumin and 1 µM 
prostaglandin E1 pH 7.4) and counted by a hematocytometer. 
 
Platelet HUVEC binding 
Platelets (108 per ml) were incubated with infected HUVEC (96 wells plate) (PUUV, BPL 
inactivated PUUV or mock control) for 30 minutes at 37°C. After incubation, monolayers were 
washed three times with RPMI and cells were fixed with formalin. After fixation, formalin was 
discarded and cells were incubated for 30 minutes at 37°C/5% CO2 with PBS 0.05% H2O2. After 
three washing steps cells were incubated with rabbit polyclonal anti-human CD41a antibody 
(1:500). The following steps were as described earlier for IPOX. After incubation with HRP-
labelled goat anti-rabbit conjugate (1:1000) TMB was added to the wells for substrate reaction. 
After 10 minutes reaction was stopped by addition of 0.5 M sulphuric acid and optical density 
(OD) was measured at 450 nm using Tecan ELISA reader. CD41a expression OD was calculated 
by subtracting the blanc OD value (wells incubated without platelets but with detection 
antibody and conjugate). Rabbit polyclonal anti-CD3 (1:500) served as an isotype control. 
 
Platelet PUUV binding 
To test if changes in CD41a expression was related to direct binding between PUUV and 
platelets, a mechanism shown in Hantaan and Andes virus infection (366), a pull down assay 
was designed. To this end, we first coated ELISA plates with PUUV or a control virus (VSV) 
(100µl of 106 virus particles in DMEM at 4 oC overnight)  followed by platelet incubation (107 
platelets). Subsequently, cells were washed five times with PBS and the bound platelets were 
quantified by using a platelet detection antibody (anti-CD41a 1:500 in dilution buffer)  followed 
by a conjugate substrate reaction. CD41a expression was calculated by subtraction of the OD 
measured in the wells without platelet incubations (blanco) to correct for direct (a-specific) 
anti-CD41a antibody binding to PUUV and anti-CD3 was used as isotype control. Subsequently, 
ELISA plates were coated with mouse monoclonal anti-PUUV glycoprotein- or isotype control 
antibody (IgG2 corona virus)  (1:500 in PBS at 4 oC overnight)  followed by incubation with 
PUUV to capture the virus followed by platelet incubation, detection antibody and conjugate 
substrate reaction. Thirdly, to further confirm platelet PUUV binding, ELISA plates were coated 
with an anti-platelet antibody (1:500 in PBS at 4 Co overnight), followed by incubation with 
fresh isolated platelets and eventually an incubation step with PUUV or VSV followed by a 
hantavirus detection antibody (mouse mAB anti-PUUV-glycoprotein 1:500). After washing 
substrate reaction was achieved by conjugate addition and TMB reaction steps. As a final step 
we studied the potential blocking of platelet binding by PUUV particles by the addition of a 
blocking step with polyclonal human anti PUUV serum. PUUV coated plates and plates coated 
with 5 day old virus free VeroE6 medium were incubated with a polyclonal PUUV serum (1:50) 
from a case described in (308) or with a PUUV IgG negative control human serum from a 
healthy volunteer (also 1:50). The following platelet binding steps and CD41 detection were the 
same as in the earlier experiments.   
 
Von Willebrand factor and plasminogen activator inhibitor type-1 quantification  
After infection, in a 24-well plate, supernatants (500 µl) were subsequently removed and cells 
were lysed, after three washing steps, using a 15 minute incubation with 500 µl PBS 1% TritonX-
100 followed by centrifugation (10 min. 400 x g). Cell-free supernatants and supernatant from 
cell lysates were measured using a PAI-1 antigen and VWF ELISA kits according the 
manufacturer’s instructions (both from Zymugen, Hyphen Biomed, France). 
 
Tissue factor cell surface expression 
HUVEC in 96 wells plates were fixed with 4% formalin and incubated with rabbit polyclonal anti-
tissue factor antibody (1:500) followed by incubation with the respective conjugate (1:500). 
After washing TMB was added for substrate reaction and reaction was stopped after 10 
minutes by addition of 0.5 M of sulphuric acid. OD 450 nm value was measured on Tecan ELISA 
reader.  
 
Tissue factor cell lysate concentration 
Cell lysates were prepared as described under 2.5. ELISA plates were coated with a mixture of 
50 µl cell lysate and 50 µl PBS over night at  4 oC together with a standard curve of recombinant 
tissue factor (Innovin; Siemens Healthcare Diagnostics, Germany). After blocking wells were 
incubated with rabbit polyclonal anti-tissue factor antibody (1:500) followed by incubation with 
the respective conjugate (1:500). After washing TMB was added for substrate reaction and 
reaction was stopped after 10 minutes by addition of 0.5 M of sulphuric acid. OD 450 nm value 
was measured on Tecan ELISA reader.  
 
Thrombin generation 
Thrombin generation in platelet-poor plasma (PPP) was measured directly on HUVEC surface, in 
a 96 well plate, by recalcification of 80 µl of pooled citrated plasma from healthy donors added 
to the monolayer of infected and uninfected cells. In summary, cells were washed three times 
with RPMI and 80 µl freshly thawed plasma was added to the monolayer together with 60µl of 
HEPES buffer (25 mM Hepes, 137 mM NaCl, 0.1% albumin). On the same plate a serial dilution 
of recombinant tissue factor (TF) (Innovin; Siemens Healthcare Diagnostics, Germany) in the 
absence of cells. Finally, 60µl of HEPES calcium (25 mM Hepes, 137 mM NaCl, 0.1% Albumin, 38 
mM CaCl(2)) was added to plasma. Directly after recalcification, OD 450 nm value was 
measured using a Tecan ELISA reader in a kinetic cycle measuring every 45 seconds for 1 hour. 
Thrombin generation time was defined as the time at half-maximal OD.  
 
Vitronectin – PAI-1 complex levels 
ELISA plates were coated with anti-vitronectin antibody (1:500 in PBS at 4 Co overnight), 
incubated with supernatant from PUUV infected or non-infected HUVEC followed by incubation 
with polyclonal anti-PAI-1 antibody (1:500)  and subsequent conjugate-substrate reaction. PBS 
incubation was used as a blanc control and anti-CD3 antibody (1:500) incubation as an isotype 
control. 
 
Statistics 
All statistical analyses were performed using GraphPad Prism 5.01 for Windows. When 
comparing two groups we made use of a Student's t test or Mann Whitney U, depending on the 
distribution of the data. For the comparison between multiple groups non-parametric Kruskal-
Wallis test was used with Dunn’s multiple comparison test or a one-way ANOVA with Tukey’s 
multiple comparisons test, depending on the distribution of the data. P values ≤0.05 were 
considered significant.  
  
Results 
 
PUUV infects and  replicates in primary endothelial cells  
To prevent PUUV from in vitro loss of virulence, virus stocks of not more than four passages 
were prepared. Freshly isolated HUVEC were infected with MOI 0.5 and 3. The PUUV infected 
and replicated in HUVEC, as is summarized in Figure 1. Non-infected cells (Figure 1A, B) showed 
no red peroxidase staining, confirming specificity of the PUUV-staining. From 24 hours post 
infection with a low MOI infection (0.5) onward (Figure 1C) only a small percentage (+/-10%) of 
the cells were infected , which strongly increased after 48 hours (figure 1D), resulting in 50% of 
infected stained cells. Twenty-four hours after infection at a MOI of 3 about 40%-50% of cells 
were infected (Figure 1E), which increased further to 80% by 48 hours (Figure 1F). Comparable 
kinetics were seen when viral RNA copy numbers were determined. To this end, viral RNA 
numbers were estimated both in supernatant (Figure 1G) and cell lysate (Figure 1H). At both 
MOIs the number of viral RNA increased significantly (2-Log) after 48 hours (Kruskal-Wallis; p = 
0.0028), in the supernatant as well as in the cell lysate, confirming active viral replication. Viral 
replication reached a plateau at 72 hours post infection. 
Furthermore western-blot analysis of the cell lysate for PUUV nucleoprotein confirmed 
infection of HUVEC (Figure 1I). The viral copy numbers in the supernatant or cell lysate of 
HUVEC incubated with BPL inactivated virus served as a  control for non-replicating virus. 
Consistently, the RNA copy numbers did not increase over time indicating the efficient 
inactivation of the virus by BPL treatment. Efficient inactivation was confirmed by negative IPOX 
staining of the HUVEC incubated with BPL inactivated PUUV (data not shown). 
 
 
 
Figure 1. PUUV immune peroxidase (IPOX) staining and viral copy numbers after infection 
with a multiplicity of infection (MOI) of 0.5 and 3.  
Mock infected cells (A&B) showed no red peroxidase staining for PUUV nucleoprotein after 24 
(A) and 48 (B) hours. Twenty-four hours after infection with MOI 0.5 (C) a small number of cells 
stained positive, which, increased at 48 hours (D). Infection with MOI 3 resulted in more infected 
cells after 24 hours (E), which increased slightly at 48 hours post infection (F). Analysis of viral 
replication showed a more than 2-log increase of viral copy numbers in both supernatant (G) 
and cell lysates (H), suggesting active viral replication. Bars represent standard error of the 
mean. BPL inactivation of the virus lead to no increase in viral copy numbers in the supernatant 
and a negative IPOX staining (data not shown). Furthermore infection was confirmed by 
western blot for the presence of the PUUV nucleoprotein in the cell lysate and Von Willebrand 
Factor to confirm the character of the endothelial cells (I). The first four lanes show control wells 
with only one band present at the upper side of the blot (VWF). The last for lanes show the 
presence of both VWF and the PUUV nucleoprotein (approx. 55kDa 10ug/lane).   
 
 
Increased CD41a expression after incubation of platelets on HUVEC upon PUUV infection 
Gavrilovskaya and colleagues reported the potential of Hantaan and Andes virus to bind 
quiescent platelets via ανβ3 integrin (366). Since this observation is of much importance in 
further understanding the alterations in primary haemostasis and its role in disease 
mechanisms in HFRS we decided to confirm this mechanism for PUUV using a different 
approach. First we assessed the ability of quiescent platelets to bind to PUUV infected HUVEC 
(Figure 2). Binding of platelets was determined by measuring the intensity of CD41a (platelet 
glycoprotein IIb), a heterodimeric integral membrane protein present only on platelets and 
megakaryocytes. CD41a expression was significantly higher on the HUVEC monolayer after 
infection with a MOI of 0.5,or 3 compared to the control.  Detection of CD41a expression did 
not differ when platelets were not added to the HUVEC monolayers, suggesting that there was 
no non-specific anti-CD41a binding to infected cells. Furthermore there was no difference in OD 
values when an isotype control (anti-CD3) was used to detect platelets. Based on CD41a 
expression, statistically significant differences were measured between infected wells and wells 
incubated with virus free VeroE6 medium (negative control) at 24 hours post infection (one way 
ANOVA, MOI 3 vs. NEG p < 0.01, MOI 0.5 vs Neg p < 0.05). After 48 hours of infection this 
difference in CD41a expression was also significant between MOI 3 infected wells and the BPL 
inactivated virus control (one way ANOVA, MOI 3 vs. NEG p < 0.001 and MOI 3 vs. BPL p <0.001; 
MOI 0.5 vs. NEG p < 0.05). Taken together, the data indicate that platelets bind to cultures 
incubated with PUUV. HUVEC incubated with BPL did show a trend to increased platelet CD41a 
expression (Figure 2), but this was not statistically significant. 
 
Von Willebrand factor (VWF) is not increased during PUUV infection of HUVEC  
We measured VWF antigen in cell free supernatant and VWF expression on the surface of 
infected HUVEC. Increased  VWF production may be a general inflammatory response of 
endothelial cells that could be evoked as a result of PUUV infection. However, at the time 
points where platelet binding increased, HUVEC infected with PUUV showed no alteration in 
VWF activity, as determined by ELISA, in neither the supernatant nor the cell lysate (Figure 3) 
compared to BPL or negative control. 
 
 
 
 
Figure 2. Increased platelet binding to PUUV infected HUVEC. 
Increased optical density (OD) of CD41a was measured both 24 (A) and 48 (B) hours after 
infection with both low and moderate MOI and platelet incubation on HUVEC surface. P values 
(* p < 0.05 ** p < 0.01 *** p = <0.001) are the result of one way ANOVA testing with Tuckey’s 
multiple comparison posttest. Bars represent the standard error of the mean. Incubation with 
an isotype control antibody (polyclonal anti-CD3) did not lead to increased OD on infected or 
control HUVEC.  
 
Platelets bind directly to PUUV  
Next we looked whether the platelets could bind directly to PUUV particles. For this purpose we 
performed an in-house developed platelet pull down-assay using quiescent platelets. To this 
end, several experiments were conducted to demonstrate specificity of this binding. Figure 4 
shows results of binding of platelets to virus-coated ELISA plates (Figure 4 panel A). More 
platelets (Mann-Whitney U; p=0.0022) adhered to plates directly coated with PUUV compared 
to plates coated with a virus control (VSV), which was cultured under the same conditions as 
PUUV. 
Subsequently, to control if the binding of platelets was directly to the PUUV particles and not 
due to another factor present in the VeroE6 supernatant we made use of a sandwich ELISA 
principle. PUUV was incubated on ELISA plates with wells coated with a monoclonal IgG2 
specific for the glycoprotein of PUUV or with a IgG2 control antibody. By this approach 
significantly more platelets bound to the wells where PUUV was captured compared to wells 
with no PUUV capture  (Mann-Whitney U ; p = 0.0022) (Figure 4B).  
To confirm direct binding between platelets and PUUV, platelets were captured to anti-CD41 
coated ELISA plates and incubated with virus followed by detection with a PUUV specific 
antibody. To control for binding between PUUV detection antibody and captured platelets, 
control wells were incubated with VSV. PUUV detection was significantly higher in the wells 
incubated with PUUV compared to VSV (Mann-Whitney U ; p = 0.0043) (Figure 4C). These 
experiments collectively suggest that platelets can specifically bind to PUUV.  
Finally, we show in Figure 4D that the binding of platelets to PUUV particles could be blocked by 
addition of a blocking step with human serum from a recovered PUUV case. When wells coated 
with PUUV were incubated with human serum with proven PUUV neutralizing IgG antibodies 
significantly less platelets adhered to the wells compared to wells incubated with a PUUV 
negative human control serum (Figure 4D). 
 
 
 
 
 
 
Figure 3. Von Willebrand factor 
(VWF) in cell free supernatant.  
No increased VWF antigen is seen 
in the cell free supernatant of 
PUUV infects HUVEC  in 
comparison to non-infected (NEG) 
and inactivated virus control (BPL) 
infected HUVEC. Data are 
representative of three 
independent experiments.  
 
 
 
 
 
Figure 4. PUUV and platelets bind to each other  
In a pull down assay platelets adhere better to PUUV virus particles compared to vesicular 
stomatitis virus (VSV) (A) (Mann Whitney U p= 0.0022). When virus was captured with a PUUV 
glycoprotein antibody (B), platelets were able to bind to the captured virus, in contrast to wells 
coated with an IgG2 control antibody (anti-coronavirus glycoprotein) (Mann Whitney U p= 
0.0022), resulting in no capture of PUUV during the incubation process, controlling for potential 
other factors present in the virus stock medium.  When platelets were bound to plates coated 
with an anti-CD41a antibody (C), the PUUV particles were able to bind to platelets based on the 
significant increase in PUUV detection OD compared to wells incubated with VSV particles, thus 
no PUUV present (Mann Whitney U p = 0.0043). The binding between PUUV and platelets could 
be blocked by the addition of a blocking step with human anti-PUUV serum (D) which show a 
decreased CD41 expression when compared to the PUUV coated wells incubated with a PUUV 
negative control serum. In all experiments no difference in OD was measured when  an isotype 
control antibody was used. Data are representative of three independent experiments. 
 
 
 
 
 
Increased thrombin generation and tissue factor expression after PUUV infection of HUVEC  
To test the hypothesis whether increased thrombin generation observed in acute PUUV 
patients is the result of increased TF expression on endothelial cells we incubated HUVEC, 
infected with PUUV at a MOI of  3 or with a virus free five day old Vero E6 medium (control) 
with a polyclonal anti-TF antibody. By this approach we showed that TF expression was 
significantly increased with an almost two-fold increase in OD value 48 hours post infection 
(Figure 5A, Mann Whitney U; p = 0.0047). Cells infected with PUUV also showed an increased TF 
concentration when the cell lysates of PUUV infected wells were compared to the lysates of 
control wells (both mock and BPL). Subsequently we wanted to prove that the increase in TF 
expression on the endothelial cell surface was of biological significance and would led to 
increased thrombin generation. Thrombin generation was quantified directly on infected 
endothelial cells by incubating normal plasma on cells and initiating coagulation by the addition 
of calcium ions. Infected cells induced plasma clotting faster due to increased thrombin 
generation (Figure 5 panel B &  C). Using a calibration curve with purified TF in the absence of 
endothelial cells, we quantified HUVEC TF production after virus infection and after incubation 
with a virus free medium control. TF concentration showed a statistically significant increase for 
MOI 3 at 24 hours compared to the negative control and the HUVEC infected with MOI 0.5 (one 
way ANOVA; p < 0.01) and at 48 hours post infection compared to the negative control (one 
way ANOVA; p < 0.001) . The MOI 0.5 infection led to higher levels of TF on the HUVEC surface 
only after 48 hours post infection  (one way ANOVA; p<0.05) when compared to mock.   
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. PUUV infection of HUVEC induces tissue factor expression resulting in enhanced 
thrombin generation 
MOI 3 infection resulted in increased TF expression (A, Mann Whitney U p = 0.0002) on HUVEC 
surface after 48 hours (A) and in the cell lysate (B). Thrombin generation time (TGT) was 
significantly decreased, indicating more thrombin formation, for cells infected with PUUV (MOI 
3) at 24 (C) and 48 (D) hours post infection (one way ANOVA; 24 hr p < 0.01 & 48 hr p < 0.001). 
Results are shown with whiskers from minimum to maximum. MOI 0.5 infection resulted in 
shortened TGT 48 hours post infection (one way ANOVA p  < 0.001). Mean tissue factor (TF) 
concentration, calculated from TGT standard curve, increased more than 9-fold after MOI 3 
infection (one way ANOVA 24 & 48h  p<0.01). MOI 0.5 infection increased TF concentration 3-
fold after 48 hours (one way ANOVA p<0.05) (E & F; bars represent standard error of the mean). 
Data are representative of three independent experiments. 
 
Increased levels of PAI-1 and PAI-1-vitronectin complexes in HUVEC supernatant after 
infection with PUUV 
Important proteins in the regulation of fibrinolysis show close interactions with the pathogenic 
hantavirus receptor ανβ3 integrin. For instance vitronectin, a stabilizer of plasminogen activator 
type-1 (PAI-1) activity in plasma, is largely regulated by this receptor (62;371). To study 
potential changes in regulators of fibrinolysis we first measured PAI-1 levels in the cell-free 
supernatant and supernatant of cell lysate from 24-well plates infected with PUUV or control 
infections. The total PAI-1 antigen (the combination of levels in the supernatant and cell lysate) 
was significantly increased 48 hours post infection (Kruskal-Wallis; p<0.05) with MOI 3 (Figure 
6A).  Subsequently, we tested if in our model PAI-1 would bind to vitronectin, since this binding 
is associated with increased/prolonged PAI-1 activity (372), and if this interaction is altered 
during infection. ELISA plates coated with a monoclonal antibody against vitronectin, incubated 
with supernatant from our experiments (pooled, control or from MOI 3 infected wells) followed 
by incubation with PAI-1 antibody suggested formation of PAI-1 vitronectin complexes due to 
an increase in optical density compared to incubation with PBS (mean expression in medium 
490 mOD (+/- 100) versus 370 mOD (+/- 70) p = 0.02). If supernatants were tested separately 
(PUUV versus mock) levels of PAI-1 vitronectin complexes were increased after PUUV infection 
(Mann-Whitney U; p = 0.03) (Figure 6B). 
 
Figure 6. Plasminogen 
activator inhibitor type 1 
production and PAI-1 
vitronectin complex 
formation in HUVEC infected 
with PUUV.  
Total plasminogen activator 
inhibitor type-1 (PAI-1) 
concentration was 
significantly increased on 
time points 48 post PUUV 
infection (black) (one way ANOVA, p < 0.05) compared to BPL inactivated control (grey) or 
negative medium control (white). Panel B shows the PAI-1 vitronectin complex levels in HUVEC 
infected with PUUV (black) or non-infected controls (white). After 48 hours of infection PAI-1 
vitronectin levels were increased compared to the mock infection (Mann Whitney U p = 0.03) 
(B). Data are representative of three independent experiments. 
  
Discussion 
The present study addresses platelet binding to PUUV infected cells and activation of secondary 
haemostasis after endothelial cell PUUV infection. With the lack of a valid and accessible animal 
model for old-world hantavirus infection, we remain dependent on ex vivo cell culture models 
to address questions regarding virulence and pathogenesis (307). Taking into account the 
recently found association of PUUV infection with cardiovascular disease (352) and 
haemorrhagic complications that may occur during infection, the interaction between PUUV 
and the coagulation system especially warrants further attention. Since PUUV tends to rapidly 
lose virulence upon in vitro cell passages the use of low passaged isolates is of vital importance 
(373). Therefore, we have put a lot of emphasis on obtaining low passage PUUV isolates and 
optimisation of the hemostatic assays under the right biosafety regulations using primary cell 
cultures.  
Based on haemostatic changes seen in several clinical studies, most from Northern Europe, we 
decided to study specific parts of the coagulation system in vitro. We started by studying the 
effects of PUUV infection on formation of a platelet plug, the major event in primary 
haemostasis. Binding of platelets by PUUV infected cells could explain thrombocytopenia in 
acute PUUV patients, since it would result in wasting or loss of platelets adhered to these cells 
(63;366). Especially if we make notice of the ability of hantaviruses to infect megakaryocytes 
and thereby lead to a decreased production of platelets, in addition to the loss of platelets 
adhered to infected cells (374;375). In our model it seems that PUUV infection increases 
binding of platelets to the surface of HUVEC compared to control cells (Figure 2). Here we 
assumed increased CD41a expression observed in the first experiments was the result of an 
increased number of platelets on the HUVEC. Theoretically, increased CD41a detection could 
also be due to an increased expression of CD41a on platelets, after 30 minutes incubation with 
infected HUVEC, rather than an actual increase in platelet numbers. While we cannot rule this 
out based on our experiments, we blocked extrinsic platelet activation by prostaglandin 
treatment making platelet activation less likely. Furthermore, in line with studies performed 
with more pathogenic hantaviruses (366), we tested specific binding of platelets to PUUV 
particles. Judged from results from the platelet pull down experiments (Figure 3) this seemed to 
be a specific binding between virus and platelets which could be reversed by the addition of 
PUUV neutralizing antibodies. In these experiments we controlled for aspecific binding of 
antibodies (isotype control experiments), factors present in the virus culture medium (5 day old 
VeroE6 medium as a control) and binding of platelet detection antibody directly to PUUV. 
We expected the increased platelet binding to co-occur with increased VWF production, as a 
general inflammatory response during infection. However, the observation that VWF 
concentration does not change during PUUV infection, further suggested a VWF-independent 
mechanism for platelet binding in HFRS. Results from earlier studies showed an increased VWF 
concentration in hospitalized PUUV patients (63). One should keep in mind that overall plasma 
VWF level in any patient represents the state of the total endothelial cell layer and not only that 
of infected cells, as is the case in our model. Furthermore we are studying the acute response 
of endothelial cells in the first 48 hours after infection, a time point at which PUUV patients are 
generally not considered to be hospitalized and tested. The increase of VWF in all three 
conditions (control, BPL and PUUV) over time in our HUVEC model could be the result of an 
increased number of cells or a sign of in vitro stress and activation of the endothelial cells. Since 
it seems highly unlikely the cells still multiply after the formation of a full monolayer, which is 
present at the time of infection, we believe that also non infected cells show a certain level of 
activation when in culture. 
Gravilovskaya, and colleagues were the first to study the interaction of hantaviruses (Andes and 
Hantaan) with platelets, and concluded that there was a specific binding of Hantaan and Andes 
virus particle particles to ανβ3 integrins present on both endothelial cells and platelets (366).  
Interestingly, our experiment showed a trend to increased number of platelets bound to the 
BPL-inactivated virus treated cultures, suggesting active replication was unnecessary and 
inactivated virus, bound to the cell surface, might also bind to integrins present on platelets. 
For the interpretation of our data one should take in mind that we made use of a MOI 3 BPL at t 
= 0 hours and that the BPL inactivated virus will not replicate. Therefore at timepoint t = 24 and 
t = 48 the BPL control will most likely be comparable to the MOI 0.5 infection. It could very well 
be the case that when increasing the MOI for the BPL infection a more comparable result to the 
MOI 3 infection would be observed. 
PUUV infections of HUVEC directly increased the expression of TF on the cell surface and in the 
cell lysate compared to controls. This resulted in drastic activation of secondary haemostasis in 
our cell model during PUUV infection. Data from a direct clotting assay on the cell monolayer 
gives interesting insights in the potential mechanism behind increased thrombin generation 
seen in acute PUUV patients (134;354). A clear pro-coagulant state, the result of an increased 
expression of TF on the surface of PUUV infected cells, resulted in enhanced thrombin 
generation. Increased thrombin generation (decreased thrombin time, overall increase in 
prothrombin fragments 1+2, antithrombin and protein C) that Laine et al observed in acute 
PUUV patients (354),(134) could very well be the result of direct infection of endothelial cells 
and concomitant increased production of TF. Whether increase in TF is a general defence 
response or if the virus actually benefits from TF, as is seen in certain herpesvirus infections 
(376), remains unknown. However, excess of TF production during infection could lead to 
increased clotting and eventually consumptive coagulopathy or even DIC, a severe condition 
that is only seen in a small percentage of PUUV patients (134), but which could be one of the 
factors contributing to the haemorrhagic complications seen in HFRS. Especially since increased 
TF expression has been proven to play an important role in the pathogenesis of other viral 
haemorrhagic fevers like Marburg and Ebola (46;47).  
Since alterations in PAI-1 levels are related to renal disturbances comparable to that seen in 
hantavirus disease (377;378) and functional polymorphisms in PAI-1 were related to more 
severe disease in acute PUUV patients (379), we also studied PAI-1 and regulators of PAI-1 
activity. Infection with PUUV increases PAI-1 production, which would in vivo lead to decreased 
fibrinolysis. The ανβ3 integrin receptor plays an important role in PAI-1/vitronectin complex 
formation (353). Increased ανβ3 expression during PUUV infection combined with competitive 
binding of hantavirus with vitronectin for ανβ3 could hypothetically lead to further alterations 
in PAI-1 half-life and stability. The increased level of vitronectin-PAI-1 complexes in the 
supernatant of PUUV infected cells further strengthens this hypothesis. Considering that an 
increase in PAI-1 and vitronectin could result in renal impairment, and even cause a nephritis-
like response, pledges for further evaluation of interaction between ανβ3 integrin, PAI-1, 
vitronectin and hantaviruses.  
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Abstract 
 
“Estimates indicate that there are over 1 million cases per year of rodent-borne haemorrhagic 
fever in humans world-wide. The majority of these cases are caused by infection with 
pathogenic hantaviruses and Leptospira. Although these are different biological pathogens, 
Leptospira being spirochetes and hantaviruses being negative stranded RNA viruses, both can 
cause very similar clinical disease in humans, often characterized by haemorrhage and renal 
failure. In the present study, a comparative analysis of the proteomic changes in primary 
isolated, in vitro cultivated human umbilical vein endothelial cells (HUVEC) were characterized 
after 48 hours of infection with a low passage strain of the Old-World Puumala hantavirus 
(PUUV) and a virulent isolate of Leptospira interrogans serovar Copenhageni. Both pathogens 
proved to efficiently infect the endothelial cells and replicate during the 48 hours of incubation 
without causing any major cytopathic effects. The protein profiles of infected versus non-
infected HUVEC and between cells infected with PUUV, Leptospira or in ‘control’ conditions 
(pathogen free medium) were compared via 2-D differential fluorescent gel electrophoresis 
(DIGE). Differentially expressed proteins were identified by mass spectrometry. Comparison of 
infected versus non-infected HUVEC led to the identification of five proteins whose expression 
was significantly diminished after infection with both pathogens. Comparison of Leptospira-
infected versus PUUV-infected HUVEC identified five proteins which were uniquely differentially 
expressed in PUUV infected HUVEC, suggesting specific roles in replication or (anti-) viral 
responses in the infected cells. Differentially expressed proteins identified in this study warrant 
further investigation to understand pathogenic  mechanisms of infection, and give a unique 
insight into the early host response of endothelial cells during infection with PUUV or 
Leptospira.” 
  
Introduction 
Rodent-borne haemorrhagic fevers can be caused by a number of pathogens including 
pathogenic hantaviruses and Leptospira species. Both of these neglected pathogens are able to 
cause a disease with highly similar clinical features and share many epidemiological 
characteristics (297).  Leptospirosis, is one of the most wide spread zoonotic diseases in the 
world and the highest incidence is seen in developing countries with a warm and humid 
climate, but the disease also occurs in industrialized countries (179). It is caused by infection 
with pathogenic Leptospira species, helical shaped bacteria, which are directly or indirectly 
transmitted by most mammalian species, notably  rodents. Clinical symptoms range from a mild 
febrile disease to a severe triad of hepatic injury, renal failure and haemorrhage, better known 
as Weil’s disease. In the past 20 years, Leptospiral Pulmonary Haemorrhage Syndrome (LPHS) 
has been increasingly recognized in humans and a number of domestic and wild animal species. 
LPHS is characterized by severe lung bleedings with a case fatality rate up to 80% (380). Due to 
the overlapping symptoms, acute leptospirosis can easily be mistaken for the so-called 
Haemorrhagic Fever with Renal Syndrome (HFRS); the second largest cause of rodent-borne 
haemorrhagic fever in the world (297). HFRS is the result of infection with a pathogenic 
hantavirus circulating in Europe or Asia, often referred to as “Old-World” hantaviruses. 
Pathogenic hantaviruses are transmitted by rodent excreta and transmission occurs after 
inhalation of virus-containing aerosols (307).  Patients with HFRS can present with a wide 
variety of symptoms (348). However, hallmark symptoms of HFRS are, like in leptospirosis, renal 
failure potentially accompanied by (severe) bleeding complications (297). HFRS incidence is 
high in South-East Asia while it is also known to be endemic in large parts of Europe (296). 
For both pathogens, the way they cause disease, and especially the way they cause 
haemorrhage and renal failure, remains largely unknown.  Based on in vitro and animal and 
human in vivo data, there is a strong suggestion that endothelial cells play a pivotal role in the 
pathogenesis of both HFRS and leptospirosis. For leptospirosis this assumption is supported by 
clinical data in severe leptospirosis patients from Indonesia who showed extreme activation of 
coagulation, which in many cases was followed by (fatal) haemorrhage (381;382). In vitro work 
showed the ability of Leptospira to transmigrate through endothelial cell monolayers. 
Furthermore, outer membrane proteins and killed Leptospira cause up-regulation of several 
markers of endothelial activation like I-CAM and E-Selectin suggesting alterations in the 
functionality of the vascular endothelium (210;383;384).    
In vitro and in vivo studies demonstrate that hantaviruses directly infect and replicate in 
endothelial cells, without causing any cytopathic effects. There is a strong suggestion that the 
function of endothelial cells is hampered during or due to hantavirus infection (62). For 
instance, hantavirus infected endothelial cells have a decreased migratory function in vitro and 
show a VEGF-depended increase in permeability. Furthermore, platelets tend to adhere to 
hantavirus infected endothelial cells (360;366). 
In order to study the factors involved in the changes in the vascular endothelium in rodent-
borne haemorrhagic fever we chose a comprehensive, discovery based, proteomic approach. 
We hypothesized that both the virus (Puumala hantavirus) and the bacterium (Leptospira) 
directly alter the proteome of endothelial cells and that the specific changes will indicate a 
mechanism behind the observed endothelial cell dysfunction. Based on the pathogens shared 
characteristics in clinical manifestations, epidemiology, and asymptomatic reservoir status, we 
hypothesize that these pathogens might share a similar mode of action on endothelial cells.  In 
other words, the specific changes seen in protein abundance in both infections could very well 
play an important role in the mechanism behind the endothelial cell dysfunction.  Furthermore, 
we aim to perform the first proteomic analysis of hantavirus-infected endothelial cells 
compared to uninfected and Leptospira-infected controls.    
Materials and Methods 
Ethics statement 
For the use of fresh umbilical veins for primary cell culture written informed consent was 
obtained and the protocol was reviewed by the Medical Ethics Committee from the Erasmus 
Medical Center. This committee concluded that the Medical Research Involving Human Subjects 
Act does not apply on the presented study and that therefore official approval of this study by 
the Committee was not required. Human umbilical vein endothelial cells (HUVEC) were 
harvested from fresh umbilical veins from healthy mother and baby after written informed 
consent for usage in multiple studies in the exotic viruses workgroup of the department of 
Viroscience, Erasmus Mc, the Netherlands, all for viral haemorrhagic fever pathogenesis 
studies, including the study presented in this manuscript. Isolated cells were de-identified and 
therefore could not be traced back to the original donor. For the isolation of Puumala 
hantavirus Prof. H. Henttonen form  at METLA forest research institute, Vantaa, Finland 
provided lung tissue of Myodes glareolus from Konnevesi, Finland, which were collected with 
permission of the Konnevesi local authorities and performed according to the Cruelty to 
Animals Act, 1876. The same method has been described in recent PLos one publications by the 
group of professor Henttonen (385;386). According to the Finnish Act on the Use of Animals for 
Experimental Purposes (62/2006) and a further decision by the Finnish Animal Experiment 
Board (May 16th, 2007), the technique employed to capture rodents, i.e., snaptrapping (the 
animal capture technique, i.e., using traps that instantly kill the animal) that was used is not 
considered an animal experiment and therefore requires no animal ethics license from the 
Finnish Animal Experiment Board. The species captured for this study, Myodes glareolus, 
neither is protected nor included in the Red List of Finnish Species. Animal trapping took place 
on private and Finnish national forest by permit (1013/204/2002). Landowners were consulted 
and the trapping was allowed before the study was conducted. 
The isolation and ethical approval for the Leptospira interrogans serovar Copenhageni 
(RJ16441) has been described earlier in (387) for this study we used the first passage isolate of 
the leptospires and no longer the blood or any samples of the patient was required. For the 
housing and passages of the RJ16441 J. Nally and S.S. Schuller had ethical approval from the 
ethics committee of the University College Dublin, Dublin, Ireland. 
Cells 
Human umbilical vein endothelial cells (HUVEC) were harvested from fresh umbilical veins from 
healthy mother and baby . Isolated cells were de-identified and therefore could not be 
traced back to the original donor. Umbilical cords were stored in sterile 500 ml PBS + 
gentamycin (50 µg/ml) (Leo Pharmaceutical Products, Denmark). The veins were rinsed with 
PBS containing 50 U/ml heparin (Leo Pharmaceutical Products). Subsequently, cells were 
detached with 0.1% collagenase solution (C6885, Sigma Aldrich, USA). Cell suspension was 
collected in a sterile 50 ml tube followed by centrifugation (2 x 5 minutes; 300 x g). The cell 
pellet was re-suspended in HUVEC medium (human endothelial-SFM medium, Invitrogen, USA) 
containing 10% human serum (Lonza, the Netherlands), 20% filtrated Fetal Bovine Serum (FBS); 
penicillin/streptomycin 100 U/ml, 20 ng/ml fibroblast growth factor (Peprotech, USA) and 10 
ng/ml of endothelial cell growth factor (Peprotech). Cell suspensions were cultured in flasks 
pre-coated with 20 μg/ml of fibronectin (Roche, the Netherlands). Passage two cells from one 
specific donor were used for this study. The identity of the endothelial cells was confirmed by 
flow cytometry using Ulex europeus lectin (EY laboratories, USA), anti-CD31 antibody (Sigma 
Aldrich, USA) and Von Willebrand Factor staining (Dako, the Netherlands). 
 
Virus and Bacteria 
Puumala (PUUV) hantavirus was isolated from lungs of Myodes glareolus. Virus was isolated by 
an in-house developed protocol (Chapter 3.1). Briefly, lungs were homogenized (10% w/v) and 
added onto veroE6 cells and incubated for 60 minutes (37oC; 5% CO2). Supernatant was 
discarded and cells were washed three times and incubated with fresh veroE6 medium 
(Dulbecco’s Modified Eagle Medium containing 10% FBS, 100 U/ml penicillin-streptomycin 
solution, 1% HEPES buffer and 1% sodium bicarbonate (all from Gibco, Life Sciences, USA) for 
an additional five days. Virus stocks of up to passage four were created. The virus titre was 
determined using immune peroxidase reaction (IPOX), and TCID50 was calculated using the 
Karber formula (367). A low passage isolate of Leptospira interrogans serovar Copenhageni 
(RJ16441) was used, originally isolated  from blood cultures of a clinically infected human 
patient with LPHS as described in (387). The organism was maintained in Ellinghausen-
McCollough-Johnson-Harris (EMJH) semisolid medium (EMJH medium containing 0.2% noble 
agar and 200 μg/ml 5-fluorouracil) or liquid culture medium (EMJH medium with 6% rabbit 
serum) at 30°C under aerobic conditions and regularly passaged though guinea pigs to preserve 
its virulence (for which ethical approval was given by the University College Dublin). Leptospira 
were harvested at the log phase of their growth (1-2 x 108/ml) and washed 2 times in RPMI 
medium before being re-suspended in HUVEC medium. 
 
Infection 
In a 24 well plate, 2.4 x 105 endothelial cells were incubated with a multiplicity of infection 
(MOI) of 3 either with PUUV, Leptospira, or normal HUVEC medium (without antibiotics, with 
20% FBS and no human plasma) as a control. After 48 hours of incubation, HUVEC were washed 
three times with 10 mM Tris 1 mM EDTA buffer (pH 8). Proteins were solubilised by adding 100 
μl solubilisation buffer (7 M urea, 2 M thiourea, 1% Amidosulfobetaine-14). Samples were 
stored at -800C until further analysis. 
Infection kinetics  
Infection of endothelial cells was assessed by immune peroxidase staining (IPOX). Briefly, 
supernatant was discarded from a full monolayer of 24 well plate seeded HUVEC and cells were 
washed three times with phosphate buffered saline (PBS). Because it was unclear whether the 
leptospires would remain extracellular or migrate intracellular, a two-way strategy for antigen 
detection was used. At the given time point, cells were treated either with permeabilization 
(100% -20oC methanol fixation) or without permeabilization (4% formalin fixation). Cells were 
fixed and incubated at -20oC for 30 minutes. Methanol was discarded and cells were incubated 
for 60 minutes at 37 oC with 100 μl 0.05% H2O2 in PBS, to block endogenous peroxidases. Cells 
were washed three times and incubated (60 minutes) either with 500μl rabbit polyclonal anti-
Leptospira interrogans serovar Copenhageni (1:500, KIT Biomedical Research, The Netherlands) 
or with  500μl  rabbit anti-Puumala virus nucleoprotein (1:500, Bei Resources, USA) antibodies. 
Cells were washed (PBS 0.05% tween) followed by incubation with HRP-labelled goat anti-rabbit 
IgG conjugate (1:500). Antibodies and conjugate were diluted in dilution buffer (PBS 0.5% BSA, 
2% NaCl and 1% normal goat serum). Colour development was achieved by addition of 3-
amino-9-ethylcarbazole (AEC) substrate (AEC dissolved in dimethylformamide buffered with 
acetate buffer pH 5). The percentage of infected cells was determined by manual counting.   
Viral replication was also determined by RNA copy number quantification. The viral RNA 
quantity was measured with a real-time qRT-PCR assay (TaqMan®Fast Virus 1-Step Master Mix, 
Invitrogen, Life Sciences) using Applied Biosystems® 7500 Real-Time PCR system. The RNA copy 
number in each sample was calculated from a standard curve generated by in vitro transcribed 
PUUV RNA standard. RNA run-off transcripts were generated using a segment amplified with 
pan-hantavirus degenerative PCR primers as described in  (370) . PCR products were separated 
on 1% agarose gel and bands of correct size were collected for DNA gel extraction using 
MinElute Gel Extraction Kit Protocol (Qiagen, United States). DNA fragments were cloned into 
the pCR4 vector using the TOPO® TA Cloning KIT (Life Technologies) and One Shot® TOP10 
chemically competent E.coli were transformed with the recombinant vector (QIAGEN, 
California). At least five colonies were collected for further analyses. Plasmid DNA was purified 
using MinElute DNA purification kit (QIAGEN). Plasmid DNA was linearized by restriction 
digestion (NotI for negative strand RNA and PstI for positive strand RNA). Run-off transcripts 
were synthesized using T3 RNA polymerase for negative strand and T7 RNA polymerase for 
positive strand (MEGAscript® T3 and T7 transcription kits, Life technologies), followed by DNase 
treatment (Ambion® TURBO DNA-free™ Life Technologies), according to manufacturer’s 
manual. The amount of RNA in the stock was determined using nanodrop. Copy numbers in the 
standards were calculated using RNA concentration and sequence length with a calculator 
(http://endmemo.com/bio/dnacopynum.php). 
Leptospira were quantified using a real-time TaqMan® based quantitative PCR based on the 
lipl32 gene for the quantitation of pathogenic Leptospira species based on the protocol 
described in (388). The DNA copy number per sample was calculated from a standard curve 
generated by a serial dilution of cultured leptospires counted by darkfield microscopy with the 
use of a Helber counting chamber.   
 
1 Dimensional (1-D) Gel Electrophoresis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 
12% polyacrylamide gels with a discontinuous buffer system. For 1-D gel electrophoresis, 
resolving gels were cast using 12% polyacrylamide, 1.5 M Tris-buffer at pH 8.8, 0.1% SDS, 
ammonium persulfate (APS), tetramethylethylenediamine (TEMED), and then overlaid with a 
stacking gel  to concentrate the protein prior to separation (4% polyacrylamide, 0.5 M Tris-
buffer pH 6.8, distilled water, 0.1% SDS, APS, TEMED). Samples from hantavirus, leptospirosis or 
mock control infections were defrosted and protein concentration was quantified using RC/DC 
(Biorad, LifeScience research). 5 μg of protein was mixed with an equal volume of 2 x sample 
loading buffer (1 M Tris/HCl pH 6.8, 2% beta-mercaptoethanol, 4% SDS, 20% glycerol, 0.2% 
bromophenol blue) and boiled for 10 min in order to achieve SDS-binding and denaturation. 
Gels were placed into a Mini-Protean II cell (Bio-Rad) and the chamber then filled with SDS 
electrophoresis buffer (25mM Tris base, 0.192 mM glycine, 0,1% SDS, pH 8.3). Samples were 
loaded into the precast loading bays of the stacking gels. A molecular marker (MagicMark, 
Invitrogen) was loaded into the first lane of each gel. Electrophoresis was then performed for 
about 70 min at 160 V until the tracking dye contained in the sample buffer ran off the lower 
end of the gels.  
 
 
2 Dimensional (2-D) Gel Electrophoresis 
For 2-D gel electrophoresis, proteins were first separated according to their isoelectric point 
using 7 cm immobilised pH gradient (IPG) strips with a pH range of 4-7 and 3-10 (GE 
Healthcare). Strips were rehydrated overnight in rehydration solution containing 30mM DTT, 
0.5% IPG buffer, bromophenol blue, protein sample and solubilisation buffer (7 M urea, 2 M 
thiourea, 1% ASB-14) to a final volume of 126 μl or 450 μl per 7 cm strip respectively. Isoelectric 
focusing was performed using an Ettan IPGphor IEF System (GE Healthcare) using the settings 
detailed in Table 2. After isoelectric focusing, strips were either processed immediately or 
frozen at -80°C until further use. For second dimension separation, strips were defrosted and 
transferred into SDS equilibration buffer (6M urea, 75mM Tris-HCl, pH 8.8, 29,3% glycerol, 2% 
SDS and 0.002% bromophenol blue) with 1% DTT for 10 min. followed by a second equilibration 
buffer containing 2.5% iodoacetamide for 10 min. The strips were rinsed with electrophoresis 
running buffer and overlaid to 12% polyacrylamide gels and sealed with agarose gel with 
bromophenol blue (tracking dye). Gels were run at 160 V for 70 min in a Mini-Protean II cell 
(Bio-Rad). 
  
2-D DIGE  
To comparatively analyze protein abundance in HUVEC, cells incubated either with PUUV, 
leptospires or a control infection, were labelled using Cy3 and Cy5 dyes for 2D-DIGE analysis. 
The design and flow of this experiment is summarized in Figure 1. Dyes were received frozen 
and kept at -20°C until use (Interchim, France). The dyes were reconstituted in 
dimethylformamide (DMF) to 1mM stock solutions. The stock solutions were then further 
diluted with DMF to 400 pmol/μl working solutions. The Cy2 label was used for the internal 
control which was used Foron each gel. The internal control was made from, 50 µg of protein of 
an internal standard, consisting of a pool of equal protein amounts from all samples included in 
the experiment, was used and labelled with Cy2. While 50 µg of protein from PUUV, 
leptospirosis or control infected endothelial cells were labelled with 400 pmol (1 μl) Cy3 or Cy5. 
The samples were left to incubate on ice for 30 min. The labelling was then quenched by 
addition of 1 µl of 10mM lysine per µl of CyDye. After labelling the samples were separated in 
first and second dimension as described under 2D-SDS PAGE electrophoresis except using 24 
cm pH 4-7 IEF strips. During the entire experiment the samples were protected from light in 
order to prevent degradation of the CyDye labels. After protein separation, gels were scanned 
using the Typhoon fluorescence gel scanner (GE Healthcare) with the following wave lengths: 
520 nm for Cy2, 580 nm for Cy3 and 670 nm for Cy5. The gels were pre-scanned at a pixel size 
of 500 μm and the photomultiplier tube (PMT) voltage adjusted in order to ensure that the spot 
intensities for each CyDye were within a range of 60000-80000U. For data analysis gels were 
scanned at a pixel size of 100 μm. 
 
 
Figure 1. DIGE experimental design for the analysis of differentially expressed proteins 
between non infected, Puumala hantavirus infected and Leptospira interrogans Copenhageni 
infected Human Umbilical Vein Endothelial cells 48 hours post infection. 
 
 
Statistical and spot analysis  
 All statistical analyses for infection kinetic experiments were performed using the 
software GraphPad Prism 4.01 for Windows. The data were expressed as mean or median with 
or without standard deviation or 95% confidence interval. Differences with  p≤0.05 were 
considered statistically significant.  
Differences in spot volumes were analyzed by use of the ProgenesisSameSpots® software 
(http://www.nonlinear.com) following the producer’s instructions. Gels were aligned and the 
spot volumes of the individual samples normalized against the internal standard. Statistical 
criteria for significant differences in spot volumes were: p≤0.05, q≤0.2 and power ≥0.9.   
 
 
Protein digestion and Identification 
 The differentially expressed protein spots were excised from 2-D DIGE gels and manually 
digested with trypsin. After digestion, the peptides were solubilized in 2μl (acetonitrile 50%, 
TFA 0.1%) and 0.7μl of the peptide mixture spotted on a MALDI target plate. A total of 0.7 μl of 
matrix solution (alpha cyano-4-hydroxycinnamic acid in 50% ACNacetonnitrile/ 0.1% 
trifluoroacetic acidTFA) was added. All MS and MS/MS analyses were performed using a 5800 
MALDI TOF/TOF (Applied Biosystems, Foster City, CA, USA) internally calibrated with the known 
masses of trypsin autocleavage products in MS and externally with fragments from Glu-
fibrinopeptide in MS/MS. For each sample, one MS spectrum was acquired and the 10 most 
intense precursors were subsequently selected for MS/MS analysis. An ABsciex ProteinPilot 
platform was used for database searches on an in-house MASCOT server (version 2.3, Matrix 
Science, matrixscience.com, London, UK). Peaks with a signal to noise ratio of more than 10 for 
MS-analysis and more than 4 for MS/MS analysis were included in the peak list. Combined MS 
and 10 MS/MS spectra from each spot were used to perform a search against a Swissprot 
database (downloaded on the 21st January 2013) with the taxonomy Homo sapiens database 
(20307 sequences) and subsequently against all entries (542782 sequences). A mass window of 
100 ppm for the precursor and 0.5 Da for the fragments was tolerated. During the database 
searches, the following parameters were defined: two missed cleavages, fixed 
carbamidomethylation of cysteine, variable oxidation of methionine and tryptophan, 
tryptophan to kynurenine or double oxidation to N-formylkynurenine. Proteins were 
considered as being identified when two peptides matched with a score above 40, the peptide 
threshold score or when one high-scoring peptide together with the MS-data resulted in a 
protein expect value <01e-005. All identifications were manually validated, as previously 
described (389). During the acquisition of data, an effort was made to explain as many as 
possible of the peaks observed in the MS spectra, resulting in an increase in the sequence 
coverage for the reported identifications, the identification of multiple proteins in an important 
number of spots. The biological meaning of identified semi-tryptic peptides (peptides partially 
resulting from non-tryptic cleavages), was searched using SignalP or MitoProt 
(expasy.org/tools) for the prediction of signal-and transit-peptides respectively. 
 
Functional pathway analysis of identified proteins 
 Protein identifications were imported into IPA ® and mapped to items in the Ingenuity ® 
knowledge base to identify known regulatory pathways. Core analysis was performed for 
proteins with significant changes in abundance between infected HUVEC versus non-infected 
HUVEC followed by the hantavirus specific analysis (PUUV infected HUVEC versus non-infected 
+ Leptospira infected cells). 
  
Results 
 
Infection of HUVEC 
 Given our hypothesis that rodent-borne haemorrhagic fevers effect endothelial cells in a 
similar manner, infected HUVEC were examined at 48 hours post-infection with a MOI 3 of 
either PUUV or Leptospira in order to identify those initial protein changes in infected cells prior 
to any cytopathological changes. This was based on previous work by Kraus and colleagues who 
observed a potent interferon response in endothelial cells during hantavirus infection that 
plateaued at 48 hours post-infection (390). Similarly, evaluation of low and moderate MOI’s 
using low passage PUUV on hemostatic parameters in endothelial cells have determined 
significant changes by 48 hours in the absence of any apparent cytopathological changes 
(Goeijenbier et al,. manuscript in review). 
 
The morphology of PUUV infected HUVEC did not differ from non-infected controls over the 
time course of infection (Figure 2A & B) and no cytopathological effects were observed. 
Infection was visualized by IPOX, which confirmed the intracellular presence of PUUV 
nucleoprotein in over 90% of cells (Figure 2D). The 2log increase in viral copy numbers detected 
in the supernatant of infected HUVEC (Figure 2E) and the 3log increase in viral copy numbers 
measured in the HUVEC cell lysate confirmed efficient replication of PUUV in this primary 
culture HUVEC model. 
Figure 2. Infection of HUVEC with 
Puumala hantavirus. 
The morphology of non-infected 
Human Umbilical Vein Endothelial 
cells (HUVEC) (2A) and HUVEC 
infected with a Puumala hantavirus 
multiplicity of infection of 3 (2B) is 
shown in the upper two panels. The 
morphology of the HUVEC did not 
seem to differ between the two 
conditions and the cells did not show 
any obvious cytopathology effects 
over the time course of infection. Red 
positive staining in the Puumala 
hantavirus infected HUVEC 48 hours 
post infection (2D) shows the 
presence of Puumala hantavirus 
nucleoprotein in almost 100% of the cells, confirming infection. The 2log increase in viral copy 
numbers seen in the supernatant of infected HUVEC (2E) and the 3log increase in viral 
copynumbers measured in the HUVEC cell lysate (2F) confirms efficient and effective replication 
of the Puumala hantavirus in the HUVEC model.    
 
The morphology of Leptospira infected HUVEC did not differ from non-infected controls over 
the time course of infection (Figure 3A & B) and no cytopathological effects were observed. 
Immunohistochemistry and PCR confirmed the infection of HUVEC with Leptospira. In order to 
determine if the Leptospira remained extracellular or penetrated the endothelial cells, to 
survive intracellular, immunohistochemistry was performed with and without permeabilization 
of the cells (Figure 3D & 3E). Extracellular Leptospira were detected in the absence of 
permeabilization (Figure 3D) whilst permeabilization allowed detection of multiple intracellular 
leptospires (Figure 3E).  Quantitative real time PCR showed that the number of leptospires did 
not change in the cell supernatant (Figure 3F) whilst it almost doubled in the cell lysate (Figure 
3G) (p = 0.0022 Mann Whitney-U test). Results indicate a generation time of approximately 24 
hours which is typical of pathogenic isolates of Leptospira in culture (391) and confirms 
replication of L. interrogans in our HUVEC model. 
 
 
Figure 3. Incubation of 
HUVEC with Leptospira 
interrogans Copenhageni. 
The morphology of non-
infected Human Umbilical 
Vein Endothelial cells 
(HUVEC) (3A) and HUVEC 
48 hours incubated with a 
Leptospira interrogans 
multiplicity of infection of 
3 (3B) is shown in the 
upper two panels. The 
morphology of the HUVEC 
does not seem to differ 
between the two conditions and the cells do not show any obvious cytopathology effects over 
the time course of infection. In order to determine if L. interrogans remained extracellular or had 
penetrated HUVEC cells to survive intracellular, immunohistochemistry was performed. 
Compared to the control cells (3C), HUVEC incubated with Leptospira stained positive for the 
presence of the bacteria 48 hours after incubation (3 D&E). We performed a staining with a 
rabbit polyclonal anti- L. interrogans antibody without permeabilization of the cells 
(paraformaldehyde fixation fixation; 3D) to show the extracellular presence of Leptospira and a 
staining with permeabilization of the cells (methanol fixation; 3E) which showed clear 
intracellular presence of Leptospira. Survival and replication was further confirmed by a 
quantitative real time PCR where the amount of Leptospira could be calculated from a standard 
curve. The number of leptospires did not change in the supernatant (3F) while it almost doubled 
in the cell lysate (3G) which remained a significant increase over time when the results of the 
supernatant and cell lysate  were added up for each specific well (3H). 
 
Altered protein abundance in HUVEC infected with PUUV or Leptospira   
 No significant differences in protein abundance were detected between the 
cell lysates from PUUV, Leptospira, or control infected endothelial cells when compared by 1D-
PAGE (Figure 4). Despite absent cytopathology in cells infected either with PUUV or Leptospira, 
functional changes and differences in cytokine production have previously been observed (62).  
However, evaluation by 2-D PAGE protein separation showed differences in the spot pattern 
and spot intensities (Figure 5). For example, three protein spots that are diminished after 
infection with PUUV and Leptospira  were observed in the 3-10 pH range (Figure 5). Due to 
increased spot resolution, more differences in spot patterns are detectable by 2D gel 
electrophoresis in the 4-7 pH range. Given the apparent differences in the proteome between 
PUUV- and Leptospira-infected HUVEC compared to the control condition in the 4-7 pH range, a 
DIGE experiment was performed. 
 
Figure 4. 1D-SDS-PAGE of HUVEC 
lysate 48 hours after infection 
with PUUV, Leptospira 
copenhageni or a mock control. 
1D SDS PAGE gel of cell lysates of 
HUVEC”s infected with a control 
infection (C), Leptospira 
copenhageni (L) or Puumala 
hantavirus (H). 10 μg protein from 
the three different conditions 
were loaded per lane and 
separated via 1-D SDS-PAGE. Gels 
were fixated with 10%  
             methanol, 7% glacial acetic acid  
             followed by Sypro Ruby staining. 
 
 
Figure 5. 2-D-SDS-PAGE electrophoresis of HUVEC lysate 48 hours after infection with  a 
medium control, Leptospira copenhageni or Puumala hantavirus (PUUV). SyproRuby stained 
proteins from  in vitro cultured endothelial cells infected with Leptospira, Puumala hantavirus or 
a control infection separated in the first dimension with a PH range from 3-10 and 4-7. Good 
protein separation is achieved with the majority of the proteins having an apparent molecular 
weights between 25 and 220 kDa. The red square shows three clear proteins present in the pH 
3-10 separation in the control condition which are absent in both Leptospira and PUUV infected 
HUVEC. Red squares in the pH4-7 separation show a clear example of a protein present in the 
control condition and absent or severely reduced in abundance in both infections while the 
green circle show two examples of proteins with higher expression in the PUUV infected HUVEC 
after 48 hours of incubation.  
  
  
In order to account for biological and technical variation, samples from 3 wells (each containing 
2.4 x 105 HUVEC) were pooled to provide one sample for Cydye labelling resulting in a total of 
12 (3 x 4) biological replicates for each of the three conditions that were compared over six gels 
(Figure 1). 
In total, 1228 proteins were aligned between the three conditions over 6 gels (Figure 6). 
Comparison of the proteome of infected HUVEC with non-infected controls, identified 97 (7.9%) 
of 1228 protein spots with significant differences in the mean normalized spot volume (p<0.05, 
q<0.2 and power > 0.9) (Figure 8 & Table S1). Eighteen of the 97 proteins were present in 
greater abundance (1.1-1.6 fold change; Table S1) compared to 79 which were present with a 
lower abundance (1.8-13 fold range) (Figure 6 & Table S 1). Standardized normalized expression 
profiles showed proteins which were decreased (Figure 8A) or increased (Figure 8B) in infected 
HUVEC compared to non-infected controls. 
When PUUV infected HUVEC were compared to non-infected controls, there were 36 proteins 
(2.9%) with an altered abundance of which 25 proteins were increased (p≤0.05, q≤0.2 and 
power≥0.9, 1.3-21 fold range) compared to 11 proteins that were decreased (p≤0.05, q≤0.2 and 
power≥0.9, 4.6-16 fold range) (Figure 6B and Table S1). Subsequently, the design of this 
comparative proteomic approach facilitated comparison of the proteome of PUUV-infected 
HUVEC with Leptospira-infected HUVEC (Figure 7B). In this way, differentially expressed 
proteins specific for PUUV infected HUVEC, and not those regulated as a result of a more 
general inflammatory response, could be identified. Comparison of the proteome of PUUV-
infected HUVEC with Leptospira infected HUVEC identified that 15 of the 25 proteins that were 
increased in abundance were specific to PUUV infected HUVEC whilst 10 were increased in both 
PUUV-infected and Leptospira infected HUVEC (p≤0.05, q≤0.2 and power≥0.9, 1.6-15 fold 
range) (Figure 7B). All proteins with decreased abundance in PUUV infected HUVEC were also 
decreased in the proteome of HUVEC infected with Leptospira (Figure 7B).  
 
Figure 6. 2D-map of HUVEC. Differentially expressed (DE) proteins identified between infected 
and non-infected HUVEC (4A) and Puumala hantavirus HUVEC compared to non-infected HUVEC 
(4B). Proteins identified by mass spectrometry are highlighted by a green arrow. In 4B proteins 
highlighted by a purple circle are those proteins that also showed a significant altered protein 
abundance when compar Puumala hantavirus infected HUVEC with Leptospira interrogans 
infected HUVEC. Spot number corresponds to the numbers as listed for the identified proteins in 
Table 1 and for all DE proteins in Table S1.  
 
Figure 7. Venn-Diagram of the differentially expressed (DE) proteins between control, 
Puumala hantavirus and Leptospira interrogans infected HUVEC. We used the data on protein 
abundance from the 2D-DIGE analysis for two different analysis. At first we compared the 
proteome of infected HUVEC (Puumala hantavirus and Leptospira) to non-infected HUVEC 
(Panel A). This resulted in 18 up regulated proteins and 79 down regulated proteins after p, q 
and power analysis. The number between brackets represent the number of proteins identified 
by mass spectrometry. Subsequently we performed the first analysis of the proteome of 
hantavirus infected endothelial cells to non-infected cells which resulted in 25 up-regulated and 
11 down-regulated proteins of which 10 upregulated proteins also met the p, q  and power 
criteria when compared to the Leptospira infected cells. 
 
Figure 6. Standardized normalized volume for all spots that met statistical criteria. 
The standarized normalized volume for all spots with a different protein abundance that met 
the statistical criteria of p≤0.05, q≤0.2 and Power≥0.9. Panel A shows the down regulated 
proteins when comparing infected versus non-infected HUVEC while panel B shows the up 
regulated proteins from this analysis. Standardized expression volume in the analysis between 
Puumala hantavirus infected versus non-infected and Leptospira infected endothelial cells are 
shown in panel C (down regulated) and panel D (up regulated). 
 
Identification of differentially expressed proteins 
 Of the five proteins identified by mass spectrometry in the analysis between infected 
and non-infected HUVEC, all were decreased in abundance and most are predicted to be 
cytoplasmic. The identified proteins consisted of cytoskeleton proteins, a transporter and an 
enzyme (Figure 5 & Table 1). The expression of vimentin, a type III integral filament essential for 
cell shape and stabilizing cytoskeletal interaction, was consistently identified in lower amounts 
in infected HUVEC compared to the uninfected controls. Vimentin, identified in spot 488, 
showed a decreased fold-change of 5.1 with a matching p-value of 0.001. Another protein that 
plays an important role in actin formation, heat shock protein beta-1, was identified from spot 
1045, and was 3.1 times down-regulated in infected cells. Furthermore, a 60 kDa heat shock 
protein (spot 361), which plays a role in mitochondrial protein folding and assembly, showed a 
7.1 fold down-regulation in the infected cells (p = 0.0008). The remaining proteins whose 
abundance was decreased after infection comprised albumin (8.8 fold change; p = 0.0003) and 
keratin, type II cytoskeletal 1. Two isoforms of the cytoskeletal keratin were identified (protein 
spot 212 & 414) and both isoforms showed >3 fold decrease after infection. In endothelial cells, 
cytoskeletal keratin type II, regulated by the KRT1 gene, is membrane bound and has been 
reported to participate in complement activation, fibrinolysis, angiogenesis and the response to 
oxidative stress (392).   
 
Of the 12 proteins identified by mass spectrometry in the comparison between PUUV-infected 
and non-infected cells (Figure 5B & Figure 6B), 10 proteins were increased in abundance whilst 
one was decreased (Table 1). The 5 proteins which were increased in abundance in PUUV-
infected cells compared to non-infected cells and compared to Leptospira infected cells and 
identified by mass spectrometry include 2 peptidases, 1 enzyme, 1 transporter, and 1 pre-
mRNA binding protein. Four of these five proteins have been reported in the literature to play a 
role during viral infection (Table 1). Protein disulfide isomerase (2.2 fold change; p = 0.002) is 
the only protein in this group that has been associated with infection with another causative 
agent of viral haemorrhagic fever, as this protein is up regulated during dengue virus infection. 
Leucine aminopeptidase 3 was identified from spot 447. This multifunctional amino peptidase 
showed a 3-fold increase in the PUUV-infected HUVEC with excellent reproducibility over the 
biological replicates (Figure S3). Furthermore, N-ethylmaleimide-sensitive factor attachment 
protein alpha (αSNAP), encoded by the NAPA gene, was 1.6 fold upregulated after hantavirus 
infection. The αSNAP protein is important in intracellular membrane fusion and vesicular 
trafficking and specifically in the transport of Weibel-Palade bodies in endothelial cells (393). 
Furthermore, when comparing the proteome of PUUV infected endothelial cells and Leptospira 
infected endothelial cells, pre-mRNA processing factor 19 showed a 2.3 fold increased protein 
abundance.  
Proteins that showed a significant increased protein abundance after PUUV infection compared 
to non-infected cells but no significant increase when compared to HUVEC infected with 
Leptospira included: “Heat shock protein 90kDa beta member 1, Tryptophan-tRNA ligase, 
Selenide water dikinase 1, Heat shock 70kDA protein 5 and Aldehyde dehydrogenase 1”. The 
replicate results from 2D-DIGE analysis of Heat shock 70kDa protein 5 (3 fold up-regulated, p = 
1.8e-05) is shown in Figure 9. This protein is known to play a role in the assembly of multimeric 
proteins and was proven to be involved in Ebola and Marburg infection in vitro (Table 1). 
Compared to Leptospira-infected HUVEC, protein abundance of this protein was 2.2 fold 
increased after PUUV infection, however due to a q-value above the threshold it did not reach 
statistical significance (Table S1). The only protein with a decreased expression after hantavirus 
infection that could be identified by mass spectrometry was albumin, a known negative acute 
phase protein. No leptospiral or viral proteins were identified by mass spectrometry. In multiple 
spots, proteins derived from fetal bovine serum (FBS) were identified (Dataset S5). The amount 
of FBS added to cell culture (20%) was consistent in all three conditions and therefore FBS 
derived proteiins were not considered to be not differentially expressed and excluded from 
data analysis. In spot 439, four proteins were identified (Table 1), of which all four theoretically 
could have a potential role in the early host response to PUUV infected endothelial cells. 
However, additional analysis is required to identify the protein(s) responsible for the increased 
abundance measured in the spot.  
 
 
Figure 9.  Example of a differential expressed protein. Protein with spot number 252: up 
regulated 3 fold in Puumala hantavirus infected HUVEC p = 0,000188; q = 0,04 and power = 
>0.9995; Identified by MALDI TOF as heat shock 70kDa protein 
 
 
 
 
  
ID & spot fold UP/Down P Power q Score Protein & Location  Swiss prot Literature summary Ref. 
Infected versus Non-infected HUVEC 
VIM 
488 
5.1 Down 0.001 0.98 0.03 97 
(+64) 
Vimentin (cytoplasm) Class-III intermediate 
filaments 
Virology: receptor, essential for replication and virus 
survival.  
Endothelial cell: migration, adhesion and sprouting. 
(394) 
HSPB1 
1045
 
2.9 Down 0.002 0.97 0.03 161 Heat shock 27kDa 
protein 1 (cytoplasm) 
Involved in stress 
resistance and actin 
organization 
Virology: essential for Influenza A replication. (395) 
HSPD1 
361 
7.1 Down 0.0008 0.99 0.02 90 
(+31) 
Heat shock60kDa protein 
1 (cytoplasm) 
Enzyme; Implicated in 
mitochondrial protein 
import and 
macromolecular assembly. 
N.A. N.A. 
KRT1 
414 
 
 
212 
3.2 Down 0.004 
 
0.93 
 
0.04 111 Keratin type-1, 
(cytoplasm or membrane 
bound) 
Regulate activity of kinases 
via binding to integrin 
beta-1 and the 
receptor of activated 
protein kinase C 
(RACK1/GNB2L1).  
Endothelial cell: complement activation, fibrinolysis, 
angiogenesis and response to oxidative stress. 
(394) 
3.5 Down 0.02 0.96 0.04 126 
ALB 
341 
8.8 Down 0.003 >0.99 0.02 85 Albumin (extracellular 
space) 
Transporter; regulation of 
the colloidal osmotic 
pressure 
Virology: down regulated in acute dengue virus infection. (396) 
PUUV infected versus Non-infected HUVEC and Lepto infected HUVEC 
PDIA3 
441 
2.2 UP 0.002 >0.99 0.2 807 
(+118) 
Protein disulfide 
isomerase family A. 
member 3, (cytoplasm) 
Peptidase, Modulate 
folding of newly 
synthesized glycoproteins 
Virology: MHC complex formation, dengue virus 
replication, aVβ3 binding (Puumala virus receptor), host 
factor required for HIV infection. 
Endothelial cell: thrombus formation, Tissue factor 
activation. 
(397-403) 
NAPA 
930 
1.6 UP 0.001 0.99 0.1 47 
(+39) 
N-ethylmaleimide-
sensitive factor 
attachment protein. 
Alpha (cytoplasm) 
Transporter, Required for 
vesicular transport 
between the endoplasmic 
reticulum and the Golgi 
apparatus 
Virology: BK virus attachment, crucial in docking and fusion 
of vesicles to target membranes. 
(404-406) 
LAP3 
447 
3.0 UP 0.0001 >0.99 0.03 228 Leucine aminopeptidase 
3 (cytoplasm) 
Peptidase, Processing and 
regular turnover of 
intracellular proteins. 
Catalyzes the 
removal of unsubstituted 
N-terminal amino acids 
from various peptides 
Virology: Elevated during herpes infection (CMV, EBV) and 
hepatitis C. 
(407) 
PRPF19 
444 
2.3 UP 0.0005 >0.99 0.07 149 Pre-mRNA processing 
factor 19 (nucleus) 
Enzyme, Plays a role in 
DNA double-strand break 
Endothelial cell: Increased expression leads to decreased 
apoptosis and increases cell survival.  
(408) 
Table 1. Identified proteins and the fold change of expression in  the proteome of Puumala (PUUV), Leptospira and mock infected 
HUVEC with a subsequent review of the literature. Protein scores greater than 70 are significant (p<0.05). In the ‘score’ column, 
score for individual peptides identified manually is added between brackets. * In spot 439 multiple proteins were identified and 
therefore it is not possible to conclude which protein is responsible for the increased abundance measured in the spot.  
 
(DSB) repair,  Structural 
component of the nuclear 
framework 
HNRNPK 
IFIT3 
VIM 
NUCB1* 
439 
3.8 UP 0.0007 >0.99 0.08 101 
86 
83 
68 
Heterogeneous nuclear 
ribonucleoprotein K 
(Interferron-induced 
protein, Vimentin, 
Nucleobinin-1) 
One of the major pre-
mRNA-binding proteins 
Virology: viral RNA splicing, pro-viral functions, interaction 
with human herpes 6, important in Entero 71 virus 
replication, supports vesicular stomatitis virus replication. 
(409-413) 
PUUV infected versus Non infected HUVEC 
HSP90B1 
108 
 
1.8 UP 0.0017 >0.99 0.1 865 
(+178) 
Heat shock protein 
90kDa beta member 1, 
(cytoplasm) 
Molecular chaperone 
functions  inprocessing 
&transport of secreted 
proteins 
Virology: rotavirus replication, increased during  vesicular 
stomatitis virus  infection, hepatitis B virus  replication 
biomarker. 
Endothelial cell:  increased during apoptosis. 
(414-418) 
WARS 
454 
 
2.2 UP 0.0001 >0.99 0.03 102 Tryptophanyl-tRNA 
synthetase (cytoplasm) 
Enzyme, eNOS activation. 
endothelial cell shear 
stress response.  
cytoskeletal reorganization 
 
Virology: (Retro)virus expression, IFN response, increased 
during influenza (H3N2) infection. 
(419-421) 
SEPHS1 
631 
1.5 UP 0.003 0.97 0.2 78 Selenide. water dikinase 
1 
Enzyme, Synthesizes 
selenophosphate from 
selenide and ATP 
N.A. N.A. 
HSPA5 
252 
3.0 Up 0.00018 >0.99 0.04 630 heat shock 70kDa 
protein 5 (cytoplasm) 
Enzyme, assembly of 
multimeric protein 
complexes inside the 
endoplasmic reticulum. 
correct folding of proteins 
and degradation of 
misfolded protein 
Virology: contributes to Ebola and Marburg virus infection 
infection in vitro, important for the release of dengue virus 
particles 
(422;423) 
ALDH1A1 
425 
 
1.5 Up 0.004 0.95 0.2 122 
(+24) 
Aldehyde dehydrogenase 
1 family. member A1, 
(cytoplasm) 
Enzyme, Binds free retinal 
and cellular retinol-binding 
protein-bound 
Virology: increased during influenza (H3N2) virus infection. 
Endothelial cell: essential for retinoic acid production. 
(421;424) 
ALB 
341 
8.8 Down 0.01 0.9 0.2 85 Albumine (extra cellular 
space) 
Transporter, regulation of 
the colloidal osmotic 
pressure 
Virology: down regulated during acute dengue virus 
infection 
(396) 
 
Functional pathway analysis of identified proteins 
The IPA ® analysis of the five proteins identified to be altered between infected and non-
infected HUVEC lead to the identification of the following top-3, statistically significant, 
pathways in molecular and cellular functions: 1) Cellular assembly and organization, 2) cellular 
function and maintenance and 3) cell-to-cell signaling and interaction. Four of the five proteins 
are involved in the proliferation of cells (p = 4.51e-03; activation z score = -2) and in the 
migration of cells (p = 1.3e-03; activation z score = -0.6). Table 2 lists the top pathways 
identified after PUUV infection that are known pathways in diseases and disorders and the 
molecular and cellular functions involved. 
 
 
Table 2. Functional groups of proteins with significant differences in abundance in HUVEC 
infected with PUUV compared to uninfected HUVEC.  A total of 12 proteins (11 up-regulated; 1 
down regulated) were mapped to functional groups using ingenuity IPA ®. The functional 
groups with the highest significance, p-values and numbers of molecules of the groups of 
diseases and disorders and molecular and cellular functions are shown. 
Group Molecules P-value Genes involved 
Diseases and disorders 
Hematological disease 7 1.72E-06 – 4.26E-02 Alb, HSPA5, PDIA3, ALDH1A1,HSPD1, KRT1, VIM 
Immunological disease 10 1.72E-06 – 2.53E-02 ALB, HSPA5, KRT1, NAPA, PDIA3, VIM, ALDH1A1, LAP3, 
HSP90B1, HSPD1 
Inflammatory disease 10 1.72E-06 – 3.01E-02 ALB, HSPA5, PDIA3, HSP90B1, HSPD1, LAP3, PDIA3, VIM, 
KRT1, ALDH1A1 
Inflammatory response 9 1.72E-06 – 4.52E-02 ALB, HSPA5, PDIA3,HSP90B1, KRT1, NAPA, VIM, HSPD1, 
HSPB1  
Respiratory disease 7 1.72E-06 – 3.39E-02 HSP90B1, HSPA5, ALB, PDIA3, HSPD1, PRPF19, VIM 
Molecular and Cellular functions 
Protein synthesis 10 6.98E-07 – 4.30 E-02 HSP90B1, HSPA5, HSPB1, HSPD1, LAP3, PDIA3, WARS, KRT1, 
ALB, ALDH1A1  
Cellular comprise 5 1.71E-06 – 1.71E-02 HSP90B1, HSPA5, HSPD1, VIM, ALB 
Cellular function and 
maintenance 
8 1.71E-06 – 3.85E-02 HSP90B1, HSPA5, VIM, HSPB1, NAPA, ALB, HSPD1, PDIA3 
Cell death & survival 10 4.00E-06 – 4.75E-02 ALB, ALDH1A1,  HSP90B1, HSPA5, HSPB1, HSPD1, NAPA, 
PDIA3, PRF19, VIM  
Cell growth & proliferation 11 1.40E-05 – 4.52E-02 ALB, ALDH1A1, HSP90B1, HSPA5, HSPB1, LAP3, PDIA3, 
PRPF19, VIM, WARS 
Discussion 
Rodent-borne haemorrhagic fevers caused by either PUUV or leptospiral infection, occur with 
high incidence in humans across the world, causing significant morbidity and mortality. Both 
infections cause a very similar clinical picture in humans, often accompanied by renal failure 
and respiratory problems. A clear understanding of the pathogenic mechanisms of both PUUV 
infection and leptospirosis is lacking (62;210). Based on clinical observations and earlier in vitro 
work, it is likely that endothelial cell responses to infection with PUUV or Leptospira play a key 
role in the pathogenicity of both diseases. So far, few studies have examined host cell 
alterations following infection with either Leptospira or hantavirus (210;425). These studies 
mainly focused on microarray analysis of the transcriptome of infected cells. To date no studies 
analyzed the interplay between hantavirus and host cells using proteomic analysis, while for 
Leptospira, proteomic studies were performed mainly studying the pathogen, rather than the 
host, or serum from infected patients (426;427) 
The aim of this study was to test the hypothesis that overlapping proteome changes in 
endothelial cells infected with a virulent low-passage isolate of a pathogenic hantavirus and a 
virulent human isolate of a pathogenic Leptospira occur. To this end we comparatively analyzed 
the proteomes of primary isolates of immune competent human endothelial cells infected with 
either PUUV or Leptospira.   
We previously concluded that low passage PUUV isolates efficiently infected and replicated in 
the HUVEC primary cell culture (Goeijenbier et al., manuscript under review). Immune 
peroxidase staining showed the presence of intracellular PUUV nucleoprotein with the amount 
of infected cells reaching 90% after 48 hours. Interestingly, leptospiral DNA, as quantified by 
qRT-PCR, increased in the cell lysate over time. Taken in mind that there was a clear 
intracellular staining positive for the presence of Leptospira this suggests the ability of the 
leptospires to move intracellular, something that has been suggested before, and possibly even 
replicate intracellularly. This observation could be interesting for future studies on potential 
survival mechanisms of the leptospires in vivo, but also aligns with our approach to compare 
the proteome of infected HUVEC after intracellular bacterial and viral infection.  
All proteins with decreased abundance in PUUV infected HUVEC were also decreased in the 
proteome of cells infected with Leptospira (Figure 5B) which could suggest down regulation of 
proteins as a common pathway in the origin of endothelial dysfunction. Most of the five 
proteins identified by mass spectrometry, in the analysis between infected and non-infected 
HUVEC, are predicted to be cytoplasmic proteins, which aligns with the usage of intra cellular 
pathogens. For instance mass spectrometry identified the cytoplasmic protein vimentin as more 
than 5-fold down regulated protein after infection. Vimentin plays an important role in 
endothelial cell adhesion and sprouting. Regulation of this specific protein is driven by 
posttranslational modifications such as phosphorylation and cleavage by intracellular proteases 
(394). Decreased functioning of vimentin leads to defects in (endothelial) cell attachment, 
migration, signaling and vascularization (394). Since it has been shown that the migratory 
function of endothelial cells decreases during hantavirus infection, the exact role of vimentin in 
this pathogenic process should be examined in greater detail, especially since the decrease of 
vimentin occurred in both infections of pathogens that cause endothelial cell dysfunction in 
vivo. 
All proteins with decreased abundance in PUUV infected HUVEC were also decreased in cells 
infected with Leptospira (Figure 5B) which could mean that down regulation of these proteins is 
a common pathway in the origin of endothelial dysfunction.  
Furthermore, our experimental design made it possible to use the bacterial infection as an extra 
control condition for PUUV infection and specifically study the host proteome changes in 
hantavirus infected endothelial cells; this is of great interest since hantaviruses are the only 
known viruses that specifically target endothelial cells (62). Some of the proteins with increased 
abundance after hantavirus infection, including “Protein disulfide isomerase family A member 
3, Heterogeneous nuclear ribonucleoprotein K and Heat shock protein 90kDa beta member 1” 
are proven to be essential, or important, host factors for the replication of certain viruses as 
shown in Table 1. In spot 439 multiple proteins were identified and therefore it is not possible 
to conclude which of these proteins abundance was changed or if multiple proteins contributed 
to the increased fluorescence. A logical explanation would be the increase in Interferon-
induced protein with tetratricopeptide repeats 3 (IFIT3) since HUVEC are immune competent 
cells and upon viral infection would respond by interferon production. However also 
heterogeneous nuclear ribonucleoprotein K (HnRNP k) has been associated with intracellular 
processes of several viruses. Dengue virus core proteins bind HnRNP k and thereby alters the 
function of the protein (413). Furthermore HnRNP k stimulates vesicular stomatitis virus 
replication, which, like PUUV is a negative stranded RNA virus, and seems also play a role in 
positive strand RNA virus replication; like hepatitis C and Enterovirus 71 (412;428;429). 
Interestingly HnRNP k interacts with vimentin and the intermediate filaments of vimentin are 
essential for nuclear HnRNP k expression and in this combination both proteins are essential for 
dengue virus replication and the release of virus particles (430).  The decreased levels of 
vimentin during PUUV infection seem rather contradictory to this hypothesis. However, since 
an immune competent cell line was used, cell defense response upon PUUV infection could 
result in unexpected changes of the expression of these proteins (431;432). Based on our 
observations these proteins are excellent candidates for future studies on inhibition of PUUV 
replication involving siRNA or other knock out experiments exploring their potential role in 
hantavirus or more general negative stranded RNA virus replication. Another interesting 
observation that could be a lead for future studies is the more than 2-fold increase of protein 
disulfide isomerase (PDIA3). PDIA3 is important in thrombus formation and its capture in a 
thrombus depends on beta3 integrins (400;401). Hantavirus in vitro studies showed a drastic up 
regulation of beta3 integrins, also known to be the receptor for hantavirus infection, during 
endothelial cell infection with different pathogenic hantaviruses (62;360;365). Furthermore 
PDIA3 seems to be a trigger for tissue factor dependent fibrin generation, a process which we 
recently showed to be heavily increased during HUVEC infection with PUUV (Goeijenbier et al. 
manuscript submitted) (402).  No leptospiral or viral proteins were identified by mass 
spectrometry analysis. Of interest are three spots which were the most highly up regulated 
proteins in the PUUV infected endothelial cells (Table S1 spot 477, 486 and 746) that could not 
be identified but are highly likely to be of viral origin. Increasing the protein load from HUVEC 
infected cells with the respective pathogen on the gel for spot picking could overcome this 
shortcoming in the future. 
 
In summary, we identified a number of proteins from primary cultured HUVEC with 
changed abundance during PUUV and Leptospira infection. Many of these proteins are 
important factors in cell maintenance and functioning while also at least five of them have been 
proven to play an essential role in the replication of specific viruses.  Future studies should 
focus on knock down and elimination experiments to increase the understanding of the 
pathogenic mechanisms behind PUUV and leptospiral infection. 
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Abstract 
 
Objectives: Previous studies concluded that haemorrhage is one of the most accurate prognostic 
factors of mortality in leptospirosis. Therefore, endothelial cell activation was investigated in 
relation to disease severity in severe leptospirosis Methods: Prospective cohort study of severe 
leptospirosis patients. Plasma levels of sE-selectin and Von Willebrand factor (VWF) were 
determined. Consequently, an in vitro endothelial cell model was used to assess endothelial 
activation after exposure to virulent Leptospira. Finally, immune activation, as a potential 
contributing factor to endothelial cell activation, was determined by soluble IL2-receptor (sIL-2r) 
and soluble  Fas-ligand (sFasL) levels.  
Results: Plasma levels of sE-selectin and VWF strongly increased in patients compared to 
healthy controls. Furthermore, sE-selectin was significantly elevated (203 ng/ml vs. 157 ng/ml, p 
< 0.05) in survivors compared to non-survivors. Endothelial cells exposed to virulent Leptospira 
showed increased VWF expression. E-selectin and ICAM-1 expression did not change. 
Immunohistochemistry revealed the presence of intracellular Leptospira and qPCR suggested 
replication. In vivo analysis showed that increased levels of sFasL and sIL-2r were both strongly 
associated with mortality. Furthermore sIL-2r levels were increased in patients that developed 
bleeding and significantly correlated to duration of hospital stay. 
Discussion: Markers of endothelial activation and immune activation  were associated with 
disease severity in leptospirosis patients.  
 
 
  
Introduction 
 
Leptospirosis is an infectious disease of global importance (297). The disease is caused by 
spirochetes that are spread by the urine of infected animals. Mucous membranes, small cuts 
and abraded skin are the usual points of entry. Although the clinical course varies widely, 
leptospirosis can be fatal in up to 85% of all cases, especially in those that develop (pulmonary) 
haemorrhage (433;434). The more common mild form of leptospirosis is characterized by non-
specific symptoms such as: acute fever, headache, chills, myalgia and conjunctival suffusion. In 
most severe forms, the clinical picture of leptospirosis may encompass jaundice, renal failure 
and haemorrhaging of skin, mucous membranes and/or lungs. Post mortem pathological 
findings confirm widespread haemorrhaging and endothelial cell dysfunction resulting in 
generalized oedema (297;435).  
Clinical data from severe leptospirosis patients show significant activation of coagulation, which 
in many cases is followed by (often fatal) haemorrhage (381;382). Although the 
pathophysiology of the haemorrhagic diathesis in leptospirosis remains unclear, bleeding could 
very well be the result of endothelial cell dysfunction, since the endothelium is the key player in 
regulation of haemostasis (9). Under physiological conditions the vascular endothelium inhibits 
coagulation, prevents platelet aggregation and due to low levels of expressed adhesion 
molecules, it precludes adherence and migration of leukocytes. Injury or activation of 
endothelial cells in response to pathogens or to inflammatory cytokines can cause bleeding due 
to the loss of integrity of the blood vessel resulting in consumptive coagulopathy and/or 
vascular leakage (436). Thus far, in vitro work showed the ability of Leptospira to transmigrate 
through endothelial cell monolayers (210). Furthermore, an increase in adhesion molecules on 
the surface of human umbilical vein endothelial cells (HUVEC) was measured, when cells were 
incubated with Escherischia coli expressing leptospiral outer membrane proteins or with a 
recombinant leptospiral lipoprotein (383;384).  
However, the exact role for endothelial cell activation, or source of damage, in the 
pathogenesis of leptospirosis remains unclear. In particular, it is not known whether  
haemorrhage is a direct function from exposure to the pathogen, or indirectly via host response 
factors (437). The aim of this work was to investigate endothelial cell activation in relation to 
bleeding in patients suffering from severe leptospirosis using a combined in vivo, in vitro, in vivo 
approach. To do so, we first determined the state of the endothelium in patients with severe 
leptospirosis, using soluble E-selectin (sE-selectin), a marker of activity expressed exclusively on 
the surface of endothelial cells (438) (438) and von Willebrand factor (VWF), also a sensitive 
marker of endothelial cell activation. We then evaluated the interaction between virulent 
Leptospira and endothelial cells in vitro using HUVEC. Combined, these results led us to 
hypothesise that T-cells play a more prominent role in the pathogenesis of severe leptospirosis. 
This hypothesis was tested in patients with severe leptospirosis by measuring the T-cell 
activation marker soluble IL2-receptor (sIL2-r) and the immune mediated cell damage marker 
soluble Fas Ligand (sFas).  
 
Materials and methods 
 
Patients and controls 
Consecutive patients with severe leptospirosis were included from February 2005 till 
September 2006 at the Dr. Kariadi hospital, Semarang, Indonesia. Severe leptospirosis was 
defined as hospitalized patients with a high clinical suspicion of leptospirosis, presenting with at 
least one of the following symptoms or signs: jaundice, renal failure, thrombocytopenia and/or 
bleeding and a positive LeptoTek Dri-Dot assay (Biomérieux), confirmed by microscopic 
agglutination test (MAT). We defined bleeding as the spontaneous occurrence of: petechiae, 
ecchymosis, epistaxis, gum bleeding, haematuria, melena, hematemesis and/or haemoptysis. 
After written informed consent was given, blood samples were taken on admission and during 
follow up at day 1, 2, 7 and 14. Citrated blood was centrifuged immediately and plasma aliquots 
were stored at -70°C until further analyses. As controls, 20 healthy Indonesian (Javanese) 
volunteers (no fever, no complaints at time of blood withdrawal) were tested. The medical 
ethics committee of the Dr. Kariadi hospital approved the study protocol. 
 
Leptospirosis diagnosis 
Clinical diagnosis of leptospirosis was confirmed by MAT and IgM enzyme linked 
immunosorbent assay (ELISA). For the MAT a panel of 31 serovars was used (28 pathogenic 
serovars and 3 non-pathogenic serovars). A titre of  ≥ 1:320 on a single sample, seroconversion 
or at least fourfold titre rise in paired samples or a titre ≥ 1:80 in a single sample from early 
deceased patients, were considered to be positive. 
 
Soluble E-Selectin and Von Willebrand Factor  
Both endothelial markers, sE-selectin (R&D Systems, Minneapolis, MN, USA) and VWF 
(antibodies from Dako, Glostrup, Denmark) were determined by ELISA on citrated plasma 
samples.  
 
Cells 
Human umbilical vein endothelial cells (HUVEC) were harvested from fresh umbilical veins from 
healthy mother and baby. Isolated cells were de-identified and therefore could not be traced 
back to the original donor. Umbilical cords were stored in sterile 500 ml PBS + gentamycin (50 
µg/ml) (Leo Pharmaceutical Products, Denmark). The veins were rinsed with PBS containing 50 
U/ml heparin (Leo Pharmaceutical Products). Subsequently, cells were detached with 0.1% 
collagenase solution (C6885, Sigma Aldrich, USA). Cell suspension was collected in a sterile 50 
ml tube followed by centrifugation (2 x 5 minutes; 300 x g). The cell pellet was re-suspended in 
HUVEC medium (human endothelial-SFM medium, Invitrogen, USA) containing 10% human 
serum (Lonza, the Netherlands), 20% filtrated Fetal Bovine Serum (FBS); penicillin/streptomycin 
100 U/ml, 20 ng/ml fibroblast growth factor (Peprotech, USA) and 10 ng/ml of endothelial cell 
growth factor (Peprotech). Cell suspensions were cultured in flasks pre-coated with 20 μg/ml of 
fibronectin (Roche, the Netherlands). Passage two cells from one specific donor were used for 
this study. The identity of the endothelial cells was confirmed by flow cytometry using Ulex 
europeus lectin (EY laboratories, USA), anti-CD31 antibody (Sigma Aldrich, USA) and Von 
Willebrand Factor staining (Dako, the Netherlands). 
 
Bacteria and infection 
For the in vitro experiments the highly virulent, low passage isolate L. interrogans serovar 
Copenhageni (strain RJ16441) was used (henceforth denoted as: “virulent strain”). This strain 
was originally isolated from blood cultures of a patient with leptospirosis pulmonary 
haemorrhage syndrome as described in (387). The organism was maintained in Ellinghausen-
McCollough-Johnson-Harris (EMJH) semisolid medium (EMJH medium containing 0.2% noble 
agar and 200 μg/ml 5-fluorouracil) or liquid culture medium (EMJH medium with 6% rabbit 
serum) at 30°C under aerobic conditions and regularly passaged though guinea pigs to preserve 
its virulence (for which ethical approval was given by the University College Dublin). Leptospira 
were harvested at the log phase of their growth (1-2 x 108/ml) and washed 2 times in RPMI 
medium before being re-suspended in HUVEC medium. For the infection 2.4 x 105 endothelial 
cells were incubated with a multiplicity of infection (MOI) of 10 either with the virulent 
pathogenic strain, or a multi-passaged non-virulent pathogenic, Leptospira interrogans serovar 
Copenhageni strain Wijnberg isolate (henceforth denoted as: “non-virulent strain”). The 
negative control consisting of bacteria free normal HUVEC medium (without antibiotics, with 
20% FBS and no human plasma). After 24 and 48 hours of incubation, HUVEC were washed 
three times with PBS and formalin (no cell permeabilization) or methanol (with cell 
permeabilization) fixed.  
 
Infection kinetics 
For the evaluation of the infection kinetics of viable Leptospira in the endothelial cell model, we 
used an in house developed immune peroxidase staining procedure (Goeijenbier et al. 
manuscript submitted). Briefly, HUVEC were washed three times with PBS. Cells were fixed with 
absolute methanol (-20oC) for permeabilization at -20oC for 30 minutes or with 4% formalin for 
no permeabilization and incubated at room temperature for 30 minutes. After fixation, fixative 
was discarded and cells were incubated for 30 minutes at 37oC with 100 μl of 0.05% H2O2 in 
PBS, to block endogenous peroxidases. Subsequently, cells were washed three times with PBS 
and incubated for 60 minutes with polyclonal rabbit anti-Leptospira interrogans serovar 
Copenhageni antibody (1:500, KIT Biomedical Research, the Netherlands). Cells were washed 
with PBS-0.05% Tween 20  followed by incubation with HRP-labelled goat anti-rabbit IgG 
conjugate (1:500; Dako, the Netherlands). Colour development was achieved by the addition of 
3-amino-9-ethylcarbazole (AEC) substrate (AEC dissolved in dimethylformamide buffered with 
acetate buffer of pH 5). In addition, Leptospira were quantified using a real-time TaqMan® 
based quantitative PCR based on the lipl32 gene for the quantitation of pathogenic Leptospira 
species. The DNA copy number per sample was calculated from a standard curve generated by 
a serial dilution of cultured Leptospira counted by dark-field microscopy with the use of a 
Helber counting chamber.   
 
Von Willebrand factor, ICAM-1 and E-Selectin expression  
HUVEC in 96 wells plates were fixed with 4% formalin and incubated with rabbit polyclonal anti-
VWF antibody (1:500; Dako, Denmarkt), mouse monoclonal anti-ICAM-1 (1:500; Invitrogen, 
USA) or mouse monoclonal anti-E-selectin (1:500; Pierce antibodies, USA) followed by 
incubation with the respective conjugate (1:500; Dako). After washing TMB was added for 
substrate reaction and reaction was stopped after 10 minutes by addition of 0.5 M of sulphuric 
acid. Optical density at 450 nm value was read with Tecan ELISA reader. 
 
Soluble Fas Ligand and soluble IL-2 receptor levels 
T- cell activation marker sIL-2r and cell death marker soluble Fas ligand were measured in EDTA 
plasma samples using commercially available ELISA kits (Thermo Scientific, USA; Invtrogen, USA, 
respectively) according to the manufacturer’s recommendations.   
 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 5.01 for Windows. When 
comparing two groups we made use of a Student's t test or Mann Whitney U, depending on the 
distribution of the data. For the comparison between multiple groups, both for the in vivo and 
in vitro results, non-parametric Kruskal-Wallis test was used with Dunn’s multiple comparison 
test or a one-way ANOVA with Tukey’s multiple comparisons test, depending on the 
distribution of the data. P values ≤0.05 were considered significant.  
 
 
 
 
  
Results 
Endothelial cell activation in patients with severe leptospirosis  
 
Patients 
Fifty-two patients with severe leptospirosis were included in the study, of which 37 (71%) were 
male. The median age was 45 (IQR 33-55) years. Fourteen patients (27%) died during the course 
of infection. The median time from admission to death was 3 days. Bleeding was apparent in 31 
(60%) patients; of these, 21 survived and 10 died (difference not significant). Signs of bleeding 
included: petechiae (n= 25), ecchymoses (n= 3), epistaxis (n= 2), melaena (n= 7), haematemesis 
(n= 2) and haematuria (n=1). On admission, 5 patients were stratified as non-septic, 28 as septic 
and 19 as severe septic. Statistically, bleeding was equally distributed among the non-septic, 
septic and severe septic patients. The median plasma creatinine and bilirubin levels were 5.4 
mg/dl (IQR 3.1-7.6) and 8.3 mg/dl (IQR 3.4-20) respectively. Liver enzymes levels were only 
mildly elevated: ASAT 66 U/l, ALAT 53 U/l. Thrombocytopenia (platelets ≤100x109/L) was 
recognized in 32 (62%) subjects and was significantly associated with bleeding (OR 4.6, 95%CI: 
1.3-16). 
 
The endothelium is highly activated in patients with severe leptospirosis 
Soluble E-selectin (mean: 169 ng/ml; SD 73) and VWF (mean: 500%; SD 182) levels in all 52 
severe leptospirosis patients were strongly elevated on admission (Figure 1). The controls 
displayed significant lower mean values of sE-selectin (29 ng/ml; SD 9) and VWF (91%; SD 29) 
(Figure 1A & B). Both endothelial cell markers decreased gradually during follow up, but did not 
reach normal values by day 14 post admission. When comparing subgroups of patients with 
(n=31) and without (n=21) haemorrhagic manifestations on admission, no significant difference 
was observed in sE-selectin (175 ng/ml vs. 161 ng/ml; p = .50) or VWF (511% vs. 483%; p = .60) 
levels. However, subgroup analysis of patients that did not survive infection revealed a mean 
concentration of sE-selectin that was higher when compared to patients that survived (p < 
0.05). Mean plasma levels of VWF were lower in the survivors (489%, SD 182) compared to non-
survivors (530%,SD 186), but this difference did not reach statistical significance. In regard to 
disease severity, comparison of  non-septic, septic and severe septic patients on admission and 
mean sE-selectin levels were: 136 ng/ml (SD 40), 186 ng/ml (SD 77) and 153 ng/ml (SD 70), 
respectively. Mean VWF levels were 432 % (SD 126), 538 % (SD 209) and 463 % (SD 141) 
respectively. These differences between non-septic, septic and severe septic patients were not 
significant.  
 
 
Figure 1. Plasma levels of soluble E-selectin (sE-Selectin) and von Willebrand factor (VWF) in 
patients with severe leptospirosis 
VWF (A) and sE-selectin (B) plasma levels over time in patients suffering from severe 
leptospirosis (n= number of patients per timepoint). Results are presented as means with error 
bars indicating the standard error of the mean. The values denoted in the bars indicate the 
number of available samples. * p-value < 0.0001 (significant difference from controls). Soluble E-
Selectin levels were increased in non-survivors at the day of hospital admission (day 0) (C; p < 
0.05) 
 
In vitro analysis of endothelial cell activation in leptospirosis 
 
Leptospira penetrate, survive and replicate within endothelial cells  
 
While studying proteomic alterations of HUVEC infected with live pathogenic Leptospira 
(Goeijenbier et al. manuscript submitted), we noticed the ability of virulent Leptospira to persist 
within endothelial cells. To analyse the behaviour of Leptospira in the endothelial cell culture, 
using 10 Leptospira per endothelial cell, immune peroxidase staining was performed with and 
without cell permeabilization. Figure 2 shows positive staining of intra- and extra-cellular 
Leptospira in endothelial cells, 48 hours post infection. When cells were formalin fixed, only 
extracellular Leptospira were detected. Fixed cells with cell permeabilization (methanol fixed 
cells) revealed the presence of both intra- and extra-cellular Leptospira. Furthermore, 
quantitative real time PCR showed a statistically significant increase of total leptospiral DNA (p 
< 0.05). When the quantity of leptospiral DNA from the supernatant and cell lysate were added 
up, with the goal to quantify total leptospiral DNA, a significant increase was observed. In the 
first 48 hours after infection, leptospiral DNA increased from a mean of 6.3 x 104 (SD 1.2 x 104) 
copies to 1.85 x 105 (SD 2.6 x 104).  
 
 
  
Figure 2. Immune peroxidase staining of HUVEC infected with Leptospira. The morphology of 
non-infected Human Umbilical Vein Endothelial cells (HUVEC) (2A) and HUVEC 48 hours 
incubated with a Leptospira interrogans multiplicity of infection of 10 (2B) is shown in the upper 
two panels and did not seem to differ between the two conditions. Panel C-F show the results of 
immunohistochemistry staining for the presence of extra cellular leptospira (C 10x & D 20x) and 
intra cellular Leptospira (E 10x & F 20x). After rigorous washing  and cell permeabilization still 
clear intracellular staining is present in E and F suggesting the presence of at least Leptospira 
proteins inside the endothelial cells. 
 
 
 
 
Virulent pathogenic Leptospira upregulate expression of VWF on the HUVEC surface of 
endothelial cells 
To study if viable pathogenic Leptospira could directly increase markers of endothelial cell 
activation on the endothelial cell surface, we exposed HUVEC to virulent leptospires. To this 
end, 3 x 105 Leptospira (MOI 10) were incubated with endothelial cells. At 24 and 48 hours post 
infection, cells were formalin fixed and endothelial activation markers were quantified by 
incubation with a polyclonal antibody and HRP-labelled conjugate reaction. Both bacteria free 
medium and the non-virulent pathogenic L. interrogans serovar Copenhageni served as 
controls. Figure 3 shows the significant increase in VWF expression on HUVEC surface at 24 and 
48 hours post infection with the virulent pathogenic L. interrogans serovar Copenhageni strain 
RJ16441 after the subtraction of blank optical density (OD) values and isotype control (rabbit 
polyclonal anti CD-3). The non-virulent pathogenic L. interrogans serovar Copenhageni strain 
Wijnberg was not able to induce significant VWF expression. Cell surface expression of E-
selectin and ICAM-1 was not significantly changed at these time points when compared to the 
two control groups (data not shown). 
 
 
 
Figure 3. Cell surface quantification of von Willebrand factor (VWF) on infected and non-
infected endothelial cells. Results of the cell surface quantification of VWF expressed by Optical 
Density (OD) after incubation with Von Willebrand antibody and matching conjugate after 24 
(A) and 48 (B) hours of infection. Compared to both a non-virulent control of Leptospira 
interrogans and a bacteria free medium control the VWF OD expression is increased on HUVEC 
surface when incubated with live virulent Leptospira interrogans serovar Copenhageni (p < 
0.001). 
 
 
In vivo markers of immune activation and cell death in severe leptospirosis patients  
 
Soluble Interleukin 2 receptor levels are associated with survival and bleeding in severe 
leptospirosis patients 
Since the in vitro experiments showed that virulent Leptospira were able to induce VWF 
expression on HUVEC, but not the endothelial cell activation markers E-selectin and ICAM-1, we 
aimed to study potential host factors in relation to endothelial cell dysfunction and 
consequently haemorrhage. 
At first we tested plasma levels of the T -cell activation marker sIL2-r in the previous discussed 
cohort of severe leptospirosis patients. Admission sIL-2r levels were elevated with a mean value 
of 4700 U/mL (SD 3000 u/mL) and were significantly (p < 0.001) higher when compared to the 
healthy control group (Figure 4A), which showed a mean value of 600 U/mL (SD 200). 
Furthermore subgroup analysis showed that sIL-2r levels were significantly increased in patients 
that did not survive the infection (p < 0.01) (Figure 4B) and in those who developed bleeding 
during the course of infection (p < 0.05) (Figure 4C). The association between disease severity 
and sIL-2r levels was further confirmed by the statistically significant correlation between the 
number of days of hospital admission and sIL2-r levels at the day of admission (Spearman r 0.1-
0.6; p < 0.05), when non-survivors were excluded from the analysis. 
Plasma levels of sFAS Ligand are increased in severe leptospirosis patients that did not survive 
To further assess the association between immune activation and disease severity in severe 
leptospirosis we tested the specific marker of immune mediated cell damage soluble Fas LIgand 
ligand. SFAS ligand was increased in non-survivors on the day of admission with a Log10 mean 
value of 2.7 ng/mL (SD 0.4) compared to a Log10 mean value of 1.9 ng/mL (SD 0.5) in survivors 
and 1.8 ng/mL (SD 0.3) in controls. On admission, the soluble Fas ligand (sFas ligand) plasma 
levels were significantly increased in non-survivors when compared to survivors (p < 0.01) and 
control patients (p < 0.01) (Figure 5). With a large variability in the data, no significant results 
were obtained when comparing bleeding to non-bleeding, or for correlations of markers of 
severe disease.  
 
 
Figure 4. Soluble IL-2 receptor (sIL-2r) plasma levels in patients with severe leptospirosis. 
Levels of sIL-2r were significantly increased in severe leptospirosis patients at the day of hospital 
admission (4A; *** = p < 0.001). Furthermore, when performing subgroup analysis sIL2-r levels 
were higher in non-survivors compared to survivors (4B; ** = p < 0.01). The same holds true for 
patients that did develop bleeding and patients that did not (4C; * = p < 0.05). When correlating 
sIL2-r levels with days of hospital admission a significant correlation was seen with a Spearman 
r of 0.35 (4D; 0.1-0.6 95% CI p = 0.03) 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. Soluble Fas ligand levels in 
severe leptospirosis patients. 
Patients that did not survive 
leptospirosis infection had higher sFAS 
ligand plasma levels at hospital 
admission than patients that survived 
or  healthy controls (** p < 0.01). 
Between brackets are the number of 
included patients. HC stands for 
healthy controls. Bar represents the 
median. 
 
 
 
 
Discussion 
This study aimed to investigate the role of endothelial cell activation and subsequent 
dysfunction in the pathophysiology of severe leptospirosis both in vivo and in vitro. At first, 
patterns of the endothelial cell activation markers sE-selectin and VWF were measured in 
patients with severe leptospirosis. Plasma levels of sE-selectin and VWF were highly increased 
in patients with severe leptospirosis (p < 0.01) reflecting considerable activation, or damage, of 
the endothelium. When comparing samples taken at the day of hospital admission, sE-selectin 
levels were significantly increased in patients that did not survive(p <0.05). Although the 
association between mortality and the specific endothelial cell marker sE-selectin suggests a 
prominent role of the endothelium in the pathophysiology of severe leptospirosis, both VWF 
and sE-selectin levels were not significantly associated with bleeding in our cohort. These 
observations suggest that another factor also contributes to the bleeding diathesis in patients 
with severe leptospirosis. However, our assays were not able to distinguish between 
endothelial damage versus endothelial cell activation. Soluble E-selectin has its physiological 
activity on the endothelial cell surface, whereas VWF mediates adhesion of platelets to sites of 
vascular damage and is important for platelet aggregation by binding the GP IIb/IIIa platelet 
receptor. Both sE-selectin and VWF are released by endothelial cells when contacted with 
bacterial proteins, such as endotoxin(439;440). Intravenous administration of endotoxin into 
humans caused a dose dependent increase of sE-selectin, establishing its role as a quantitative 
marker of inflammation induced endothelial activation (439). The role of sE-selectin in the 
pathogenesis of leptospirosis could very well be comparable to the one that has been 
extensively studied in bacterial sepsis where sE-selectin was proven to be an excellent marker 
for organ dysfunction (441). Activated endothelium can cause an imbalance in the ignition of 
the plasmatic coagulation pathways, which can lead to both thrombosis and bleeding. High 
levels of sE-selectin were observed in the present study, reflecting endothelial cell activation or 
damage. Furthermore, several studies have indicated that sE-selectin is elevated during septic 
conditions and that high levels are associated with poor clinical outcome (441) and therefore 
further analysis of this marker in leptospirosis is warranted. Elevated levels of VWF have been 
observed in several inflammatory disease states, including sepsis and septic shock. However 
data that correlate plasma levels of VWF with disease severity and patient outcome are 
inconsistent (441). 
Secondly we addressed the capability of live, virulent Leptospira to activate primary culture 
endothelial cells in vitro, with the hypothesis that endothelial cell activation or damage could 
be a direct result of interactions of the pathogen with the host endothelium. Interestingly, 
infection with a MOI of 10 of the virulent Leptospira resulted in significant increased VWF cell 
surface expression when compared to cells incubated with bacteria free control medium or 
with a MOI 10 of culture attenuated non-virulent Leptospira. The specificity of this finding was 
supported by the fact that a non-virulent, multiple passaged control was used from the same 
serovar (Copenhageni). The activation markers E-selectin and ICAM-1 did not differ significantly 
after incubation with virulent Leptospira compared with the control groups, suggesting another 
mechanism than direct pathogen induced expression like we observed with VWF. However, our 
primary endothelial cell culture is limited to 48 hours of culture, while we must take note that 
leptospirosis patients have likely been exposed at least five days before showing symptoms, 
based on the mean incubation time of leptospirosis (179).  
Thus far, data on the interaction between the endothelial cell and Leptospira are scarce. 
Leptospira were shown to induce endothelial cell adhesiveness for neutrophils in an 
experimental model, using HUVEC and sonicated Leptospira (442). Leptospiral peptidoglycan 
(which is not expressed on the surface of viable Leptospira) but not leptospiral LPS (which is 
surface exposed), actively induced the observed endothelial cell adhesiveness for neutrophils. 
Vieira et al. reported expression of E-selectin and ICAM-1 by HUVEC when directly stimulated 
with the leptospiral lipoprotein LIC10365 in a dose-dependent matter (384). Pathological 
studies suggest that the haemorrhagic phenomena in leptospirosis patients are due to capillary 
wall damage (435;443). One could speculate that Leptospira might be able to damage 
(endothelial) cell membranes directly or indirectly by production of toxins. It has been shown 
that pathogenic Leptospira contain different genes encoding for proteases and other products 
that can cause host cell membrane degradation like: sphingomyelinases and phospholipases 
(444). Of interest is the fact that VWF expression, but not E-selectine and ICAM-1, significantly 
increased on endothelial cells following incubation with live virulent Leptospira. Clearly 
endothelial cell responses to viable Leptospira, simulating a more physiological condition, differ 
from endothelial cell responses to inactivated Leptospira or leptospiral proteins as was shown 
in previous studies. Furthermore, future research should include different strains of Leptospira, 
since Leptospira strains clearly differ in phenotype and even associated with a different clinical 
presentation when they infect human. Indeed, analysis of the infection kinetics and the viability 
of the virulent Leptospira in culture revealed intracellular Leptospira and increased leptospiral 
DNA over the time of infection underlining the importance of the interaction between viable 
bacteria and endothelial cells. Moreover results suggest alternative, indirect pathogenic 
mechanisms that lead to VWF expression, and other pathways that may result in endothelial 
dysfunction. Hence it was hypothesised that the presence of intra endothelial Leptospira, or 
Leptospira stuck to the cell surface of endothelial cells, may lead to endothelial cell activation or 
even damage as a bystander effect from a targeted immune response. 
In the third part of the study, plasma levels of the B, but especially T cell activation marker sIL2-
receptor and the immune mediated cell death marker sFas ligand were measured. Both 
markers showed significantly increased levels in those patients that did not survive infection. 
Furthermore sIL2-receptor levels were increased in patients that developed haemorrhage and 
positively correlated to the duration of hospital admission. Petro et al. demonstrated highly 
increased sIL-2r levels in a patient with severe leptospirosis admitted to the hospital in 
Germany and a possible correlation towards disease severity (445). This study confirms the 
relation between sIL-2r levels and disease severity in leptospirosis in a cohort. Furthermore, 
corticosteroid treatment, and subsequent T-cell suppression, might increase survival chances in 
severe pulmonary leptospirosis (446); future studies focussing on the role of T-cells in severe 
leptospirosis should be executed. The increased levels of sFas ligand in non-survivors in our 
cohort is of great interest for further discussion. First of all since sFas ligand seems to play an 
important role in the induction of acute lung injury and induces apoptosis in endothelial cells 
(447;448). Furthermore, increased levels of sFas ligand are associated with higher Sequential 
Organ Failure Assessment scores suggesting a potential role for this protein in bacterial sepsis 
(449). In our cohort sFas ligand plasma levels at the day of hospital admission seems an 
excellent prognostic factor for non-survival.  However, the large variability in sFas ligand levels 
in our cohort, the relative small numbers of patients included and the absence of kinetic 
analysis of sFas ligand levels in all patients warrants larger (prospective) studies. Furthermore, 
one should take in mind that only patients with severe leptospirosis were enrolled in our study. 
In a previous study, sE-selectin was shown to be elevated in 20 Thai patients with mild 
leptospirosis (450). These levels were higher (albeit not significantly) compared to patients 
presenting with murine typhus, scrub typhus, typhoid, dengue fever or uncomplicated malaria 
but lower compared to our results. Of future interest would be the differentiation between 
endothelial cell activation and endothelial cell damage in (severe) leptospirosis. A better 
understanding of endothelial cell damage rather than activation would be of great interest, for 
instance by measuring circulating endothelial cells which have been shown to correlate to 
disease severity in Haemorrhagic Fever with Renal syndrome, a disease with many clinical 
similarities with leptospirosis (358). 
 
In conclusion, results demonstrate that markers of endothelial cell activation are strongly 
elevated in patients with severe leptospirosis. Furthermore, in vitro viable virulent Leptospira 
moved intracellular where they caused an increase in VWF expression on the cell surface of the 
endothelial cells. Furthermore, the T-cell activation marker sIL2-r and immune related cell 
damage marker sFas ligand were statistically significantly increased in severe leptospirosis 
patients and associated with mortality. Future studies are needed to establish the precise role 
of the endothelial cell in the pathophysiology of leptospirosis while prognostic clinical cohort 
studies should include whether the use of sIL-2r and sFas ligand as prognostic biomarkers in 
severe leptospirosis is of use. 
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Abstract 
 
 “Epidemiological studies relate influenza infection with vascular diseases including myocardial 
infarction. In several animal model studies the procoagulant effects of influenza virus infection 
have been investigated. Since these studies made use of animals only susceptible to laboratory 
animal adapted influenza viruses, their results are hard to translate to human influenza. 
Therefore we decided to study the influence of different human influenza virus infections on 
coagulation in the ferret influenza model. Ferrets were infected with either a seasonal-, 
pandemic- or highly pathogenic avian influenza (HPAI-H5N1) virus strains, or mock,infected. In a 
14 day interval (only 4 days for HPAI-H5N1) with in total 7 time points, 4 animals were 
euthanized per timepoint and citrated plasma was tested for prothrombin time (PT), activated 
partial thromboplastin time (aPTT), Von Willebrand factor activity (VWF), thrombin-
antithrombin complex levels and D-dimer. Lung tissue was used for fibrin staining. All influenza 
virus infected animals showed alterations in haemostasis. Specifically on day 4 post infection, a 
four second rise in both PT and aPTT was observed. D-dimer concentrations increased in all 3 
influenza groups with the highest concentrations in the pandemic influenza group. Von 
Willebrand factor activity levels increased early in infection suggesting endothelial cell 
activation. Mean thrombin-antithrombin complex levels increased in both pandemic and  HPAI-
H5N1 virus infected ferrets. At tissue level, fibrin staining showed intracapillary fibrin deposition 
especially in HPAI-H5N1 virus infected ferrets. This study showed hemostatic alterations both at 
the circulatory and at the tissue level upon infection with different influenza viruses in an animal 
model  closely mimicking human influenza virus infection. Alterations largely correlated with the 
severity of the  respective influenza virus infections.” 
Background 
There are three manifestations of influenza in humans: seasonal, avian and pandemic influenza. 
Seasonal influenza is caused by influenza A or B viruses which infect 5-15% of the human 
population every year (66). Symptoms vary from mild respiratory complaints to fatal respiratory 
distress due to multiple organ failur. Symptoms depend largely, however, on the health and 
immune status of the infected individual and the pathogenicity of the specific virus involved. 
While avian influenza A viruses cause sporadic zoonotic infections in humans, that do not 
spread efficiently among humans (451), these infections may result in respiratory disease 
manifestations that range from mild to fatal, which among other variables largely depends on 
the virulence of the virus involved. Although most seasonal influenza virus infections are self-
limiting, they do cause a considerable burden of disease that may be aggravated by 
complications of the infection (452). Patients with chronic illness are particularly at risk of 
developing these complications when suffering from (seasonal) influenza, like the observed 
increased risk for developing cardiovascular disease during or shortly after influenza virus 
infection (453). This observation is supported by the results of two intervention studies which 
showed a risk reduction of myocardial infarction after influenza vaccination, which later was 
confirmed by a meta-analysis carried out among 292,383 patients. This analysis showed 
significant reductions in myocardial infarction, all-cause mortality, and major adverse cardiac 
events in the influenza vaccinated groups (454-456). However, the etiological pathway and the 
frequency by which influenza predisposes for clinically relevant thrombotic disease has yet to 
be determined. Current data suggest that influenza virus infection causes an unbalanced 
coagulation manifested by a procoagulant state (for review see (20;80-82)). Indications for this 
increased clotting tendency have come from clinical, experimental mouse and in vitro data. 
Clinical reports range from mild increased coagulation and fibrinolysis markers such as von 
Willebrand factor (VWF) and D-dimer levels, to disseminated intravascular coagulation 
observed in severe avian influenza (83-85). Experimental mouse data indicate a procoagulant 
state characterized by increased thrombin generation, fibrin deposition, and an impaired 
fibrinolysis (86;87). However, as the mouse is not a natural host to influenza virus, mouse 
influenza models use mouse-adapted influenza viruses which cause a disease quite different 
from that of human influenza (457). Collectively experimental animal studies and 
epidemiological data have largely remained inconclusive and cannot readily be translated into 
clinically relevant conclusions.  
The laboratory ferret (Mustela putorius furo) is not only susceptible to human isolates of 
seasonal, avian and pandemic influenza viruses, but pathogenesis and severity of the respective 
clinical manifestations of these infections are to a large extent similar to those found in humans 
(458;459). Therefore, to address the hypothesis that humans at risk for vascular disease may 
develop clinically overt vascular thrombosis during or shortly after influenza virus infection 
(460), we collected plasma samples during a time course pathogenesis experiment in which 
ferrets were infected with seasonal-, avian- or pandemic influenza viruses (461). Even though 
ferrets are not generally considered to represent the high risk patients for vascular thrombotic 
disease, they do offer a biologically variable and reliable animal model to address the activation 
of coagulation during influenza virus infection. Prothrombin time, activated partial 
thromboplastin time, von Willebrand factor (VWF) activity, D-dimer levels, and thrombin-
antithrombin complexes were measured in sequentially collected plasma samples. In addition 
fibrin staining was carried out on the lungs of infected animals upon euthanasia to address the 
coagulation status at the tissue level. All these parameters were evaluated in relation to 
virological parameters and data on disease severity.  
 
Material & Methods 
Experimental design 
Samples from 104, 11-month old, male, outbred ferrets (Mustela putorius furo) were used for 
this experiment as described previously (461). Animals were inoculated both intratracheally and 
intranasally with one of three influenza viruses, or with control material (mock). All three 
influenza virus strains had been directly derived from patient isolates. For seasonal influenza, 
H3N2 virus (A/Netherlands/177/2008) (458), for pandemic influenza,  pH1N1 influenza virus 
(A/Netherlands/602/2009) (462) and for highly pathogenic avian influenza virus (HPAI) the 
H5N1 strain (A/Indonesia/5/2005) were used (463). Virus stocks were passaged three times in 
Madin-Darby Canine Kidney (MDCK) cells and titrated according to standard methods. The 
viruses were clarified and reached an infectious virus titre of 107.4 median tissue culture 
infectious dose (TCID50) per ml for H3N2 virus, and 10
7.8 TCID50 for both pH1N1 and HPAI-H5N1 
virus (464). The inoculum of the control group consisted of MDCK culture derived material 
which had been subjected to the same procedure to control for respiratory tract damage not 
related to replicating virus (461). Inocula consisted of 3 mL volumes of virus preparations with 
106 TCID50 given per animal partly intratracheally and partly intranasally. Ferrets were randomly 
selected for any of the predefined time points before the start of the experiment. Four ferrets 
were euthanized per time point. Each ferret was sampled twice: before inoculation and when 
sacrificed. This resulted in 104 samples analyzed before inoculation (28 mock, 28 H3N2, 28 
pH1N1 and 20 H5N1) and 4 samples per virus per time point (Table 1). During euthanasia, 
citrated blood was drawn by cardiac puncture in 3mL citrate tubes and plasma was prepared 
for testing in coagulation assays.  
 
 
  
Ethics statement 
To reduce the numbers of experimental animals used, we combined the earlier published 
influenza pathogenesis study (461) with the current study addressing questions related to 
activation of coagulation and tissue fibrin deposition during influenza virus infection. Animal 
housing and experiments were all in compliance with European guidelines (EU directive on 
animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997) as 
documented previously (461). The study protocol was approved by the independent animal 
experimentation ethical review committee of the Netherlands Vaccine Institute (permit number 
200900201). Animal welfare was observed on a daily basis, and animal handling was performed 
under light anesthesia using a mixture of ketamine and medetomidine. After handling, 
atipamezole was administered to antagonize the effect of medetomidine.  
 
Coagulation assays 
Prothrombin time (PT) and activated partial thromboplastin time (APTT) were measured using a 
BCS-XP coagulation analyzer (Siemens Healthcare Diagnostics) according to the instructions of 
the manufacturer. Clotting was initiated with Thromborel S (PT) and Pathrombin SL (APTT). 
VWF ristocetin cofactor activity was also determined on the BCS-XP with reagents of the 
manufacturer, and was expressed as percentage of normal pooled human plasma. Thrombin-
antithrombin complexes (TAT, Siemens Healthcare Diagnostics) and D-dimer levels 
(Asserachrom, Roche, The Netherlands) were measured using enzyme-linked immunosorbent 
assay. All these assays were carried out within the BSL-3 setting after careful calibration and 
validation. 
 
Pathology and fibrin staining 
Gross pathology and histopathology were evaluated as previously described (461). Relative lung 
weight was used as a validated measure of gross pathology and lung inflammation (465). For 
detection of fibrin, tissues were stained with the Lendrum staining according manufacturers’ 
protocol (MSB RRSK2-100 stain kit, Atom scientific). On each slide a small piece of human 
placenta was added as a positive control. Semi-quantitative assessment of fibrin expression in 
the lungs was performed as follows: for the alveoli, 25 arbitrarily chosen, 20x objective, fields of 
lung parenchyma of one lung section were examined by light microscopy for the presence of 
fibrin, without the knowledge of the identity of the animals. The scores (+ or -) were multiplied 
by 4 and presented as percentage.  
 
  
Virology 
The presence of virus and virus replication in the respiratory tract were measured by 
determining infectious virus titres at different sites of the upper respiratory tract (URT) and 
lower respiratory tract (LRT). These results were combined with data retrieved by measuring 
viral antigen expression using standardized semi-quantitative immunohistochemistry carried 
out at different sites of the LRT as described previously (461). 
 
Statistics 
All statistical analyses were performed using the software SPSS PASW statistics 17.0 and 
GraphPad Prism 4.01 for Windows. The data were expressed as mean or median with or 
without standard deviation or 95% confidence interval as described in figure and table legends. 
The compared groups are summarized in Table 1. The means per time point between the 
influenza virus infected groups and the mock control infected group were analyzed using the 
Mann-Whitney U test. Furthermore, values at the predefined time point of euthanasia were 
compared with pre-inoculation samples using paired t-testing. Differences with p≤0.05 were 
considered statistically significant. For comparison of individual association between virological 
parameters and coagulation markers we used Pearson correlation coefficient, and transformed 
to match a normal distribution if needed. For correlation analysis we used Bonferroni 
correction for multivariable comparison setting p-value threshold to p≤0.01.  
 
 
RESULTS 
Clinical signs, pathology and virology of ferrets after infection with H3N2-, pH1N1- or highly 
pathogenic H5N1 avian – influenza viruses 
 
Clinical signs, pathological changes and virological parameters of this time course experiment in 
ferrets have been reported previously (461). Data important for this study are summarized in 
Table 2. In short, clinical signs varied greatly between the three influenza virus and mock 
infected groups. All animals infected with H3N2, pH1N1, or mock infection, survived the 
infections. H3N2 virus infected ferrets showed mild clinical signs; nasal discharge, sneezing, 
decreased tendency to eat, and bodyweight decrease by 11% (SD 8.5-13%) at 7 dpi. Detection 
of infectious virus was restricted to the nose and peaked at 1 dpi. Upon necropsy the lungs of 
the H3N2 infected ferrets showed up to 10% consolidation by gross pathology while the relative 
lung weights did not differ from the controls. 
Ferrets infected with the pH1N1 virus showed more severe clinical signs compared to the 
seasonal H3N2 virus infected ferrets, with a body weight decrease around 15% (SD 11.4-18.6%). 
Viral titres during pH1N1 virus infection also peaked at 1 dpi, but occurred at similar levels 
throughout the whole respiratory tract. One ferret in the pH1N1 group developed severe 
dyspnea. Relative lung weights increased compared to those of the mock infected animals 
starting from day 1. Their relative lung weights (weight of lung divided by bodyweight 
multiplied by 100) had increased from 0.6 % (SD 0.57-0.65) to 1.3 % (SD 1.0-1.6). The lungs of 
the pH1N1 virus infected ferrets showed up to 70% consolidation by gross pathology.  
The HPAI-H5N1 virus infected ferrets showed more severe clinical signs with dyspnea leading to 
hypoxia. On 2.5 dpi, one animal died and one animal was euthanized for ethical reasons. On 3 
dpi, another animal died before it could be euthanized. H5N1 virus was predominantly found in 
the alveoli and viral titres peaked for a longer period, from 1 to 3 dpi. Upon necropsy the lungs 
of the H5N1 infected ferrets showed up to 100% consolidation by gross pathology and relative 
lung weight was increased up to 2.78% of total body weight, while pre-inoculation samples had 
a mean relative lung weight of 0.66%. Mock infected ferrets showed no significant clinical signs 
or weight loss. Only minor consolidations in about 10% of the lung tissue were found upon 
necropsy. 
To assess a potential link between hemostatic alterations with total virus titres we generated 
the areas under the curve (AUC) from the virus titre as shown in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Distribution of the ferrets used in this study.  Ferrets were sampled before inoculation 
with a mock control suspension, H3N2-, pH1N1- or H5N1 influenza virus. Coagulation analysis 
values from the different groups were compared using Mann-Whitney U test (X to Y). 
Subsequently values from the predefined timepoints were analyzed with the pre inoculation 
(P.I.) values using paired t-test (Y to Z). 
  
Group P.I. ½ dpi 1 dpi 2 dpi 3 dpi 4 dpi 7 dpi 14 dpi X 
 
 
 
 
 
Y 
Mock 28 4 4 4 4 4 4 4 
H3N2 28 4 4 4 4 4 4 4 
pH1N1 28 4 4 4 4 4 4 4 
H5N1 20 4 4 4 4 4 0 0 
total 104 16 16 16 16 16 12 12 
Z 
Day  1 2 3 4 7 14 
Bodyweight H3N2 -51 
(16-86) 
-100 
(9-190) 
-69 
(33-104) 
-124 
(117-130) 
-186 
(141-231) 
-205 
(101-309) 
pH1N1 -68 
(22-114) 
-169 
(161-176) 
-142 
(74-210) 
-250 
(185-315) 
-251 
(190-312) 
-193 
(19-368) 
H5N1 -70 
(35-105) 
-131 
(112-149) 
-170 
(142-198) 
-190 
(135-246) 
┼ ┼ 
Control -44 
(31-57) 
-20 
(+30 - -69) 
+7 
(+40- -25) 
-34 
(+19 - -88) 
-62 
(+10 - -134) 
-46 
(+30 – 123) 
Relative  
lung weight 10-2 gram 
H3N2 0.6 
(0.5-0.7) 
0.6 
(0.6-0.7) 
0.6 
(0.5-0.6) 
0.6 
(0.5-0.7) 
0.6 
(0.6-0.7) 
0.6 
(0.5-0.6) 
pH1N1 0.8 
(0.7-0.8) 
1.0 
(0.9-1.2) 
1.1 
(0.9-1.2) 
1.2 
(1.1-1.3) 
1.3 
(1.0-1.6) 
0.7 
(0.6-0.8) 
H5N1 0.9 
(0.6-1.2) 
1.4 
(1.1-1.7) 
1.7 
(1.2-2.2) 
2.4 
(2.0-2.7) 
┼ ┼ 
Control 0.7 
(0.7-0.8) 
0.7 
(0.6-0.8) 
0.6 
(0.6-0.6) 
0.6 
(0.6-0.7) 
0.6 
(0.6-0.7) 
0.6 
(0.5-0.7) 
Lung damage 
 % 
H3N2 3.8 
(0-8.5) 
2.5 
(0-5.4) 
0 0 0 1.3 
(0-3.8) 
pH1N1 22.5 
(17.5-27.5) 
25.0 
(19.2-30.8) 
40.0 
(31.8-48.1) 
45.0 
(35.0-55.0) 
47.5 
(30.4-64.6) 
25.0 
(19.2-30.8) 
H5N1 25.0 
(12.1-37.9) 
55.0 
(35.9-74.2) 
62.5 
(40.3-84.7) 
77.5 
(55.3-99.7) 
┼ ┼ 
Control 3.8 
(1.3-6.3) 
6.3 
(1.5-11) 
6.3 
(1.5-11) 
1.3 
(0-3.8) 
5.0 
(5-5) 
3.8 
(1.3-6.3) 
Turbinates/ nasal concha 
logTCID50 
H3N2 7.0 
(5.5-8.5) 
6.3 
(5.4-7.3) 
5.1 
(3.9-6.2) 
4.8 
(3.4-6.1) 
neg  neg  
pH1N1 8.2 
(8.0-8.5) 
8.0  
(7.7-8.3) 
7.6  
(7.0-8.2) 
7.0  
(6.2-7.9) 
neg neg 
H5N1 4.8 
(3.5-6.1) 
5.0 
(4.4-5.6) 
5.6 
(4.1-7.0) 
4.9 
(3.4-6.4) 
┼ ┼ 
Trachea 
logTCID50 
H3N2 2.4 
(<1.7-3.1) 
neg neg  neg  neg  neg  
pH1N1 5.5 
(5.0-6.0) 
5.4 
(5.0-5.9) 
5.9  
(5.6-6.3) 
5.5 
(4.3-6.9) 
neg neg 
H5N1 5.5 
(4.7-6.3) 
4.7 
(4.2-5.1) 
5.1 
(4.1-6.2) 
4.7 
(3.4-6.0) 
┼ ┼ 
Lung 
logTCID50 
H3N2 neg Neg Neg neg neg neg 
pH1N1 7.5 
(7.2-7.8) 
5.2  
(4.7-5.8) 
5.5  
(5.1-6.0) 
5.6 
(5.1-6.2) 
neg Neg 
 H5N1 6.6 (6.0-7.2) 5.2 (4.7-5.6) 5.8 (5.5-6.1) 5.2 (4.7-5.6) ┼ ┼ 
Table 2. Overview of the clinical data (bodyweight decrease, relative lung weight, lung damage) and 
 Virological parameters.   
Virus Day Virus titre* Lung virus 
AUC# 
Respiratory tract 
 AUC# 
 H
3
N
2
 
0.5 3.5 (2.9-4.2) neg 0 
1 7.0 (5.5-8.5) neg 2.6 
2 6.3 (5.4-7.3) neg 9.3 
3 5.1 (3.9-6.2) neg 15 
4 4.8 (3.4-6.1) neg 19.9 
p
H
1
N
1
 
0.5 26.0 (24.3-27.7) 0 0 
1 31.7 (31.1-32.3) 3.6 14.4 
2 27.0 (26.4-27.6) 10.0 43.8 
3 27.0 (25.7-28.4) 15.4 70.8 
4 25.7 (23.4-28.0) 20.1 97.1 
H
5
N
1
 
0.5 22.3 (19.5-25.2) 0 0 
1 27.61 (24.4-
30.8) 
3.1 12.5 
2 24.8 (22.3-27.3) 9.0 38.7 
3 26.1 (22.0-30.8) 14.5 64.3 
4 26.0 (23.9-28.0) 19.9 90.5 
 
Table 3. Viral parameters for correlation tests with coagulation results from 0.5-4 dpi.  
* Total virus titre in logTCID 50 (cumulative titres of all organs with significant virus titres: “lung, 
nasal concha, trachea, bronchus and bronchial lymph nodes”) (+/- SD) # AUC was calculated 
from virus titres curves. 7 dpi and 14 dpi were excluded from the analysis because we data 
points from 5 & 6 dpi are not available potentially resulting in over or underestimation of the 
true AUC  
 
 
 
 
 
 
 
 
 
Both prothrombin time and activated partial thromboplastin time show transient 
prolongations during influenza virus infection in ferrets 
 
To evaluate tissue factor pathway activation of the coagulation cascade we tested the 
prothrombin time (PT) for all samples. Before inoculation all ferrets had PTs within normal 
range.  
Figure 1 (row A) summarizes the PT results over time for all four groups. For both the H3N2 
virus and pH1N1 virus groups, PT values increased with approximately 4 seconds at 4 dpi 
compared to pre-inoculation samples (H3N2 p= 0.001, pH1N1 p= 0.02) and the mock infected 
animals at the same day (H3N2 p= 0.03, pH1N1 p= 0.03). In the H5N1 infected ferrets, PT 
prolongation started at 2 dpi with a prolongation up to 16 seconds in individual animals. A clear 
trend is seen with PT increasing up to 30 seconds at 3 dpi. On multiple occasions ferrets died 
before samples could be drawn, consequently the data depend on a small number of 
observations with a potentially strong survival bias. On 4 dpi only one sample met the quality 
criteria for PT testing in the H5N1 group with a PT of 13.4 seconds, a 1.4 second increase 
compared to mean + SD from day 0 and mock samples (+/- SD). No significant changes in PT 
were observed over time in the mock infected group. Row B in Figure 1 shows the Activated 
partial thromboplastin time (APTT) a measurement of the intrinsic pathway of coagulation. 
APTT´s showed similar trends as PT´s. At 4 dpi, APTT´s were prolonged in all the three infected 
groups (Figure 1). H3N2 virus and pH1N1 virus infected ferrets showed mean APTT’s of 27.8 
(26.1-29.6) and 24 (19.6-28.4) seconds respectively while for the mock group this was 19.7 
(18.5-20.9) seconds. Paired testing showed that the pH1N1 virus infected ferrets had 
significantly prolonged APTT’s than the samples from pre inoculation (p = 0.02). No significant 
difference was seen compared to the mock infected group, potentially due to lack of power. 
Comparing 4 dpi samples with all pre-inoculation samples results in significant differences for 
both H3N2 and pH1N1 (H3N2 p = 0.001 pH1N1 = 0.02). Three out of four ferrets inoculated 
with H3N2 and sacrificed at 4 dpi already showed APTT prolongation before inoculation. This 
was not observed in any of the other pre-inoculation samples, but hampers the interpretation 
of the significant lengthening on 4 dpi compared to the mock infected group (p = 0.03) resulting 
in a non-significant result in paired sample testing. HPAI-H5N1 virus infected ferrets showed a 
trend toward prolonged APTT on 3 dpi with a mean of 28 (17.1-38.9) seconds and on 4 dpi 26.3 
(17.3-25.3) seconds, which was statistically significant when compared to all APTT results in pre 
inoculation samples (3 dpi p = 0.02 ,4 dpi p = 0.02) .        
 
 
  Figure 1. Haemostasis markers during influenza virus infection in ferrets. PT (row A), APTT 
(row B), VWF activity  (row C) and D-dimer levels (row D) in ferrets infected with mock, H3N2-, 
pH1N1- or H5N1 influenza virus. Asterisk represents a p value < 0.05 in the paired samples  (t = 
0) or compared to the mock infection at the same time point. All influenza variants lead to 
(transient) increases in PT and APTT. Differences were especially observed on day 4 post 
infection For PT 18 and for APTT 22 out of 208 samples could not be tested due to due to 
technical failure or insufficient plasma volumes. VWF increase is seen in all three influenza virus 
groups, especially early after infection in pH1N1 and H5N1 virus infected ferrets with 
statistically significant results in the earliest time points after infection. D-Dimer levels were 
raised in all 3 influenza groups with the highest levels seen in the pH1N1 virus infected ferrets.   
X represents no data available since for H5N1 on day 7 and 14 no ferrets were alive. 
Increased Von Willebrand factor activity during influenza virus infection in ferrets suggests 
endothelial cell activation 
To study endothelial cell activation Von Willebrand Factor activity (VWF) was measured. Figure 
1 (row C) summarizes the results indicating that, compared to mock infection, VWF activity 
tends to early increase in all three influenza virus infected groups. H3N2 virus infected ferrets 
showed increased VWF activity from 2 dpi onward. Significant differences were observed at 2, 3 
and 4 dpi compared with mock infected ferrets on the same time points (2, 3 & 4 dpi, p= 0.028). 
Compared to all day 0 samples, drawn before inoculation, Mann Whitney U testing shows 
significant results for 3 and 4 dpi (3 dpi, p = 0.004 and 4 dpi, p = 0.003). For the pH1N1 virus 
infected group mean VWF activity differed significantly at 1 and 2 dpi compared to all pre-
inoculation samples (1 dpi, p = 0.0025, 2 dpi, p = 0.001). At these time points, VWF activity was 
also significantly higher compared to the pre-inoculation samples from the same ferrets in 
paired testing (p= 0.03). HPAI-H5N1 virus infected animals showed trends of increased VWF 
activity early after infection with highest levels seen at 1 (p=<0.05)  and 2 dpi (p=<0.05).  
 
Increased D-dimer levels during influenza virus infection in ferrets confirms a procoagulant 
state 
D-dimer levels, fibrin degradation products that are markers of both fibrinolysis and 
coagulation, were quantified and results are listed in row D of Figure 1. Control ferrets had 
relatively low D-dimer levels with a slight increase the first days after inoculation and returning 
to normal values at 7 dpi. This increase is most likely associated with the minor inflammation 
seen after inoculation with the mock cell suspension. After infection, D-dimer levels increased 
in all infected animals with the highest levels in the H1N1 virus infected animals (Figure 1). D-
dimer levels were significantly higher in both the H3N2 and pH1N1 virus infected ferrets at all 
time points (H3N2 p = 0.028; pH1N1 p = 0.028) compared to the mock infected group and to 
the pre-inoculation samples of the same animals (H3N2 p= 0,005; pH1N1 p= 0.003). D-dimer 
levels remained higher, compared to mock, until 7 dpi (H3N2 p = 0.028 pH1N1 p = 0.028). HPAI-
H5N1 virus infected animals showed significant increases compared to the pre-inoculation 
samples (p = 0.005) on 2 dpi compared to mock infected ferrets. 
 
Plasma thrombin-antithrombin complexes are especially increased after infection with highly 
pathogenic avian influenza H5N1 virus 
To further analyze activation of coagulation all ferrets were tested for plasma thrombin-
antithrombin (TAT) complexes (Figure 2). Highest TAT levels were seen in HPAI-H5N1 virus 
infected ferrets with a trend of increased TAT generation. To analyze the total TAT formation 
and compare to D-dimer formation during the course of infection we combined all data from ½ 
to 4 dpi of each group. This resulted in increased TAT levels for both H1N1 and HPAI-H5N1 virus 
infected groups (p=<0.05) and an increase in D-dimer formation during all three influenza virus 
infections (panel E & F Figure 2).  
 
 
 
Figure 2. Thrombin-antithrombin complexes in ferrets infected with mock (A), H3N2 (B)-, 
pH1N (C)- or H5N1(D)  influenza virus. Bar represents median in scatterdot. Asterisk represents 
a p value < 0.05 in the paired samples (t = 0) or compared to the mock infection. E shows mean 
TAT levels during the first episode of infection (day ½ to 4) F shows mean D-dimer levels during 
the first episode of infection (day ½ to 4). Samples drawn before infection could not be analyzed 
due to exogenous TAT formation during venapuncture.  
 
 
 
Fibrin tissue staining suggests activation of coagulation at tissue level 
The Lendrum staining on alveolar lung tissues showed predominantly the presence of fibrin 
deposition (orange-red color) in many capillaries in the alveolar walls in the HPAI-H5N1 virus 
infected group (Figure 3). Intermediate numbers of capillaries stained positive in the H3N2 virus 
infected group, a few capillaries of the pH1N1 virus infected group and in none in a negative 
control sample from an uninfected ferret. However, the differences did not reach statistical 
significance when compared to the mock infected group. The mock infected group inoculated 
with uninfected cell derived material did show minor signs of inflammation which were the 
result of intra tracheal inoculation. This resulted in an intermediate numbers of capillaries 
positive for fibrin staining. In the slides stained for fibrin, there is no or very little presence of 
fibrin in the lumen of the bronchial submucosal glands with no significant difference between 
the virus groups. Only in few pH1N1 and H5N1 infected animals in rare lumina of bronchial 
submucosal glands there was little staining of fibrin, despite the differences in inflammation 
within the glands between the viruses. The staining pattern in the capillaries surrounding the 
bronchi is similar as that in the lung parenchyma. 
 
 
Figure 3. Fibrin (Lendrum) staining of ferret lung tissue. Lendrum staining expressing fibrin 
(red) in lung tissue of a control ferret or 4 days after inoculation of different influenza viruses. 
No staining in a non-infected ferret (A), occasional intracappilairy staining of fibrin in ferrets 
inoculated with H3N2 (B) and pH1N1 (C), and multifocal intracapillary staining in ferrets 
inoculated with H5N1 (D). Panel E shows the results of a semi-quantitative scoring of fibrin 
deposition obtained by examining 25 images per slide. 
 
 Comparison of coagulation parameters with virological and disease severity data. 
 In HPAI-H5N1- and pH1N1 virus infected animals VWF activity increased in the first two days 
after infection, coinciding with peak virus titres. D-dimer levels increased during the first days 
after infection to peak at 3 and 4 dpi, when virus titres started to significantly decrease. In these 
animals, highest levels in clotting times were seen at 4 dpi when a peak in relative lung weights 
was also observed. There was a significant correlation between multiple parameters in all three 
influenza groups (summarized in Table 3). Correlation analysis revealed positive correlation 
between PT values and AUC of the virus titres for the H3N2 virus (R = 0.8, p <0.01) and pH1N1 
virus (R = 0.7, p <0.01). D-dimer levels significantly positively correlated with virus titre AUC and 
body weight decrease for the pH1N1 virus infected group. If we combine all data and thereby 
generate a dataset from influenza A virus infected ferrets, significant positive correlations can 
be seen between many of the virological and clinical parameters compared to the coagulation 
parameters. All significant R values are listed in Table 4 with those of most interest being body 
weight decrease with VWF, PT, APTT and D-dimer levels. Virus titre AUC’s correlated 
significantly with PT, APTT and D-dimer levels.  
 
  
Correlation H3N2 pH1N1 H5N1 H1N1+H5N1 Influenza A 
PT -Titre total# NS -0.6 (-0.9—0.1) * NS -0.5 (-0.75- -0.1) * NS 
PT -AUC total# 0.8 (0.4-0.9) *** 0.7 (0.3-0.9) ** NS 0.4 (0.1-0.7) * 0.4 (0.2-0.7)** 
PT -Body weight NS 0.8 (0.4-0.9)** NS 0.5 (0.1-0.7)* 0.5 (0.2-0.7) ** 
PT -Lung weight NS 0.6 (0.05-0.9) * NS NS 0.4 (0.05-0.6) * 
APTT -Titre total# -0.5 (-0.8 - -0.1) 
* 
NS NS NS NS 
APTT -AUC total# 0.8 (0.6-0.9) *** NS NS NS 0.3 (0.05-0.6) * 
APTT -Body weight NS 0.6 (0.2-0.9) ** NS 0.5 (0.1-0.7) ** 0.4 (0.2-0.6) ** 
APTT -Lung weight NS NS NS NS 0.3 (0.1-0.6) * 
VWF-Titre total# -0.6 (-0.8-0.1) * NS NS NS NS 
VWF-AUC total# 0.7 (0.4-0.9)** NS NS NS NS 
VWF-Body weight NS NS NS NS 0.4 (0.1-0.6) * 
VWF-Lung weight NS NS NS NS NS 
D-dimer -Titre total# NS NS NS NS NS 
D-dimer -AUC total# NS 0.6 (0.2-0.8)* NS 0.5 (0.1-0.7) * 0.4 (0.2-0.6 )**  
D-dimer -Body weight NS 0.7 (0.2-0.9) ** NS 0.5 (0.2-0.7)** 0.5 (0.2-0.7) *** 
D-dimer -Lung weight NS NS NS NS NS 
TAT -Titre total# NS NS NS NS 0.3 (0.1-0.6) * 
TAT -AUC total# NS NS NS NS NS 
TAT -Body weight NS NS 0.6 (0.2-0.9) * NS NS 
TAT -Lung weight NS NS NS 0.5 (0.1-0.7)** 0.3 (0.01-0.5) * 
Table 4. Correlation between virological parameters and markers of haemostasis.  
Virological parameters are listed in table 2. For each influenza virus group coagulation values 
were correlated to virological and clinical parameters. This was also done for the complete 
influenza A group (H3N2 + pH1N1 + H5N1) and for the combination of pH1N1 and H5N1 
because these two viruses are able to infect the complete respiratory tract instead of only the 
upper respiratory tract which is the case for H3N2. Pearson correlation coefficients are given if 
the values were statistically significant. * p <0.05 ** p < 0.01 *** P < 0.001 if not significant NS 
is listed in the table.  
 
Discussion 
The present study demonstrates, for the first time, procoagulant effects at the circulatory and 
tissue level in a ferret influenza model, largely proportional to the severity of influenza virus 
infection. These findings are in line with earlier epidemiological, clinical, animal and in vitro data 
(69;84-86;455;460;466;467). Ferrets have been shown to be an adequate model to study the 
coagulation cascade (468-470) with PT and APTT normal values varying from 11.6-12.7 and 
18.9-22.3 seconds respectively. This is comparable to our 104 pre-inoculation ferret samples 
(PT 11.7 (+/- 0.1) and APTT 19.8 (+/- 2.2)) (469).  
Like in humans, highly pathogenic avian influenza virus infection causes severe disease in 
ferrets, which may include bleeding complications and multi-organ failure (471;472). In our 
experiments, HPAI-H5N1 virus inoculated ferrets showed severe disease, which in some cases 
resulted in spontaneous death. Analysis of the coagulation cascade in these animals confirmed 
the severity of infection with prolongation of global coagulation assays and signs of activated 
endothelium. PT and APTT values increased already from 2 dpi onward with individual ferrets 
showing an increase up to 20 seconds. This observation is suggestive for consumptive 
coagulopathy which is strengthened by the high levels of fibrin deposition in the lung 
capillaries. Consumptive coagulopathy could be the result of extreme activation of coagulation, 
for instance due to increased tissue factor production as is seen in other (severe) viral diseases 
as Ebola haemorrhagic fever . The exact role for consumptive coagulopathy in highly pathogenic 
H5N1 infection warrants further research, but hypothetically the excess of coagulation activity 
could lead to microthrombosis in the pulmonary alveoli leading to respiratory distress or even 
multi organ failure (47). The procoagulant changes were seen both at the tissue level and in the 
circulation, suggested by the TAT increase. The statistically significant increase in D-dimer levels 
confirms this procoagulant state. However, D-dimer levels were lower in HPAI-H5N1 virus 
inoculated ferrets compared to ferrets infected with H3N2 virus and especially compared to the 
ferrets infected with pH1N1 virus. A possible explanation for this phenomenon could be the 
inhibition of fibrinolysis by high levels of plasminogen-activator type 1 activity (PAI-1) during 
H5N1 virus infection. Unfortunately we could not test PAI-1 activity in ferret plasma with the 
currently available human PAI-1 activity assays. Since plasminogen is proven to play an 
important role in influenza pathogenesis further exploring the biology, activation and inhibition 
of plasminogen in influenza infection would be of great interest (473). 
The second virus we used in our experiments was pH1N1. Although less severe compared to 
HPAI-H5N1 virus infected ferrets, pH1N1 virus infection caused severe pneumonia with lung 
damage in ferrets. While ferrets infected with pH1N1 virus showed remarkably high levels of D-
dimer, tissue fibrin deposition was not as prominent as seen in HPAI-H5N1 virus infected 
ferrets. Activated coagulation in other organs than the respiratory tract or a systemic activation 
of coagulation could explain this phenomenon. These severe procoagulant changes in the 
circulation could be the result of a specific immune activation during pH1N1 virus infection. A 
possible explanation can be found in the work of Monsalvo et al. who showed an excessive 
amount of pathogenic immune complexes, which are known to have systemic procoagulant 
effects, in fatal pH1N1 cases (474;475). Furthermore, TAT levels significantly increased in the 
first 4 days after infection and at 4 dpi there was a remarkable prolongation of PT and APTT 
values up to 4 seconds. The very ‘sudden’ increase of clotting times at 4 dpi is suggestive for a 
consumptive coagulopathy, possibly similar to what was seen in DIC due to HPAI-H5N1 virus 
infection and bacterial sepsis (476). Clotting times had normalized at 7dpi, however, indicating 
that in contrast to bacterial sepsis, the consumptive coagulopathy is transient and less severe. 
The ‘sudden’ onset of clotting time prolongation may be of interest to evaluate specific 
coagulation factor changes during influenza infection. 
To evaluate the influence of a more ‘moderate’ influenza virus infection, seasonal H3N2 virus 
was also included in the experiments. Although this influenza virus in general causes ‘moderate’ 
disease in humans and ferrets, it did cause significant procoagulant changes in the model with 
hemostatic alteration comparable to those of pH1N1 virus infected ferrets. However, TAT levels 
did not increase suggesting a more moderate procoagulant state compared to H1N1- and H5N1 
virus infected animals.  
Since the ageing human population is prone to both an increase in cardiovascular disease and 
to complications during and after infection with seasonal and avian influenza viruses (477;478), 
further exploration of the interplay between influenza and haemostasis would be of great 
interest. Most of the associations found in Table 3 show positive correlations between 
coagulation parameters and markers of inflammation (body weight decrease and relative lung 
weight increase). This comes as no surprise since the bidirectional cross-talk between 
coagulation and inflammation has been studied very well, whereby inflammation in general 
evokes a procoagulant response (479-481). The specific disturbances in the tightly regulated 
balance between clotting, anti-coagulation and inflammation could be a target for novel 
intervention strategies in influenza. Following our observational study, an intervention model 
could further evaluate the role of coagulation in influenza virus pathogenesis and the potential 
processes for targeted intervention, for example by targeting protease receptor type-2 (PAR-2) 
activation in influenza pathogenesis. PAR-2 is an important receptor in both inflammation and 
coagulation, and recently described to have a major role in the damage seen after the 
inflammatory response during influenza virus infection (482;483). While statins may also be 
interesting candidates for future studies. Statins may counteract specific inflammatory 
responses such as seen after acute coronary syndrome, and thereby may decrease mortality 
when given to influenza patients. Studying the influence of statin treatment on the 
procoagulant changes during influenza virus infection and the role these changes have in the 
postulated increased risk of myocardial infarction would be of great interest (484-486).  
Collectively the data generated by our study will pave the way for further exploration of novel 
treatment and intervention strategies for influenza and its complications. Furthermore, based 
on the correlation between the viral infection -  and coagulation parameters in this experiment, 
coagulation tests could serve as valuable biomarkers predicting disease severity.   The ferret 
model likely offers the best opportunity to explore these options in a preclinical setting 
optionally also linked to host genetics since ferrets represent an outbred population. 
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Abstract 
 
“Haemorrhagic fever with renal syndrome (HFRS) caused by hantaviruses and transmitted by 
rodents is a significant public health problem in China, and, based on the analysis of high 
endemic HFRS areas, seems to occur more frequently in selenium-deficient regions. To study the 
role of selenium concentration in HFRS incidence we used a multidisciplinary approach 
combining ecological analysis with preliminary experimental data. The incidence of HFRS in 
humans was about six times higher in severe selenium-deficient and double in moderate 
deficient areas compared to non-deficient areas. This association became statistically stronger 
after correction for other significant environment-related factors (low elevation, few grasslands, 
or an abundance of forests) and was independent of geographical scale by separate analyses for 
different climate regions. A case-control study of HFRS patients admitted to the hospital 
revealed increased activity and plasma levels of selenium binding proteins while selenium 
supplementation in vitro decreased viral replication in an endothelial cell model after infection 
with a low multiplicity of infection (MOI). Viral replication with a higher MOI was not affected 
by selenium supplementation. Our findings provide a valuable clue that selenium deficiency 
contributes to an increased prevalence of hantaviruses infections in both humans and rodents. 
However, future studies should further examine the exact mechanism behind this observation 
before selenium supplementation in deficient areas could be implemented for HFRS prevention.”
Introduction 
Haemorrhagic fever with renal syndrome (HFRS) is a zoonotic disease with a severe clinical 
presentation characterized by, as the name suggests, fever and renal failure potentially 
complicated by haemorrhage and shock (297). The disease is the result of infection with an Old-
World pathogenic hantavirus, which are negative stranded RNA viruses from the Bunyaviridae 
family (307). Pathogenic hantaviruses are shed in the excreta of their reservoir rodents and in 
most cases each hantavirus is associated with a specific rodent host (296). In mainland China 
HFRS is either caused by infection with the Hantaan virus (HTNV) or the Seoul virus (SEOV) 
carried by the striped field mice (Apodemus agrarius) and Norway rats (Rattus rattus) 
respectively (116;487-489). HFRS is a significant public health problem in mainland China with 
an annualized average incidence reported up to 120 per 100,000 persons per year for the high 
endemic parts of the country (489).  Case fatality rates (CFR) range from 0.1% to 15%, 
depending on the causative hantavirus and specific characteristics of the infected individual 
(54). To increase insight in HFRS epidemiology in China we previously identified hantavirus 
counties with the highest HFRS incidence per year in China and defined them as hantavirus 
‘hotspots’ (489). Further analysis of these hotspots revealed that most of them are categorized 
as being a ‘selenium-deficient’ area. This made us decide to further explore the association 
between hantavirus infection and selenium deficiency. 
Selenium is an essential micronutrient for many life forms, including humans, and has been 
suggested to play a role in multiple physiological and pathological processes (490;491). In 
contrast to many other micronutrients, the intake of selenium varies worldwide, ranging from 
decreased or even a severe deficient dietary intake to an elevated selenium intake, while even 
toxic concentrations in crops and feed have been reported in literature (492-494). Low intake of 
selenium, subsequently leading to decreased selenium levels in the circulation, might directly 
lead to diseases such as endemic cardiomyopathy (Keshan disease) or deformative 
osteoarthritis (Kashin-Beck disease) which is a relatively common disease in China (495-497). 
Furthermore, multiple studies suggest selenium levels to influence the occurrence and outcome 
of multiple other diseases including cancer and heart disease.  Most important for this study is 
the fact that the association between selenium levels and disease outcome is also seen in 
diseases of infectious origin (498;499). For instance, the incidence, virulence and progression of 
viral infections like human immunodeficiency virus (HIV), coxsackie virus, and influenza virus 
infections are influenced by selenium deficiency (500-503). The exact role of selenium 
concentration in these infections is not totally understood. However, experimental studies 
show selenium to play multiple roles in the immune response to infectious diseases. It has been 
shown that selenoproteins are essential for activated T-cell function and it seems they are 
involved in the modulation of inflammatory responses, for instance by inducing the interferon 
response (504-507). Selenium deficiency affects T-cell immunity by suppressing T-cell 
proliferation and causing defects in T-cell-dependent antibody responses (508).  
To explore the relation between HFRS incidence and selenium concentration in China, we 
decided to use a multi-disciplinary translational approach combining ecological, clinical and in 
vitro experiments. The aims of our study are 1) to examine to which extent human HFRS 
incidence and hantavirus infection rates of human and rodent reservoirs are associated with 
measures of selenium deficiency, controlling for other potentially confounding environmental 
factors, and 2) to explore where in the chain of the occurrence of a hantavirus infection, from 
rodent reservoir to human case, selenium concentration might have its influence. By studying 
levels of selenium binding proteins in acute HFRS patients (glutathione peroxidase (GPx3)) and 
the in vitro effects of selenium supplementation in a well-established puumala hantavirus 
(PUUV) endothelial cell model (HUVEC).   
 
 
Results 
Ecological analysis 
During 2005-2010, a total of 74,118 HFRS cases, including 914 deaths, were reported in 1,960 of 
the 2,922 counties in mainland China. The average annual HFRS incidence varied greatly over 
counties, ranging from 0 to 54 per 100,000 person-years, with a median of 0.1 per 100,000 
person-years. Areas were divided by selenium concentration in crops and feed in to selenium 
non-deficient (>=0.06 ppm), moderate-deficient (0.03 - 0.05 ppm) and severe deficient (<= 0.02 
ppm) areas. The moderate- and severe selenium-deficient areas covered 37.3% and 31.8% of 
the country, respectively (Figure 1). The average annual HFRS incidence in severe selenium-
deficient areas (2.27 per 100,000 person-years) was almost 3 times higher than in moderate 
deficient areas (0.83 per 100,000 person-years), which on its turn was double that in non-
deficient areas (0.40 per 100,000 person-years) (Table 1). Both of the hotspots of highest 
incidence of HFRS were located on the selenium-deficient belt of China: one in the eastern 
areas of northeastern China, the other in the central areas of mainland China (Figure 1).  
Figure 1. Geographic distribution of hemorrhagic fever with renal syndrome (HFRS) incidence in relation to 
selenium content of crops and feed in mainland China. The background of the map with color gradient 
presents the selenium content of crops and feed, and the dots with size and color gradient display the average 
annual incidence of HFRS from 2005 to 2010. Areas without dots do not have reported cases of HFRS. The thick 
grey lines are boundaries of 5 climate regions of China. The thin black circles indicate the 40 surveillance sites 
for hantaviruses infection in rodent hosts (used in Figure 2). Ppm is parts per million. 
 
 Variables (unit) a 
Average yearly incidence 
(95% CI, per 100,000 
person-years) 
Univariate analysis  Multivariate analysis 
Crude IRR (95% CI) P-value  Adjusted IRR (95% CI) P-value 
Selenium content (categorical, ppm)         
>= 0.06 (non-deficient areas) 0.40 (0.32 - 0.48 ) 1 -  1 - 
0.03 - 0.05 (moderate deficient areas) 0.83 (0.70 - 0.95 ) 2.07 (1.73 - 2.46) < 0.001  2.43 (2.04 - 2.88) < 0.001 
<= 0.02 (severe deficient areas) 2.27 (1.85 - 2.70 ) 5.68 (4.64 - 6.95) < 0.001  7.77 (6.29 - 9.61) < 0.001 
Elevation (categorical, 1000 m)       
< 0.4 1.33 (1.14 - 1.52 )      
0.4 - 1.37 (1.05 - 1.70 )      
0.8 - 0.58 (0.35 - 0.81 )      
1.6 - 0.17 (0.00 - 0.33 )      
> 3.2 0.08 (0.00 - 0.16 )      
Elevation (continuous, 1000 m)  0.46 (0.41 - 0.50) < 0.001  0.40 (0.35 - 0.46) < 0.001 
Croplands (categorical, %)       
< 20 0.98 (0.76 - 1.20) 1 -  1 - 
20 - 1.03 (0.84 - 1.23 ) 1.04 (0.86 - 1.26) 0.659  1.14 (0.93 - 1.39) 0.200 
> 50 1.13 (0.91 - 1.35 ) 1.14 (0.94 - 1.38) 0.185  1.03 (0.84 - 1.27) 0.766 
Forests (categorical, %)       
< 5 0.90 (0.72 - 1.09 ) 1 -  1 - 
5 - 1.01 (0.81 - 1.21 ) 1.11 (4.62 - 7.11) 0.285  1.53 (1.26 - 1.87) < 0.001 
> 40 1.21 (0.98 - 1.45 ) 1.32 (1.42 - 2.27) 0.004  1.53 (1.26 - 1.86) < 0.001 
Grasslands (categorical, %)       
< 2 1.20 (1.02 - 1.38 ) 1 -  1 - 
2 - 1.41 (1.13 - 1.70 ) 1.18 (0.98 - 1.41) 0.082  0.92 (0.77 - 1.10) 0.365 
> 20  0.44 (0.32 - 0.55 ) 0.38 (0.31 - 0.45) <  0.58 (0.45 - 0.74) < 0.001 
0.001 
Population density (categorical, 1000 
persons per km2) 
      
< 0.2 1.38 (1.10 - 1.65 )      
0.2 - 0.98 (0.82 - 1.14 )      
> 0.5 0.73 (0.61 - 0.84 )      
Population density (continuous, 1000 
persons per km2) 
 0.97 (0.95 - 0.99) 0.001  1.00 (0.98 - 1.02) 0.728 
GDP (categorical, 10 million Yuan per 
km2 ) 
      
< 0.08 1.22 (0.94 - 1.50 )      
0.08 - 1.07 (0.90 - 1.25 )      
> 0.4  0.84 (0.70 - 0.96 )      
GDP (continuous, 10 million Yuan per 
km2 ) 
 0.91 (0.88 - 0.93) < 0.001  0.93 (0.90 - 0.96) < 0.001 
Table 1. The association between haemorrhagic fever with renal syndrome (HFRS) incidence and selenium content of crops and feed 
by Poisson regression, using data from 2005 to 2010 in mainland China, both univariately and corrected for other influencing factors 
in multivariate analysis. IRR is incidence rate ratio. CI is confidence interval. For all continuous variables, we also report categorical 
results to allow inspection of the data and to assess whether the continuous assumption was justified. These categorical variables 
were not considered in the Poisson regression. 
  
  
Table 2. The association between HFRS incidence and selenium content by multivariate Poisson regression in different climate 
regions, corrected for other influencing factors (not shown). Region I = temperate monsoon climate; Region II = sub-tropical 
monsoon climate; Region III = tropical monsoon climate. Region II and Region III were combined due to the small area of Region III. 
In Region IV (highland hibernal climate) and Region V (temperate continental climate), almost all cases were located in severe 
selenium-deficient and moderate selenium-deficient areas, expect for 2 cases locating in non-deficient areas in Region V, not 
allowing statistical analysis due to the low numbers. IRR is incidence rate ratio. CI is confidence interval.
Variables (unit) 
Region I   Region II & Region III 
Adjusted IRR (95% CI) P-value  Adjusted IRR (95% CI) P-value 
Selenium content of crops and feed 
(categorical, ppm) 
     
>= 0.06 (non-deficient areas) 1   1  
0.03 - 0.05 (moderate deficient areas) 1.70 (1 .27 - 2.27) < 0.001  0.85 (0.67 - 1.08) 0.181 
<= 0.02 (severe deficient areas) 3.45 (2.49 - 4.79) < 0.001  2.80 (1.92 - 4.09) < 0.001 
  
Univariate Poisson regression analyses revealed that HFRS incidence was significantly 
associated with selenium content of crops and feed, average elevation, proportion of areas of 
forests and grasslands, population density, and GDP. Multivariate analysis showed that the 
adjusted IRR (7.77) in severe selenium-deficient areas was even higher than the crude IRR 
(5.68) in comparison with non-deficient areas (Table 1), while elevation, proportion of areas of 
forests and grasslands, and GDP remained significantly associated with HFRS incidence.  
Although selenium content was disproportionately spread over the five climate regions of 
China (Figure 1), similar associations between HFRS incidence and selenium content could be 
demonstrated within these regions (Table 2). The regions with many severe selenium-deficient 
areas had the highest IRR in Region I, and in Regions II and III combined. In Region IV, only 58 
HFRS cases were reported, but all of them came from severe selenium-deficient areas. Out of 
the 131 reported HFRS cases in Region V, 28, 103, and 2 cases were located in severe selenium-
deficient areas, moderate deficient areas, and non-deficient areas, respectively (Figure 1), and 
the corresponding annual incidences were 0.073, 0.152, and 0.003 per 100,000 human-years, 
respectively. Due to the low numbers, statistical analyses were not conducted for Regions IV 
and V.  
To verify the association between selenium deficiency in  crops and feed and the percentage 
of infected reservoir rodents, the hantavirus infection rate of rodent hosts in relation to 
selenium content of crops and feed was investigated for 40 surveillance sites through China 
(see the circles in Figure 1 for their locations). Both HFRS incidence in humans (Figure 2A) and 
hantavirus infections in rodents (Figure 2B) were negatively correlated with selenium content 
of crops and feed. The nonparametric equality-of-medians tests indicated that a significant 
difference on both HFRS incidence in humans (χ2 = 15.6, P < 0.001) and hantaviruses infection 
rates in rodents (χ2 = 6.8, P = 0.034) were found among these three areas.  
  
 
Clinical analysis 
Glutathione peroxidase (GPx3) concentrations and GPx activity in acute HFRS patients 
To study whether selenium levels differed between HFRS cases and healthy controls a case-
control study was executed which assessed the glutathione peroxidase 3 (GPx3) concentrations 
and glutathione peroxidase (GPx) enzyme activity, the major selenium binding proteins in 
humans, in acute HFRS patients and healthy controls. In total, 77 acute HFRS cases were 
included for GPx3 concentration measurement of which 61 (79.2%) were male. Concentration 
levels were compared to GPx3 concentrations measured in 72 healthy controls of which 36 
were male (50%). Age did not differ significantly between the two groups (p = 0.6). GPx3 
concentrations in ng/ml are shown in Figure 3. Acute male HFRS patients showed mean GPx3 
levels of 0.56 (0.28-0.84 ng/ml), while male healthy controls showed statistically significant 
lowered GPx3 levels of 0.28 (0.19-0.37) (p=<0.001). In female HFRS patients, a similar trend was 
observed showing statistically significant increased levels of GPx3 in HFRS patients compared to 
female healthy controls: 0.56 (0.23-0.89 ng/ml) versus 0.26 (0.19-0.33 ng/ml) (p=0.001).  
GPx activity levels were measured in a second cohort of HFRS patients. Samples from 80 acute 
HFRS cases (87.5% male) and 85 healthy controls (54.1% male) were tested for GPx activity. 
Again, age did not differ significantly between the two groups (p = 0.2). Figure 3 visualizes the 
increased GPx activity levels in acute male HFRS patients versus controls (p = 0.001), while 
there is no significant difference between cases and controls for female HFRS patients.   
Figure 2. Correlation between HFRS 
incidences in humans, hantaviruses 
infections in rodents and selenium content.  
The rodent data were from 40 surveillance 
sites in mainland China during the years  
2005 - 2008. The points reflect (A) average 
incidences of HFRS in human for the counties 
each surveillance site and (B) annual average 
hantaviruses infections in rodents for each 
surveillance site, and the lines represent the 
median bands. Selenium content of crops and 
feed <= 0.02 ppm represents severe selenium-
deficient areas; 0.03 - 0.05 ppm represents 
moderate selenium-deficient areas; >= 0.06 
ppm represents non-deficient areas.  
 
  
 
 
Figure 3. Glutathione peroxidase (GPx3) concentrations (A) and GPx activity (B) in HFRS 
patients and healthy controls. Asterisks (**) represent a p value smaller than 0.01 (p < 0.01).  
GPx3 levels (A) were increased in acute HFRS patients compared to controls. Furthermore, GPx 
enzyme activity levels (B) in nmol/min/ml were higher in male HFRS patients compared to 
controls. 
 
In vitro analysis of the influence of selenium on hantavirus replication 
To study the influence of selenium concentration on hantavirus replication in a well-established 
immune competent cell line of human origin we infected Human Umbilical Vein Endothelial 
Cells (HUVEC) with a low passage virulent isolate of puumala hantavirus (PUUV) with or without 
selenium supplementation. Figure 4 shows the viral copy numbers in each replicate measured 
every 24 hours up to 72 hours post infection of HUVEC’s with a multiplicity of infection (MOI) of 
0.05. Viral copy numbers significantly decreased after selenium supplementation of 200 ng/ml, 
suggesting a decrease in viral replication. If the number of virus particles of the inoculum 
increased to MOI 1 or even 3 the decrease in virus replication was no longer significant. This 
suggests that only at a low percentage of infected cells, after infection with a low MOI, 
selenium supplementation of 200 ng/ml affects viral replication.        
  
Figure 4. Viral copy numbers with or without the supplementation of selenium to cultured 
endothelial cells infected with Puumala hantavirus. Selenium supplementation (200 ng/ml of 
sodium selenite) to the culture medium leads to decreased viral replication after infection with a 
multiplicity of infection (MOI) of 0.05. Data was 10-log transformed to reach a normal 
distribution. 
 
Discussion 
HFRS is one of the most severe viral infectious diseases in mainland China (350;488). 
Furthermore, China is known to be one of the most severely selenium-deficient countries in the 
world (509;510), while in multiple aspects selenium deficiency is linked to pathophysiological 
mechanisms (504;506). By analyzing all reported HFRS cases in mainland China during a 6-year 
period, we found that the annual HFRS incidence was significantly lower in non-selenium-
deficient areas, relative to moderate selenium-deficient and severe selenium-deficient areas.  
After adjusting for other influential factors, the incidence of HFRS remained significantly 
associated with selenium deficiency. In severe selenium-deficient areas, the average HFRS 
incidence was about 6 times higher than that in non-deficient areas. The association between 
HFRS incidence and selenium deficiency was present in all 5 climate regions of China. 
Furthermore, HFRS incidence in humans and hantaviruses infection rates in rodent hosts were 
negatively correlated with selenium for 40 surveillance sites across the country. The highly 
heterogeneous distribution of HFRS incidence and the strong variation in selenium content of 
crops and feed give us a unique opportunity to explore the possible link between HFRS 
incidence and selenium.  
The low incidence of HFRS in southwestern China, which is a commonly selenium-deficient 
area shows that selenium deficiency could not be the only determinant for the occurrence of 
HFRS. Other factors influencing the reservoir distribution and rodent exposure should also be 
 considered for the occurrence of HFRS. In our study, we found low elevation to be another 
important determinant for HFRS in mainland China, which could be explained by the preference 
for low elevation by the HNTV reservoir species (489;511). Similarly, the distribution of land use 
(croplands, forests and grasslands) is associated with agricultural activities, possibly related to 
rodent densities. Furthermore, population density and GDP reflect the human living conditions 
and could very well relate to potential exposure of humans to rodents and their excreta (297). 
All of these determinants, despite selenium deficiency, were unfavorable for HFRS incidence in 
southwestern China. 
The very strong association between HFRS incidence and selenium concentration made us 
further explore which mechanisms potentially underlie this observation. The mechanisms that 
drive HFRS incidence are complex and multi-factorial (324;512) but basically include three main 
segments:  1) reservoir ecology, 2) virus ecology and 3) human factors. Interpretations of earlier 
studies on selenium and infectious disease suggest a potential role of each of these segments. 
By executing the first preliminary experiments on the potential mechanisms between HFRS and 
selenium, we tried to estimate how selenium concentrations most likely have their effect. At 
first we looked at human factors in the relation between selenium and HFRS by performing a 
case-control study in HFRS cases and comparing the plasma concentration and activity of the 
major selenium binding proteins GPx and GPx-3 (513). We thereby hypothesized that deficiency 
in selenium could either increase the hosts’ susceptibility to hantavirus infection, leading to 
more infections, or increase the host response to the hantavirus infection, which would lead to 
a more severe disease and thus an increase of reported HFRS cases. However, HFRS patients 
showed an increase in GPx3 levels, and also GPx activity was significantly higher in acute HFRS 
male patients. This observed pattern seems contradictory to the hypothesis that selenium 
deficiency affects the human factor in the occurrence of a HFRS case, especially since other 
studies describe a decrease in GPx3 activity during viral infection and sepsis (514;515), and 
suggests that the possible mechanism has its effect on the reservoir rodent or the virus.  
Our preliminary in vitro data show that selenium supplementation decrease viral replication 
in immune competent cells after infection with a (very) low infectious dose. However, 
increasing the infectious dose eliminated this effect, suggesting a role for selenium only in low 
viral load infections in vitro and thereby a (weak) immune stimulant effect of selenium 
supplementation. This effect could be bigger in vivo since earlier observed effects of selenium 
supplementation on natural killer- and T cell activity do not play a role in the in vitro cell model. 
This suggests that the mechanism behind our observation does not lie in the human host but 
might concern a prolonged or increased viral load in the reservoir, which potentially leads to 
prolonged and increased virus shedding. Furthermore, a direct mutating effect of selenium on 
the virus, resulting in changes in the viral fitness, cannot be excluded. This is an observation 
that has also been described in influenza virus studies (516;517). Unfortunately with our 
current assays and the samples available we were not able to measure selenium concentrations 
 in the reservoir rodents. To fully address these questions, further experiments should focus on 
selenium levels in the reservoir species, for instance in rodent cell lines, and explore the effect 
of selenium supplementation and deficiency on infectivity and viral fitness. 
In this study, a significant ecological association between HFRS incidence and selenium 
deficiency was found, also after adjusting for other environmental and social-demographic 
variables. However, the lack of more precise data on the selenium content of crops and feed 
and additional data on selenium contents in soils, food grains, and the human body is a 
limitation of the study.  A further drawback of our study is the fact that our preliminary 
experiments exploring a potential mechanism behind this observation did not result in a clear 
conclusion. Still, our results provide possible targets for focused prevention and control of HFRS 
(i.e. the areas of selenium deficiency with low elevation, few grasslands, or an abundance of 
forests). Furthermore, our findings might provide valuable information for risk evaluation of 
HFRS epidemics and thereby identify target populations for vaccination and health education. 
Additional experimental studies should further explore possible mechanisms of how selenium 
deficiency leads to an increased risk of HFRS.  If this relationship holds, then this would provide 
rationale for preventive measures of HFRS, such as providing selenium supplements, either 
through fertilization of crops or as a preventive medicine for humans in severe selenium-
deficient regions. 
 
Materials and Methods 
Epidemiological data collection and management 
Since 1950, HFRS has been included in the list of notifiable infectious diseases in mainland 
China. Cases were reported using a standard protocol formulated by the Chinese Center for 
Disease Control and Prevention (CISDCP). HFRS was initially diagnosed clinically by signs and 
symptoms according to the guideline issued by the Ministry of Health, China. Since 1982, 
reported cases have also been confirmed by standard serological tests such as enzyme-linked 
immunosorbent assays and indirect immuno-fluorescence assays (488;518). In this study, we 
included all HFRS cases reported to the CISDCP during 2005 to 2010. Information on age, sex, 
occupation, residence address, working address, onset date and location, hospital admission 
date, and clinical outcomes were retrieved from the diagnostic application form sent to the 
reference laboratory. Demographic data of each county were obtained from the National 
Bureau of Statistics of China.  
Information on hantaviruses infections in rodent hosts was collected from 40 surveillance 
sites across the country according to a protocol developed by CISDCP  (519). Several 
investigation spots were selected within each surveillance site for surveys of rodent hosts twice 
every year: March-April and September-October. A total of 100-150 traps per patch with 
peanuts as bait were placed for 2-3 consecutive nights at each investigation spot and at least 
200 rodents were caught from each surveillance site every year. Lung tissues of rodents were 
 collected and stored in liquid nitrogen, and then examined for hantaviruses antigens using 
indirect immunofluorescent assay (IFA), as previously described by Lee and others (520). 
To assess the association between the number of HFRS cases and selenium deficiency, the 
investigation data on selenium content of crops and animal feed in various areas were obtained 
from the Chinese Academy of Agricultural Sciences (488;521). All counties were classified into 3 
categories according to the average selenium concentration of crops including corn, barley, 
rice, sorghum, millet, potatoes, broad beans, wheat, etc., grown in that areas: non-selenium-
deficient areas (>=0.06 ppm), moderate selenium-deficient areas (0.03 - 0.05 ppm), and severe 
selenium-deficient areas (<= 0.02 ppm) (521). Data on geographic and social-demographic co-
variables, possibly associated to the incidence of HFRS, including elevation, land use (i.e. 
distribution of croplands, forests and grasslands), population density, and gross domestic 
product (GDP), were also collected. Elevation data were derived from a shuttle radar 
topography mission database with a spatial resolution of 1 km (522). Data of land use and GDP 
were collected with a spatial resolution of 1 km from the Institute of Geographical Sciences and 
Natural Resources Research, Chinese Academy of Sciences. The population density of each 
county was obtained from the National Bureau of Statistics of China. The average elevation, 
proportion of area of land use, population density, and average GDP for each county were then 
extracted by overlapping the county boundary and each of co-variables using ArcGIS 9.2 
software (ArcGIS 9.2, Environmental Systems Research Institute, Redlands, CA, USA) . 
Spatial analysis of HFRS incidence 
Each HFRS case was geo-referenced to the corresponding polygons of the China digital map 
through the linkage of the 6-digit county geo-code. The average annual incidence was 
calculated for each county, and a thematic map was created and overlapped onto the map of 
selenium concentration of crops and feed by using ArcGIS 9.2. Based on average annual 
incidence, all counties were grouped into four HFRS categories: non-endemic, low endemic 
(incidence < 5.0 per 100,000 person-years), medium endemic (5.0 to 30.0 per 100,000 person-
years), and high endemic (> 30.0 per 100,000 person-years).  
 
Ecological analysis 
We used a Poisson regression to test for a relationship between incidence of HFRS and 
selenium deficiency. The cumulative number of HFRS cases per county was set as the outcome 
variable, and population size of each county was included as offset. The environmental and 
social-demographic factors, average elevation, proportion of areas of croplands, forests, and 
grasslands, population density, and average GDP for each county, were included as co-
variables. For each continuous variable, we also reported the average yearly incidence of HFRS 
for different categories to allow inspection of the data and to assess whether the continuous 
assumption was justified. The categorical results for continuous variables were not included in 
the Poisson regression. The incidence rate ratio (IRR) in response to the change of the variable 
 by a given amount (1,000 m for elevation, 1000 persons per km2 for population density, and 10 
million Yuan per km2) was used to determine the impact of each variable on HFRS incidence. 
The 95% confidence interval (CI) and corresponding P-value were estimated after correcting for 
over dispersion, because of the nature of infectious diseases with spatial clustering patterns 
(522). First, univariate analyses were performed to examine the effect of each variable 
separately, and then multivariate analysis was performed by including all co-variables with a 
P<0.20 in the univariate analysis. We also performed the regression analyses separately for the 
5 climate regions: temperate monsoon (I), sub-tropical monsoon (II), tropical monsoon (III), 
highland hibernal (IV) and temperate continental (V) (523). 
To verify the influence of selenium deficiency on hantavirus infection in rodents, we 
investigated the association between selenium content of crop and animal feed in each county 
and hantaviruses infection rates in the rodent hosts caught from the 40 surveillance sites in the 
period from 2005 to 2008. Hantaviruses infection rates were plotted against the selenium 
content category (non-deficient areas, moderate deficient areas and severe deficient areas). 
The differences in infection rates were examined using the nonparametric equality-of-medians 
test (524). 
 
Clinical epidemiological study 
Selenium levels in acute HFRS patients and controls 
To study whether the occurrence of a HFRS case is associated with lowered circulatory 
selenium levels, we compared HFRS cases to non-infected healthy controls. We decided to 
measure the plasma activity and concentration of one of the major selenium binding proteins in 
human serum: glutathione peroxidase (activity of collective GPx and concentration of 
glutathione peroxidase -3 (GPx-3).  GPx activity and GPx-3 concentration in the circulation is 
directly correlated to selenium concentrations (515). Blood samples of HFRS patients were 
collected, after informed consent, from spring 2009 to winter 2010 at the Xi’an No.8 Hospital in 
the Shaanxi Province, China. All cases showed conspicuous clinical signs of HFRS and whose 
blood samples were tested by laboratory experiment (HNTV RT-PCR positive, or IgM, or IgG 
HNTVG-antibody positive). Eighty-five control (non-HFRS patients and HV-antibodies negative) 
samples were collected among healthy volunteers in Xi’an, Shaanxi Province. All plasma 
samples were stored in -80 oC until use.  
GPx activity was measured by commercially available Glutathione Peroxidase Assay Kit 
(BioVision, USA) through a coupled reaction with glutathione reductase (GR) according to the 
manufacturers manual. Briefly, in the assay, GPx reduce Cumene Hydroperoxide, and oxidize 
glutathione (GSH) to glutathione (GSSG). The generated GSSG is reduced to GSH with 
consumption of NADPH by GR. The decrease of NADPH is proportionally to GPx activity in the 
reactions. The decrease of NADPH was measured by absorbance at 340 nm, which was used to 
calculate the GPx Activity.  
 GPx3 concentration was measured using an Enzyme-linked Immunosorbent Assay Kit as by 
manufacturer’s instructions (Uscn inc. Wuhan, China). Plasma samples were prepared in two 
dilutions and each dilution was measured in duplicate. Briefly, standards or plasma samples 
were added to the microtitre plate with pre-coated GPx3 specific antibody. The plates were 
washed after they were incubated at 37 oC for 2 hours. After biotinylated GPx3 antibody were 
added and incubated at 37 oC for 1 hour, the plates were washed again. Horseradish Peroxidase 
(HRP) conjugated Advin was added and incubated for 30 minutes. After the plates were 
washed, TMB substrate solution was added. The reaction was terminated by addition of sulfuric 
acid solution. The samples’ absorbance was read at 450 nm using a plate reader. The GPx3 
concentration was calculated by the standard curve. 
 
In vitro assessment of the influence of selenium on hantavirus replication 
To study the influence of selenium concentration on hantavirus replication we studied the 
kinetics of the infection of an immune competent cell line (primary isolated human umbilical 
vein endothelial cells (HUVEC)) with a low passage hantavirus isolate. This model was chosen 
based on the relation between immune activation (i.e. interferon inducement) and selenium 
concentrations, mentioned in the introduction (506;508;515). HUVEC were harvested from 
fresh umbilical veins, kindly provided by the Erasmus MC birth center. Cells were isolated as 
described in Chapter 3.1. Briefly, Human umbilical vein endothelial cells (HUVEC) were 
harvested from umbilical veins (kindly provided by the Erasmus MC birth-center). Umbilical 
cords were stored in sterile 500 ml PBS + gentamycin (50 µg/ml) (Leo Pharmaceutical Products, 
Denmark). The veins were rinsed with PBS containing 50 U/ml heparin (Leo Pharmaceutical 
Products). Subsequently, cells were detached with 0.1% collagenase solution (C6885, Sigma 
Aldrich, USA). Cell suspension was collected in a sterile 50 ml tube followed by two times 
centrifugation (5 minutes; 300 x g). The cell pellet was re-suspended in HUVEC medium (human 
endothelial-SFM medium) (Invitrogen, USA) containing 10% human serum (Lonza, the 
Netherlands), 20% filtrated FBS; penicilin/streptomycin 100 U/ml, 20 ng/ml fibroblast growth 
factor (Peprotech, USA) and 10 ng/ml of endothelial cell growth factor (Peprotech). Cell 
suspensions were cultured in flasks pre-coated with 20 μg/ml of fibronectin (Roche, the 
Netherlands). Passage two cells from one specific donor were used for this study. The identity 
of the endothelial cells was confirmed by flow cytometry using Ulex europeus lectin (EY 
laboratories, USA), anti-CD31 antibody (Sigma Aldrich, USA) and Von Willebrand Factor staining 
(Dako, the Netherlands). HUVEC were seeded into 24-well plates (Corning, U.S.A.). Confluent 
monolayers were infected with a multiplicity of infection (MOI) of 0.05, 1 or 3, with infectious 
puumala (PUUV) hantavirus freshly isolated from chronically infected bank voles (Myodes 
glareolus), kindly provided by Prof. Heikki Henttonen, METLA Forest Research Institute, 
University of Helsinki, Finland. Cells were incubated for 60 minutes at 37 oC in 5% CO2. After 
incubation, the supernatant was discarded and cells were washed three times with RPMI 1640 
 (Gibco, Life Sciences). Subsequently, 500ul of fresh HUVEC medium was added to the wells 
without addition of selenium or supplemented with 200 ng/ml of cell culture suitable sodium 
selenium (Sigma Aldrich, the Netherlands). HUVEC were incubated for 72 hours at 37 oC in 5% 
CO2. Viral replication was determined by RNA copy number quantification as described (369). 
The quantity of viral RNA was measured with in a real-time qRT-PCR assay (TaqMan®Fast Virus 
1-Step Master Mix, Invitrogen, Life Sciences) using Applied Biosystems® 7500 Real-Time PCR 
system. The RNA copy number in each sample was calculated from a standard RNA curve 
generated by an in vitro transcribed PUUV RNA standard derived from in vitro RNA transcripts 
generated using a segment amplified with pan-hantavirus degenerative PCR primers as 
described (525). 
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 Abstract 
 
“Background Modified Vaccinia virus Ankara (MVA) is a promising viral vector platform for 
H5N1 influenza vaccine development. Preclinical evaluation of MVA-based H5N1 vaccines 
showed their immunogenicity and safety in various animal models, warranting clinical 
evaluation. Methods In this randomized double-blind phase I/IIa study young healthy volunteers 
were immunized once or twice with a normal dose (108 plaque forming units (pfu)) or a tenfold 
lower dose of either the MVA-H5-sfMR (vector encoding the hemagglutinin gene of influenza 
A/Vietnam/1194/04 virus (H5N1 subtype) or MVA-F6-sfMR (empty vector) vaccine. Healthy 
volunteers that received the MVA-H5-sfMR vaccine were eligible for a boost immunization one 
year after the first immunization. Primary safety endpoints were local and/or systemic 
reactions. Secondary outcomes were hemagglutination inhibition (HI) and virus-neutralization 
(VN) antibody titres in the sera from the healthy volunteers. The trial is registered at the Dutch 
Trial Register (www.trialregister.nl) (NTR registration number: NTR3401).Findings 79 of the 80 
healthy volunteers that were enrolled completed the study. No serious adverse events occurred. 
The majority of the healthy volunteers experienced one or more local and systemic reactions. 
Healthy volunteers that received the tenfold lower dose were prone to develop less systemic 
reactions. The MVA-H5-sfMR 108 pfu vaccine induced significantly higher antibody responses 
after one and two immunizations. 27 of the 39 eligible healthy volunteers were enrolled in the 
boost immunization study. The results indicated that a single shot MVA-H5-sfMR 108 pfu prime 
immunization resulted in higher antibody responses upon boost immunization than two shots 
with MVA-H5-sfMR at a ten-fold lower dose. Interpretation This study illustrates that the MVA-
based pandemic H5N1 vaccine was well-tolerated and immunogenic and underlines that vaccine 
candidates arising from the MVA platform hold great promise for the future.” 
 
 
 Introduction 
Avian influenza viruses are continuously introduced into the human population with variable 
impact for infected individuals and the population at large. First reports of human infection 
with highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype date back to 1997 
(526). Since their re-occurrence in 2003, H5N1 viruses have infected at least 650 humans and 
386 of these cases were fatal (527). To facilitate fast-track vaccine development for these 
viruses the European Medicines Agency (EMA) has developed a pandemic vaccine mock-up 
dossier for Europe. The A(H1N1)2009 pandemic highlighted that in spite of the possibility for 
fast-track licensing of conventional vaccines, the delay between onset of the pandemic and 
arrival of vaccines on the market proved to be unacceptable (528). Consequently the 
production and distribution time of vaccines in the early pandemic period still is an unsolved 
problem that should be taken into account in the development of candidate vaccines against 
future, possibly emerging H5N1 pandemic viruses (529).   
The immunogenicity of H5N1 vaccine formulations based on traditional vaccine platforms is low 
compared to that of seasonal influenza vaccines, resulting in the need to use multiple-shot 
immunization regimens or the addition of an adjuvant. The limited immunogenicity is not only 
associated with the relative naivety of the human population towards these avian influenza 
viruses, but also results from an intrinsic limited immunogenicity of the H5 hemagglutinin (HA). 
This phenomenon was identified for various avian influenza-virus derived HA’s, like H5, H7, and 
H9 (530). Couch et al have assessed the immunogenicity of various avian influenza vaccines and 
found that the secondary structures of the vaccine antigens may affect their immunogenicity 
(530). It is difficult to ensure consistency of the appropriate morphology when the vaccine is 
produced with traditional methods of virus inactivation and breakdown through treatment with 
detergents. Furthermore, Couch et al illustrated that in comparison with seasonal influenza 
virus HA’s, the conformation of avian influenza HA’s and their uptake and processing by 
immune cells is similar and does not result in limited immunogenicity. This indicates that avian 
influenza vaccine development could profit considerably from novel vaccine production 
platforms such as those based on recombinant proteins, virosomes and viral or bacterial 
vectors (531-534).  An additional challenge for H5N1 vaccine development is the explosive 
antigenic diversification of avian H5N1 viruses in the past decades, which has resulted in the 
emergence of a plethora of virus clades, subclades and lineages (535).  
Consequently a future HA-based pandemic H5N1 vaccine should be suitable for fast and large-
scale production and preferably present HA in its native multimeric form. Viral vectors such as 
adenoviruses and poxviruses have proven to be potent antigen-presentation platforms that 
comply largely with these requirements (536-538). Poxviruses and more specifically Modified 
Vaccinia virus Ankara (MVA) are of special interest. The latter is replication-deficient in 
mammalian cells which is a clear advantage from a safety perspective. This will eventually allow 
for large-scale immunization campaigns that may also include the classical high-risk groups for 
 influenza. Preclinical evaluation of MVA-based H5N1 vaccines showed their immunogenicity 
and safety in various animal models, warranting clinical evaluation (539-544).  
Here we present data from the first-in-man phase I/IIa clinical trial conducted with the MVA-
HA-based H5N1 vaccine MVA-H5-sfMR assessing its safety and immunogenicity. This is the first 
ever demonstration that a MVA-based H5N1 candidate vaccine is safe and immunogenic in 
humans. 
 
Materials & Methods 
Study Design 
The phase 1/2a study was randomized and double-blind performed in a single center: Erasmus 
Medical Center, Rotterdam, the Netherlands. The primary study objective was assessment of 
safety. The immunogenicity of the vaccines was assessed as a secondary objective. Our working 
hypothesis was that a recombinant MVA-based H5 vaccine is safe and immunogenic in humans. 
Both the healthy volunteers and the physicians who did the examinations and administered the 
vaccine were blinded for the vaccine. Eighty young adult volunteers were recruited (both male 
and female). When they met the inclusion and exclusion criteria (as described in the study 
protocol) and provided written informed consent the healthy volunteers were randomly 
assigned to one of the eight study arms (n=10 per arm). The arms of the study were based on 
the number of immunizations (one or two), the immunization dose (107 or 108 pfu) and the 
vaccine (MVA-H5-sfMR or MVA-F6-sfMR) (see Table 1). Sample size was calculated based on the 
mean antibody titres obtained in the preclinical study with a prime and boost immunization 
with an MVA-H5 vaccine in macaques (539).  
At the first visit (week 0) blood was drawn (max 34ml) and for pregnancy was excluded within 
15-30 minutes prior to the vaccine administration among women who participated. 
Subsequently, the healthy volunteers received one immunization, administered as a solution of 
0.5mL through intramuscular injection in the deltoid muscle. Healthy volunteers were observed 
for one hour at the trial unit and a blood sample was taken. Then they were sent home with an 
ear thermometer and diary card for them to keep track of possible side-effects during seven 
subsequent days. In week 4 a blood sample was drawn from all healthy volunteers followed by 
a second immunization for the healthy volunteers in study arms 5-8. After an observation 
period of one hour a blood sample was taken again they were asked to complete a diary card 
for the next seven days. Eight and twenty weeks after their first immunization all healthy 
volunteers returned for their close-out visit at which the last blood sample was taken. The study 
design was reviewed and approved by the Central Committee on Research involving Human 
Subjects (CCMO) in the Netherlands. The trial is registered at the Dutch Trial Register 
(www.trialregister.nl) (NTR registration number: NTR3401). 
 
 
 Safety Assessment 
The safety of the vaccine candidates was assessed using multiple tests and scores. Each subject 
underwent a short physical examination prior to the immunization. Heart rate, blood pressure 
and body temperature were registered, the injection site was examined and questions were 
asked on possible pre-existing conditions. This physical examination was repeated 1 hour after 
immunization and an additional examination was performed if necessary upon indication 
during the 1 hour observation period post immunization. Before and 1 hour after immunization 
blood was drawn to measure clinical chemical and haematological parameters in order to 
detect acute effects that occurred upon immunization. Four weeks after the first immunization 
all healthy volunteers again underwent the short physical examination and were asked by a trial 
physician if they had experienced any adverse reactions during and after the first week post 
immunization. Subsequently blood was drawn to measure the parameters as described above. 
Only the healthy volunteers that received a second immunization, determined by 
randomisation, had an additional examination and blood sampling 1 hour after immunization.  
To assess reactogenicity of the vaccine, the healthy volunteers received a diary card to be 
completed during the first seven days post immunization. In addition they received an 
earthermometer to measure their body temperature twice a day (morning and evening). 
 
Booster immunization strategy 
In order to assess the possibility to boost of the H5-specific immune response, healthy 
volunteers that received the MVA-H5-sfMR vaccine during the main study were approached for 
a follow-up study (if they approved of this by informed consent). Healthy volunteers that 
agreed to a booster immunization received a single shot of MVA-H5-sfMR with the same dose 
that they received originally. Immunizations were performed 1 year after the first MVA-H5-
sfMR immunization. Prior to the booster blood was drawn to determine baseline influenza virus 
H5-specific and MVA-IgG specific antibody responses. Healthy volunteers received a diary card 
to be completed during the first seven days post immunizations. Four weeks after their visit the 
healthy volunteers returned and blood was drawn to determine the boost-effect of the MVA-
H5-sfMR immunization. 
 
Detection of influenza virus H5-specific antibodies 
Serum was obtained from blood that was collected and centrifuged in coagulation tubes 
(Greiner Bio-one, Alphen a/d Rijn, the Netherlands). Sera were treated with a receptor-
destroying enzyme (cholera filtrate) and then heat-inactivated at 56C. Subsequently the sera 
were pretreated with horse erythrocytes after which the sera were ready to be tested for the 
presence of anti-H5 antibodies. This was tested in the hemagglutination inhibition assay (HI) 
with an adapted protocol using 1% horse erythrocytes and four HA-units of either the 
homologous influenza H5N1 virus A/VN/1194/04 (clade 1) or the antigenically distinct strain: 
 A/Indonesia5/05 (A/IND/5/05) (clade 2.1). For serology, viruses were used from which the multi 
basic cleavage site in the HA, associated with high virulence, was deleted by reverse genetics. 
The use of these reverse genetics (RG) viruses in the HI assay was validated and the obtained 
antibody titres were comparable with those against the wild type strains (data not shown). 
The sera were also tested for the presence of virus-neutralizing antibodies using a micro virus 
neutralization (VN) assay with the RG viruses described above. The VN assay was performed as 
described previously (545). Sera from MVA-H5-SFMR immunized New Zealand White Rabbits 
and Cynomolgus Macaques were used as a positive controls in both the HI and VN assays. For 
calculation purposes serum samples with an antibody titre of <10 were arbitrarily assigned a 
titre of 5. Seroconversion was arbitrarily defined as a post-vaccination titre of ≥20 or a fourfold 
rise in the antibody titre when the previous titre was >10. Antibody titres of ≥40 were arbitrarily 
considered to be seroprotective. 
 
Detection of MVA-specific antibodies 
Serum samples were tested for the presence of MVA-specific immunoglobulin G (IgG) 
antibodies. To this end, Baby Hamster Kidney-21 (BHK-21) cells (permissive for MVA virus 
infection) were infected with MVA-F6-sfMR at an MOI of 10 and incubated for 6-8 hours. In 
parallel, serum samples were preincubated with uninfected BHK-21 cells. After the incubation 
period serum was added to either uninfected or infected BHK-21 cells in triplicates. The cells 
were incubated for 16 hours at 4◦C and then washed and subsequently incubated with a FITC-
labelled Rabbit anti-human IgG antibody preparation (DAKO, Glostrup, Denmark). Cells were 
analysed by flow cytometry using a FACS Canto (BD Biosciences, Breda, The Netherlands). The 
fold-increase in FITC-positive cells was calculated by dividing the values from the sera incubated 
with the infected cells by that from the corresponding sera incubated with the uninfected cells. 
 
Randomization and masking 
Study subjects were assigned to one of the eight study groups based on a computer-generated 
randomization list with 10 blocks of 8 randomized study arms. The randomization code was 
kept by the hospital pharmacist till the end of the study period. Based on the list a generic label 
was generated by the hospital pharmacy that masked the content of the vaccine vial and only 
indicated a reference to the respective recipient. A trial nurse would check the content of the 
vial and would fill the syringe from the vial and provide this with the masked label to the trial 
physician. 
 
Statistics 
To assess statistical significance of the differences between groups the Mann-Whitney U test 
was performed using IBM SPSS Statistics 22. For the analysis of the HI and VN antibody titres 
the log2 values of the titres were used. 
 Results 
Study demographics 
Within 2 months after recruitment start (December 2012), eighty healthy young adults, 18-28 
years of age (mean= 21.9 ± 2.0), were enrolled in the study. Females comprised 61% of these 
volunteers. All healthy volunteers were randomly assigned to one of the eight arms of the 
study. The male-females ratio’s per study arm are indicated in Table 1. Study immunizations 
began in February 2013 and the last study visits took place in July 2013. Of the eighty healthy 
volunteers enrolled, 79 completed the study. Thirty-nine of these healthy volunteers received 
one or two immunizations with the MVA-H5-sfMR vaccine and thus were eligible for inclusion 
in a booster immunization study that was performed one year later (January 2014).  Twenty-
seven healthy volunteers were enrolled in this follow-up study and received a booster 
immunization. 
 
Table 1. Immunisation dosing schedules in young healthy adults  
Study population Young Healthy adults 
 Single immunization Two immunizations 
Vaccine MVA-H5-sfMR MVA-F6-sfMR MVA-H5-sfMR MVA-F6-sfMR 
Dose (pfu) 108 107 108 107 108 107 108 107 
 Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 
Week 0 Visit 1 n=10 
4 / 6 
n=10 
6 / 4 
n=10 
6 / 4 
n=10 
3 / 7 
n=10 
3 / 7 
n=10 
2 / 8 
n=10 
4 / 6 
n=10 
2 / 8 
Week 4 Visit 2 n=91 
4 / 5 
n=10 
6 / 4 
n=10 
6 / 4 
n=10 
3 / 7 
n=10 
3 / 7 
n=10 
2 / 8 
n=10 
4 / 6 
n=10 
2 / 8 
Week 8 Visit 3 n=9 
4 / 5 
n=10 
6 / 4 
n=10 
6 / 4 
n=10 
3 / 7 
n=10 
3 / 7 
n=10 
2 / 8 
n=10 
4 / 6 
n=10 
2 / 8 
Week 20 Visit 4 n=9 
4 / 5 
n=10 
6 / 4 
n=10 
6 / 4 
n=10 
3 / 7 
n=10 
3 / 7 
n=10 
2 / 8 
n=10 
4 / 6 
n=10 
2 / 8 
1 year after visit 1 
Vaccine  MVA-H5-sfMR MVA-F6-sfMR MVA-H5-sfMR MVA-F6-sfMR 
Dose (pfu) 108 107 108 107 108 107 108 107 
  Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 
Week 0 Boost visit 1 n=5 
3 / 2 
n=7 
4 / 3 
n.a.2 n.a. n=6 
1 / 5 
n=9 
2 / 7 
n.a. n.a. 
Week 4 Boost visit 2 n=5 
3 / 2 
n=7 
4 / 3 
n.a. n.a. n=6 
1 / 5 
n=9 
2 / 7 
n.a. n.a. 
 MVA=modified vaccinia virus Ankara. MVA-H5-sfMR=vector encoding the haemagglutinin gene 
of influenza A/Vietnam/1194/2004 virus H5N1 subtype). MVA-F6-sfMR=empty vector. 
pfu=plaque-forming units. NA=not applicable because only individuals who were immunised 
with MVA-H5-sfMR in the first part of the study were eligible for a booster immunisation. 
*Individuals who received an immunisation at that timepoint. †One individual discontinued after 
visit 1 because of time constraints and side-effects after the first immunisation. 
 
Safety 
No serious adverse events occurred during either the main or the follow-up study. Eleven 
adverse events were registered during the study period (indicated for the respective group and 
study period in Tables2-4. One subject (group 6) experienced severe headache and 
lightheadedness during the first hour after vaccination and received paracetamol. This event 
may have been related to the vaccination. No further acute effects were observed during the 
observation period nor during the subsequent physical examination. The ten other adverse 
events occurred in the four weeks after immunization. One subject in group 8 reported 
erythema nodosum, which was unlikely but possibly related to vaccination. Five healthy 
volunteers (group 1, 8) reported respiratory illness and/or sore throat during the first week post 
immunization, which is most likely unrelated to vaccination. Their respiratory illness was 
accompanied by flu-like symptoms. One subject in group 5 reported a local reaction at the 
injection site (evening post immunization) characterized by red spots (1-2 cm in diameter). The 
other three healthy volunteers (group 2, 6, 7) suffered from other conditions unlikely to have a 
causal relation to the vaccination. Blood samples of all healthy volunteers were analyzed for the 
before mentioned biochemical and haematological parameters. The majority of the values were 
within the standard ranges (specified per sex). The deviations that were observed were either 
pre-existing or isolated deviations that could be attributed to the healthy volunteer’s 
background and/or lifestyle. One subject had an elevated CK after vaccination which could have 
a causal relation to the vaccination, but this did not result in clinical symptoms and was not 
accompanied by any other biochemical deviation. Diary cards filled in for a period of seven days 
after each immunization recorded local and systemic reactions after the first immunization 
(Table 2A-B), the second immunization (Table 3A-B) and the booster immunization (Table 4A-B). 
The majority of the healthy volunteers reported one or more local and systemic reactions, 
occurring within 72 hours post immunization and the majority of the reported reactions 
resolved within 6 days post immunization. Focusing on the local reactions, pain at the injection 
site was reported most and was graded as mild-moderate by most healthy volunteers and only 
a minority reported the pain as severe. Itch, swelling and redness were only reported in a few 
cases distributed over the different groups. No difference in incidence and severity of the local 
reactions were experienced after the first, second or booster immunization. Most healthy 
volunteers experiencing systemic reactions reported them to be mild to moderate. There was 
 no clear difference in incidence and severity of the systemic reactions after one, two or the 
booster immunization. There appeared however to be a dose-response effect, as the 107 pfu 
dose of either the MVA-H5-sfMR or MVA-F6-sfMR vaccines resulted in less reported systemic 
reactions than the108 pfu dose. Overall the MVA-H5-sfMR and MVA-F6-sfMR vaccines were well 
tolerated. 
Group 1 2 3 4 5 6 7 8 
Immunization MVA-H5-
sfMR 108 
MVA-H5-
sfMR 107 
MVA-F6-
sfMR 108 
MVA-F6-
sfMR 107 
MVA-H5-
sfMR 108 
MVA-H5-
sfMR 107 
MVA-F6-
sfMR 108 
MVA-F6-
sfMR 107 
Local reactions (N) 7/9 7/10 8/10 4/10 9/10 7/10 4/10 2/10 
Itch None 89% (8) 100% (10) 100% (10) 100% (10) 100% (10) 80% (8) 100% (10) 90% (9) 
mild 
moderate 
severe 
11% (1) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
20% (2) 
- 
- 
- 
- 
- 
10% (1) 
- 
- 
Pain None 22%(2) 40% (4) 20% (2) 70% 10% 30% (3) 50% (5) 80% (8) 
mild 
moderate 
severe 
 
22% (2) 
11% (1) 
45%  (4) 
(1.5 days)* 
60% (6) 
- 
- 
40% (4) 
30% (3) 
10%  (1) 
(1.0 days) 
30% 
- 
- 
30% 
30% 
30% 
50% (5) 
20% (2) 
- 
40% (4) 
10% (1) 
- 
 
20% (2) 
- 
- 
 
Redness None 67% (6) 70% (7) 100% (10) 80% 90% 100% (10) 100% (10) 100% (10) 
mild 
moderate 
severe 
22% (2) 
11% (1) 
- 
30% (3) 
- 
- 
- 
- 
- 
20% 
- 
- 
10% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
diameter1 8.0mm 2.5mm - 7.5mm 2.0mm - - - 
Swelling None 100% (9) 90% (9) 90% (9) 90% 90% 100% (10) 90% (9) 100% (10) 
mild 
moderate 
severe 
- 
- 
- 
10% (1) 
- 
- 
10% (1) 
- 
- 
10% 
- 
- 
10% 
- 
- 
- 
- 
- 
10% (1) 
- 
- 
- 
- 
- 
 
Table 2A: Local reactions after the 1st immunization 
 
Group 1 2 3 4 5 6 7 8 
Immunization MVA-H5-
sfMR 
108 
MVA-H5-
sfMR 107 
MVA-F6-
sfMR 108 
MVA-F6-
sfMR 107 
MVA-H5-
sfMR 108 
MVA-H5-
sfMR 
107 
MVA-F6-
sfMR 108 
MVA-F6-
sfMR 107 
Systemic reactions (N) 8/91 9/10 10/10 6/102 10/10 8/10 9/10 7/103 
Rise in 
Bodytemp 
(>37.5⁰C) 
N 56% (5) 40% (4) 70% (7) 50% (5) 70% (7) 30% (3) 40% (4) 40% (4) 
Range 37.6-38.2 37.6-38.5 37.6-39.1 37.6-38.3 37.6-39.9 37.6-39.0 37.8-39.0 37.8-39.0 
Days 1.2 3.5 2.4 2.0 1.3 2.0 1.5 1.5 
Headache None 33.3%  (3) 60% (6) 30% (3) 70% (7) 10% (1) 70% (7) 60% (6) 70% (7) 
mild 
moderate 
severe 
 
33.3% (3) 
33.3% (3) 
- 
 
20% (2) 
20% (2) 
- 
 
30% (3) 
30% (3) 
10% (1) 
(1.0 days) 
10% (1) 
20% (2) 
- 
40% (4) 
30% (3) 
20% (2)  
(1.0 days) 
- 
20% (2) 
10% (1)  
(2.0 days) 
20% (2) 
20% (2) 
- 
10% (1) 
10% (1) 
10% (1) 
Myalgia None 33.5% (3) 40% (4) 10% (1) 50% (5) - 20% (2) 30% (3) 50% (5) 
mild 
moderate 
severe 
 
22% (2) 
11% (1) 
33.5% (3) 
(1.0 days)* 
40% (4) 
20% (2) 
- 
 
40% (4) 
30% (3) 
20% (2)  
(2.0 days) 
50% (5) 
- 
- 
10% (1) 
60% (6) 
30% (3) 
(2.0 days) 
50% (5) 
30% (3) 
- 
- 
60% (6) 
10% (1) 
(1.0 days) 
40% (4) 
10% (1) 
- 
Arthralgia None 89% (8) 100% (10) 70% (7) 100% (10) 100% (10) 100% (10) 100% (10) 100% (10) 
mild 
moderate 
severe 
 
- 
- 
11% (1) 
(1.0 days)  
- 
- 
- 
 
- 
20% (2) 
10% (1) 
(2.0 days) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 Chills None 45% (4) 90% (9) 50% (5) 100% (10) 40% (4) 80% (8) 30% (3) 70% (7) 
mild 
moderate 
severe 
 
- 
22% (2) 
33% (3) 
(1.0 days) 
- 
- 
10% (1) 
 
10% (1) 
10% (1) 
30% (3)  
(1.0 days) 
- 
- 
- 
30% (3) 
20% (2) 
10% (1)  
(1.0 days) 
20% (2) 
- 
- 
30% (3) 
30% (3) 
10% (1) 
(2.0 days) 
20% (2) 
10% (1) 
- 
Malaise None 22% (2) 90% (9) 20% (2) 90% (9) 40% (4) 70% (7) 50% (5) 80% (8) 
mild 
moderate 
severe 
 
33.5% (3) 
33.5% (3) 
11% (1) 
(1.0 days) 
- 
- 
10% (1) 
(3.0 days) 
10% (1) 
40% (4) 
30% (3)  
(1.0 days) 
- 
10% (1) 
- 
20% (2) 
30% (3) 
10% (1)  
(1.0 days) 
10% (1) 
10% (1) 
10% (1)  
(1.0 days) 
- 
40% (4) 
10% (1)  
(1.0 days) 
10% (1) 
10% (1) 
- 
Fatigue None 67% (6) 60% (6) 60% (6) 90% (9) 50% (5) 50% (5) 40% (4) 80% (8) 
mild 
moderate 
severe 
 
11% (1) 
- 
22% (2) 
(1.0 days) 
10% (1) 
10% (1) 
20% (2) 
(1.5 days) 
- 
30% (3) 
10% (1)  
(1.0 days) 
- 
10% (1) 
- 
30% (3) 
20% (2) 
- 
20% (2) 
20% (2) 
10% (1) 
(1.0 days) 
40% (4) 
20% (2) 
- 
10% (1) 
10% (1) 
- 
 
Table 2B: Systemic reactions after the 1st immunization 
Group 5 6 7 8 
Immunization MVA-H5-
sfMR 
108 
MVA-H5-
sfMR 107 
MVA-F6-
sfMR 108 
MVA-F6-
sfMR 107 
Local reactions (N) 8/101 8/10 4/102 7/10 
Itch None 90% (9) 70% (7) 90% (9) 90% (9) 
mild 
moderate 
severe 
10% (1) 
- 
- 
20% (2) 
10% (`1) 
- 
10% (1) 
- 
- 
10% (1) 
- 
- 
Pain None 40% (4) 40% (4) 60% (6) 40% (4) 
mild 
moderate 
severe 
 
- 
30% (3) 
30% (3) 
(1.0 days) 
30% (3) 
30% (3) 
- 
20% (2) 
20% (2) 
- 
60% (6) 
- 
- 
Redness None 70% (7) 90% (9) 70% (7) 80% (8) 
mild 
moderate 
severe 
30% (3) 
- 
- 
10% (1) 
- 
- 
30% (3) 
- 
- 
20% (2) 
- 
- 
diameter 2.0mm 2.0mm 3.0mm 2.0mm 
Swelling None 50% (5) 90% (9) 70% (7) 80% (8) 
mild 
moderate 
severe 
30% (3) 
20% (2) 
- 
10% (1) 
- 
- 
30% (3) 
- 
- 
20% (2) 
- 
- 
Table 3A: Local reactions after the 2nd immunization 
  
 Table 3B: Systemic 
reactions after the 
2nd immunization 
 Reported sore 
throat and 
respiratory illness, 
started on day 1 
post immunization 
*days in 
parenthesis are 
mean number of 
days reaction was 
reported as severe 
  
Group 5 6 7 8 
Immunization MVA-H5-
sfMR 108 
MVA-H5-sfMR 
107 
MVA-F6-
sfMR 108 
MVA-F6-
sfMR 107 
Systemic reactions (N) 10/10 9/10 8/10 5/101 
Rise in 
Bodytemp 
(>37.5⁰C) 
subjects 40% (4) 40% (4) 30% (3) 40% (4) 
Range 37.6-39.1 37.6-38.3 37.6-38.4 37.6-37.9 
Days 2.0 2.3 2.3 2.5 
Headache None - 60% (6) 60% (6) 80% (8) 
mild 
moderate 
severe 
 
60% (6) 
30% (3) 
10% (1) 
(1.0 days)* 
20% (2) 
10% (1) 
10% (1) 
(1.0 days) 
20% (2) 
10% (1) 
10% (1) 
(1.0 days) 
20% (2) 
- 
- 
Myalgia None 30% (3) 20% (2) 20% (2) 50% (5) 
mild 
moderate 
severe 
 
40% (4) 
10% (1) 
20% (2) 
(1.0 days) 
40% (4) 
40% (4) 
- 
40% (4) 
30% (3) 
10% (1) 
(1.0 days) 
40% (4) 
10% (1) 
- 
Arthralgia None 90% (9) 100% (10) 90% (9) 100% (10) 
mild 
moderate 
severe 
 
- 
- 
10% (1) 
(1.0 days) 
- 
- 
- 
 
10% (1) 
- 
- 
- 
- 
- 
Chills None 70% (7) 100% (10) 80% (8) 100% (10) 
mild 
moderate 
severe 
 
- 
20% (2) 
10% (1) 
(1.0 days) 
- 
- 
- 
 
10% (1) 
10% (1) 
- 
- 
- 
- 
Malaise None 60% (6) 70% (7) 80% (8) 90% (9) 
mild 
moderate 
severe 
 
20% (2) 
10% (1) 
10% (1) 
(1.0 days) 
10% (1) 
10% (1) 
10% (1) 
(1.0 days) 
10% (1) 
- 
10% (1) 
(1.0 days) 
10% (1) 
- 
- 
Fatigue None 40% (4) 50% (5) 70% (7) 90% (9) 
mild 
moderate 
severe 
 
20% (2) 
30% (3) 
10% (1) 
(6.0 days) 
20% (2) 
10% (1) 
20% (2) 
(1.0 days) 
10% (1) 
20% (2) 
- 
10% (1) 
- 
- 
 Group 1 2 5 6 
Boost immunization MVA-H5-
sfMR 108 
MVA-H5-
sfMR 107 
MVA-H5-
sfMR108 
MVA-H5-
sfMR 107 
Local reactions (N) 4/5 5/7 6/61 8/9 
Itch None 100% (5) 86% (6) 67% (4) 78% (7) 
mild 
moderate 
severe 
- 
- 
- 
14% (1) 
- 
- 
33% (2) 
- 
- 
11% (1) 
11% (1) 
- 
Pain None 40% (2) 43% (3) - 22% (2) 
mild 
moderate 
severe 
 
40% (2) 
20% (1) 
- 
 
29% (2) 
14% (1) 
14% (1) 
(1.0 days)* 
17% (1) 
33% (2) 
50% (3) 
(1.3 days) 
45% (4) 
33% (3) 
- 
 
Redness None 60% (3) 86% (6) 33% (2) 89% (8) 
mild 
moderate 
severe 
40% (2) 
- 
- 
14% (1) 
- 
- 
67% (4) 
- 
- 
11% (9) 
- 
- 
diameter 10.0mm 3.0mm 2.7mm 8.0mm 
Swelling None 80% (4) 86% (6) 33% (2) 78% (7) 
mild 
moderate 
severe 
20% (1) 
- 
- 
14% (1) 
- 
- 
67% (4) 
- 
- 
22% (2) 
- 
- 
Table 4A: Local reactions after the boost immunization 
 One subject reported on his/her diary card that he/she had flu-like symptoms before the 
immunization *days in parenthesis are mean number of days reaction was reported as severe 
 
 
  
  
 
 
Table 4B: Systemic 
reactions after the 
boost immunization 
  
Group 1 2 5 6 
Boost immunization MVA-H5-
sfMR 
108 
MVA-H5-
sfMR 
107 
MVA-H5-
sfMR 
108 
MVA-H5-
sfMR 
107 
Systemic reactions (N) 5/5 7/7 6/6 9/9 
Rise in 
Bodytemp 
(>37.5⁰C) 
Subjects 100% (5) 71% (5) 50% (3) 44% (4) 
Range 37.7-38.5 37.6-38.2 37.6-38.2 37.6-39.0 
Days 1.6 3.2 2.7 1.3 
Headache None 40% (2) 71% (5) - 22% (2) 
mild 
moderate 
severe 
 
40% (2) 
20% (1) 
- 
 
29% (2) 
- 
- 
 
16.5% (1) 
67% (4) 
16.5% (4) 
(1.0 days)* 
33% (3) 
33% (3) 
11% (1) 
(1.0 days) 
Myalgia None - 14% (1) 17% (1) 33% (3) 
mild 
moderate 
severe 
 
60% (3) 
40% (2) 
- 
 
14% (1) 
72% (5) 
- 
 
- 
33% (2) 
50% (3) 
(1.0 days) 
33% (3) 
22% (2) 
11% (1) 
(1.0 days) 
Arthralgia None 60% (3) 86% (6) 67% (4) 78% (7) 
mild 
moderate 
severe 
40% (2) 
- 
- 
- 
14% (1) 
- 
16.5% (1) 
16.5% (1) 
- 
11% (1) 
11% (1) 
- 
Chills None 20% (1) 72% (5) 67% (4) 78% (7) 
mild 
moderate 
severe 
 
- 
40% (2) 
40% (2) 
(1.0 days) 
14% (1) 
14% (1) 
- 
 
- 
33% (2) 
- 
 
- 
22% (2) 
- 
 
Malaise None 20% (1) 43% (3) 33% (2) 56% (5) 
mild 
moderate 
severe 
 
- 
60% (3) 
20% (1) 
(1.0 days) 
43% (3) 
14% (1) 
- 
 
- 
50% (3) 
17% (1) 
(1.0 days) 
22% (2) 
11% (1) 
11% (1) 
(1.0 days) 
Fatigue None 20% (1) 72% (5) 50% (3) 56% (5) 
mild 
moderate 
severe 
 
20% (1) 
40% (2) 
20% (1) 
(1.0 days) 
14% (1) 
14% (1) 
- 
 
33% (2) 
17% (1) 
- 
 
44% (4) 
- 
- 
 
 H5-specific immune responses 
Pre- and post-immunization sera were tested for the presence of H5 specific antibodies in the 
HI and VN assay against homologous H5N1 influenza A/VN/1194/04 virus (Table 5) and 
heterologous H5N1 influenza A/IND/5/05 virus (Table 6). Four weeks after the first 
immunization antibodies were detectable against both A/H5N1 viruses and titres were higher in 
healthy volunteers that received the 108 pfu dose of MVA-H5-sfMR, groups 1 and 5 
respectively. The A/VN/1194/04-specific HI GMT of the latter was significantly higher than that 
in groups 2 and 6, in which healthy volunteers had received the tenfold lower dose of the MVA-
H5-sfMR vaccine. A second immunization (groups 5 and 6) further boosted the antibody 
response as measured at 8 weeks after the first immunization. HI GMT also rose for group 1, 
despite the lack of a second immunization, and were significantly higher than that of group 2. 
HI GMT of group 5 was significantly higher than that of groups 1, 2 and 6. Over time antibody 
titres waned as measured on time point 20 weeks, however titres for group 5 remained 
significantly higher than those of groups 1, 2 and 6. In the main study the maximal 
seroconversion rates (% of healthy volunteers with at least a four-fold increase in titre) and 
seroprotection rates (% of healthy volunteers with a titre of ≥40) were reached after two 
immunizations (at 8 weeks) in group 5, 100% and 80% respectively. The HI data were confirmed 
by those obtained with the VN assay though VN GMT generally were lower in the latter. 
The extra immunization in the follow-up study resulted in a substantial boost of the antibody 
responses against the homologous A/VN/1194/04 (Figure 1) and heterologous A/IND/5/05 
strain (Figure 2). Highest GMTs were measured for group 1 with a 100% seroconversion and 
100% seroprotection rate (Appendix 2). The titres in this group were significantly higher than in 
group 6 in the HI assay against the A/VN/1194/04 strain and significantly higher than group 2 in 
the VN assay against the A/IND/5/05 strain. Also for group 2 100% seroconversion and 100% 
seroprotection were reached with the extra immunization.  
Sera were not only tested against the homologous H5N1 influenza A/Vietnam/1194/04 virus 
but also against viruses from antigenically distinct clades: H5N1 influenza 
A/Turkey/Turkey/1/2005 virus (clade 2.2) and the transmissible variant of the H5N1 influenza 
A/Indonesia/5/2005 virus (clade 2.1) as described recently (451;546).  Furthermore, the 
boosting effect was also confirmed for the antibody responses against these viruses (dara not 
sown). Of the healthy volunteers immunized twice with MVA-F6-sfMR 10e8 pfu, three out of 
ten seroconverted in the HI assay (two had seroprotective antibodies titres) with a GMT of 10.1 
(SD=2.8). One of ten healthy volunteers immunized twice with the 10-fold lower dose 
seroconverted (GMT 5.7 (SD=1.6)). 
 
 
 
 
 
  
 
 
 
 
 
Figure 1: Mean HI (A) and VN (B) 
antibody titers against influenza 
A/Vietnam/1194/04 virus of the 
healthy volunteers that received 
a boost immunization after one 
year.  
To assess statistical significance 
of the differences between groups 
the Mann-Whitney U test was 
performed. For the analysis of the 
HI and VN antibody titers the log2 
values were used of the titers of 0 
weeks to 20 weeks for the 
complete groups (thus including 
the healthy volunteers that did 
not receive a booster 
immunization). For the 1 year and 
4 weeks post boost immunization 
the statistics logically were 
performed with the boosted 
individuals only. *Antibody titers 
were significantly higher than in 
groups 2 and 6. ** Antibody titers 
were significantly higher than in 
group 6.  *** Antibody titers were 
significantly higher than in groups 
1, 2 and 6. **** Antibody titers 
were significantly higher than in 
group 6. 
 
 
 
 
 
  
 
 
 
Figure 2: Mean HI (A) and VN (B) 
antibody titers against influenza 
A/Indonesia/5/05 virus of the 
healthy volunteers that received a 
boost immunization after one year.  
To assess statistical significance of 
the differences between groups the 
Mann-Whitney U test was 
performed. For the analysis of the 
HI and VN antibody titers the log2 
values were used of the titers of 0 
weeks to 20 weeks for the complete 
groups (thus including the healthy 
volunteers that did not receive a 
booster immunization). For the 1 
year and 4 weeks post boost 
immunization the statistics logically 
were performed with the boosted 
individuals only. *Antibody titers 
were significantly higher than in 
group 2 (MVA-H5-sfMR 107). 
 
  
 Table 5: Cumulative seroconversion and seroprotection against homologous H5N1 virus 
influenza A/Vietnam/1194/2004 (clade 1) 
   Time after 1st immunization 
   0wks 4 weeks  8 weeks 20 weeks 
Group   HI VN  HI VN HI VN 
1 Single shot 
MVA-H5-
sfMR 
108 pfu 
Seroconversion* 
Im
m
u
n
iz
at
io
n
 
N
=
9
 
33% (3)  11% (1) 
- 
56% (5) 11% (1) 56% (5) 22% (2) 
Seroprotection 22% (2) - 33% (3) 11% (1) 11% (1) 11% (1) 
GMT (SD) 13.6 (3.2)1 5.8 (1.6) 18.5 (3.1) 9.3 (6.3) 7.3 (3.2) 9.3 (4.1) 
2 Single shot 
MVA-H5-
sfMR 
107 pfu 
Seroconversion 
N
=
1
0
 
10% (1) - 50% (5) - - - 
Seroprotection - - 10% (1) - - - 
GMT (SD) 5.7 (1.6) -  11.8 (2.7) - - - 
5 Two shot 
MVA-H5-
sfMR 
108 pfu 
Seroconversion 
Im
m
u
n
iz
at
io
n
 
N
=
1
0
 
40% (4) 10% (1) 
Im
m
u
n
iz
at
io
n
 
50% (5) 20% (2) 50% (5) 20% (2) 
Seroprotection 30% (3) 10% (1) 40% (4) 20% (2) 20% (2) 10% (1) 
GMT (SD) 13.7 (3.6) 6.2 (1.9) 20.8 (3.7) 9.3 (4.1) 11.5 (3.4) 7.1 (2.1) 
6 Two shot 
MVA-H5-
sfMR 
107 pfu 
Seroconversion 
N
=
1
0
 
30% (3) - 50% (5) 10% (1) - 10% (1) 
Seroprotection - - 20% (2) - - - 
GMT (SD) 7.6 (2.0) -  11.5 (2.3) 5.7 (1.6) - 5.0 (1.0) 
Table 6: Cumulative seroconversion and seroprotection against heterologous H5N1 virus 
influenza A/Indonesia/5/2005 (clade 2.1) 
   Time after 1st immunization 
   0wks 4wks  8wks 20wks 
Group   HI VN  HI VN HI VN 
1 Single shot 
MVA-H5-sfMR 
108 pfu 
Seroconversion* 
Im
m
u
n
iz
at
io
n
 N
=9
 56% (5) 11% (1 
- 
78% (7) 11% (1) 78% (7) 33% (3) 
Seroprotection 56% (5) 11% (1) 44% (4) 11% (1) 44% (4) 11% (1) 
GMT (SD)  22.6 (4.6) 9.3 (6.3) 30.2 (3.8)
2 9.3 (6.3) 12.2 (3.7) 12.6 (6.3) 
2 Single shot 
MVA-H5-sfMR 
107 pfu 
Seroconversion 
N
=1
0
 30% (3) 10% (1) 40% (4) 10% (1) 40% (4) 10% (1) 
Seroprotection 10% (1) - - - - - 
GMT (SD)   8.5 (2.4) 5.7 (1.6)  9.2 (2.3) 5.0 (1.0) 6.2 (1.6) 5.0 (1.0) 
5 Two shot 
MVA-H5-sfMR 
108 pfu 
Seroconversion 
Im
m
u
n
iz
at
io
n
 N
=1
0
 80% (8) 10% (1) 
Im
m
u
n
iz
at
io
n
 
100% (10) 50% (5) 100% (10) 40% (4) 
Seroprotection 60% (6) - 80% (8) 30% (3) 70% (7) 20% (2) 
GMT (SD)  39.3 (4.1)
1 5.7 (1.6) 108.1 (2.4)3 14.1 (3.4) 43.9 (3.4)3 12.3 (3.7) 
6 Two shot 
MVA-H5-sfMR 
107 pfu 
Seroconversion 
N
=1
0
 20% (2) 10% (1) 50% (5) 10% (1) 50% (5) 20% (2) 
Seroprotection 20% (2) - 30% (3) - - - 
GMT (SD)   8.1 (2.4) 5.7 (1.6)  15.8 (3.2) 5.0 (1.0) 6.9 (2.0) 5.7 (1.6) 
 MVA-specific IgG responses 
MVA-specific IgG responses are expressed as fold increase in mean fluorescence (FIMF) (Figure 
3). Four weeks after the first immunization differences between the different groups were 
minimal and the mean responses ranged from 1.62 to 2.1 FIMF. The second immunization for 
groups 5-8 induced significantly higher (p values <0.05) MVA-specific IgG responses at time 
point 8 weeks when compared to groups 1-4 that did not receive a second immunization 
(exception: the difference between group 3 and 6 was not significant). The responses waned for 
all groups between 8 and 20 weeks and at the latter time point  MVA-specific IgG response in 
Groups 5, 7 and 8 were significantly higher (p values <0.05) than in Group 2. Group 7 also had a 
significantly higher response than Group 6 (p=0.04). The boost immunization for groups 1, 2, 5 
and 6 resulted in a rise in MVA-specific IgG responses as measured four weeks after the 
booster. Differences between the groups were minimal. 
 
 
Figure 3: MVA specific antibody responses after the first, second and booster immunization.  
MVA-specific IgG antibodies were measured in serum by incubating it with uninfected or MVA 
infected BHK-21 cells and subsequently analyzing these cells by labeling them with an anti-
human IgG antibody and measuring the mean fluorescence of the cells on the FACS. MVA-
specific IgG antibody responses are expressed as fold increase in mean fluorescence, calculated 
by dividing the values from the sera incubated with the infected cells by that from the 
corresponding sera incubated with the uninfected cells. To assess statistical significance of the 
differences between groups the Mann-Whitney U test was performed. For the analysis of the 
MVA-specific IgG antibody responses values were used of 0 weeks to 20 weeks for the complete 
 groups (thus including the healthy volunteers that did not receive a booster immunization). For 
the 1 year and 4 weeks post boost immunization the statistics logically were performed with the 
boosted individuals only. *The MVA-specific IgG response in groups 5, 6, 7 and 8 was 
significantly higher (p values <0.05) than in groups 1, 2, 3 and 4 (exception: the difference 
between group 3 and 6 was not significant). **The MVA-specific IgG response in groups 5, 7 and 
8 was significant higher (p values <0.05) than in group 2. Group 7 also had a significant higher 
response than Group 6 (p=0.04). 
 
Discussion 
Here we demonstrate for the first time safety and immunogenicity of an influenza A/H5N1 
candidate vaccine based on the replication deficient viral vector MVA in humans. The 
reactogenicity of MVA-H5-sfMR in young healthy adults was mild to moderate and apart from 
the limited number of adverse events, local and systemic reactions are acceptable and are in 
line  with reports of clinical evaluations of other MVA-based vaccines (for review see (547)). The 
ten-fold lower dose of MVA-H5-sfMR was slightly less reactogenic than the 108 pfu dose, but its 
immunogenicity was lower. The latter induced significantly higher antibody responses, 
especially after two immunizations. One immunization with a dose of 108 pfu of MVA-H5-sfMR 
primed for the highest antibody responses upon boost immunization given after one year. Such 
a regimen would be of interest considering a pre-pandemic immunization scenario to establish 
priming for a H5N1-specific antibody response in a naïve population that could be boosted once 
a pandemic H5N1 virus would emerge. 
Of interest, the antibodies induced after MVA-H5-sfMR immunization cross-reacted with 
influenza A/H5N1 viruses of antigenically distinct clades of H5N1 viruses, which suggests that 
this vaccine based on the clade 1 virus A/Vietnam/1194/04 would afford some level of 
protection to H5N1 viruses belonging to other clades  as was demonstrated previously in mice 
and non-human primates (539-541).  
Currently circulating H5N1 viruses do not spread efficiently from human-to-human. A handful 
of mutations has been identified that are associated with gain-of-function and would allow 
these viruses to spread from human-to-human. Most of the mutations have been identified in 
avian influenza viruses currently circulating in birds and it has been shown that they may 
accumulate upon mammalian passage of these viruses (546). This possible scenario 
underscores the need for the development of effective vaccines. Therefore, numerous 
attempts have been made to develop such vaccines. Only with high doses of conventional 
vaccine preparations or the use of adjuvants appreciable H5N1 virus specific antibody 
responses could be induced (533). Here we demonstrate that the MVA-H5-sfMR replication-
deficient vector vaccine candidate was immunogenic and that especially a booster vaccination 
given after one year, resulted in high antibody titres. The boosting effect observed here is 
reminiscent of the booster effect observed with an adjuvanted heterologous H5 vaccine (548).  
 To compare the immunogenicity of this vaccine with conventional H5N1 inactivated 
(un)adjuvanted vaccine candidates head to head clinical trials are necessary. 
A limitation of the use of vector-based influenza vaccines may be interference of vector-specific 
immunity induced by natural infections or vaccination that could affect the immunogenicity of 
subsequent immunizations with vaccines based on the same vector (549). The MVA-based 
platform does apparently not suffer from this possible drawback as was shown previously 
(550). In the present study we also showed that the MVA-H5-sfMR vaccine elicits strong 
anamnestic antibody responses to the influenza virus HA upon second and third immunizations 
despite the induction of anti-vector immunity upon the first immunization (549). 
The boostability of the transgene encoded antigen-specific antibody response can probably be 
attributed to the administration of a relatively high dose of replication deficient MVA, resulting 
in an incomplete round of replication and co-incited expression of the transgene. The entry of 
MVA into the cells that eventually express and present the antigen, can apparently not be 
blocked by pre-existing MVA specific antibodies. This is not surprising, as antibody-mediated in 
vitro neutralization of poxviruses is notoriously inefficient and its mechanistic correlation to in 
vivo protection remains still unclear (551). T cell mediated anti-viral immunity requires at least 
one round of infection, gene expression and antigen presentation before becoming active and 
efficient recombinant antigen synthesis is possible even in the presence of strong MVA-specific 
CD8+ T cell responses (552). This aspect favours the use of this vector over replication 
competent viral vectors, like adenoviruses, that may suffer from pre-existing immunity against 
naturally occurring adenoviruses or vaccination induced vector neutralizing antibodies. The use 
of such vectors may have to rely on multiple serotypes and/or genetically modified variants, 
which could complicate practical and regulatory acceptance of the vaccine. Thus, our data show 
that MVA vector-specific immunity cannot abrogate the ability of the MVA-H5 vaccine to induce 
strong H5-specific booster responses. However, it is still unknown to what extent the priming of 
an H5-specific response could be modulated by anti-vaccinia immunity. This first-in-man study 
included only vaccinia naïve individuals and the capacity of MVA-H5 to elicit primary H5-specific 
immunity in healthy volunteers that were vaccinated against smallpox remains to be studied. 
Such follow-up studies would also inform about a potential influence of anti-vaccinia immunity 
on vaccine reactogenicity. 
Although that this was only a single centre trial, both the safety and immunogenicity data 
observed in humans with the MVA-H5-sfMR candidate vaccine are in accordance with previous 
results that we obtained with MVA-H5 candidate vaccines in mice and non-human primates. In 
addition, the MVA-influenza platform could be employed for the development of vaccines 
against emerging influenza viruses of subtypes other than H5N1. This way a library could be 
established consisting of recombinant MVA vaccines, each with a prototype HA gene (e.g. H5, 
H7, H9, H10) that can be used as a seed virus for fast up scaling of production on a suitable 
 platform such as CEFs which are a well-established cell substrate that allows for large scale 
production of recombinant MVA viruses in a short time. 
In conclusion, the present study demonstrates the favorable safety and immunogenicity profile 
of the MVA-based H5N1 vaccine and underlines that vaccine candidates arising from this 
platform hold great promise for the future. 
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 CHAPTER 5.1  
 
 
Summarizing discussion 
 
Summary of the main findings 
Haemorrhage and thrombosis during or shortly after any infection is one of the major causes of 
morbidity and mortality seen in infectious diseases. The disruption of the haemostatic balance 
and/or disruption of the endothelial cell barrier during viral infection thereby have a major 
impact on human health. Further understanding of the mechanisms behind the changes in 
haemostatic and endothelial cell function is a necessity for the development of adequate 
intervention methods. Although considerable progress has been made in unravelling the 
mechanisms behind interactions between haemostasis, endothelial cells and certain viruses, a 
large part of this knowledge remains extremely limited. Furthermore lack of awareness of some 
of these infections related to coagulation disturbances contributes to the burden of disease of  
these pathogens. The studies that form this thesis can be divided in to three parts: 
“Epidemiology, Pathogenesis and Prevention”. Using the combination of epidemiological data, 
basal and clinical pathogenesis studies, and implementation of prevention measurements, the 
aim was to cover most important aspects related to (viral) infections and mechanisms of 
thrombosis and bleeding.  
After an introduction, which provides the reader more insight into coagulation disorders in viral 
disease, this thesis starts with an overview of the studies related to serological evidence of 
circulation of neglected haemorrhagic fever pathogens in the Netherlands and Suriname. First, 
Chapter 2.1 summarizes the details of a case report that led to the start of our research line 
focussing on hantavirus awareness and pathogenesis. The time it took to adequately diagnose 
the patient presented in this case and the overall lack of awareness for hantavirus infections by 
clinicians triggered our interest in hantavirus and subsequent rodent-borne haemorrhagic fever 
pathogens. The second part of Chapter 2.1 gives more insight into these neglected pathogens 
of rodent-borne haemorrhagic fever and summarizes the literature. Knowledge gained by 
reviewing the literature facilitated the formation of the hypothesis that hantavirus disease is an 
underdiagnosed cause of haemorrhagic fever in the Netherlands.  To do so we performed a 
retrospective cohort study testing sera from leptospirosis suspected, but tested negative, 
patients that did not travel outside of the Netherlands for the possibility of a hantavirus 
infection. The results of the “ Hanta-Hunting” are presented in Chapter 2.2. Based on these 
results we concluded that there are a substantial number of missed cases of hantavirus 
infections in the Netherlands. The same strategy was applied to test a clinical cohort in 
Suriname. In Chapter 2.3 we retrospectively provide strong suggestion for symptomatic 
 hantavirus infections in Suriname. Furthermore, we prospectively detected the introduction 
and emergence of the chikungunya virus to the mainland of Suriname. Phylogenetic analysis 
showed that the virus was most likely introduced from the Caribbean, which is still suffering 
from a large outbreak.  
 
This thesis then continues with pathogenesis studies focussing on haemorrhage and clotting in 
infectious diseases. We attempted to determine the mechanism behind the disruption of 
primary and secondary haemostasis in acute Puumala hantavirus infected patients by using an 
in vitro endothelial cell model. Using this model, Chapter 3.1 shows increased tissue factor 
expression and platelet binding by virus particles as possible mechanisms for developing 
haemorrhage. This hypothesis driven approach was the impetus for a helicopter view approach 
used to continue pathogenesis research. Chapter 3.2 shows the results of proteome changes in 
hantavirus-infected endothelial cells. The results in Chapter 2.1 and Chapter 2.2 show a strong 
overlap in clinical signs and symptoms between haemorrhagic fever and renal syndrome (HFRS) 
and leptospirosis, another rodent-borne haemorrhagic fever pathogen caused by pathogenic 
Leptospira. Based on this observation pathogenic Leptospira were chosen as a control in this 
proteomic approach. Using a bacterium (Leptospira interrogans serovar Copenhageni) as a non-
virus control with similar clinical manifestations in humans we could identify both virus specific 
proteins and potentially syndrome-specific candidate proteins. These data resulted in the study 
described in Chapter 3.3, and is an example of an in vivo – in vitro – in vivo approach. We first 
studied the endothelial cell response in acute leptospirosis patients and continued with 
laboratory experiments studying the mechanisms behind endothelial cell activation in 
leptospirosis. Finally, we confirmed our findings in patients again. The pathogenesis studies end 
with an animal (ferret) experiment to study coagulation activation in influenza virus disease in 
depth. Three different influenza virus strains were used, differing in virulence and clinical 
manifestations. Chapter 3.4 shows activation of coagulation and fibrin deposition on the tissue 
level in both seasonal, pandemic and highly pathogenic avian influenza virus infection in this 
ferret model. The work described in the first two parts of this thesis consists of experiments 
with highly virulent pathogens (hantaviruses, avian influenza, chikungunya) all having a great 
potential for major impact on human health and welfare. Prevention remains the cornerstone 
of infectious disease control. In the third and final part of this thesis we focussed on disease 
prevention by ecology and vaccination all with the goal to minimize the burden of disease of 
the studied pathogens.  Focussing on newly identified risk factors and prevention tools, this 
section of the thesis starts with Chapter 4.1 showing the strong association between selenium 
deficiency and hantavirus infection incidence, both in humans and reservoir rodents. Before 
selenium supplementation can be implemented as a  disease prevention method,many more 
studies are needed. This international collaborative work could be of major importance in 
further understanding hantavirus incidence and outbreaks, however to be so the mechanism 
 behind this association should be revealed. This thesis ends with an effective prevention tool in 
Chapter 4.2, listing the results of a phase I/IIa trial studying the safety and immunogenicity of a 
modified vaccinia Ankara virus presenting the hemaglutinin of the H5N1 avian influenza, a virus 
of which its pathogenicity is demonstrated in Chapter 3.4. Our results indicated the usefulness 
and effectivity of this vaccine for H5N1 while it also illustrates that this specific vector could be 
very suitable as a platform for vaccine production of all pathogens mentioned in this thesis. 
 
Part I Epidemiology 
Hantaviruses- widely spread, under-recognized and preventable?       
This thesis starts with a summary of the clinical observations that led to the formulation of the 
first hypothesis tested in Chapter 2.2. Both the case report, discussed in the introduction of this 
chapter, and literature analysis of the spread, awareness and clinical manifestations of 
hantavirus disease, revealed certain difficulties and challenges for adequate hantavirus 
diagnosis. It has been described previously that hantavirus disease might be confused with 
dengue virus infection, leptospirosis or other viral infections, potentially leading to under-
diagnosis and missed cases in other countries (553-555). To test this hypothesis for the 
Netherlands, we selected a cohort with symptoms and absolute certainty of no international 
travel history in the period before disease onset. In collaboration with the Royal Tropical 
Institute (KIT) we tested a cohort of leptospirosis suspected patients for the presence of 
hantavirus antibodies which resulted in the Hanta-Hunting study discussed in Chapter 2.2. Since 
leptospirosis diagnostics are done by manual addition of live Leptospira to patient sera, 
knowledge of the exact travel history of the patient is crucial for knowing which specific serovar 
is needed for the diagnostic test. This resulted in the availability of detailed information on 
patient history, living area and risk factors associated with environment or human behaviour. 
Patients that, with absolute certainty, had no chance of being potentially infected outside of 
the Netherlands were included in the Hanta-Hunting study.  We chose a design with optimal 
sensitivity and decided to first screen the cohort using a pan-hantavirus Enzyme Linked 
Immunoabsorant Assay (ELISA). The high seroprevalence of hantavirus antibodies in this cohort 
made us consider the possibility of false positive results or extensive cross reactivity in the 
serological diagnosis of hantavirus infections. Further confirmation by use of Immune 
Fluoresence Assay’s (IFA) and eventually virus neutralization tests revealed a significant number 
of cases with absolute certainty of being a missed hantavirus case at the time of disease. The 
occurrence of unrecognized hantavirus cases has direct implications for clinicians. The clinical 
outcome of a hantavirus infection will greatly benefit from early diagnosis, which can reduce 
costs related to unnecessary tests and treatment. Furthermore, screening the Hanta-Hunting 
cohort resulted in direct implications for routine hantavirus and leptospirosis diagnostics. First 
of all, although a substantial number of undiagnosed hantavirus cases were discovered the 
Hanta-Hunting cohort also revealed a large number of false positives. This  shows the need for 
 confirmation of unexpected results by gold standard virus neutralization tests in hantavirus 
epidemiological studies. The low specificity of routine hantavirus serology and subsequently the 
value of a single positive hantavirus test warrants further research. Also of interest is the fact 
that samples of leptospirosis positive patients revealed high optical density values in the 
commercial hantavirus ELISA tests (unpublished data). Since these results could not be 
confirmed by neutralization, important questions remain. First of all, papers describing possible 
co-infections of hantavirus and Leptospira, based only on ELISA or IFA test results, should be 
carefully analysed and in our opinion no solid conclusions should be drawn from those 
observations yet (553-555).  Furthermore, cross reactivity between antibodies against 
Leptospira and pathogenic hantaviruses can be of interest. These two entirely different 
pathogens, a virus and a bacterium, colonize the same organ in rodent reservoirs and therefore 
co-evolution could have led to viral and bacterial proteins with great cross reactivity. These 
proteins can be both of importance for the usefulness of diagnostic assays but also for potential 
vaccine design.  
The results from the Hanta-Hunting study lead to collaboration with the public health institute 
of Suriname (B.O.G.). We consequently tested a large fever cohort for the presence of new 
pathogens causing haemorrhage in Suriname. Results are discussed in Chapter 2.3. As in the 
Netherlands, a high seroprevalence of hantavirus disease was suspected on the basis of ELISA 
and IFA results. These results could not, however, be confirmed by virus neutralization. This 
illustrates the pitfall in neutralization as a gold standard test in hantavirus disease. The assay is 
only as strong as the (hanta)viruses available to run the test with. We made use of an “Old-
World” hantavirus and tested neutralizing antibody titres against the “New-World”  Andes 
hantavirus. The Andes virus is known to circulate in the southern parts of South America, 
mainly in Argentina and Chile and its reservoir is proven to be the Oligoryzomys longicaudatus 
(longtailed pygmy rice rat). Suriname is located in the northern part of South-America and 
rodent populations seem to differ from those reported in southern parts of South America. 
Since each pathogenic hantavirus is associated with one specific rodent species as reservoir 
host it could be that different, or even undiscovered, hantaviruses circulate in Suriname. 
Despite the lack of confirmation by neutralization, we do provide a strong suggestion of 
hantavirus circulation in Suriname. This observation warrants further attention. Molecular 
detection of hantaviruses in acute patients or reservoir rodents could address the presence or 
absence of hantavirus circulation in Suriname.        
 
 
 
 
 
 
 Part II Pathophysiology  
Hantavirus infection, primary- and secondary haemostasis and fibrinolysis 
In Part II, we changed focus to identifying disease mechanisms behind viral haemorrhagic fevers 
and viral infections associated with thrombosis. By using two viruses as models we aimed to 
further elucidate pathophysiology in the relation between viral infections and thrombosis 
and/or bleeding. As previously mentioned, we chose hantaviruses as a model for viral 
haemorrhagic fever pathogens. This is due to the fact that hantaviruses directly infect 
endothelial cells early in disease. This makes direct effects of the virus on endothelial function 
an obvious possibility in the origin of endothelial cell dysfunction (62). In Figure 2 of the 
introduction of this thesis we summarized the current knowledge of hantavirus infection, 
haemostasis and endothelial cells. Figure 1 in this discussion summarises this knowledge, now 
with the data and knowledge from our endothelial cell studies. The experiments executed in 
Chapter 3.1 were based on a hypothesis largely formed by clinical observations in acute 
Puumala hantavirus patients and the strong increased risk in myocardial infarction during or 
shortly after Puumala infection (556). Several large cohort studies done by Laine et al. showed 
increased levels of markers related to activation of coagulation in Puumala patients. Many of 
these markers showed a strong correlation to disease severity (63;354). We aimed to provide 
insight into the mechanism behind coagulation activation by making use of a reliable and 
representative model. Since animal models for hantavirus disease are not accessible, hantavirus 
research still depends on in vitro experiments. Therefore, we have put much effort into the 
isolation of both primary endothelial cell cultures and low passage virulent Puumala hantavirus 
stocks. After a long design and optimization period we tested several hypothesis.  Firstly, the 
fact that platelets are able to directly bind to PUUV particles can be of importance in further 
understanding primary haemostasis and its role in Puumala virus disease mechanisms. Platelets 
appear to be essential for the development of arterial occlusion, given that platelet aggregation 
inhibitors are first choice for preventive treatment in cardiovascular disease.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 . Summary of, and what this thesis adds to, the knowledge of the interaction 
between endothelial cells and hantavirus infection  
As discussed in the introduction of this thesis, the changes in haemostasis seen during 
hantavirus infection the result of two different pathways. At first, dendritic cells (DC) and 
macrophages (MO) produce pro-inflammatory cytokines during hantavirus infection promoting 
the procoagulant shift. Platelets bind to hantavirus infected cells via virus glycoproteins present 
on the infected cells. Furthermore, polymorphonucleur neutrophils (PMN) release neutrophil 
extracellular traps (NETs) upon binding of hantaviruses to these cells, which in turn continue to 
stimulate platelet aggregation and secondary coagulation. We now add to this overview that 
hantavirus infection of endothelial cells directly leads to an increase of tissue factor and 
subsequent thrombin generation. Furthermore a direct binding between Puumala hantavirus 
and quiescent platelets is possible. Further contributing to the procoagulant changes is the 
increased release of thefibrinolysis regulator plasminogen activator inhibitor type-1 (PAI-1). 
Possibly inhibition of fibrinolysis is further enhanced by an increase in PAI-1 stability due to the 
increased formation of PAI-1-vitronectin complexes during Puumala infection. Furthermore, 
proteome analysis of infected endothelial cells revealed multiple upregulated proteins during 
hantavirus infection. 
 We hypothesized that the binding of platelets to infected cells would coincide with an increase 
in VWF expression. However, antigen detection of VWF in cell lysates and quantitation of 
excreted VWF in supernatant of infected cells showed no alterations in VWF concentration 
discussed in Chapter 3.1. Unpublished data (Figure 2) shows quantitation of the cell surface 
expression of VWF on PUUV infected endothelial cells. It seems that VWF expression is actually 
decreased on 48 and 72 hours after infection. Since a decrease in VWF could lead to bleeding 
manifestations, one of the hallmark symptoms of hantavirus infections leading to HFRS, 
confirmation of these results could reveal interesting facts about the mechanism behind 
bleeding in HFRS. This is particularly so, as changes in VWF levels also influence the activity of 
coagulation factor eight which might have consequences for the haemostatic balance.  
 
 
Figure 2 (unpublished data). 
A decreased VWF surface expression is seen 
after 48 hours post infection on the surface of 
PUUV infected HUVEC in comparison with the 
negative (NEG) and inactivated (BPL) control 
after of Mann Whitney U test (p = <0.05). 
 
 
 
 
 
Furthermore, the proteins identified in Chapter 3.2 could give direction to future studies. 
Although there were fewer proteins compared to related proteomic studies of in vitro infection 
models, most of the identified proteins appeared to interact in multiple processes important for 
virus host interactions. Proteins such as protein disulphide isomerase, N-ethylmaleimide 
sensitive factor, and heterogeneous nuclear ribonucleoprotein K, have been shown to be 
essential in the replication and/or attachment processes of multiple viruses. Since effective 
anti-viral therapeutics for hantaviruses are not available, these proteins, if confirmed by siRNA 
or other knock down experiments, can be of interest.   
 
Influenza  
Activation of coagulation and transient consumptive coagulopathy  
We finalize our work on disease mechanisms with an in-depth study of viruses associated with 
thrombosis. As a representative of viral infections potentially resulting in thrombosis, we 
evaluated the activation of coagulation in influenza virus disease. Data are presented in 
Chapter 3.4. In this chapter we describe the drastic signs of activation of coagulation in the 
 circulation and deposition of fibrin on the tissue level. Many of the coagulation markers 
correlated with markers of disease severity, but there were some discrepancies. For instance, 
high D-dimer levels in relative mild seasonal H3N2 infection raises questions. A systemic switch 
to a pro-coagulant state could theoretically add to an already present predisposition for 
cardiovascular disease and metaphorically speaking be the straw that breaks the camel’s back 
(or as we would say in Dutch the drop that makes the bucket flood). Since our data are 
observational, further elimination experiments are needed to understand the exact 
mechanisms between influenza virus infection and activation of coagulation. One of the biggest 
questions that remain after interpreting the results of this thesis is the question why, when and 
how a viral infection results in either thrombosis or  bleeding or possibly both. Based on our 
results it seems that both haemorrhagic and ‘thrombotic’ infections lead to pro-coagulant shift 
of the haemostatic balance. Whether this increased clotting tendency leads to a thrombotic or 
haemorrhagic event lies in very subtle differences. The correlation between coagulation 
markers and disease severity in influenza and the massive fibrin depositions in highly 
pathogenic avian influenza H5N1 virus suggest a possible relationship between the 
‘aggressiveness’ or virulence of a virus and the coagulation response. This is in line with the 
observations that the severest (acute) viral infections are often associated with bleeding 
complications (Ebola, Marburg, dengue haemorrhagic fever etc.). It could very well be that 
viruses that cause a more temperate (chronic) disease (Human Immunodeficiency Virus [HIV], 
Cytomegalovirus [CMV]), continuously trigger the haemostatic balance towards a pro-coagulant 
state that, in specific cases, may lead to thrombosis. The haemorrhagic fever viruses deliver a 
comparable trigger to a much bigger extent, potentially resulting in consumptive coagulopathy 
and other pathological mechanisms associated with vascular dysfunction/bleeding. Based on 
our experimental work and review of the literature we strongly believe that the magnitude of 
the pro-coagulant trigger during viral infection, the way endothelial cells are activated (due to 
cytokines or direct infection)  and even in which organ they are activated, all seem to play an 
important role in the origin of thrombosis or bleeding.    
 
Endothelial cells and influenza virus 
Another interesting comparison between hantaviruses and influenza viruses in light of 
haemostasis is the different role endothelial cells play in the pathogenesis of both diseases. In 
hantavirus infection the endothelium seems to be a target cell for direct infection resulting in 
endothelial dysfunction. Influenza viruses, however, have a more complicated relation with 
endothelial cells. Short and colleagues extensively reviewed the role of endothelial cells in 
influenza virus infection (557;558). They suggest that influenza virus infection of endothelial 
cells is most likely absent in humans and other mammals. Thus, indirect endothelial activation 
seems more important than direct infection of endothelial cells with influenza virus in damage 
to the alveolar epithelial–endothelial barrier (557). This would mean that the signs of an 
 activated endothelium in the ferrets tested in Chapter 3.4 is more likely to be a secondary 
response to epithelial cell infection. Of interest would be to study the endothelial cell response 
towards infection of closely located epithelial cells, ideally under flow conditions. A final 
possible mechanism behind the coagulation activation in influenza virus infection is the role of 
neutrophils. The release of neutrophil extracellular traps (NETs) has been shown to play an 
important role in both ARDS and influenza virus disease. NETs are formed by chromatin fibers 
that neutrophils release while undergoing cell death. They have recently been shown to be an 
absolute necessity for the development of vascular thrombus (559). NETs can capture platelets 
and increase fibrin deposition (560) and thereby are very likely to contribute to pro-coagulant 
changes in viral infections. 
 
Part III prevention 
 
Prevention: “ Knowledge as Anti-Virus”  
After studying the magnitude and awareness of hantavirus disease in Part I and unravelling 
of disease mechanisms in Part II we aimed to also put effort into prevention possibilities. Part III 
discusses ecology and prevention of the emerging pathogens used in the experimental studies 
in this thesis. The link between dietary insufficiency and hantavirus incidence was discussed in 
Chapter 4.1. The fact that low selenium levels so strongly correlate to incidence levels of HFRS 
in China, both in humans and rodents, warrant further in depth studies. The actual occurrence 
of a hantavirus infection is a multifactorial process, with many steps from reservoir rodent to 
human case, which can influence the occurrence (and outcome) of an infection (Figure 3). 
Theoretically many of these points could be influenced by decreased selenium intake. Based on 
our results it seems unlikely that humans with lower selenium levels are more prone to 
hantavirus infections. A direct mutating effect on the virus, as is described for influenza (516), 
due to high selenium levels could alter viral fitness and survival. However, selenium 
supplementation to our in vitro culture only mildly suppressed replication when using a very 
low infectious dose. The great limitation of our in vitro model in this case is the absence of 
immune cells, as many publications suggest an immunostimulant role for selenium on T-cells 
and macrophages in particular (507;508). Keeping the literature in mind, our experimental 
results discussed in chapter 4.1, and looking at the chain of a hantavirus infection in Figure 3, it 
seems most likely that selenium concentration changes have their effect in reservoir rodents. 
Either immune activation due to high selenium levels decreases the virus shedding in these 
rodents or rodents in selenium deficient areas have an increase in virus titre and subsequent 
shedding. This both leads to alterations in the hantavirus exposure to humans. Future 
experiments should determine whether the association between selenium concentration and 
hantavirus incidence holds true. This would potentially provide rationale for preventive 
 measures of HFRS, such as providing selenium supplements, either through fertilization of crops 
or as a preventive medicine for humans in severe selenium-deficient regions. 
 
 
 
Figure 3. Chain graph of the occurrence of a hantavirus infection. Orange circles represent the 
steps from risk of infection in rodents to the occurrence and recognition of clinical cases. These 
steps can be influenced by the blue circles, while the red arrows indicate intervention 
possibilities. (Goeijenbier & De Vlas ©) 
 
Another effective way of preventing infection would be by vaccinating populations at risk 
against hantaviruses. Currently, inactivated virus vaccines are licensed in China and Vietnam. 
Moreover, several new molecular vaccine approaches are in pre-clinical stages of development. 
However, the further development of hantavirus vaccines is largely hampered by the lack of 
adequate animal models and research funding (561). Another interesting possibility would be 
the use of viral vectors expressing hantavirus proteins from the pathogenic hantaviruses 
circulating in a specific area. These can be tailored to certain areas due to the stringent host 
restriction of pathogenic hantaviruses. In China, for instance, a vaccine protecting against 
Hantaan and Seoul would be of great use. In this respect the use of modified pox viruses like 
the Modified Vaccinia Ankara would be of great interest. Not only because of the accessible and 
effective technique to express viral proteins on this viral vector but also because in Chapter 4.2 
we have shown the safety and immunogenicity of such a vector.  
 
Despite improved sanitation and the availability of effective antibiotics and vaccines, infectious 
diseases are still a major cause of disability, death, and socio-economic decline for millions of 
people. The burden of these infectious diseases is highest in lower income areas, while 
 knowledge and expertise related to prevention and 
treatment is often limited. These observations are 
confirmed by recent outbreaks of Ebola in West-Africa. 
As illustrated by Figure 3, the occurrence of a 
hantavirus infection is a good example of an infectious 
disease where prevention could benefit from 
counselling people at risk. Hantavirus infection can be 
prevented by changes in human behaviour and by 
reducing risk factors. To make youth aware of viral 
transmission risks and adequate prevention tools we started with a project called: “Viruskenner 
– knowledge as anti-virus” in 2010. In the Viruskenner project, high school children are taught 
using tailor made teaching programs and guided by motivated young scientists.  These students 
learn  about specific characteristics of (viral) diseases that have a high impact on society. 
Widespread availability of knowledge and expertise can increase awareness of adequate 
preventative measures for  young people and, in so doing,  reduce the spread and impact of 
infectious diseases. For vector-borne disease prevention, measures like introduction and use of 
mosquito nets and repellent lotion, or with sex education, promoting safe sex and thereby 
decreasing HIV and other sexually transmitted diseases. Although these measures are available, 
without proper education and promotion, they will not be effective.  The Viruskenner module 
was first tested in a small setting in the Netherlands and subsequently in Suriname. First 
students were taught about a specific infectious diseases. The students then created what they 
thought would be an effective prevention method for specific viral diseases such as HIV, dengue 
or hantavirus. The outcomes of a collaboration between scientists, experts of latest trends and 
peer communication (high school students) resulted in innovative and useful prevention tools. 
After the pilot phase, a large collaborative Viruskenner project has been set up this year (2015), 
with the project running simultaneously in the Netherlands, Suriname and Indonesia. 
Prospective cohort studies should reveal if this approach is a  (cost)effective way to reduce the 
burden of infectious diseases. For now, Viruskenner is a stimulating educational method 
resulting in increased awareness and knowledge among groups of high school students. 
 
Future perspectives & Concluding remarks 
Coagulation disturbances play a vital role in the pathogenesis of many viral infections. Both 
haemorrhagic and thrombotic complications are associated with a high morbidity and 
mortality, confirming the essential role haemostatic imbalance plays in disease pathogenesis. 
For both viral haemorrhagic fever pathogens and the (often respiratory) viruses associated with 
vascular thrombosis further understanding of the mechanism behind this interaction and 
subsequent tailored treatment and/or prevention measurements will decrease the burden of 
these diseases. Hantaviruses proved to be a solid model for the study of mechanisms of 
 haemorrhage in humans. Though recently, steps have been taken toward the understanding of 
endothelial damage and dysfunction in hantavirus disease (53;562), the actual mechanism of 
how they can cause haemorrhage remains largely unknown. An interesting approach would be 
studying the hantavirus effects on endothelial cells of specific vascular beds. Endothelial cells 
have multiple important functions in vascular biology such as maintenance of haemostatic 
balance and the integrity of the vascular wall. Recent advances in the field of vascular biology 
suggest a large heterogeneity within the endothelial cells throughout the body (563). This 
heterogeneity of the endothelium comprises both molecular and functional features resulting 
in vascular bed-specific haemostasis and response to stimuli. This is shown by the fact that 
endothelial cells show organ- and site-specific characteristics throughout the different 
segments of the vascular tree adjusted to different micro-environmental conditions (564). This 
heterogenic functionality is further emphasized by differences in the expression of various 
molecules, like VE-cadherin and CD31, throughout the various vascular segments of the body 
(565). Furthermore, anti-coagulant responses seem to differ greatly between tissues. By 
regulation of the production of specific anti-coagulants a vascular bed sets it haemostatic set-
point, which greatly differs between the organs. To describe this phenomen the term vascular 
bed-specific haemostasis is used and seems to be the result of the interplay between 
extracellular signals, cell-subtype specific signalling pathways and transcriptional regulation. 
This could all be of importance in the mechanism behind the process that determines if a viral 
infection leads to thrombosis or bleeding (9). This research could be extended to studying the 
endothelial cell responses, assumed to be at the onset of disease in hantavirus infections, in 
reservoir hosts. Both homology and molecular mimicry between reservoir hosts and humans 
partially explains varying degrees of disease severity between different hantaviruses (53). 
Comparison of endothelial cell reactions in asymptomatic reservoir hosts versus the reaction 
observed in spill-over symptomatic hosts would give insight into the essential mechanisms of 
the development of hantavirus disease.  
 At the other end of this spectrum are the thrombotic events related to viral 
infection. The repeated strong association between respiratory infections and myocardial 
infarction warrants much more attention. Rather than confirming the association by large 
epidemiological studies, future studies should focus on identifying those at risk for the 
development of a thrombotic event and subsequent methods of prevention. It is not yet clear 
why some viruses have a strong influence on coagulation and are associated with thrombotic 
complications or bleeding, while in other viral infections this effect is limited. The complex 
interplay between the host, the virus (virulence), the vector and the environment (infection 
pressure in the community) will define clinical presentation and outcome. This might explain 
the different clinical presentation of viral infections in various parts of the world. Furthermore, 
differences in clinical presentation could also be explained by diverse tropism of viruses, such 
as monocytes or endothelial cells. It is not yet clear whether a pathogen associated with 
 bleeding or thrombosis exerts its effect through direct infection of a target cell, through 
pathogen-specific cross reacting antibodies, or via inflammatory mediators. In addition, 
inherited host factors most certainly play a role in disease severity. For implementing specific 
therapeutic interventions, it is crucial to know which side of the haemostatic balance the 
patient is on in the course of the present infection. In acute infections this is extremely difficult 
to determine and might be the main reason that theoretically hopeful interventions (anti-TF, 
activated protein C), were less successful or even disappointing in clinical practice. Before new 
(anti) coagulants are designed or tested we should consider testing the usability of a sensitive 
marker to determine the coagulation imbalance in a patient.  
 The proteome analysis of infected cells is a potential powerful platform in the 
further understanding of early host response in viral infections. To prevent the generation of 
large quantities of data of up and down regulated proteins, future experiments should ideally 
be combined with in vivo data and elimination experiments. By using the proteomic approach, 
both targets for the inhibitions of viral replication could be identified as protein changes 
associated with the development of disease. The latter might be a potential target for tailor 
made therapy in the form of protein inhibition or supplementation.  
Furthermore, more knowledge is required regarding dietary insufficiencies and its effect on 
viral infections and potentially disease severity. The strong association between selenium 
concentrations and HFRS incidence warrant further attention and might hold valuable clues 
regarding both disease transmission and reservoir immune status. Eventually this could lead to 
tailor made prevention. With the continuous emergence of very severe infections like Ebola, 
highly pathogenic avian influenza virus and New World hantaviruses, the development of 
prevention strategies should be prioritized. Evaluation of the MVA platform discussed in 
Chapter 4 and its suitability for immunization against hantaviruses or Ebola and Marburg would 
be a very favourable approach if combined with studies addressing vector immunity in the 
population and safety in immunocompromised patients.  
  
 CHAPTER 5.2 
 
Nederlandse samenvatting 
 
Hemostase en virus infecties 
Het ontstaan van een bloeding of trombose gedurende of kort volgend op een infectie is een 
van de meest prominente oorzaken van morbiditeit en sterfte ten gevolge van infectieziekten. 
Hoewel aanzienlijke vooruitgang is geboekt in het ontrafelen van ziekte mechanismen in 
bijvoorbeeld bloedvergiftiging (sepsis) en chronische virus infecties (HIV, hepatitis B,C), is de 
kennis over de mechanismen die verantwoordelijk zijn voor het ontstaan van bloedingen en/of 
trombose ten tijde van virale infecties zeer beperkt. In dit proefschrift wordt de invloed van 
virale infectie op de bloedstolling bestudeerd. De focus ligt op de rol van de endotheelcel in dit 
proces, aangezien deze cel een belangrijke rol speelt in de regulering van de bloedstolling. 
Daarnaast wordt de epidemiologie van bloedende koortsen bestudeerd. Het proefschrift besluit 
met een overzicht van mogelijke methoden van preventie van deze veelal ernstige 
ziekteverwekkers. De introductie, weergegeven in hoofdstuk 1, geeft de lezer meer inzicht in 
verstoringen van de balans in de bloedstolling ten tijde van virale infecties. Er wordt een 
uitgebreide samenvatting gegeven met daarin een overzicht van de huidige kennis op het 
gebied van virus infecties en mechanismen van trombose en stolling. Tevens is er in dit 
hoofdstuk aandacht voor de onderzoeksgebieden waar nog kansen liggen voor de verbetering 
van het inzicht in de verstoring van deze balans. 
  
Hantavirus infecties 
In een groot deel van dit proefschrift ligt de nadruk op onderzoek betreffende hantavirussen. 
Hantavirussen zijn kleine RNA virussen die via knaagdieren worden overgedragen op mensen. 
Het virus bevindt zich in de uitwerpselen van deze knaagdieren en kunnen via kleine 
stofdeeltjes ingeademd worden. Afhankelijk van het type hantavirus kan dit leiden tot twee 
verschillende aandoeningen. In Europa en Azië ziet men veelal problemen met nieren en 
bloedstolling terwijl een hantavirus infectie in Noord- en Zuid-Amerika eerder zorgt voor het 
falen van zowel de longen als het hart. In beide ziektebeelden lijkt hierbij het functieverlies van 
de endotheelcel centraal te staan.  
 
Directe aanleiding voor het opstarten van een hantavirus onderzoekslijn was een patiënt 
van wie het klinische beloop is beschreven in het case report welke de inleiding vormt van 
hoofdstuk 2. Gedurende het ziekteproces viel op dat er een lange tijd nodig was voor het 
stellen van de diagnose van een acute hantavirus infectie. Tevens bleek dat, in het algemeen, 
clinici een hantavirus infectie binnen Nederland veelal niet (direct) overwogen in hun 
 differentiaal diagnose. Literatuuronderzoek deed de hypothese ontstaan dat de algehele 
toename van hantavirus infecties in Europa, binnen Nederland niet werd opgemerkt, door het 
feit dat er geen gericht diagnostisch onderzoek wordt ingezet. Vervolgens is deze hypothese 
bevestigd in hoofdstuk 2.2 doormiddel van het nauwkeurig nagaan van een grote 
patiëntengroep, verdacht van een klinisch vergelijkbare aandoening. Patiënten die op basis van 
symptomen of risicofactoren getest werden op de, tevens via knaagdieren overgedragen, 
aandoening leptospirose zijn voor deze studie uitgebreid getest op de mogelijkheid van een 
acute hantavirus infectie. Dit werd gedaan in de  zogenaamde Hanta-Hunting studie. 
Doormiddel van eenzelfde strategie wordt vervolgens in hoofdstuk 2.3 aangetoond dat er in 
Suriname aanwijzingen zijn voor het circuleren van hantavirussen welke bij mensen ziekte 
kunnen veroorzaken. Tevens faciliteerde de studie in Suriname de implementatie van 
diagnostische technieken waarmee de introductie en uitbraak van chikungunya in Suriname 
vervolgens is waargenomen. De genetische analyse liet zien dat dit virus meest waarschijnlijk 
geïntroduceerd is vanuit het Caribisch gebied, een gebied dat momenteel nog steeds gebukt 
gaat onder een grote chikungunya uitbraak. 
      
Hantavirus interactie met endotheel 
In het vervolg van het proefschrift wordt gebruik gemaakt van hantavirus infectie als model 
voor een bloedende koorts. Hantavirussen die voor ziekte zorgen bij mensen oefenen een 
vrijwel direct effect uit op endotheel cellen, al vroeg nadat zij het lichaam zijn binnen 
gedrongen. Onderzoek tot nu toe heeft zich vooral gericht op de invloed die het virus heeft op 
de doorlaatbaarheid van de endotheel barrière. In hoofdstuk 3.1 is gebruik gemaakt van een 
endotheelcel model om enkele klinische observaties, gemaakt in met het Puumala hantavirus 
geïnfecteerde patiënten, nader te verklaren. In zieke patiënten geïnfecteerd met het Puumala 
hantavirus, het type virus dat in Nederland maar o.a. ook in Finland en Zweden voor 
ziektegevallen zorgt, laat zien dat de stollingscascade reeds in de vroege fase van de infectie 
geactiveerd is. Vervolgens is de mate van activatie direct gecorreleerd met de ernst van de 
ziekte. Infectie van vers geïsoleerde en gekweekte endotheelcellen met het Puumala hantavirus 
liet zien dat Tissue Factor expressie direct verhoogd werd, wat er voor zorgde dat de thrombine 
generatie sterk toeneemt. Daarnaast blijkt  dat infectie van deze endotheelcellen er tevens toe 
leid dat bloedplaatjes vastplakken aan geïnfecteerde endotheelcellen, iets wat geremd kon 
worden door de virusdeeltjes eerst te blokkeren met antistoffen. Uit de experimenten 
beschreven in dit hoofdstuk blijkt dat het Puumala hantavirus zowel de primaire als secundaire 
stolling direct beïnvloedt. Vervolgens is in hoofdstuk 3.2 gekeken naar elke significante 
waarneembare verandering in de volledige mix van eiwitten binnen een hantavirus 
geïnfecteerde endotheelcel. Dit ‘proteomics’ experiment resulteerde in de identificatie van 
verschillende eiwitten die in hogere concentratie of juist lagere concentratie binnen de cel 
aanwezig zijn ten tijde van een hantavirus infectie vergeleken met ‘gezonde’ cellen. Tevens 
 maakten wij voor dit experiment gebruik van de bacterie Leptospira interrogans als extra 
controleconditie. Dit omdat de ziekte die veroorzaakt wordt door deze bacterie, zoals eerder 
vermeld, voor een soortgelijk klinisch beeld zorgt na infectie. Dit terwijl de ziekteverwekkers, 
een virus en een bacterie, juist zoveel van elkaar verschillen. Op deze manier hoopten wij zowel 
virus specifieke eiwitten te identificeren als eiwitten die specifiek zijn in het verloop van het 
ziekteproces. Een overeenkomst tussen beide infecties was de afname van eiwitten die 
essentieel zijn voor het geraamte (cytoskelet) van de endotheelcel. In hoofdstuk 3.3 werd de 
interactie tussen Leptospira en endotheelcellen verder onderzocht waarbij een van de 
belangrijkste bevindingen was dat de mate van de afweerrespons van het lichaam sterk 
geassocieerd is met de ernst van de ziekte. Dit wekt de sterke suggestie dat niet alleen de 
bacterie maar tevens de respons van het lichaam hierop uiteindelijk bijdraagt aan de ernst van 
ziekte.  
 
Influenza virus infecties en hemostase 
Vervolgens werd de focus in dit proefschrift verlegd naar virale infecties die geassocieerd zijn 
met verstopping van een bloedvat; trombose. Hiervoor is gekozen voor influenza virus als 
model. In een diermodel hebben wij gekeken naar de mate van stollingsactivatie ten tijde van 
infectie met influenza virussen van verschillende mate van ziekmakend vermogen; virulentie. 
Zowel bij infectie met een veel voorkomende, relatief milde, seizoensgriep als tijdens infectie 
met de hoog pathogene H5N1 vogelgriep was de stollingscascade geactiveerd. Echter veel 
markers van ernst van ziekte en virologische parameters correleerden met de gemeten 
stollingsproducten. Dit wordt beschreven in hoofdstuk 3.4. De belangrijkste vraag die overblijft 
na afronding van dit proefschrift is hoe, in welke hoedanigheid en waar wordt bepaald of een 
bepaalde virale infectie resulteert in trombose, bloeding of zelfs beide. Zowel de bloedende 
koortsen als virus infecties, geassocieerd met trombose bestudeerd in dit proefschrift, zorgen 
voor een activatie van de stolling. Hoe deze stollingsactivatie uiteindelijk zal leiden tot bloeding 
of trombose wordt bepaald door zeer subtiele verschillen. Een belangrijke rol is weggelegd voor 
de virulentie, ook wel te omschrijven als de agressiviteit van het virus, iets wat gezien wordt bij 
de meest ernstige hemorrhagische koortsen zoals Ebola en Marburg. Het zou kunnen dat 
mildere of chronische infecties een weliswaar continue, maar mildere activatie van de stolling 
veroorzaken die uiteindelijk tot trombose zou kunnen leiden, in combinatie met andere 
triggers. Andere factoren die hierin een rol zouden kunnen spelen, zullen in de toekomst verder 
moeten worden uitgezocht.  Hierbij kan men denken aan: in welk orgaan het vaatbed is 
aangedaan en of het endotheel direct door het virus of via de immuunrespons wordt 
geactiveerd.  
 
 
 
 Manieren van preventie 
Het proefschrift eindigt met een tweetal hoofdstukken gericht op het voorkomen van de 
infecties behandeld in de eerdere delen. In hoofdstuk 4.1 onderzochten wij omgevingsfactoren 
in relatie tot het voorkomen van infectieziekten. Wij toonden een sterke associatie aan tussen 
selenium concentratie in gewassen en de incidentie van hantavirus infecties in China. Op basis 
van vervolgstudies in patiënten en experimenten in het eerder beschreven endotheelcel model 
suggereren wij dat de variaties in selenium concentratie zeer waarschijnlijk effect hebben op de 
verspreiders van hantavirus infecties in China, ratten en bosmuizen. Of en hoe uiteindelijk 
selenium suppletie het aantal hantavirus infecties kan doen dalen, zal moeten worden 
uitgewezen in vervolgstudies. Aansluitend op dit hoofdstuk laten wij in hoofdstuk 4.2 de 
effectiviteit en veiligheid zien van preventie door middel van vaccinatie met een gemodificeerd 
pokkenvirus (MVA). Op het oppervlak van dit ongevaarlijke virus is een belangrijk oppervlakte 
eiwit van het zeer gevaarlijke vogelgriepvirus tot expressie gebracht. Het gebruik van vector als 
vaccinatie biedt een veelbelovend perspectief voor bescherming tegen vele andere virussen, 
zoals bijvoorbeeld hantavirussen. Vervolgonderzoek zal moeten uitwijzen of brede inzet van 
vaccinatie middels MVA ook daadwerkelijk mogelijk is. 
  
In dit proefschrift is enerzijds verspreiding en diagnostiek van virale bloedende koortsen 
bestudeerd. Anderzijds werd de interactie tussen virale infecties en de stollingscascade 
uitgebreid onderzocht. Samengevat heeft het onderzoek beschreven in dit proefschrift 
bijgedragen aan de kennis van virale infecties en interactie met daarachterliggende 
mechanismen van trombose en bloeding. Een hantavirus infectie, met als mogelijk gevolg een 
bloedende koorts, is een diagnose die in ieder geval in Nederland en Suriname nog al eens over 
het hoofd wordt gezien. Illustratief hiervoor zijn de vele gepubliceerde patiënten casussen, 
waarvan één in dit proefschrift, en de resultaten van de Hanta-Hunting studie. Wat betreft de 
pathogenese studies lijken op het eerste gezicht zowel virussen die bloedingen veroorzaken als 
virussen die juist verstopping van een bloedvat kunnen veroorzaken een vergelijkbaar effect te 
hebben op de bloedstolling. Factoren die bepalend zijn of een virusinfectie leidt tot trombose 
of bloeding zullen gezocht moeten worden in zeer subtiele verschillen. Hierin lijkt dat zowel de 
hevigheid van de respons op infectie als het orgaan dat is aangedaan van groot belang kan zijn.   
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think you’re amazing, it was an absolute honor to be your paranimf and you have such a great 
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ook al mijn (oud) kamergenoten willen bedanken, Zeli, Dineke, Widagdo, Kirsten, Coen en 
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Esmeralda. Wie ik echt niet mag vergeten is natuurlijk Flora-Flower-Fleur, mijn maatje tijdens 
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Viroclinics! Stefan van Vliet, altijd bereid wat sequence advies te geven of een klein pilsje mee 
te pakken. Over kleine pilsjes gesproken Sander Herfst en Dirk Eggink ik hoop er nog wel een 
paar met jullie te mogen delen! Mi boy J-Siegers, ook wel koning pinteman van de afdeling 
(mits het natuurlijk IPA’s betreft), altijd gezellig met jou en volgens mij ga jij zo een vies 
jaloersmakend goede PhD neerzetten pik! 
Kirsty, dit kan lekker in het Nederlands, het flu-endotheel-stol werk was echt wel gaaf! Ik ben 
best onder de indruk van hoe fanatiek jij wetenschap bedrijft, ik ben dan weer wat minder 
onder indruk hoe lang het duurt voordat je op een wattsapp berichtjes reageert en hoeveel 
biertjes je kan drinken (niet echt Australië waardig).   
 De collega’s waar ik mee heb samenwerkt op de tiende, Corine altijd gezellig en leuk, Jean-Luc 
zo jammer dat je naar Utrecht ging en in het begin van de hantavirus PCR dankjewel Cedrick en 
Suzan voor jullie tips en hulp. Ook  bedankt voor Hans Kruining altijd flexibel en behulpzaam, 
jouw actie om binnen 48 uur een fles gevallen medium weer in huis te hebben heeft hoofdstuk 
3.2 gered, ik weet niet of ik dat eigenlijk wel eens heb verteld dus bij deze!! Natuurlijk extra 
veel dank voor mijn Suriname maatje Georgina, wat een avonturen en wat was het leuk samen 
op het BOG lab! Dit is hopelijk pas het begin Georgina!   
De dames van het secretariaat, altijd bereid te helpen als ik weer voor de vijftiende keer die 
week een handtekening nodig heb, de fax niet aan de praat krijg of moest proberen Ab te 
pakken te krijgen, Loubna, Simone, Maria en Anouk bedankt! 
Rudy, Marga, Ahmed, Hans & Jane van het KIT en meer specifiek het leptospiroselab. Onze 
samenwerking heb ik altijd als zeer prettig ervaren en ik ben jullie heel dankbaar dat ik altijd 
welkom was bij jullie op het lab te ‘klussen’. Altijd denken jullie (en vaak ook helpen) mee aan 
nieuwe experimentjes! 
Chantal! Fantastisch dat jij in de grote commissie zit, we hebben spannende tijd gehad met de 
hanta studies ik heb enorm veel van je geleerd. Op het gebied van epidemiologie, data 
interpretatie en het opschrijven van de paper. Hopelijk komt er nog veel meer uit onze hanta-
pijplijn. 
Dan prof.dr. Joost Meijers, beste Joost, ik heb erg veel geleerd van onze samenwerkingen aan 
papers en plannen van experimenten. Je bent altijd kritisch maar altijd op een goede en 
prettige manier. Minstens zo fijn vind ik dat je eigenlijk altijd als eerste een reactie op een 
nieuwe paper gaf of een antwoord op een prangende vraag mijn. Ook Kamran, erg veel dank 
voor als je hulp bij de TGT assays en hoofdstuk 3.1 en natuurlijk iedereen van de Meijers groep 
die zorgde voor gezelligheid en wetenschappelijke input bij de AMRO meetings! 
Lennert, of Leonaar, wat was het fijn dat jij besloot bij ons te komen werken man. Ik ben erg 
trots dat jij mijn paranimf bent en nog trotser op alle mooie avonturen die we samen hebben 
beleefd binnen en buiten werk. Je bent minstens net zo gek als ik en altijd de eerste die ja zegt 
als ik wat nieuws bedenk, van Mud Masters tot Athene. Ik vind het bijzonder hoe jij, in zo een 
korte tijd, van nieuwe collega tot goede vriend bent getransformeerd!  
Dan de nieuwe lichting, Wesley een absolute aanwinst en een prachtige kerel, het gaan mooie 
jaren worden. Laura onze nieuw telg in de viruskenner familie, heerlijk jouw enthousiasme en 
energie!  
All international collaborations: Purwati, Fedik and Musofa in Surabaya and Soemantri, Hussein 
and Supriatna in Semarang. Prof.dr Resida en de collega’s van B.O.G. zeker de dames van het 
 Lab! The people from Beijing institute of Microbiology especially Liqun Fang and Prof. Cao, 
loved working together on the selenium project! Jarlath and Simone, my time in Dublin was one 
of the highlights of my PhD, you guys are so great and so much fun. Jarlath you are one brilliant 
scientist but even more you are truly a great person and so much fun to hang out with, 
preferably with a pint of Guinness or two. Simone you rock! I loved the 2D stuff together in the 
lab and I am sure we will continue working together in the future, all the best in Bern. Prof. 
Henttonen, Howdy Heikki, thank you for letting me stay in Vantaa and teaching me valuable 
knowledge about bank voles, also prof.dr. Antti Vaheri for your help with the start of our 
research line and writing of Puumala papers. Ake Lundkvist, an absolute honor to have you in 
my committee, but even more thanks for your help with the neutralization assays together with 
Jenny. Niet echt internationaal, maar wel een belangrijke samenwerking, Sake de Vlas, zowel 
het schrijven als de RGHI grant aanvraag, de selenium paper en de trip naar China waren heel 
erg leerzaam en bovenal leuk!  
Alle studenten die geholpen hebben Samar, Eurydice, Leanne, Vincent en Jeroen. Ik heb super 
veel geleerd door jullie te begeleiden en vele van jullie hebben enorm veel bijgedragen aan de 
inhoud van dit boekje! 
Dan nu de mensen die bedankt moeten worden voor steun en hulp niet direct gerelateerd aan 
de werkvloer. Allereerst het Cirion bestuur, een stimulerende mooie groep van mensen. 
Speciaal aandacht natuurlijk voor Ton, wat ben ik blij dat we besloten toch nog eens wat te 
gaan drinken nadat het contact wat was verwaterd! We gaan nog een hoop avonturen beleven 
samen en Cirion door laten groeien! Ook wil ik specifiek nog even Maarten en Abigail noemen, 
gewoon omdat jullie zo leuk zijn en eigenlijk allebei, los van elkaar, vaak goed advies hebben 
gegeven over allerhande aan belangrijke beslissingen.  
Frank van Vliet en Jan Nouwen, ik heb de master I&I als zeer leerzaam en minstens zo prettig 
ervaren. Frank met name dank voor jouw tomeloze inzet om zaken voor elkaar te krijgen, waar 
ik met name van geprofiteerd heb bij het regelen van de Cum Laude voor mijn master diploma. 
Natuurlijk ook mijn mede master I&I studenten. In het bijzonder dan toch Bas. Ouwe koning, 
dankzij jouw fanatisme en enthousiasme ben ik toch behoorlijk fit geworden na mijn switch 
naar Rotterdam! Het is gewoon altijd gezellig en lachen met jou en je mooie gezinnetje! Ik 
wacht met smart op de dag van jouw verdediging! 
Nick en Lucas, extreem mooie poema’s, die bul die ik over hield aan zes jaar UvA was leuk maar 
jullie vriendschap toch minstens zo mooi. Zeker nu met de toevoeging van de wintersportclub: 
Tom, Marit (je staat erin hoor!), M-die, Pim, Marly (volgend jaar weer mee), Jos-R (verwacht in 
2016 Marjolein mee in de Multibus) en natuurlijk Felientje. Jullie zijn stuk voor stuk te gek en ik 
hoop dat we nog jaaaaaaaaren op reis gaan samen. Kid & Denise noem ik natuurlijk ook even 
enerzijds omdat het met Kid altijd zo heerlijk zeuren op het begrip promoveren en publiceren 
 is, anderzijds omdat jullie altijd zo gezellig zijn en als laatste omdat jullie nu wel mee MOETEN 
op wintersport. 
Team Tanga mooiste voetbal elftal ooit bestaan! Griekse Goden wat was Athene een mooie 
reis! Sefat en Stif briljant dat we nog steeds zo goed contact hebben. Ruben, al zien we elkaar 
maanden niet, het is altijd direct weer vertrouwd, wij kunnen werkelijk overal over praten, 
fantastisch dat je me kwam opzoeken in Ierland en wat een eer dat ik jouw getuige mag zijn bij 
je huwelijk met je prachtige bruid Noor. Tate en Milty, de studietijd is zoveel leuker geweest 
dankzij de avonturen met jullie in onze aftandse studentenflat. Niet te vergeten iedereen van 
de K.P. Smink, Staart, Ster, Woodie de ki…, we blijven gewoon die paar keer per jaar reünietjes 
houden! 
Dan het prachtige pact, een uniek stel wat al sinds begin van de studie zo een belangrijke rol 
speelt. Al neemt de frequentie van onze avonturen soms wat af, ze blijven wat betreft 
intensiteit nog altijd onvergetelijk. Thomas aka ‘T-Hondje’, zo slim, zo een discipline en bovenal 
zo een goudeerlijke en fantastische vriend. Steven aka weet ik hoeveel bijnamen, wij zorgen 
samen wel voor de nodige gekkigheid tijdens de pact trips al is het door ergens aan te hangen 
of in te duiken, bedankt voor je vriendschap en geduld! En natuurlijk Michiel, Strohoed of 
Bendit, vanaf de basisschool al zo een goede vriend en bij deze promotie mijn paranimf, wat 
ben ik daar trots op man. We steunen elkaar door dik en dun en zijn nu al zo een twintig jaar dik 
bevriend, laten we er daar nog maar zo een zestig bij gooien ouwe koning.  
Natuurlijk ook dank aan mijn familie en al mijn ooms en tantes. Zeker niet te vergeten is Alex 
mijn neef of bijna-broertje, altijd lachen en sportief! Ome Hans en Tante Sue altijd gezellig en 
heerlijk eten. Mijn fantastische schoonfamilie: Eric en Jacqueline altijd gezellig, altijd lekker 
eten en zo zorgzaam en betrokken. Eric heel veel dank voor je nakijkwerk en vele tips als er 
ergens een goede drank of culinaire aanbieding is! Pien, Tjalling en Heleen fantastische 
schoonfamilie en dank voor jullie flexibiliteit met afspraken maken rondom mijn 
verschrikkelijke agenda!  Oma Jelly altijd zo betrokken, geïnteresseerd en lief, datzelfde gold 
zeker ook voor Opa Arend. Opa Jan of opa Hoed, wat is het fijn om een opa te hebben die zo 
onvoorwaardelijk trots is op zijn kleinkinderen natuurlijk gold dat ook voor Oma Tjika. Mijn 
lieve, lieve zusje Simone, een fantastische zus en net zo een fantastische collega, ik vond het 
super dat we een paar jaar samen hebben gewerkt! Chieltje mijn zwager, je tekening staat in 
het boekje! En natuurlijk lieve kleine stoere Roan mijn neefje waar ik nu al zo trots op ben. Dan 
papa en mama, wat heb ik een hoop aan jullie te danken, onvoorwaardelijk steunen jullie me 
wat ik ook bedenk en waar ik ook naar toe wil. Ik heb altijd het heerlijke gevoel gehad dat jullie 
mijn vangnet waren en ik daarom best hier en daar een risico kon nemen. Al vanaf de 
basisschool stimuleren en motiveren jullie mij om alles uit het leven te halen wat erin zit en niet 
 op te geven bij de eerste tegenslag. Ik hoop dat jullie beseffen dat ik zonder jullie steun en 
motivatie nooit dit punt zou hebben bereikt! Ik hou van jullie. 
Dan volledig volgens traditie als laatste, Odette, mijn poppetje. Je hebt best wat te stellen 
gehad met mijn promotie plannen de laatste jaren, veel op reis, laat thuis en in het weekend 
vaak werken, soms ging je dan zelfs gezellig mee naar Rotterdam. Sterker nog, zelfs nu ik dit 
aan het typen ben het laatste stukje van mijn proefschrift, volledig volgens mijn last minute 
manier van werken, zit jij buiten op het terras van ons weekendje weg geduldig te wachten tot 
ik dit afgerond heb. Lieve Odette, wat ben ik blij dat jij ooit besloot in Amsterdam te gaan 
studeren en mij tegen het lijf liep in onze studentenflat. Ik zou nu niet meer weten wat ik 
zonder je zou moeten en geniet van elk moment samen. Jij haalt het beste in mij naar boven en 
ik hou zo ontzettend veel van jou, dit boekje is net zoveel een prestatie van jou als dat het van 
mij is. Kus voor mijn mus.    
 
 
 
 
 
 
 
 
